USRE42164E1 - Hepatitis C inhibitor tri-peptides - Google Patents
Hepatitis C inhibitor tri-peptides Download PDFInfo
- Publication number
- USRE42164E1 USRE42164E1 US12/119,609 US11960908A USRE42164E US RE42164 E1 USRE42164 E1 US RE42164E1 US 11960908 A US11960908 A US 11960908A US RE42164 E USRE42164 E US RE42164E
- Authority
- US
- United States
- Prior art keywords
- alkyl
- substituted
- formula
- amido
- amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 208000005176 Hepatitis C Diseases 0.000 title claims description 23
- 239000003112 inhibitor Substances 0.000 title claims description 20
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims abstract description 298
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 242
- 150000001875 compounds Chemical class 0.000 claims abstract description 210
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims abstract description 195
- 125000003368 amide group Chemical group 0.000 claims abstract description 188
- 150000001408 amides Chemical class 0.000 claims abstract description 147
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims abstract description 143
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims abstract description 127
- 125000003118 aryl group Chemical group 0.000 claims abstract description 120
- 125000003710 aryl alkyl group Chemical group 0.000 claims abstract description 99
- 125000005843 halogen group Chemical group 0.000 claims abstract description 74
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims abstract description 62
- 125000005119 alkyl cycloalkyl group Chemical group 0.000 claims abstract description 49
- 150000002148 esters Chemical class 0.000 claims abstract description 44
- 125000002252 acyl group Chemical group 0.000 claims abstract description 38
- 150000003839 salts Chemical class 0.000 claims abstract description 23
- 125000001188 haloalkyl group Chemical group 0.000 claims abstract description 19
- 125000004001 thioalkyl group Chemical group 0.000 claims abstract description 19
- 229920006395 saturated elastomer Polymers 0.000 claims abstract description 18
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims abstract description 17
- 125000004093 cyano group Chemical group *C#N 0.000 claims abstract description 15
- 125000004966 cyanoalkyl group Chemical group 0.000 claims abstract description 15
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims abstract description 15
- 229910052736 halogen Inorganic materials 0.000 claims abstract description 12
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims abstract description 9
- 230000003287 optical effect Effects 0.000 claims abstract description 9
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims abstract description 9
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims abstract description 6
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims abstract description 3
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims abstract 45
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 266
- -1 hydroxy, carboxyl Chemical group 0.000 claims description 169
- 238000000034 method Methods 0.000 claims description 80
- 239000000203 mixture Substances 0.000 claims description 78
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 77
- 229920002554 vinyl polymer Chemical group 0.000 claims description 70
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 67
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims description 67
- 241000711549 Hepacivirus C Species 0.000 claims description 53
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 49
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims description 38
- 125000006239 protecting group Chemical group 0.000 claims description 37
- 101800001838 Serine protease/helicase NS3 Proteins 0.000 claims description 32
- 238000011282 treatment Methods 0.000 claims description 31
- 230000008569 process Effects 0.000 claims description 29
- 238000005859 coupling reaction Methods 0.000 claims description 28
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 27
- 150000001413 amino acids Chemical class 0.000 claims description 25
- 238000010168 coupling process Methods 0.000 claims description 24
- 230000008878 coupling Effects 0.000 claims description 23
- 150000003254 radicals Chemical class 0.000 claims description 23
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 22
- 239000003795 chemical substances by application Substances 0.000 claims description 21
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 21
- 229910052799 carbon Inorganic materials 0.000 claims description 20
- 238000002360 preparation method Methods 0.000 claims description 20
- 241000124008 Mammalia Species 0.000 claims description 19
- 125000004432 carbon atom Chemical group C* 0.000 claims description 18
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 18
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 18
- 230000002829 reductive effect Effects 0.000 claims description 18
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 16
- 239000008194 pharmaceutical composition Substances 0.000 claims description 14
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 13
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 13
- 125000001424 substituent group Chemical group 0.000 claims description 13
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 12
- 230000002401 inhibitory effect Effects 0.000 claims description 12
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims description 9
- 230000009385 viral infection Effects 0.000 claims description 9
- 208000036142 Viral infection Diseases 0.000 claims description 8
- 125000000623 heterocyclic group Chemical group 0.000 claims description 8
- 102000014150 Interferons Human genes 0.000 claims description 7
- 108010050904 Interferons Proteins 0.000 claims description 7
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 7
- 239000003937 drug carrier Substances 0.000 claims description 7
- 229940079322 interferon Drugs 0.000 claims description 7
- PAJPWUMXBYXFCZ-UHFFFAOYSA-N 1-aminocyclopropanecarboxylic acid Chemical group OC(=O)C1(N)CC1 PAJPWUMXBYXFCZ-UHFFFAOYSA-N 0.000 claims description 6
- 125000006083 1-bromoethyl group Chemical group 0.000 claims description 6
- TXHAHOVNFDVCCC-UHFFFAOYSA-N 2-(tert-butylazaniumyl)acetate Chemical compound CC(C)(C)NCC(O)=O TXHAHOVNFDVCCC-UHFFFAOYSA-N 0.000 claims description 6
- 125000005999 2-bromoethyl group Chemical group 0.000 claims description 6
- KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical group NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 claims description 6
- 108060004795 Methyltransferase Proteins 0.000 claims description 6
- 241000700605 Viruses Species 0.000 claims description 6
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 6
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 6
- 125000001391 thioamide group Chemical group 0.000 claims description 6
- 108010033276 Peptide Fragments Proteins 0.000 claims description 5
- 102000007079 Peptide Fragments Human genes 0.000 claims description 5
- 125000005907 alkyl ester group Chemical group 0.000 claims description 5
- 239000012752 auxiliary agent Substances 0.000 claims description 5
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 claims description 5
- 125000000000 cycloalkoxy group Chemical group 0.000 claims description 5
- 230000010076 replication Effects 0.000 claims description 5
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 5
- 150000003573 thiols Chemical class 0.000 claims description 5
- 230000003612 virological effect Effects 0.000 claims description 5
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 claims description 4
- 125000006555 (C3-C5) cycloalkyl group Chemical group 0.000 claims description 4
- 125000005979 2-naphthyloxy group Chemical group 0.000 claims description 4
- 108010006035 Metalloproteases Proteins 0.000 claims description 4
- 102000005741 Metalloproteases Human genes 0.000 claims description 4
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 claims description 4
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 claims description 4
- 125000003545 alkoxy group Chemical group 0.000 claims description 4
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 4
- 229960000329 ribavirin Drugs 0.000 claims description 4
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 claims description 4
- 125000004963 sulfonylalkyl group Chemical group 0.000 claims description 4
- 102000006992 Interferon-alpha Human genes 0.000 claims description 3
- 108010047761 Interferon-alpha Proteins 0.000 claims description 3
- 125000001931 aliphatic group Chemical group 0.000 claims description 3
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 claims description 3
- 229960003805 amantadine Drugs 0.000 claims description 3
- 125000001246 bromo group Chemical group Br* 0.000 claims description 3
- 229910052757 nitrogen Inorganic materials 0.000 claims description 3
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 claims description 3
- 125000004665 trialkylsilyl group Chemical group 0.000 claims description 3
- 102000003996 Interferon-beta Human genes 0.000 claims description 2
- 108090000467 Interferon-beta Proteins 0.000 claims description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 2
- 125000005076 adamantyloxycarbonyl group Chemical group C12(CC3CC(CC(C1)C3)C2)OC(=O)* 0.000 claims description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 2
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims description 2
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 claims description 2
- 125000005842 heteroatom Chemical group 0.000 claims description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 2
- 229910052760 oxygen Inorganic materials 0.000 claims description 2
- 239000001301 oxygen Chemical group 0.000 claims description 2
- 125000001557 phthalyl group Chemical group C(=O)(O)C1=C(C(=O)*)C=CC=C1 0.000 claims description 2
- 229910052717 sulfur Chemical group 0.000 claims description 2
- 239000011593 sulfur Chemical group 0.000 claims description 2
- 125000006000 trichloroethyl group Chemical group 0.000 claims description 2
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 claims description 2
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 2
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 2
- 125000001589 carboacyl group Chemical group 0.000 claims 22
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- 125000005493 quinolyl group Chemical group 0.000 claims 2
- 150000003556 thioamides Chemical class 0.000 claims 2
- OPCMVVKRCLOEDQ-UHFFFAOYSA-N 1-(4-chlorophenyl)-2-(methylamino)pentan-1-one Chemical compound ClC1=CC=C(C=C1)C(C(CCC)NC)=O OPCMVVKRCLOEDQ-UHFFFAOYSA-N 0.000 claims 1
- 125000005978 1-naphthyloxy group Chemical group 0.000 claims 1
- AEOCXXJPGCBFJA-UHFFFAOYSA-N ethionamide Chemical compound CCC1=CC(C(N)=S)=CC=N1 AEOCXXJPGCBFJA-UHFFFAOYSA-N 0.000 abstract description 5
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 135
- 239000000243 solution Substances 0.000 description 99
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 91
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 84
- 0 [1*]C.[2*][C@@H]1C[C@@H](C(=O)NC2(C(=O)O)CC2)N(C(=O)[C@H]([3*])N(B)[Y])C1 Chemical compound [1*]C.[2*][C@@H]1C[C@@H](C(=O)NC2(C(=O)O)CC2)N(C(=O)[C@H]([3*])N(B)[Y])C1 0.000 description 73
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 60
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 58
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 55
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 54
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 53
- 235000019439 ethyl acetate Nutrition 0.000 description 52
- 238000005160 1H NMR spectroscopy Methods 0.000 description 50
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 50
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 48
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 46
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 45
- 239000007787 solid Substances 0.000 description 45
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 42
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 42
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 41
- 239000011541 reaction mixture Substances 0.000 description 38
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 37
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 36
- 230000015572 biosynthetic process Effects 0.000 description 34
- 239000012267 brine Substances 0.000 description 33
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 33
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 33
- 238000003786 synthesis reaction Methods 0.000 description 32
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 30
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 29
- 229940024606 amino acid Drugs 0.000 description 29
- 235000001014 amino acid Nutrition 0.000 description 28
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 27
- 239000002253 acid Substances 0.000 description 27
- 229940093499 ethyl acetate Drugs 0.000 description 27
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 27
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 27
- 239000002904 solvent Substances 0.000 description 26
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 24
- 239000003921 oil Substances 0.000 description 24
- 235000019198 oils Nutrition 0.000 description 24
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 24
- 238000003818 flash chromatography Methods 0.000 description 21
- 238000003556 assay Methods 0.000 description 20
- 239000011347 resin Substances 0.000 description 20
- 229920005989 resin Polymers 0.000 description 20
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 19
- 230000000694 effects Effects 0.000 description 19
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 18
- 239000012044 organic layer Substances 0.000 description 18
- 239000011780 sodium chloride Substances 0.000 description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 17
- 239000002585 base Substances 0.000 description 17
- 238000001914 filtration Methods 0.000 description 17
- 238000004128 high performance liquid chromatography Methods 0.000 description 17
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 16
- QYDDAGORFBJNSK-UHFFFAOYSA-N [CH2-][OH+]C1=CC(C2=CC=CC=C2)=NC2=C1C=CC(OC)=C2 Chemical compound [CH2-][OH+]C1=CC(C2=CC=CC=C2)=NC2=C1C=CC(OC)=C2 QYDDAGORFBJNSK-UHFFFAOYSA-N 0.000 description 16
- 238000006243 chemical reaction Methods 0.000 description 16
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 15
- 101710144111 Non-structural protein 3 Proteins 0.000 description 15
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 15
- 150000001412 amines Chemical class 0.000 description 15
- 239000000725 suspension Substances 0.000 description 15
- 102000004190 Enzymes Human genes 0.000 description 14
- 108090000790 Enzymes Proteins 0.000 description 14
- 229940088598 enzyme Drugs 0.000 description 14
- 238000003756 stirring Methods 0.000 description 13
- 239000000758 substrate Substances 0.000 description 13
- 102000004196 processed proteins & peptides Human genes 0.000 description 12
- 108010016626 Dipeptides Proteins 0.000 description 11
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 11
- 101800001020 Non-structural protein 4A Proteins 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 11
- 238000004992 fast atom bombardment mass spectroscopy Methods 0.000 description 11
- 239000012074 organic phase Substances 0.000 description 11
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 10
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 10
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 10
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 10
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 10
- 239000000872 buffer Substances 0.000 description 10
- 239000003153 chemical reaction reagent Substances 0.000 description 10
- 239000000463 material Substances 0.000 description 10
- RAXXELZNTBOGNW-UHFFFAOYSA-N 1H-imidazole Chemical compound C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 9
- 239000000706 filtrate Substances 0.000 description 9
- 150000002466 imines Chemical class 0.000 description 9
- 208000015181 infectious disease Diseases 0.000 description 9
- 150000004702 methyl esters Chemical class 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 8
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 8
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 8
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 8
- KWKJPISTDOLECT-ZCFIWIBFSA-N [CH2-][C+](=O)N[C@H](C)C(C)(C)C Chemical compound [CH2-][C+](=O)N[C@H](C)C(C)(C)C KWKJPISTDOLECT-ZCFIWIBFSA-N 0.000 description 8
- YOWQWFMSQCOSBA-UHFFFAOYSA-N [CH2-][C+](C)OC Chemical compound [CH2-][C+](C)OC YOWQWFMSQCOSBA-UHFFFAOYSA-N 0.000 description 8
- PCULDZYZGZDPIJ-UHFFFAOYSA-N [CH2-][OH+]C1=CC(C2=CC=CC=C2)=NC2=C1C=CC=C2 Chemical compound [CH2-][OH+]C1=CC(C2=CC=CC=C2)=NC2=C1C=CC=C2 PCULDZYZGZDPIJ-UHFFFAOYSA-N 0.000 description 8
- PUDPTYLLYNPWOH-UHFFFAOYSA-N [CH2-][OH+]C1=NC(C2=CC=CC=C2)=NC2=C1C=CC=C2 Chemical compound [CH2-][OH+]C1=NC(C2=CC=CC=C2)=NC2=C1C=CC=C2 PUDPTYLLYNPWOH-UHFFFAOYSA-N 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 239000010410 layer Substances 0.000 description 8
- 239000012047 saturated solution Substances 0.000 description 8
- 239000007790 solid phase Substances 0.000 description 8
- 238000004809 thin layer chromatography Methods 0.000 description 8
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 8
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 7
- 239000007821 HATU Substances 0.000 description 7
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 7
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 7
- 108010076039 Polyproteins Proteins 0.000 description 7
- PZBFGYYEXUXCOF-UHFFFAOYSA-N TCEP Chemical compound OC(=O)CCP(CCC(O)=O)CCC(O)=O PZBFGYYEXUXCOF-UHFFFAOYSA-N 0.000 description 7
- LDROHFLBGQWJAK-UHFFFAOYSA-N [CH2-][C+](=O)NC(C)(C)C Chemical compound [CH2-][C+](=O)NC(C)(C)C LDROHFLBGQWJAK-UHFFFAOYSA-N 0.000 description 7
- XFYMNFDFNVQDBJ-UHFFFAOYSA-N [CH2-][OH+]C1=CC=NC2=C1C=CC(Cl)=C2 Chemical compound [CH2-][OH+]C1=CC=NC2=C1C=CC(Cl)=C2 XFYMNFDFNVQDBJ-UHFFFAOYSA-N 0.000 description 7
- 239000003443 antiviral agent Substances 0.000 description 7
- 239000008346 aqueous phase Substances 0.000 description 7
- 239000007822 coupling agent Substances 0.000 description 7
- 238000010511 deprotection reaction Methods 0.000 description 7
- 238000011534 incubation Methods 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 239000000543 intermediate Substances 0.000 description 7
- 238000010647 peptide synthesis reaction Methods 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 238000010992 reflux Methods 0.000 description 7
- 239000000741 silica gel Substances 0.000 description 7
- 229910002027 silica gel Inorganic materials 0.000 description 7
- WORJRXHJTUTINR-UHFFFAOYSA-N 1,4-dioxane;hydron;chloride Chemical compound Cl.C1COCCO1 WORJRXHJTUTINR-UHFFFAOYSA-N 0.000 description 6
- FVTVMQPGKVHSEY-UHFFFAOYSA-N 1-AMINOCYCLOBUTANE CARBOXYLIC ACID Chemical compound OC(=O)C1(N)CCC1 FVTVMQPGKVHSEY-UHFFFAOYSA-N 0.000 description 6
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 6
- BAZSITKSXXHTNS-UHFFFAOYSA-N 4-chloro-7-methoxy-2-phenylquinoline Chemical compound N=1C2=CC(OC)=CC=C2C(Cl)=CC=1C1=CC=CC=C1 BAZSITKSXXHTNS-UHFFFAOYSA-N 0.000 description 6
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 6
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 6
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 6
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 6
- 102000012479 Serine Proteases Human genes 0.000 description 6
- 108010022999 Serine Proteases Proteins 0.000 description 6
- IHHWHOQLONHZMR-UHFFFAOYSA-N [CH2-][C+]1=CSC(NC(C)=O)=N1 Chemical compound [CH2-][C+]1=CSC(NC(C)=O)=N1 IHHWHOQLONHZMR-UHFFFAOYSA-N 0.000 description 6
- 150000001732 carboxylic acid derivatives Chemical group 0.000 description 6
- FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Substances CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 description 6
- FAMRKDQNMBBFBR-UHFFFAOYSA-N ethyl n-ethoxycarbonyliminocarbamate Chemical compound CCOC(=O)N=NC(=O)OCC FAMRKDQNMBBFBR-UHFFFAOYSA-N 0.000 description 6
- 239000000284 extract Substances 0.000 description 6
- 230000007062 hydrolysis Effects 0.000 description 6
- 238000006460 hydrolysis reaction Methods 0.000 description 6
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 239000001488 sodium phosphate Substances 0.000 description 6
- 229910000162 sodium phosphate Inorganic materials 0.000 description 6
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 6
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 5
- JGABMVVOXLQCKZ-UHFFFAOYSA-N 2-phenyl-1h-quinolin-4-one Chemical class N=1C2=CC=CC=C2C(O)=CC=1C1=CC=CC=C1 JGABMVVOXLQCKZ-UHFFFAOYSA-N 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 5
- 101000851058 Homo sapiens Neutrophil elastase Proteins 0.000 description 5
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 description 5
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 5
- 102100033174 Neutrophil elastase Human genes 0.000 description 5
- 108010067372 Pancreatic elastase Proteins 0.000 description 5
- 102000016387 Pancreatic elastase Human genes 0.000 description 5
- 102000035195 Peptidases Human genes 0.000 description 5
- 108091005804 Peptidases Proteins 0.000 description 5
- 229920001213 Polysorbate 20 Polymers 0.000 description 5
- 239000004365 Protease Substances 0.000 description 5
- 229940122055 Serine protease inhibitor Drugs 0.000 description 5
- 101710102218 Serine protease inhibitor Proteins 0.000 description 5
- DBUWCJSMHMGCAZ-UHFFFAOYSA-N [CH2-][OH+]c1cc(-c2ccccc2)nc2ccc([N+](=O)[O-])cc12 Chemical compound [CH2-][OH+]c1cc(-c2ccccc2)nc2ccc([N+](=O)[O-])cc12 DBUWCJSMHMGCAZ-UHFFFAOYSA-N 0.000 description 5
- 239000012131 assay buffer Substances 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 238000003776 cleavage reaction Methods 0.000 description 5
- 239000012230 colorless oil Substances 0.000 description 5
- 150000005690 diesters Chemical class 0.000 description 5
- 229910052739 hydrogen Inorganic materials 0.000 description 5
- 239000001257 hydrogen Substances 0.000 description 5
- 230000002519 immonomodulatory effect Effects 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium hydroxide monohydrate Substances [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 5
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 5
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 5
- 230000036515 potency Effects 0.000 description 5
- 235000019419 proteases Nutrition 0.000 description 5
- 230000007017 scission Effects 0.000 description 5
- 239000003001 serine protease inhibitor Substances 0.000 description 5
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 5
- BENKAPCDIOILGV-RQJHMYQMSA-N (2s,4r)-4-hydroxy-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid Chemical compound CC(C)(C)OC(=O)N1C[C@H](O)C[C@H]1C(O)=O BENKAPCDIOILGV-RQJHMYQMSA-N 0.000 description 4
- YXHKONLOYHBTNS-UHFFFAOYSA-N Diazomethane Chemical compound C=[N+]=[N-] YXHKONLOYHBTNS-UHFFFAOYSA-N 0.000 description 4
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 4
- 239000004471 Glycine Substances 0.000 description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 4
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 4
- AHVYPIQETPWLSZ-UHFFFAOYSA-N N-methyl-pyrrolidine Natural products CN1CC=CC1 AHVYPIQETPWLSZ-UHFFFAOYSA-N 0.000 description 4
- 101800001014 Non-structural protein 5A Proteins 0.000 description 4
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 4
- 101800001554 RNA-directed RNA polymerase Proteins 0.000 description 4
- JJSHQEMAAVPEFV-UHFFFAOYSA-N [CH2-][C+](=O)NC1CCCCC1 Chemical compound [CH2-][C+](=O)NC1CCCCC1 JJSHQEMAAVPEFV-UHFFFAOYSA-N 0.000 description 4
- ANCMUYJAJOGCCV-UHFFFAOYSA-N [CH2-][C+](=O)OCC(C)C Chemical compound [CH2-][C+](=O)OCC(C)C ANCMUYJAJOGCCV-UHFFFAOYSA-N 0.000 description 4
- MHNNAWXXUZQSNM-UHFFFAOYSA-N [CH2-][C+](C)CC Chemical compound [CH2-][C+](C)CC MHNNAWXXUZQSNM-UHFFFAOYSA-N 0.000 description 4
- FJNNQQFTXMJWEQ-UHFFFAOYSA-N [CH2-][C+](C)CC.[CH2-][C+](C)CC Chemical compound [CH2-][C+](C)CC.[CH2-][C+](C)CC FJNNQQFTXMJWEQ-UHFFFAOYSA-N 0.000 description 4
- UIFUVEPTFQPRDX-UHFFFAOYSA-N [CH2-][C+](C)OC(C)(C)C Chemical compound [CH2-][C+](C)OC(C)(C)C UIFUVEPTFQPRDX-UHFFFAOYSA-N 0.000 description 4
- ZIFHFFOAEFKJJL-UHFFFAOYSA-N [CH2-][C+](C)OCC1=CC=CC=C1 Chemical compound [CH2-][C+](C)OCC1=CC=CC=C1 ZIFHFFOAEFKJJL-UHFFFAOYSA-N 0.000 description 4
- MMUQYXAWSLMYLQ-UHFFFAOYSA-N [CH2-][C+]1=CC=CN=C1 Chemical compound [CH2-][C+]1=CC=CN=C1 MMUQYXAWSLMYLQ-UHFFFAOYSA-N 0.000 description 4
- BXMDEJLXNNRDSR-UHFFFAOYSA-N [CH2-][C+]1=CSC(C)=N1 Chemical compound [CH2-][C+]1=CSC(C)=N1 BXMDEJLXNNRDSR-UHFFFAOYSA-N 0.000 description 4
- MFNQUFGJQAOLJU-UHFFFAOYSA-N [CH2-][C+]1=CSC(N)=N1 Chemical compound [CH2-][C+]1=CSC(N)=N1 MFNQUFGJQAOLJU-UHFFFAOYSA-N 0.000 description 4
- OBQLQBMDQUANNJ-UHFFFAOYSA-N [CH2-][C+]1=CSC(NC(C)C)=N1 Chemical compound [CH2-][C+]1=CSC(NC(C)C)=N1 OBQLQBMDQUANNJ-UHFFFAOYSA-N 0.000 description 4
- XSGHLZBESSREDT-UHFFFAOYSA-N [CH2-][C+]1CC1 Chemical compound [CH2-][C+]1CC1 XSGHLZBESSREDT-UHFFFAOYSA-N 0.000 description 4
- ATSIEAZVCSLOIX-UHFFFAOYSA-N [CH2-][NH+]1CCOCC1 Chemical compound [CH2-][NH+]1CCOCC1 ATSIEAZVCSLOIX-UHFFFAOYSA-N 0.000 description 4
- AKIFOZHESCXBKM-UHFFFAOYSA-N [CH2-][OH+]CC Chemical compound [CH2-][OH+]CC AKIFOZHESCXBKM-UHFFFAOYSA-N 0.000 description 4
- 235000008206 alpha-amino acids Nutrition 0.000 description 4
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 229960005261 aspartic acid Drugs 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 238000000423 cell based assay Methods 0.000 description 4
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 4
- 235000018417 cysteine Nutrition 0.000 description 4
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- USIUVYZYUHIAEV-UHFFFAOYSA-N diphenyl ether Chemical compound C=1C=CC=CC=1OC1=CC=CC=C1 USIUVYZYUHIAEV-UHFFFAOYSA-N 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 239000006260 foam Substances 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 208000019423 liver disease Diseases 0.000 description 4
- 238000002953 preparative HPLC Methods 0.000 description 4
- 229960002429 proline Drugs 0.000 description 4
- 239000000376 reactant Substances 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 229910000104 sodium hydride Inorganic materials 0.000 description 4
- 239000011550 stock solution Substances 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- 241000701447 unidentified baculovirus Species 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 3
- AITNMTXHTIIIBB-UHFFFAOYSA-N 1-bromo-4-fluorobenzene Chemical compound FC1=CC=C(Br)C=C1 AITNMTXHTIIIBB-UHFFFAOYSA-N 0.000 description 3
- MZMNEDXVUJLQAF-YUMQZZPRSA-N 1-o-tert-butyl 2-o-methyl (2s,4s)-4-hydroxypyrrolidine-1,2-dicarboxylate Chemical compound COC(=O)[C@@H]1C[C@H](O)CN1C(=O)OC(C)(C)C MZMNEDXVUJLQAF-YUMQZZPRSA-N 0.000 description 3
- OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-dimethylpyridine Chemical compound CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 3
- RTLKJCSGNBYCKJ-UHFFFAOYSA-N 3-oxo-3-phenylpropanamide Chemical compound NC(=O)CC(=O)C1=CC=CC=C1 RTLKJCSGNBYCKJ-UHFFFAOYSA-N 0.000 description 3
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 3
- JZVUAOCDNFNSGQ-UHFFFAOYSA-N 7-methoxy-2-phenyl-1h-quinolin-4-one Chemical compound N=1C2=CC(OC)=CC=C2C(O)=CC=1C1=CC=CC=C1 JZVUAOCDNFNSGQ-UHFFFAOYSA-N 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- GRFXBVZELTXBEG-UHFFFAOYSA-N C.C.C.C.[CH2-][OH+]C1=CC(C2=NC=CC=C2)=NC(C2=NC=CC=C2)=C1.[CH2-][OH+]C1=NC(C2=CC=CC=C2)=NC2=C1C=CC=C2.[CH2-][OH+]C1=NC(N2C=CN=C2)=NC2=C1C=C(OC)C(OC)=C2.[CH2-][OH+]C1=NC(N2CCOCC2)=NC2=C1C=C(OC)C(OC)=C2 Chemical compound C.C.C.C.[CH2-][OH+]C1=CC(C2=NC=CC=C2)=NC(C2=NC=CC=C2)=C1.[CH2-][OH+]C1=NC(C2=CC=CC=C2)=NC2=C1C=CC=C2.[CH2-][OH+]C1=NC(N2C=CN=C2)=NC2=C1C=C(OC)C(OC)=C2.[CH2-][OH+]C1=NC(N2CCOCC2)=NC2=C1C=C(OC)C(OC)=C2 GRFXBVZELTXBEG-UHFFFAOYSA-N 0.000 description 3
- FTMNIFUHFQQDMM-UHFFFAOYSA-N C=[SH]CC Chemical compound C=[SH]CC FTMNIFUHFQQDMM-UHFFFAOYSA-N 0.000 description 3
- IGJQUJNPMOYEJY-UHFFFAOYSA-N CC(=O)C1=CC=CN1 Chemical compound CC(=O)C1=CC=CN1 IGJQUJNPMOYEJY-UHFFFAOYSA-N 0.000 description 3
- ACYFWRHALJTSCF-UHFFFAOYSA-N CC(=O)NC(C)(C)C Chemical compound CC(=O)NC(C)(C)C ACYFWRHALJTSCF-UHFFFAOYSA-N 0.000 description 3
- BDYXTSMYSPQKPT-UHFFFAOYSA-N COc(cc1)cc2c1c(OC)cc(-c1ccccc1)n2 Chemical compound COc(cc1)cc2c1c(OC)cc(-c1ccccc1)n2 BDYXTSMYSPQKPT-UHFFFAOYSA-N 0.000 description 3
- 102000004225 Cathepsin B Human genes 0.000 description 3
- 108090000712 Cathepsin B Proteins 0.000 description 3
- 208000006154 Chronic hepatitis C Diseases 0.000 description 3
- QMMFVYPAHWMCMS-UHFFFAOYSA-N Dimethyl sulfide Chemical compound CSC QMMFVYPAHWMCMS-UHFFFAOYSA-N 0.000 description 3
- 229940124771 HCV-NS3 protease inhibitor Drugs 0.000 description 3
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 3
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 3
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- 235000019502 Orange oil Nutrition 0.000 description 3
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium on carbon Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 3
- 239000004793 Polystyrene Substances 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 3
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 3
- BPWFWURHQFRLHN-UHFFFAOYSA-N [CH2-][C+](=O)N(C)C(C)(C)C Chemical compound [CH2-][C+](=O)N(C)C(C)(C)C BPWFWURHQFRLHN-UHFFFAOYSA-N 0.000 description 3
- HQIFLPACJPGSTR-UHFFFAOYSA-N [CH2-][C+](=O)NCC1=CC=CC=C1 Chemical compound [CH2-][C+](=O)NCC1=CC=CC=C1 HQIFLPACJPGSTR-UHFFFAOYSA-N 0.000 description 3
- JEBOBVZHZDFOMY-UHFFFAOYSA-N [CH2-][C+](=O)NN(C)C Chemical compound [CH2-][C+](=O)NN(C)C JEBOBVZHZDFOMY-UHFFFAOYSA-N 0.000 description 3
- WBTKAUHIOIRWPS-UHFFFAOYSA-N [CH2-][C+]1=CN(C(C)(C)C)N=C1.[CH2-][C+]1=CN(C)N=C1.[CH2-][C+]1=CSC(C)=N1.[CH2-][C+]1=CSC(C2=CSC(C)=N2)=N1.[CH2-][C+]1=CSC(CC)=N1.[CH2-][C+]1=CSC(N)=N1.[CH2-][C+]1=CSC(NC(C)(C)C)=N1.[CH2-][C+]1=CSC(NC(C)=O)=N1.[CH2-][C+]1=CSC(NC(C)C)=N1.[CH2-][C+]1=CSC(NC)=N1.[CH2-][C+]1=CSC(NCC)=N1.[CH2-][C+]1CCC2=C1C=CC=C2 Chemical compound [CH2-][C+]1=CN(C(C)(C)C)N=C1.[CH2-][C+]1=CN(C)N=C1.[CH2-][C+]1=CSC(C)=N1.[CH2-][C+]1=CSC(C2=CSC(C)=N2)=N1.[CH2-][C+]1=CSC(CC)=N1.[CH2-][C+]1=CSC(N)=N1.[CH2-][C+]1=CSC(NC(C)(C)C)=N1.[CH2-][C+]1=CSC(NC(C)=O)=N1.[CH2-][C+]1=CSC(NC(C)C)=N1.[CH2-][C+]1=CSC(NC)=N1.[CH2-][C+]1=CSC(NCC)=N1.[CH2-][C+]1CCC2=C1C=CC=C2 WBTKAUHIOIRWPS-UHFFFAOYSA-N 0.000 description 3
- WEHMXWJFCCNXHJ-UHFFFAOYSA-N [CH2-][C+]=CC1=CC=CC=C1 Chemical compound [CH2-][C+]=CC1=CC=CC=C1 WEHMXWJFCCNXHJ-UHFFFAOYSA-N 0.000 description 3
- CRCXTUONJIFZQT-UHFFFAOYSA-N [CH2-][OH+]c1cc(-c2ccccc2)nc2ccc(C)cc12 Chemical compound [CH2-][OH+]c1cc(-c2ccccc2)nc2ccc(C)cc12 CRCXTUONJIFZQT-UHFFFAOYSA-N 0.000 description 3
- SORGEQQSQGNZFI-UHFFFAOYSA-N [azido(phenoxy)phosphoryl]oxybenzene Chemical compound C=1C=CC=CC=1OP(=O)(N=[N+]=[N-])OC1=CC=CC=C1 SORGEQQSQGNZFI-UHFFFAOYSA-N 0.000 description 3
- 229960000583 acetic acid Drugs 0.000 description 3
- 229960003767 alanine Drugs 0.000 description 3
- 150000004703 alkoxides Chemical class 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 230000000840 anti-viral effect Effects 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 239000007900 aqueous suspension Substances 0.000 description 3
- 235000003704 aspartic acid Nutrition 0.000 description 3
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 210000004899 c-terminal region Anatomy 0.000 description 3
- 150000001718 carbodiimides Chemical class 0.000 description 3
- 150000001721 carbon Chemical group 0.000 description 3
- FZFAMSAMCHXGEF-UHFFFAOYSA-N chloro formate Chemical compound ClOC=O FZFAMSAMCHXGEF-UHFFFAOYSA-N 0.000 description 3
- 239000013058 crude material Substances 0.000 description 3
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 3
- PQVSTLUFSYVLTO-UHFFFAOYSA-N ethyl n-ethoxycarbonylcarbamate Chemical compound CCOC(=O)NC(=O)OCC PQVSTLUFSYVLTO-UHFFFAOYSA-N 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 235000013922 glutamic acid Nutrition 0.000 description 3
- 239000004220 glutamic acid Substances 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 208000010710 hepatitis C virus infection Diseases 0.000 description 3
- 229940040692 lithium hydroxide monohydrate Drugs 0.000 description 3
- NCBZRJODKRCREW-UHFFFAOYSA-N m-anisidine Chemical compound COC1=CC=CC(N)=C1 NCBZRJODKRCREW-UHFFFAOYSA-N 0.000 description 3
- 239000010502 orange oil Substances 0.000 description 3
- 229920002223 polystyrene Polymers 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 230000002797 proteolythic effect Effects 0.000 description 3
- 239000000700 radioactive tracer Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000003757 reverse transcription PCR Methods 0.000 description 3
- 229960001153 serine Drugs 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- QSUXZIPXYDQFCX-JTQLQIEISA-N (2s)-2-cyclohexyl-2-[(2-methylpropan-2-yl)oxycarbonylamino]acetic acid Chemical compound CC(C)(C)OC(=O)N[C@H](C(O)=O)C1CCCCC1 QSUXZIPXYDQFCX-JTQLQIEISA-N 0.000 description 2
- AVFZOVWCLRSYKC-UHFFFAOYSA-N 1-methylpyrrolidine Chemical compound CN1CCCC1 AVFZOVWCLRSYKC-UHFFFAOYSA-N 0.000 description 2
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 2
- FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 2
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 2
- ZNGINKJHQQQORD-UHFFFAOYSA-N 2-trimethylsilylethanol Chemical compound C[Si](C)(C)CCO ZNGINKJHQQQORD-UHFFFAOYSA-N 0.000 description 2
- UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 2
- 150000004331 4-hydroxyquinolines Chemical class 0.000 description 2
- TYMLOMAKGOJONV-UHFFFAOYSA-N 4-nitroaniline Chemical compound NC1=CC=C([N+]([O-])=O)C=C1 TYMLOMAKGOJONV-UHFFFAOYSA-N 0.000 description 2
- XDBHURGONHZNJF-UHFFFAOYSA-N 6-[2-(3,4-diethoxyphenyl)-1,3-thiazol-4-yl]pyridine-2-carboxylic acid Chemical compound C1=C(OCC)C(OCC)=CC=C1C1=NC(C=2N=C(C=CC=2)C(O)=O)=CS1 XDBHURGONHZNJF-UHFFFAOYSA-N 0.000 description 2
- 241000023308 Acca Species 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- 108090001008 Avidin Proteins 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 2
- AGIGAZDINRUUMM-UHFFFAOYSA-N C.C.C.C.C.[CH2-][OH+]C1=CC(C)=NC2=C1C=CC=C2C(F)(F)F.[CH2-][OH+]C1=CC(N)=NC2=C1C=CC(C)=C2.[CH2-][OH+]C1=CC=NC2=C1C=CC(OC)=C2.[CH2-][OH+]C1=CC=NC2=C1C=CC=C2.[CH2-][OH+]c1ccnc2cc(Cl)ccc12 Chemical compound C.C.C.C.C.[CH2-][OH+]C1=CC(C)=NC2=C1C=CC=C2C(F)(F)F.[CH2-][OH+]C1=CC(N)=NC2=C1C=CC(C)=C2.[CH2-][OH+]C1=CC=NC2=C1C=CC(OC)=C2.[CH2-][OH+]C1=CC=NC2=C1C=CC=C2.[CH2-][OH+]c1ccnc2cc(Cl)ccc12 AGIGAZDINRUUMM-UHFFFAOYSA-N 0.000 description 2
- IVMAESJDIVTZEQ-MTICXXPYSA-N C=CC1C[C@]1([NH2+][CH2-])[C+]([CH2-])=O.S Chemical compound C=CC1C[C@]1([NH2+][CH2-])[C+]([CH2-])=O.S IVMAESJDIVTZEQ-MTICXXPYSA-N 0.000 description 2
- IRDNRQIBVPTDKY-VOLNJMMDSA-N C=C[C@H]1C[C@]1(N)C(=O)OC.S Chemical compound C=C[C@H]1C[C@]1(N)C(=O)OC.S IRDNRQIBVPTDKY-VOLNJMMDSA-N 0.000 description 2
- QPIOUXKJXBVBTC-UHFFFAOYSA-N C=S(=O)(=O)C1=C(C)N=C(NC(C)=O)S1 Chemical compound C=S(=O)(=O)C1=C(C)N=C(NC(C)=O)S1 QPIOUXKJXBVBTC-UHFFFAOYSA-N 0.000 description 2
- MOQZESQJRXQXTK-UHFFFAOYSA-N C=S(=O)(=O)C1=CC=CC=C1 Chemical compound C=S(=O)(=O)C1=CC=CC=C1 MOQZESQJRXQXTK-UHFFFAOYSA-N 0.000 description 2
- CNFRGJHWQLLHDP-UHFFFAOYSA-N C=S(=O)(=O)C1=CC=CS1 Chemical compound C=S(=O)(=O)C1=CC=CS1 CNFRGJHWQLLHDP-UHFFFAOYSA-N 0.000 description 2
- SLIKWWJXVUHCPJ-UHFFFAOYSA-N CC(NN(C)C)=O Chemical compound CC(NN(C)C)=O SLIKWWJXVUHCPJ-UHFFFAOYSA-N 0.000 description 2
- NRPTXWYBRKRZES-UHFFFAOYSA-N CC(Nc1c(C)cccc1C)=O Chemical compound CC(Nc1c(C)cccc1C)=O NRPTXWYBRKRZES-UHFFFAOYSA-N 0.000 description 2
- YPMHZSOMWPJODW-UHFFFAOYSA-N C[N-][C+]1=CC=CC=C1 Chemical compound C[N-][C+]1=CC=CC=C1 YPMHZSOMWPJODW-UHFFFAOYSA-N 0.000 description 2
- OUQMXTJYCAJLGO-UHFFFAOYSA-N Cc1c[s]c(N)n1 Chemical compound Cc1c[s]c(N)n1 OUQMXTJYCAJLGO-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 238000006969 Curtius rearrangement reaction Methods 0.000 description 2
- 108010005843 Cysteine Proteases Proteins 0.000 description 2
- 102000005927 Cysteine Proteases Human genes 0.000 description 2
- 102000016911 Deoxyribonucleases Human genes 0.000 description 2
- 108010053770 Deoxyribonucleases Proteins 0.000 description 2
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 2
- GKKZMYDNDDMXSE-UHFFFAOYSA-N Ethyl 3-oxo-3-phenylpropanoate Chemical compound CCOC(=O)CC(=O)C1=CC=CC=C1 GKKZMYDNDDMXSE-UHFFFAOYSA-N 0.000 description 2
- 229940122604 HCV protease inhibitor Drugs 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- 150000008575 L-amino acids Chemical class 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 238000006751 Mitsunobu reaction Methods 0.000 description 2
- HPKJGHVHQWJOOT-ZJOUEHCJSA-N N-[(2S)-3-cyclohexyl-1-oxo-1-({(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl}amino)propan-2-yl]-1H-indole-2-carboxamide Chemical compound C1C(CCCC1)C[C@H](NC(=O)C=1NC2=CC=CC=C2C=1)C(=O)N[C@@H](C[C@H]1C(=O)NCC1)C=O HPKJGHVHQWJOOT-ZJOUEHCJSA-N 0.000 description 2
- 239000007832 Na2SO4 Substances 0.000 description 2
- 101800001019 Non-structural protein 4B Proteins 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- 102000004409 RNA Helicases Human genes 0.000 description 2
- 108090000944 RNA Helicases Proteins 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- 108010056079 Subtilisins Proteins 0.000 description 2
- 102000005158 Subtilisins Human genes 0.000 description 2
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 108700022715 Viral Proteases Proteins 0.000 description 2
- PNJWVQYNXSCCPS-UHFFFAOYSA-N [C-]#[N+]C1=CC=[C+]([CH2-])C=C1 Chemical compound [C-]#[N+]C1=CC=[C+]([CH2-])C=C1 PNJWVQYNXSCCPS-UHFFFAOYSA-N 0.000 description 2
- JSHZBBWYHULHFG-UHFFFAOYSA-N [C-]#[N+]CC1=CC=C[C+]([CH2-])=C1 Chemical compound [C-]#[N+]CC1=CC=C[C+]([CH2-])=C1 JSHZBBWYHULHFG-UHFFFAOYSA-N 0.000 description 2
- HOMOOTLAYSRPCS-UHFFFAOYSA-N [C-]#[N+]CC1=CC=[C+]([CH2-])C=C1 Chemical compound [C-]#[N+]CC1=CC=[C+]([CH2-])C=C1 HOMOOTLAYSRPCS-UHFFFAOYSA-N 0.000 description 2
- WMTYCQNOZFZIBE-UHFFFAOYSA-N [CH2+][O-]Cc1cccc2cccnc12 Chemical compound [CH2+][O-]Cc1cccc2cccnc12 WMTYCQNOZFZIBE-UHFFFAOYSA-N 0.000 description 2
- DIQRZKGLSOQXQX-UHFFFAOYSA-N [CH2-][C+](=O)C(C)C1CCCCC1 Chemical compound [CH2-][C+](=O)C(C)C1CCCCC1 DIQRZKGLSOQXQX-UHFFFAOYSA-N 0.000 description 2
- RTBWRKKLOALXFU-UHFFFAOYSA-N [CH2-][C+](=O)C(CC1CCCCC1)CC1CCCCC1 Chemical compound [CH2-][C+](=O)C(CC1CCCCC1)CC1CCCCC1 RTBWRKKLOALXFU-UHFFFAOYSA-N 0.000 description 2
- HDTRPFBUTUEUFF-UHFFFAOYSA-N [CH2-][C+](=O)C1=C(C)C(O)=CC=C1 Chemical compound [CH2-][C+](=O)C1=C(C)C(O)=CC=C1 HDTRPFBUTUEUFF-UHFFFAOYSA-N 0.000 description 2
- OGILXPOTMOZKFB-UHFFFAOYSA-N [CH2-][C+](=O)C1=CC(O)=CC=C1 Chemical compound [CH2-][C+](=O)C1=CC(O)=CC=C1 OGILXPOTMOZKFB-UHFFFAOYSA-N 0.000 description 2
- XAKBSHICSHRJCL-UHFFFAOYSA-N [CH2-][C+](=O)C1=CC=CC=C1 Chemical compound [CH2-][C+](=O)C1=CC=CC=C1 XAKBSHICSHRJCL-UHFFFAOYSA-N 0.000 description 2
- CWSZHRNJMNCMGI-UHFFFAOYSA-N [CH2-][C+](=O)CC1CCCCC1 Chemical compound [CH2-][C+](=O)CC1CCCCC1 CWSZHRNJMNCMGI-UHFFFAOYSA-N 0.000 description 2
- UOLHFRNOSWJGPM-UHFFFAOYSA-N [CH2-][C+](=O)COC1=C(C)C=CC=C1C Chemical compound [CH2-][C+](=O)COC1=C(C)C=CC=C1C UOLHFRNOSWJGPM-UHFFFAOYSA-N 0.000 description 2
- QOIXBKBGIZXANK-UHFFFAOYSA-N [CH2-][C+](=O)NC(C)(C)C(N)=O Chemical compound [CH2-][C+](=O)NC(C)(C)C(N)=O QOIXBKBGIZXANK-UHFFFAOYSA-N 0.000 description 2
- NAPYHOJHEZRLCE-UHFFFAOYSA-N [CH2-][C+](=O)NC(C)(C)CC Chemical compound [CH2-][C+](=O)NC(C)(C)CC NAPYHOJHEZRLCE-UHFFFAOYSA-N 0.000 description 2
- FKEQEFPPSJOGKI-UHFFFAOYSA-N [CH2-][C+](=O)NC(C)(C)CO Chemical compound [CH2-][C+](=O)NC(C)(C)CO FKEQEFPPSJOGKI-UHFFFAOYSA-N 0.000 description 2
- MKNLZPADMILVCT-UHFFFAOYSA-N [CH2-][C+](=O)NC(C)(C)COC Chemical compound [CH2-][C+](=O)NC(C)(C)COC MKNLZPADMILVCT-UHFFFAOYSA-N 0.000 description 2
- MIDIQAIENPQGTC-UHFFFAOYSA-N [CH2-][C+](=O)NC(C)(CC)CC Chemical compound [CH2-][C+](=O)NC(C)(CC)CC MIDIQAIENPQGTC-UHFFFAOYSA-N 0.000 description 2
- VKAPBSDZEKFHMY-UHFFFAOYSA-N [CH2-][C+](=O)NC(C)C Chemical compound [CH2-][C+](=O)NC(C)C VKAPBSDZEKFHMY-UHFFFAOYSA-N 0.000 description 2
- HVYNDMNFSCLXDG-UHFFFAOYSA-N [CH2-][C+](=O)NC1=C(C)C=CC=C1C Chemical compound [CH2-][C+](=O)NC1=C(C)C=CC=C1C HVYNDMNFSCLXDG-UHFFFAOYSA-N 0.000 description 2
- DSPNLFNRBYSRQT-UHFFFAOYSA-N [CH2-][C+](=O)NC1=CC=CC=C1 Chemical compound [CH2-][C+](=O)NC1=CC=CC=C1 DSPNLFNRBYSRQT-UHFFFAOYSA-N 0.000 description 2
- XUAFDAMVCZLCEN-UHFFFAOYSA-N [CH2-][C+](=O)NC1=NC=CS1 Chemical compound [CH2-][C+](=O)NC1=NC=CS1 XUAFDAMVCZLCEN-UHFFFAOYSA-N 0.000 description 2
- KTAJXGBTGADIOG-UHFFFAOYSA-N [CH2-][C+](=O)NCC Chemical compound [CH2-][C+](=O)NCC KTAJXGBTGADIOG-UHFFFAOYSA-N 0.000 description 2
- KWKJPISTDOLECT-LURJTMIESA-N [CH2-][C+](=O)N[C@@H](C)C(C)(C)C Chemical compound [CH2-][C+](=O)N[C@@H](C)C(C)(C)C KWKJPISTDOLECT-LURJTMIESA-N 0.000 description 2
- DIUSAGHJDPKSGS-VKHMYHEASA-N [CH2-][C+](=O)N[C@@H](C)C(N)=O Chemical compound [CH2-][C+](=O)N[C@@H](C)C(N)=O DIUSAGHJDPKSGS-VKHMYHEASA-N 0.000 description 2
- DIUSAGHJDPKSGS-GSVOUGTGSA-N [CH2-][C+](=O)N[C@H](C)C(N)=O Chemical compound [CH2-][C+](=O)N[C@H](C)C(N)=O DIUSAGHJDPKSGS-GSVOUGTGSA-N 0.000 description 2
- QYPIYAXKOISRLE-MRVPVSSYSA-N [CH2-][C+](=O)N[C@H](CC)C(C)(C)C Chemical compound [CH2-][C+](=O)N[C@H](CC)C(C)(C)C QYPIYAXKOISRLE-MRVPVSSYSA-N 0.000 description 2
- LKVSNPAQYXXNPG-UHFFFAOYSA-N [CH2-][C+](=O)OC Chemical compound [CH2-][C+](=O)OC LKVSNPAQYXXNPG-UHFFFAOYSA-N 0.000 description 2
- HWCORLPDRGTNRJ-UHFFFAOYSA-N [CH2-][C+](=O)OC(C)(C)C(Cl)(Cl)Cl Chemical compound [CH2-][C+](=O)OC(C)(C)C(Cl)(Cl)Cl HWCORLPDRGTNRJ-UHFFFAOYSA-N 0.000 description 2
- UBBNYGMRBKZZJD-UHFFFAOYSA-N [CH2-][C+](=O)OC(C)C(C)(C)C Chemical compound [CH2-][C+](=O)OC(C)C(C)(C)C UBBNYGMRBKZZJD-UHFFFAOYSA-N 0.000 description 2
- HNSAAZVXMDIALY-UHFFFAOYSA-N [CH2-][C+](=O)OC1CCC1 Chemical compound [CH2-][C+](=O)OC1CCC1 HNSAAZVXMDIALY-UHFFFAOYSA-N 0.000 description 2
- FFCZMTXIEVBYRB-UHFFFAOYSA-N [CH2-][C+](=O)OC1CCCC1 Chemical compound [CH2-][C+](=O)OC1CCCC1 FFCZMTXIEVBYRB-UHFFFAOYSA-N 0.000 description 2
- CKIMDZZHAIBFEB-UHFFFAOYSA-N [CH2-][C+](=O)OC1CCCCC1 Chemical compound [CH2-][C+](=O)OC1CCCCC1 CKIMDZZHAIBFEB-UHFFFAOYSA-N 0.000 description 2
- QUNHVWPEXOFBPE-UHFFFAOYSA-N [CH2-][C+](=O)OC1CCSC1 Chemical compound [CH2-][C+](=O)OC1CCSC1 QUNHVWPEXOFBPE-UHFFFAOYSA-N 0.000 description 2
- WDBBSJFPLZGDOM-UHFFFAOYSA-N [CH2-][C+](=O)OCC(C)(C)N Chemical compound [CH2-][C+](=O)OCC(C)(C)N WDBBSJFPLZGDOM-UHFFFAOYSA-N 0.000 description 2
- JUGKHTDBMJIOBE-ZCFIWIBFSA-N [CH2-][C+](=O)O[C@@H]1CCOC1 Chemical compound [CH2-][C+](=O)O[C@@H]1CCOC1 JUGKHTDBMJIOBE-ZCFIWIBFSA-N 0.000 description 2
- JUGKHTDBMJIOBE-LURJTMIESA-N [CH2-][C+](=O)O[C@H]1CCOC1 Chemical compound [CH2-][C+](=O)O[C@H]1CCOC1 JUGKHTDBMJIOBE-LURJTMIESA-N 0.000 description 2
- DIQRZKGLSOQXQX-MRVPVSSYSA-N [CH2-][C+](=O)[C@@H](C)C1CCCCC1 Chemical compound [CH2-][C+](=O)[C@@H](C)C1CCCCC1 DIQRZKGLSOQXQX-MRVPVSSYSA-N 0.000 description 2
- GUXYMKOQGXZMFT-SNVBAGLBSA-N [CH2-][C+](=O)[C@@H](CC(=O)O)C1CCCCC1 Chemical compound [CH2-][C+](=O)[C@@H](CC(=O)O)C1CCCCC1 GUXYMKOQGXZMFT-SNVBAGLBSA-N 0.000 description 2
- ABLWDFSMZLQRIW-CQSZACIVSA-N [CH2-][C+](=O)[C@@H](CC(=O)OCC(C)(C)C)C1CCCCC1 Chemical compound [CH2-][C+](=O)[C@@H](CC(=O)OCC(C)(C)C)C1CCCCC1 ABLWDFSMZLQRIW-CQSZACIVSA-N 0.000 description 2
- CVXXOHLWQMCQSY-SECBINFHSA-N [CH2-][C+](=O)[C@@H](O)C1CCCCC1 Chemical compound [CH2-][C+](=O)[C@@H](O)C1CCCCC1 CVXXOHLWQMCQSY-SECBINFHSA-N 0.000 description 2
- KDJAGDSVPUVEPR-UHFFFAOYSA-N [CH2-][C+](=S)NC(C)(C)C Chemical compound [CH2-][C+](=S)NC(C)(C)C KDJAGDSVPUVEPR-UHFFFAOYSA-N 0.000 description 2
- ZKMLLYLIPDJHNN-UHFFFAOYSA-N [CH2-][C+](=S)NC1CCCCC1 Chemical compound [CH2-][C+](=S)NC1CCCCC1 ZKMLLYLIPDJHNN-UHFFFAOYSA-N 0.000 description 2
- LGFWDCNAIPKLGW-UHFFFAOYSA-N [CH2-][C+](C)(C)SCC1=CC=C(C)C=C1 Chemical compound [CH2-][C+](C)(C)SCC1=CC=C(C)C=C1 LGFWDCNAIPKLGW-UHFFFAOYSA-N 0.000 description 2
- VEJITHQOMKGYKO-UHFFFAOYSA-N [CH2-][C+](C)(C)SCNC(C)=O Chemical compound [CH2-][C+](C)(C)SCNC(C)=O VEJITHQOMKGYKO-UHFFFAOYSA-N 0.000 description 2
- ANFFVMLGTUEBLS-UHFFFAOYSA-N [CH2-][C+]1=CC(F)=CC(F)=C1 Chemical compound [CH2-][C+]1=CC(F)=CC(F)=C1 ANFFVMLGTUEBLS-UHFFFAOYSA-N 0.000 description 2
- AKCCAWDRWBDHHM-UHFFFAOYSA-N [CH2-][C+]1=CC(OC)=CC=C1 Chemical compound [CH2-][C+]1=CC(OC)=CC=C1 AKCCAWDRWBDHHM-UHFFFAOYSA-N 0.000 description 2
- LSQKUIVOSBEUAZ-UHFFFAOYSA-N [CH2-][C+]1=CC2=CC=CC=C2C=C1 Chemical compound [CH2-][C+]1=CC2=CC=CC=C2C=C1 LSQKUIVOSBEUAZ-UHFFFAOYSA-N 0.000 description 2
- IBZBLRLLZYHHMD-UHFFFAOYSA-N [CH2-][C+]1=CC=C(C(=O)O)C=C1 Chemical compound [CH2-][C+]1=CC=C(C(=O)O)C=C1 IBZBLRLLZYHHMD-UHFFFAOYSA-N 0.000 description 2
- OQSJWQNOMXRCEL-UHFFFAOYSA-N [CH2-][C+]1=CC=C(C(=O)OC)C=C1 Chemical compound [CH2-][C+]1=CC=C(C(=O)OC)C=C1 OQSJWQNOMXRCEL-UHFFFAOYSA-N 0.000 description 2
- GAFBGRBPYCNUCH-UHFFFAOYSA-N [CH2-][C+]1=CC=C(C)C=C1 Chemical compound [CH2-][C+]1=CC=C(C)C=C1 GAFBGRBPYCNUCH-UHFFFAOYSA-N 0.000 description 2
- CIEWGZJDEDBECJ-UHFFFAOYSA-N [CH2-][C+]1=CC=C(Cl)C=C1 Chemical compound [CH2-][C+]1=CC=C(Cl)C=C1 CIEWGZJDEDBECJ-UHFFFAOYSA-N 0.000 description 2
- GVVVXNGTIKFYKV-UHFFFAOYSA-N [CH2-][C+]1=CC=C(F)C=C1 Chemical compound [CH2-][C+]1=CC=C(F)C=C1 GVVVXNGTIKFYKV-UHFFFAOYSA-N 0.000 description 2
- JGXXFKPAJJKWPL-UHFFFAOYSA-N [CH2-][C+]1=CC=C(N)C(C)=C1 Chemical compound [CH2-][C+]1=CC=C(N)C(C)=C1 JGXXFKPAJJKWPL-UHFFFAOYSA-N 0.000 description 2
- KADPIVGMOCAWSG-UHFFFAOYSA-N [CH2-][C+]1=CC=C(NC(C)=O)C=C1 Chemical compound [CH2-][C+]1=CC=C(NC(C)=O)C=C1 KADPIVGMOCAWSG-UHFFFAOYSA-N 0.000 description 2
- HWKHXAYAXZWMHT-UHFFFAOYSA-N [CH2-][C+]1=CC=C([N+](=O)[O-])C(C)=C1 Chemical compound [CH2-][C+]1=CC=C([N+](=O)[O-])C(C)=C1 HWKHXAYAXZWMHT-UHFFFAOYSA-N 0.000 description 2
- CCWYHRCNIUKIIZ-UHFFFAOYSA-N [CH2-][C+]1=CC=C([N+](=O)[O-])C=C1 Chemical compound [CH2-][C+]1=CC=C([N+](=O)[O-])C=C1 CCWYHRCNIUKIIZ-UHFFFAOYSA-N 0.000 description 2
- DUGROVOUJWLFOK-UHFFFAOYSA-N [CH2-][C+]1=CC=C2OCOC2=C1 Chemical compound [CH2-][C+]1=CC=C2OCOC2=C1 DUGROVOUJWLFOK-UHFFFAOYSA-N 0.000 description 2
- PJEUBMBXJOGWGY-UHFFFAOYSA-N [CH2-][C+]1=CC=CC(C(C)=O)=C1 Chemical compound [CH2-][C+]1=CC=CC(C(C)=O)=C1 PJEUBMBXJOGWGY-UHFFFAOYSA-N 0.000 description 2
- KREXNKWREGWTRU-UHFFFAOYSA-N [CH2-][C+]1=CC=CC(C2=CC=CC=C2)=C1 Chemical compound [CH2-][C+]1=CC=CC(C2=CC=CC=C2)=C1 KREXNKWREGWTRU-UHFFFAOYSA-N 0.000 description 2
- ZXFHTINNANFWLE-UHFFFAOYSA-N [CH2-][C+]1=CC=CC(CCO)=C1 Chemical compound [CH2-][C+]1=CC=CC(CCO)=C1 ZXFHTINNANFWLE-UHFFFAOYSA-N 0.000 description 2
- MKJBQHJGQWVMDH-UHFFFAOYSA-N [CH2-][C+]1=CC=CC(CO)=C1 Chemical compound [CH2-][C+]1=CC=CC(CO)=C1 MKJBQHJGQWVMDH-UHFFFAOYSA-N 0.000 description 2
- YDRHZWVHFFESJL-UHFFFAOYSA-N [CH2-][C+]1=CC=CC(OC2=CC=C(F)C=C2)=C1 Chemical compound [CH2-][C+]1=CC=CC(OC2=CC=C(F)C=C2)=C1 YDRHZWVHFFESJL-UHFFFAOYSA-N 0.000 description 2
- SLRMQYXOBQWXCR-UHFFFAOYSA-N [CH2-][C+]1=CC=CC=C1 Chemical compound [CH2-][C+]1=CC=CC=C1 SLRMQYXOBQWXCR-UHFFFAOYSA-N 0.000 description 2
- LIPCSBJESCFISK-UHFFFAOYSA-N [CH2-][C+]1=CC=CC=C1P Chemical compound [CH2-][C+]1=CC=CC=C1P LIPCSBJESCFISK-UHFFFAOYSA-N 0.000 description 2
- RSAIIBFKUJGUQI-UHFFFAOYSA-N [CH2-][C+]1=CC=CC=N1 Chemical compound [CH2-][C+]1=CC=CC=N1 RSAIIBFKUJGUQI-UHFFFAOYSA-N 0.000 description 2
- DBRGTCOFUAGYMF-UHFFFAOYSA-N [CH2-][C+]1=CC=CS1 Chemical compound [CH2-][C+]1=CC=CS1 DBRGTCOFUAGYMF-UHFFFAOYSA-N 0.000 description 2
- BEDSUAQIGTWQBN-UHFFFAOYSA-N [CH2-][C+]1=CC=NC=N1 Chemical compound [CH2-][C+]1=CC=NC=N1 BEDSUAQIGTWQBN-UHFFFAOYSA-N 0.000 description 2
- GUDAWXFNSIJOKG-UHFFFAOYSA-N [CH2-][C+]1=CN(C)N=C1 Chemical compound [CH2-][C+]1=CN(C)N=C1 GUDAWXFNSIJOKG-UHFFFAOYSA-N 0.000 description 2
- ZWWHMUOLRVRJLB-UHFFFAOYSA-N [CH2-][C+]1=CN=CC=N1 Chemical compound [CH2-][C+]1=CN=CC=N1 ZWWHMUOLRVRJLB-UHFFFAOYSA-N 0.000 description 2
- AEKQEJVVVKIVFA-UHFFFAOYSA-N [CH2-][C+]1=CSC(C2=CSC(C)=N2)=N1 Chemical compound [CH2-][C+]1=CSC(C2=CSC(C)=N2)=N1 AEKQEJVVVKIVFA-UHFFFAOYSA-N 0.000 description 2
- QAFNTAUSEDIZDF-UHFFFAOYSA-N [CH2-][C+]1=CSC(CC)=N1 Chemical compound [CH2-][C+]1=CSC(CC)=N1 QAFNTAUSEDIZDF-UHFFFAOYSA-N 0.000 description 2
- NSYSDMVYEQASDN-UHFFFAOYSA-N [CH2-][C+]1=CSC(CS(C)(=O)=O)=N1 Chemical compound [CH2-][C+]1=CSC(CS(C)(=O)=O)=N1 NSYSDMVYEQASDN-UHFFFAOYSA-N 0.000 description 2
- QNGRBCBHZMQFPC-UHFFFAOYSA-N [CH2-][C+]1=CSC(NC(C)(C)C)=N1 Chemical compound [CH2-][C+]1=CSC(NC(C)(C)C)=N1 QNGRBCBHZMQFPC-UHFFFAOYSA-N 0.000 description 2
- YFCKRKOXICSFSW-UHFFFAOYSA-N [CH2-][C+]1=CSC(NC)=N1 Chemical compound [CH2-][C+]1=CSC(NC)=N1 YFCKRKOXICSFSW-UHFFFAOYSA-N 0.000 description 2
- CDEAGSIUQGMHSD-UHFFFAOYSA-N [CH2-][C+]1=CSC(NCC)=N1 Chemical compound [CH2-][C+]1=CSC(NCC)=N1 CDEAGSIUQGMHSD-UHFFFAOYSA-N 0.000 description 2
- YRIFKGMFZURQJI-UHFFFAOYSA-N [CH2-][C+]1=CSC=N1 Chemical compound [CH2-][C+]1=CSC=N1 YRIFKGMFZURQJI-UHFFFAOYSA-N 0.000 description 2
- MHSWJEJRKKLALS-UHFFFAOYSA-N [CH2-][C+]1=NC(CC)=CS1 Chemical compound [CH2-][C+]1=NC(CC)=CS1 MHSWJEJRKKLALS-UHFFFAOYSA-N 0.000 description 2
- ARSLMHWBXROFQN-UHFFFAOYSA-N [CH2-][C+]1=NC=CS1 Chemical compound [CH2-][C+]1=NC=CS1 ARSLMHWBXROFQN-UHFFFAOYSA-N 0.000 description 2
- YULMNMJFAZWLLN-UHFFFAOYSA-N [CH2-][C+]1CCCCC1 Chemical compound [CH2-][C+]1CCCCC1 YULMNMJFAZWLLN-UHFFFAOYSA-N 0.000 description 2
- PKXHXOTZMFCXSH-UHFFFAOYSA-N [CH2-][CH+]C(C)(C)C Chemical compound [CH2-][CH+]C(C)(C)C PKXHXOTZMFCXSH-UHFFFAOYSA-N 0.000 description 2
- YHQXBTXEYZIYOV-UHFFFAOYSA-N [CH2-][CH+]C(C)C Chemical compound [CH2-][CH+]C(C)C YHQXBTXEYZIYOV-UHFFFAOYSA-N 0.000 description 2
- PPBRXRYQALVLMV-UHFFFAOYSA-N [CH2-][CH+]C1=CC=CC=C1 Chemical compound [CH2-][CH+]C1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 2
- NINOYJQVULROET-UHFFFAOYSA-N [CH2-][CH+]N(C)C Chemical compound [CH2-][CH+]N(C)C NINOYJQVULROET-UHFFFAOYSA-N 0.000 description 2
- RNFYPKLPQMWIKW-UHFFFAOYSA-N [CH2-][CH+]N(C)C1=CC=CC=C1 Chemical compound [CH2-][CH+]N(C)C1=CC=CC=C1 RNFYPKLPQMWIKW-UHFFFAOYSA-N 0.000 description 2
- UDJZTGMLYITLIQ-UHFFFAOYSA-N [CH2-][CH+]N1CCCC1 Chemical compound [CH2-][CH+]N1CCCC1 UDJZTGMLYITLIQ-UHFFFAOYSA-N 0.000 description 2
- CFZDMXAOSDDDRT-UHFFFAOYSA-N [CH2-][CH+]N1CCOCC1 Chemical compound [CH2-][CH+]N1CCOCC1 CFZDMXAOSDDDRT-UHFFFAOYSA-N 0.000 description 2
- FQJDTNLDQMTOLH-UHFFFAOYSA-N [CH2-][NH+]1CCC(C)CC1 Chemical compound [CH2-][NH+]1CCC(C)CC1 FQJDTNLDQMTOLH-UHFFFAOYSA-N 0.000 description 2
- PYGGIDIWQDATGK-UHFFFAOYSA-N [CH2-][NH+]1CCC(OC)CC1 Chemical compound [CH2-][NH+]1CCC(OC)CC1 PYGGIDIWQDATGK-UHFFFAOYSA-N 0.000 description 2
- PYBCOUSGJHDMGO-UHFFFAOYSA-N [CH2-][NH+]1CCC2=C1C=CC=C2 Chemical compound [CH2-][NH+]1CCC2=C1C=CC=C2 PYBCOUSGJHDMGO-UHFFFAOYSA-N 0.000 description 2
- MSDABKPAQWNDEZ-UHFFFAOYSA-N [CH2-][NH+]1CCCC1 Chemical compound [CH2-][NH+]1CCCC1 MSDABKPAQWNDEZ-UHFFFAOYSA-N 0.000 description 2
- MXNZXOVBZINAHQ-UHFFFAOYSA-N [CH2-][NH+]1CCCCC1 Chemical compound [CH2-][NH+]1CCCCC1 MXNZXOVBZINAHQ-UHFFFAOYSA-N 0.000 description 2
- CWTUFCBXALKBPR-UHFFFAOYSA-N [CH2-][NH+]1CCN(C)CC1 Chemical compound [CH2-][NH+]1CCN(C)CC1 CWTUFCBXALKBPR-UHFFFAOYSA-N 0.000 description 2
- JGIHYKRGTGLLOK-UHFFFAOYSA-N [CH2-][OH+]C(C)C Chemical compound [CH2-][OH+]C(C)C JGIHYKRGTGLLOK-UHFFFAOYSA-N 0.000 description 2
- ZOUBQVBRSQXMNV-UHFFFAOYSA-N [CH2-][OH+]C1=C2CCN(C(C)=O)CC2=CC=C1 Chemical compound [CH2-][OH+]C1=C2CCN(C(C)=O)CC2=CC=C1 ZOUBQVBRSQXMNV-UHFFFAOYSA-N 0.000 description 2
- LGKIENFOIFBZAI-UHFFFAOYSA-N [CH2-][OH+]C1=CC(C)=NC2=C1C=CC=C2C(F)(F)F Chemical compound [CH2-][OH+]C1=CC(C)=NC2=C1C=CC=C2C(F)(F)F LGKIENFOIFBZAI-UHFFFAOYSA-N 0.000 description 2
- RSKMXSWIOPSYPK-UHFFFAOYSA-N [CH2-][OH+]C1=CC(C2=CC=CC=C2)=NC2=C1C=C(N)C=C2 Chemical compound [CH2-][OH+]C1=CC(C2=CC=CC=C2)=NC2=C1C=C(N)C=C2 RSKMXSWIOPSYPK-UHFFFAOYSA-N 0.000 description 2
- FACYJGAWHFRMBL-UHFFFAOYSA-N [CH2-][OH+]C1=CC(C2=CC=CC=C2)=NC2=C1C=C(NC(C)=O)C=C2 Chemical compound [CH2-][OH+]C1=CC(C2=CC=CC=C2)=NC2=C1C=C(NC(C)=O)C=C2 FACYJGAWHFRMBL-UHFFFAOYSA-N 0.000 description 2
- QEDWINLSJYVWQV-UHFFFAOYSA-N [CH2-][OH+]C1=CC(C2=CSC(NC(C)=O)=N2)=NC2=C1C=CC(OC)=C2 Chemical compound [CH2-][OH+]C1=CC(C2=CSC(NC(C)=O)=N2)=NC2=C1C=CC(OC)=C2 QEDWINLSJYVWQV-UHFFFAOYSA-N 0.000 description 2
- SKMXIHUWQHHBGD-UHFFFAOYSA-N [CH2-][OH+]C1=CC(C2=CSC(NCC)=N2)=NC2=C1C=CC(OC)=C2 Chemical compound [CH2-][OH+]C1=CC(C2=CSC(NCC)=N2)=NC2=C1C=CC(OC)=C2 SKMXIHUWQHHBGD-UHFFFAOYSA-N 0.000 description 2
- MXSFHQLXYRLXQA-UHFFFAOYSA-N [CH2-][OH+]C1=CC(C2=NC=CC=C2)=NC(C2=NC=CC=C2)=C1 Chemical compound [CH2-][OH+]C1=CC(C2=NC=CC=C2)=NC(C2=NC=CC=C2)=C1 MXSFHQLXYRLXQA-UHFFFAOYSA-N 0.000 description 2
- LNLFDQCMCHMWFI-UHFFFAOYSA-N [CH2-][OH+]C1=CC=NC2=C1C=CC(OC)=C2 Chemical compound [CH2-][OH+]C1=CC=NC2=C1C=CC(OC)=C2 LNLFDQCMCHMWFI-UHFFFAOYSA-N 0.000 description 2
- CEFIOLCRHLOJPN-UHFFFAOYSA-N [CH2-][OH+]C1=NC(N2C=CN=C2)=NC2=C1C=C(OC)C(OC)=C2 Chemical compound [CH2-][OH+]C1=NC(N2C=CN=C2)=NC2=C1C=C(OC)C(OC)=C2 CEFIOLCRHLOJPN-UHFFFAOYSA-N 0.000 description 2
- JAFBIADTTVYQIF-UHFFFAOYSA-N [CH2-][OH+]C1=NC(N2CCOCC2)=NC2=C1C=C(OC)C(OC)=C2 Chemical compound [CH2-][OH+]C1=NC(N2CCOCC2)=NC2=C1C=C(OC)C(OC)=C2 JAFBIADTTVYQIF-UHFFFAOYSA-N 0.000 description 2
- LJVPLKGRDLJMCI-UHFFFAOYSA-N [CH2-][OH+]C1=NC2=C(C=CC=C2)C(Cl)=C1 Chemical compound [CH2-][OH+]C1=NC2=C(C=CC=C2)C(Cl)=C1 LJVPLKGRDLJMCI-UHFFFAOYSA-N 0.000 description 2
- SOJSREOOEIUOHS-UHFFFAOYSA-N [CH2-][OH+]CC(C)C Chemical compound [CH2-][OH+]CC(C)C SOJSREOOEIUOHS-UHFFFAOYSA-N 0.000 description 2
- TXBOOWNRLJFAKY-UHFFFAOYSA-N [CH2-][OH+]CCC Chemical compound [CH2-][OH+]CCC TXBOOWNRLJFAKY-UHFFFAOYSA-N 0.000 description 2
- RYTQUBJXEJIMPV-UHFFFAOYSA-N [CH2-][OH+]c1cc(C)nc2ccccc12 Chemical compound [CH2-][OH+]c1cc(C)nc2ccccc12 RYTQUBJXEJIMPV-UHFFFAOYSA-N 0.000 description 2
- BWQGJTDURTXHNR-UHFFFAOYSA-N [CH2-][OH+]c1ccc2ccccc2c1 Chemical compound [CH2-][OH+]c1ccc2ccccc2c1 BWQGJTDURTXHNR-UHFFFAOYSA-N 0.000 description 2
- BROWUQGUHBCYFJ-UHFFFAOYSA-N [CH2-][OH+]c1cccc2ccccc12 Chemical compound [CH2-][OH+]c1cccc2ccccc12 BROWUQGUHBCYFJ-UHFFFAOYSA-N 0.000 description 2
- KKPUBKDRQIHSSY-UHFFFAOYSA-N [CH2-][OH+]c1cccc2cnccc12 Chemical compound [CH2-][OH+]c1cccc2cnccc12 KKPUBKDRQIHSSY-UHFFFAOYSA-N 0.000 description 2
- PNZWLZXQMIINCV-UHFFFAOYSA-N [CH2-][OH+]c1cccc2ncccc12 Chemical compound [CH2-][OH+]c1cccc2ncccc12 PNZWLZXQMIINCV-UHFFFAOYSA-N 0.000 description 2
- IQPQDLLMLHCSDV-UHFFFAOYSA-N [CH2-][OH+]c1ccnc2ccccc12 Chemical compound [CH2-][OH+]c1ccnc2ccccc12 IQPQDLLMLHCSDV-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 150000001370 alpha-amino acid derivatives Chemical class 0.000 description 2
- 150000001371 alpha-amino acids Chemical class 0.000 description 2
- 108010027597 alpha-chymotrypsin Proteins 0.000 description 2
- 150000003862 amino acid derivatives Chemical class 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 150000001540 azides Chemical class 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
- HTZCNXWZYVXIMZ-UHFFFAOYSA-M benzyl(triethyl)azanium;chloride Chemical compound [Cl-].CC[N+](CC)(CC)CC1=CC=CC=C1 HTZCNXWZYVXIMZ-UHFFFAOYSA-M 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- PMMYEEVYMWASQN-IMJSIDKUSA-N cis-4-Hydroxy-L-proline Chemical class O[C@@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-IMJSIDKUSA-N 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- LJOODBDWMQKMFB-UHFFFAOYSA-N cyclohexylacetic acid Chemical compound OC(=O)CC1CCCCC1 LJOODBDWMQKMFB-UHFFFAOYSA-N 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- XXTZHYXQVWRADW-UHFFFAOYSA-N diazomethanone Chemical compound [N]N=C=O XXTZHYXQVWRADW-UHFFFAOYSA-N 0.000 description 2
- VHILMKFSCRWWIJ-UHFFFAOYSA-N dimethyl acetylenedicarboxylate Chemical compound COC(=O)C#CC(=O)OC VHILMKFSCRWWIJ-UHFFFAOYSA-N 0.000 description 2
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 2
- 238000006073 displacement reaction Methods 0.000 description 2
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 2
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
- 239000000833 heterodimer Substances 0.000 description 2
- 239000012456 homogeneous solution Substances 0.000 description 2
- 150000003840 hydrochlorides Chemical class 0.000 description 2
- 229960002591 hydroxyproline Drugs 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229940047124 interferons Drugs 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 229960003136 leucine Drugs 0.000 description 2
- 239000007791 liquid phase Substances 0.000 description 2
- 239000012280 lithium aluminium hydride Substances 0.000 description 2
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 2
- LZWQNOHZMQIFBX-UHFFFAOYSA-N lithium;2-methylpropan-2-olate Chemical compound [Li+].CC(C)(C)[O-] LZWQNOHZMQIFBX-UHFFFAOYSA-N 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 229910052987 metal hydride Inorganic materials 0.000 description 2
- 150000004681 metal hydrides Chemical class 0.000 description 2
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 2
- GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical compound [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 description 2
- 230000000269 nucleophilic effect Effects 0.000 description 2
- VMPITZXILSNTON-UHFFFAOYSA-N o-anisidine Chemical compound COC1=CC=CC=C1N VMPITZXILSNTON-UHFFFAOYSA-N 0.000 description 2
- IWDCLRJOBJJRNH-UHFFFAOYSA-N p-cresol Chemical compound CC1=CC=C(O)C=C1 IWDCLRJOBJJRNH-UHFFFAOYSA-N 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- 229920000137 polyphosphoric acid Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000011533 pre-incubation Methods 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- VVWRJUBEIPHGQF-MDZDMXLPSA-N propan-2-yl (ne)-n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)\N=N\C(=O)OC(C)C VVWRJUBEIPHGQF-MDZDMXLPSA-N 0.000 description 2
- QRDZFPUVLYEQTA-UHFFFAOYSA-N quinoline-8-carboxylic acid Chemical compound C1=CN=C2C(C(=O)O)=CC=CC2=C1 QRDZFPUVLYEQTA-UHFFFAOYSA-N 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000009097 single-agent therapy Methods 0.000 description 2
- WRIKHQLVHPKCJU-UHFFFAOYSA-N sodium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([Na])[Si](C)(C)C WRIKHQLVHPKCJU-UHFFFAOYSA-N 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 239000012312 sodium hydride Substances 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229940014800 succinic anhydride Drugs 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- 150000003512 tertiary amines Chemical class 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 2
- 229960002898 threonine Drugs 0.000 description 2
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 2
- 238000005809 transesterification reaction Methods 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 230000029812 viral genome replication Effects 0.000 description 2
- 239000003039 volatile agent Substances 0.000 description 2
- LAJAFFLJAJMYLK-CVOKMOJFSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[[(7s)-4-methoxy-7-morpholin-4-yl-6,7,8,9-tetrahydro-5h-benzo[7]annulen-3-yl]amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound N1([C@H]2CCC3=CC=C(C(=C3CC2)OC)NC=2N=C(C(=CN=2)Cl)N[C@H]2[C@H]([C@@]3([H])C[C@@]2(C=C3)[H])C(N)=O)CCOCC1 LAJAFFLJAJMYLK-CVOKMOJFSA-N 0.000 description 1
- TXTWXQXDMWILOF-UHFFFAOYSA-N (2-ethoxy-2-oxoethyl)azanium;chloride Chemical compound [Cl-].CCOC(=O)C[NH3+] TXTWXQXDMWILOF-UHFFFAOYSA-N 0.000 description 1
- OCQAXYHNMWVLRH-QZTJIDSGSA-N (2r,3r)-2,3-dibenzoyl-2,3-dihydroxybutanedioic acid Chemical class O=C([C@@](O)(C(=O)O)[C@](O)(C(O)=O)C(=O)C=1C=CC=CC=1)C1=CC=CC=C1 OCQAXYHNMWVLRH-QZTJIDSGSA-N 0.000 description 1
- YONLFQNRGZXBBF-ZIAGYGMSSA-N (2r,3r)-2,3-dibenzoyloxybutanedioic acid Chemical compound O([C@@H](C(=O)O)[C@@H](OC(=O)C=1C=CC=CC=1)C(O)=O)C(=O)C1=CC=CC=C1 YONLFQNRGZXBBF-ZIAGYGMSSA-N 0.000 description 1
- MJLQPFJGZTYCMH-LURJTMIESA-N (2s)-1-[(2-methylpropan-2-yl)oxycarbonyl]-5-oxopyrrolidine-2-carboxylic acid Chemical compound CC(C)(C)OC(=O)N1[C@H](C(O)=O)CCC1=O MJLQPFJGZTYCMH-LURJTMIESA-N 0.000 description 1
- FEFCYNYYEURJOF-GGAORHGYSA-N (2s)-1-[(3r)-3-amino-4-phenylbutanoyl]-n-[[5-chloro-2-[2-(cyclopropylamino)-2-oxoethoxy]phenyl]methyl]pyrrolidine-2-carboxamide Chemical compound O=C([C@@H]1CCCN1C(=O)C[C@H](N)CC=1C=CC=CC=1)NCC1=CC(Cl)=CC=C1OCC(=O)NC1CC1 FEFCYNYYEURJOF-GGAORHGYSA-N 0.000 description 1
- WAMWSIDTKSNDCU-ZETCQYMHSA-N (2s)-2-azaniumyl-2-cyclohexylacetate Chemical compound OC(=O)[C@@H](N)C1CCCCC1 WAMWSIDTKSNDCU-ZETCQYMHSA-N 0.000 description 1
- JXDNUMOTWHZSCB-XMTZKCFKSA-N (3s)-3-acetamido-4-[[(2s)-3-carboxy-1-[[(2s,3s)-1-[[(2s)-1-[(2s)-2-[[(1r)-1-carboxy-2-sulfanylethyl]carbamoyl]pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-oxobutanoic acid Chemical compound OC(=O)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CS)C(O)=O JXDNUMOTWHZSCB-XMTZKCFKSA-N 0.000 description 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 description 1
- LJVHJHLTRBXGMH-HNQUOIGGSA-N (e)-1,4-dibromobut-1-ene Chemical compound BrCC\C=C\Br LJVHJHLTRBXGMH-HNQUOIGGSA-N 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- LRANPJDWHYRCER-UHFFFAOYSA-N 1,2-diazepine Chemical compound N1C=CC=CC=N1 LRANPJDWHYRCER-UHFFFAOYSA-N 0.000 description 1
- CZWSZZHGSNZRMW-UHFFFAOYSA-N 1,2-dibromobutane Chemical compound CCC(Br)CBr CZWSZZHGSNZRMW-UHFFFAOYSA-N 0.000 description 1
- BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 1
- RAIPHJJURHTUIC-UHFFFAOYSA-N 1,3-thiazol-2-amine Chemical group NC1=NC=CS1 RAIPHJJURHTUIC-UHFFFAOYSA-N 0.000 description 1
- OGYGFUAIIOPWQD-UHFFFAOYSA-N 1,3-thiazolidine Chemical compound C1CSCN1 OGYGFUAIIOPWQD-UHFFFAOYSA-N 0.000 description 1
- ZFNNBIMQDHBELV-UHFFFAOYSA-N 1-[4-amino-2,6-di(propan-2-yl)phenyl]-3-[1-butyl-4-[3-(3-cyclohexylpropoxy)phenyl]-2-oxo-1,8-naphthyridin-3-yl]urea;dihydrochloride Chemical compound Cl.Cl.CC(C)C=1C=C(N)C=C(C(C)C)C=1NC(=O)NC=1C(=O)N(CCCC)C2=NC=CC=C2C=1C(C=1)=CC=CC=1OCCCC1CCCCC1 ZFNNBIMQDHBELV-UHFFFAOYSA-N 0.000 description 1
- RMSGQZDGSZOJMU-UHFFFAOYSA-N 1-butyl-2-phenylbenzene Chemical group CCCCC1=CC=CC=C1C1=CC=CC=C1 RMSGQZDGSZOJMU-UHFFFAOYSA-N 0.000 description 1
- HLDFCCHSOZWKAA-UHFFFAOYSA-N 1-fluoro-2-nitro-4-(trifluoromethyl)benzene Chemical compound [O-][N+](=O)C1=CC(C(F)(F)F)=CC=C1F HLDFCCHSOZWKAA-UHFFFAOYSA-N 0.000 description 1
- PJUPKRYGDFTMTM-UHFFFAOYSA-N 1-hydroxybenzotriazole;hydrate Chemical compound O.C1=CC=C2N(O)N=NC2=C1 PJUPKRYGDFTMTM-UHFFFAOYSA-N 0.000 description 1
- MEKOFIRRDATTAG-UHFFFAOYSA-N 2,2,5,8-tetramethyl-3,4-dihydrochromen-6-ol Chemical compound C1CC(C)(C)OC2=C1C(C)=C(O)C=C2C MEKOFIRRDATTAG-UHFFFAOYSA-N 0.000 description 1
- SXGZJKUKBWWHRA-UHFFFAOYSA-N 2-(N-morpholiniumyl)ethanesulfonate Chemical compound [O-]S(=O)(=O)CC[NH+]1CCOCC1 SXGZJKUKBWWHRA-UHFFFAOYSA-N 0.000 description 1
- CJLZUKCACMUYFP-GOSISDBHSA-N 2-[(5R)-4-[2-[3-(3-methylbutanoyloxy)phenyl]acetyl]-8-(trifluoromethyl)-1,2,3,5-tetrahydropyrido[2,3-e][1,4]diazepin-5-yl]acetic acid Chemical compound CC(C)CC(=O)OC1=CC=CC(CC(=O)N2[C@@H](C3=CC=C(N=C3NCC2)C(F)(F)F)CC(O)=O)=C1 CJLZUKCACMUYFP-GOSISDBHSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- PWKSKIMOESPYIA-UHFFFAOYSA-N 2-acetamido-3-sulfanylpropanoic acid Chemical compound CC(=O)NC(CS)C(O)=O PWKSKIMOESPYIA-UHFFFAOYSA-N 0.000 description 1
- WTTYETIBBBWBMV-UHFFFAOYSA-N 2-amino-2-cyclohexylacetic acid;2-(cyclohexylamino)acetic acid Chemical compound OC(=O)C(N)C1CCCCC1.OC(=O)CNC1CCCCC1 WTTYETIBBBWBMV-UHFFFAOYSA-N 0.000 description 1
- QDGAVODICPCDMU-UHFFFAOYSA-N 2-amino-3-[3-[bis(2-chloroethyl)amino]phenyl]propanoic acid Chemical compound OC(=O)C(N)CC1=CC=CC(N(CCCl)CCCl)=C1 QDGAVODICPCDMU-UHFFFAOYSA-N 0.000 description 1
- OFUFXTHGZWIDDB-UHFFFAOYSA-N 2-chloroquinoline Chemical compound C1=CC=CC2=NC(Cl)=CC=C21 OFUFXTHGZWIDDB-UHFFFAOYSA-N 0.000 description 1
- YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 description 1
- XWKFPIODWVPXLX-UHFFFAOYSA-N 2-methyl-5-methylpyridine Natural products CC1=CC=C(C)N=C1 XWKFPIODWVPXLX-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- LRFZIPCTFBPFLX-UHFFFAOYSA-N 3,3-dimethyl-2-[(2-methylpropan-2-yl)oxycarbonylamino]butanoic acid Chemical compound CC(C)(C)OC(=O)NC(C(O)=O)C(C)(C)C LRFZIPCTFBPFLX-UHFFFAOYSA-N 0.000 description 1
- DXSUORGKJZADET-UHFFFAOYSA-N 3,3-dimethylbutan-2-amine Chemical compound CC(N)C(C)(C)C DXSUORGKJZADET-UHFFFAOYSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- PBVAJRFEEOIAGW-UHFFFAOYSA-N 3-[bis(2-carboxyethyl)phosphanyl]propanoic acid;hydrochloride Chemical compound Cl.OC(=O)CCP(CCC(O)=O)CCC(O)=O PBVAJRFEEOIAGW-UHFFFAOYSA-N 0.000 description 1
- 125000004080 3-carboxypropanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C(O[H])=O 0.000 description 1
- WQZHTTDOYXSSAF-UHFFFAOYSA-N 3-chloro-7-methoxy-2-phenylquinoline Chemical compound N=1C2=CC(OC)=CC=C2C=C(Cl)C=1C1=CC=CC=C1 WQZHTTDOYXSSAF-UHFFFAOYSA-N 0.000 description 1
- MCSXGCZMEPXKIW-UHFFFAOYSA-N 3-hydroxy-4-[(4-methyl-2-nitrophenyl)diazenyl]-N-(3-nitrophenyl)naphthalene-2-carboxamide Chemical compound Cc1ccc(N=Nc2c(O)c(cc3ccccc23)C(=O)Nc2cccc(c2)[N+]([O-])=O)c(c1)[N+]([O-])=O MCSXGCZMEPXKIW-UHFFFAOYSA-N 0.000 description 1
- XWQVQSXLXAXOPJ-QNGMFEMESA-N 4-[[[6-[5-chloro-2-[[4-[[(2r)-1-methoxypropan-2-yl]amino]cyclohexyl]amino]pyridin-4-yl]pyridin-2-yl]amino]methyl]oxane-4-carbonitrile Chemical compound C1CC(N[C@H](C)COC)CCC1NC1=CC(C=2N=C(NCC3(CCOCC3)C#N)C=CC=2)=C(Cl)C=N1 XWQVQSXLXAXOPJ-QNGMFEMESA-N 0.000 description 1
- CWARULQNYJKOMP-UHFFFAOYSA-N 4-o-tert-butyl 1-o-methyl 2-aminobutanedioate Chemical compound COC(=O)C(N)CC(=O)OC(C)(C)C CWARULQNYJKOMP-UHFFFAOYSA-N 0.000 description 1
- KFCTXLVNHOGMHX-UHFFFAOYSA-N 6-nitro-2-phenyl-1h-quinolin-4-one Chemical compound C=1C(=O)C2=CC([N+](=O)[O-])=CC=C2NC=1C1=CC=CC=C1 KFCTXLVNHOGMHX-UHFFFAOYSA-N 0.000 description 1
- XMFXTXKSWIDMER-UHFFFAOYSA-N 7-chloro-1h-quinolin-4-one Chemical compound ClC1=CC=C2C(O)=CC=NC2=C1 XMFXTXKSWIDMER-UHFFFAOYSA-N 0.000 description 1
- YYVYAPXYZVYDHN-UHFFFAOYSA-N 9,10-phenanthroquinone Chemical compound C1=CC=C2C(=O)C(=O)C3=CC=CC=C3C2=C1 YYVYAPXYZVYDHN-UHFFFAOYSA-N 0.000 description 1
- NLTWMGGMQPDARN-UHFFFAOYSA-N 9h-fluoren-9-ylmethyl n-cyclopropylcarbamate Chemical compound C12=CC=CC=C2C2=CC=CC=C2C1COC(=O)NC1CC1 NLTWMGGMQPDARN-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 244000186140 Asperula odorata Species 0.000 description 1
- VZHVNFARNZUJIQ-UHFFFAOYSA-N B.C#NC1(C(=O)OCC)CCC1.C#NCC(=O)OCC.CCCCC.[H]OC(=O)C1(N)CCC1 Chemical compound B.C#NC1(C(=O)OCC)CCC1.C#NCC(=O)OCC.CCCCC.[H]OC(=O)C1(N)CCC1 VZHVNFARNZUJIQ-UHFFFAOYSA-N 0.000 description 1
- WWYUOQINQHSUTA-UHFFFAOYSA-N BCCP.CC.CCC.CCCC.CCCCC.CP(P)P.CPP.P Chemical compound BCCP.CC.CCC.CCCC.CCCCC.CP(P)P.CPP.P WWYUOQINQHSUTA-UHFFFAOYSA-N 0.000 description 1
- BSXPFJFYQOGVTB-SDUDGNSGSA-N BNC(C(=O)N1C[C@H](OC2=C3/C=CC(OC)=C/C3=N/C(C3=CC=CC=C3)=C\2)C[C@H]1C(=O)N[C@]1(C(=O)O)C[C@@H]1C=C)C(C)(C)C Chemical compound BNC(C(=O)N1C[C@H](OC2=C3/C=CC(OC)=C/C3=N/C(C3=CC=CC=C3)=C\2)C[C@H]1C(=O)N[C@]1(C(=O)O)C[C@@H]1C=C)C(C)(C)C BSXPFJFYQOGVTB-SDUDGNSGSA-N 0.000 description 1
- BSXPFJFYQOGVTB-HVTDCLIHSA-N BN[C@H](C(=O)N1C[C@H](OC2=C3/C=CC(OC)=C/C3=N/C(C3=CC=CC=C3)=C\2)C[C@H]1C(=O)N[C@]1(C(=O)O)CC1C=C)C(C)(C)C Chemical compound BN[C@H](C(=O)N1C[C@H](OC2=C3/C=CC(OC)=C/C3=N/C(C3=CC=CC=C3)=C\2)C[C@H]1C(=O)N[C@]1(C(=O)O)CC1C=C)C(C)(C)C BSXPFJFYQOGVTB-HVTDCLIHSA-N 0.000 description 1
- HKNAWRXMZQASJY-NNMSRROOSA-O BrC/C=C/CBr.C=C=C=C=C=C=C=C=C=C=C=C=C=C=C=C=C=C=C.C=CC1CC1(N)C(=O)OCC.C=CC1CC1(NC(=O)OC(C)(C)C)C(=O)OC.C=CC1CC1(NC(=O)OC(C)(C)C)C(=O)OCC.CC(C)(C)OC(=O)OC(=O)OC(C)(C)C.CCOC(=O)C/N=C/C1=CC=CC=C1.CCOC(=O)C[NH3+].CO.CO[Na].Cl.O=CC1=CC=CC=C1 Chemical compound BrC/C=C/CBr.C=C=C=C=C=C=C=C=C=C=C=C=C=C=C=C=C=C=C.C=CC1CC1(N)C(=O)OCC.C=CC1CC1(NC(=O)OC(C)(C)C)C(=O)OC.C=CC1CC1(NC(=O)OC(C)(C)C)C(=O)OCC.CC(C)(C)OC(=O)OC(=O)OC(C)(C)C.CCOC(=O)C/N=C/C1=CC=CC=C1.CCOC(=O)C[NH3+].CO.CO[Na].Cl.O=CC1=CC=CC=C1 HKNAWRXMZQASJY-NNMSRROOSA-O 0.000 description 1
- IAAUGSYGHOFWEW-UHFFFAOYSA-N BrCC1=CC=CC2=CC=CN=C21 Chemical compound BrCC1=CC=CC2=CC=CN=C21 IAAUGSYGHOFWEW-UHFFFAOYSA-N 0.000 description 1
- CJIXUFGQBCRLAA-BATCNRFSSA-N C#C.CC[C@@H]1C[C@]1(NC(=O)OC(C)(C)C)C(=O)OC(C)(C)C.CC[C@H]1C[C@]1(N=Cl)C(=O)OC(C)(C)C.CC[C@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H](OCC2=C3C=CC=CC3=CC=C2)CN1C(=O)OC(C)(C)C)C(=O)OC(C)(C)C.CC[C@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H](OCC2=C3C=CC=CC3=CC=C2)CN1C(=O)OC(C)(C)C)C(=O)OC(C)(C)C.[HH] Chemical compound C#C.CC[C@@H]1C[C@]1(NC(=O)OC(C)(C)C)C(=O)OC(C)(C)C.CC[C@H]1C[C@]1(N=Cl)C(=O)OC(C)(C)C.CC[C@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H](OCC2=C3C=CC=CC3=CC=C2)CN1C(=O)OC(C)(C)C)C(=O)OC(C)(C)C.CC[C@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H](OCC2=C3C=CC=CC3=CC=C2)CN1C(=O)OC(C)(C)C)C(=O)OC(C)(C)C.[HH] CJIXUFGQBCRLAA-BATCNRFSSA-N 0.000 description 1
- CKWFJEHZYGCWFT-UHFFFAOYSA-N C.C.C.C.C.[CH2-][OH+]C1=CC(C2=NC=CC=C2)=NC(C2=NC=CC=C2)=C1.[CH2-][OH+]C1=NC(C2=CC=CC=C2)=NC2=C1C=CC=C2.[CH2-][OH+]C1=NC(N2C=CN=C2)=NC2=C1C=C(OC)C(OC)=C2.[CH2-][OH+]C1=NC(N2CCOCC2)=NC2=C1C=C(OC)C(OC)=C2 Chemical compound C.C.C.C.C.[CH2-][OH+]C1=CC(C2=NC=CC=C2)=NC(C2=NC=CC=C2)=C1.[CH2-][OH+]C1=NC(C2=CC=CC=C2)=NC2=C1C=CC=C2.[CH2-][OH+]C1=NC(N2C=CN=C2)=NC2=C1C=C(OC)C(OC)=C2.[CH2-][OH+]C1=NC(N2CCOCC2)=NC2=C1C=C(OC)C(OC)=C2 CKWFJEHZYGCWFT-UHFFFAOYSA-N 0.000 description 1
- NTDNACRGJHIQLC-DRPQEYBDSA-N C.C.C=CC1CC1(NC(=O)OC(C)(C)C)C(=O)OC.C=C[C@H]1C[C@]1(N)C(=O)OC.C=C[C@H]1C[C@]1(NC(=O)OC(C)(C)C)C(=O)OC Chemical compound C.C.C=CC1CC1(NC(=O)OC(C)(C)C)C(=O)OC.C=C[C@H]1C[C@]1(N)C(=O)OC.C=C[C@H]1C[C@]1(NC(=O)OC(C)(C)C)C(=O)OC NTDNACRGJHIQLC-DRPQEYBDSA-N 0.000 description 1
- OHDWNXIIEPFDFT-UDZAWANNSA-N C.C=CC(=O)C1=CC(O[C@@H]2C[C@@H](C(=O)NC3(C)(C(=O)OC)C[C@@H]3C=C)N(C(=O)OC(C)(C)C)C2)=C2C=CC(OC)=CC2=N1.C=C[C@H]1CC1(C)(NC(=O)[C@@H]1C[C@@H](OC2=C3C=CC(OC)=CC3=NC(C(=O)O)=C2)CN1C(=O)OC(C)(C)C)C(=O)OC.CC(C)CCC(=O)Cl Chemical compound C.C=CC(=O)C1=CC(O[C@@H]2C[C@@H](C(=O)NC3(C)(C(=O)OC)C[C@@H]3C=C)N(C(=O)OC(C)(C)C)C2)=C2C=CC(OC)=CC2=N1.C=C[C@H]1CC1(C)(NC(=O)[C@@H]1C[C@@H](OC2=C3C=CC(OC)=CC3=NC(C(=O)O)=C2)CN1C(=O)OC(C)(C)C)C(=O)OC.CC(C)CCC(=O)Cl OHDWNXIIEPFDFT-UDZAWANNSA-N 0.000 description 1
- RMNBDDUWDBVCJF-DCMGHCHFSA-M C.C=CC1CC1(NC(=O)OC(C)(C)C)C(=O)OCC.C=CC1C[C@@]1(NC(=O)OC(C)(C)C)C(=O)O.C=C[C@H]1C[C@]1(NC(=O)OC(C)(C)C)C(=O)OCC.O[Na] Chemical compound C.C=CC1CC1(NC(=O)OC(C)(C)C)C(=O)OCC.C=CC1C[C@@]1(NC(=O)OC(C)(C)C)C(=O)O.C=C[C@H]1C[C@]1(NC(=O)OC(C)(C)C)C(=O)OCC.O[Na] RMNBDDUWDBVCJF-DCMGHCHFSA-M 0.000 description 1
- JQUOVPFAPXXLCO-ODGIDLLMSA-N C.CC(=O)(OCC1=CC=CC=C1)[C@H]1CC[C@@H](O)C1.COC(=O)C1=CC(O[C@H]2CC[C@H](C(=O)OCC3=CC=CC=C3)C2)=C2C=CC(OC)=CC2=N1.COC1=CC2=NC(OC)=CC(O)=C2C=C1 Chemical compound C.CC(=O)(OCC1=CC=CC=C1)[C@H]1CC[C@@H](O)C1.COC(=O)C1=CC(O[C@H]2CC[C@H](C(=O)OCC3=CC=CC=C3)C2)=C2C=CC(OC)=CC2=N1.COC1=CC2=NC(OC)=CC(O)=C2C=C1 JQUOVPFAPXXLCO-ODGIDLLMSA-N 0.000 description 1
- MPLZUFBPHKKYED-BMPHHVLPSA-N C.COC.COC(=O)C1=CC(O[C@@H]2C[C@@H](C(=O)O)N(C(=O)OC(C)(C)C)C2)=C2C=CC(OC)=CC2=N1.COC(=O)C1=CC(O[C@@H]2C[C@@H](C(=O)OCC3=CC=CC=C3)N(C(=O)OC(C)(C)C)C2)=C2C=CC(OC)=CC2=N1 Chemical compound C.COC.COC(=O)C1=CC(O[C@@H]2C[C@@H](C(=O)O)N(C(=O)OC(C)(C)C)C2)=C2C=CC(OC)=CC2=N1.COC(=O)C1=CC(O[C@@H]2C[C@@H](C(=O)OCC3=CC=CC=C3)N(C(=O)OC(C)(C)C)C2)=C2C=CC(OC)=CC2=N1 MPLZUFBPHKKYED-BMPHHVLPSA-N 0.000 description 1
- VDSFTVZCPWNGLE-UHFFFAOYSA-N C.[CH2-][C+]1=CN(C(C)(C)C)N=C1 Chemical compound C.[CH2-][C+]1=CN(C(C)(C)C)N=C1 VDSFTVZCPWNGLE-UHFFFAOYSA-N 0.000 description 1
- SPBYXPBGGKIMEB-LJHLSZDLSA-N C/C=N/C(Cl)Cl.C=C[C@H]1CC1(C)(NC(=O)[C@@H]1C[C@@H](OC2=C3C=CC(OC)=CC3=NC(C3=CSC(NC(C)=O)=N3)=C2)CN1)C(=O)OC.C=C[C@H]1CC1(C)(NC(=O)[C@@H]1C[C@@H](OC2=C3C=CC(OC)=CC3=NC(C3=CSC(NC(C)=O)=N3)=C2)CN1C(=O)OC(C)(C)C)C(=O)OC.C=C[C@H]1CC1(C)(NC(=O)[C@@H]1C[C@@H](OC2=C3C=CC(OC)=CC3=NC(C3=CSC(NC(C)=O)=N3)=C2)CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C(=O)OC.CC(C)(C)OC(=O)N[C@H](C(=O)O)C(C)(C)C.Cl Chemical compound C/C=N/C(Cl)Cl.C=C[C@H]1CC1(C)(NC(=O)[C@@H]1C[C@@H](OC2=C3C=CC(OC)=CC3=NC(C3=CSC(NC(C)=O)=N3)=C2)CN1)C(=O)OC.C=C[C@H]1CC1(C)(NC(=O)[C@@H]1C[C@@H](OC2=C3C=CC(OC)=CC3=NC(C3=CSC(NC(C)=O)=N3)=C2)CN1C(=O)OC(C)(C)C)C(=O)OC.C=C[C@H]1CC1(C)(NC(=O)[C@@H]1C[C@@H](OC2=C3C=CC(OC)=CC3=NC(C3=CSC(NC(C)=O)=N3)=C2)CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C(=O)OC.CC(C)(C)OC(=O)N[C@H](C(=O)O)C(C)(C)C.Cl SPBYXPBGGKIMEB-LJHLSZDLSA-N 0.000 description 1
- HCMOOOWZOAZVPM-UHFFFAOYSA-N C1=CC2=C(C=C1)SC=N2.C1=CNN=N1.C1=NN=CN1.C1CCSC1 Chemical compound C1=CC2=C(C=C1)SC=N2.C1=CNN=N1.C1=NN=CN1.C1CCSC1 HCMOOOWZOAZVPM-UHFFFAOYSA-N 0.000 description 1
- SLCQIOHRLRBZCO-DSMJZMJWSA-N C1=CC=C(OC2=CC=CC=C2)C=C1.COC(=O)C1=NC2=CC(OC)=CC=C2C(O)=C1.[H]/C(C(=O)OC)=C(/NC1=CC(OC)=CC=C1)C(=O)OC Chemical compound C1=CC=C(OC2=CC=CC=C2)C=C1.COC(=O)C1=NC2=CC(OC)=CC=C2C(O)=C1.[H]/C(C(=O)OC)=C(/NC1=CC(OC)=CC=C1)C(=O)OC SLCQIOHRLRBZCO-DSMJZMJWSA-N 0.000 description 1
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 description 1
- MTLRMVPOKZKPKL-UHFFFAOYSA-O C=CC1CC1(NC(=O)OC(C)(C)C)C(=O)OCC.C=CC1CC1([NH3+])C(=O)OCC.CC(C)(C)OC(=O)OC(=O)OC(C)(C)C.[Cl-] Chemical compound C=CC1CC1(NC(=O)OC(C)(C)C)C(=O)OCC.C=CC1CC1([NH3+])C(=O)OCC.CC(C)(C)OC(=O)OC(=O)OC(C)(C)C.[Cl-] MTLRMVPOKZKPKL-UHFFFAOYSA-O 0.000 description 1
- NVFKAJNWQCPVJE-CGYKBKQJSA-O C=CC1CC1(NC(=O)[C@@H]1C[C@@H](OC2=CC=NC3=CC=CC=C32)CN1C(=O)OC(C)(C)C)C(=O)OCC.C=CC1CC1(NC(=O)[C@@H]1C[C@@H](OC2=CC=NC3=CC=CC=C32)CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C1CCCCC1)C(=O)OCC.C=CC1CC1([NH3+])C(=O)OCC.C=C[C@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H](OC2=CC=NC3=CC=CC=C32)CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C1CCCCC1)C(=O)O.CC(C)(C)OC(=O)N1C[C@H](OC2=CC=NC3=CC=CC=C32)C[C@H]1C(=O)O.ClCCl.[Cl-] Chemical compound C=CC1CC1(NC(=O)[C@@H]1C[C@@H](OC2=CC=NC3=CC=CC=C32)CN1C(=O)OC(C)(C)C)C(=O)OCC.C=CC1CC1(NC(=O)[C@@H]1C[C@@H](OC2=CC=NC3=CC=CC=C32)CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C1CCCCC1)C(=O)OCC.C=CC1CC1([NH3+])C(=O)OCC.C=C[C@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H](OC2=CC=NC3=CC=CC=C32)CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C1CCCCC1)C(=O)O.CC(C)(C)OC(=O)N1C[C@H](OC2=CC=NC3=CC=CC=C32)C[C@H]1C(=O)O.ClCCl.[Cl-] NVFKAJNWQCPVJE-CGYKBKQJSA-O 0.000 description 1
- LCNNABCJXKMLAB-FFVKAHMHSA-N C=CC1CCC1(C)N.CC(CC/C=C/COP)N=C(C1=CC=CC=C1)C1=CC=CC=C1.CC/C=C/CCC.CC/C=C/CCC(C)N=C(C1=CC=CC=C1)C1=CC=CC=C1.CCC1CCC1(C)N.CCN=C(C1=CC=CC=C1)C1=CC=CC=C1.I[XeH] Chemical compound C=CC1CCC1(C)N.CC(CC/C=C/COP)N=C(C1=CC=CC=C1)C1=CC=CC=C1.CC/C=C/CCC.CC/C=C/CCC(C)N=C(C1=CC=CC=C1)C1=CC=CC=C1.CCC1CCC1(C)N.CCN=C(C1=CC=CC=C1)C1=CC=CC=C1.I[XeH] LCNNABCJXKMLAB-FFVKAHMHSA-N 0.000 description 1
- KNOLDBMIUHMJCR-XYBFWVQZSA-N C=CC1C[C@]1(NCl)C(=O)OC.C=C[C@H]1CC1(C)(NC(=O)[C@@H]1C[C@@H](OC2=C3C=CC(OC)=CC3=NC(C(=O)OC)=C2)CN1C(=O)OC(C)(C)C)C(=O)OC.COC(=O)C1=CC(O[C@@H]2C[C@@H](C(=O)O)N(C(=O)OC(C)(C)C)C2)=C2C=CC(OC)=CC2=N1.[3H]B([3H])[U] Chemical compound C=CC1C[C@]1(NCl)C(=O)OC.C=C[C@H]1CC1(C)(NC(=O)[C@@H]1C[C@@H](OC2=C3C=CC(OC)=CC3=NC(C(=O)OC)=C2)CN1C(=O)OC(C)(C)C)C(=O)OC.COC(=O)C1=CC(O[C@@H]2C[C@@H](C(=O)O)N(C(=O)OC(C)(C)C)C2)=C2C=CC(OC)=CC2=N1.[3H]B([3H])[U] KNOLDBMIUHMJCR-XYBFWVQZSA-N 0.000 description 1
- JODZWHOXRGVSKR-UHFFFAOYSA-N C=CCBr.CCC1CC1(C)C.CCC1CC1(C)C(=O)O.CCC1CC1(C)C(=O)O.CCC1CC1(C)N=N.CCC1CC1(C)NC(=O)OCC[SiH2]C Chemical compound C=CCBr.CCC1CC1(C)C.CCC1CC1(C)C(=O)O.CCC1CC1(C)C(=O)O.CCC1CC1(C)N=N.CCC1CC1(C)NC(=O)OCC[SiH2]C JODZWHOXRGVSKR-UHFFFAOYSA-N 0.000 description 1
- RUVHQTCFOYMSJL-DHESBJIOSA-N C=C[C@H]1CC1(C)(NC(=O)[C@@H]1C[C@@H](OC2=C3C=CC(OC)=CC3=NC(C(=O)CBr)=C2)CN1C(=O)OC(C)(C)C)C(=O)OC.C=C[C@H]1CC1(C)(NC(=O)[C@@H]1C[C@@H](OC2=C3C=CC(OC)=CC3=NC(C(C)=O)=C2)CN1C(=O)OC(C)(C)C)C(=O)OC Chemical compound C=C[C@H]1CC1(C)(NC(=O)[C@@H]1C[C@@H](OC2=C3C=CC(OC)=CC3=NC(C(=O)CBr)=C2)CN1C(=O)OC(C)(C)C)C(=O)OC.C=C[C@H]1CC1(C)(NC(=O)[C@@H]1C[C@@H](OC2=C3C=CC(OC)=CC3=NC(C(C)=O)=C2)CN1C(=O)OC(C)(C)C)C(=O)OC RUVHQTCFOYMSJL-DHESBJIOSA-N 0.000 description 1
- FMULBMWHXBWWLL-YUAYIRNESA-N C=C[C@H]1CC1(C)(NC(=O)[C@@H]1C[C@@H](OC2=C3C=CC(OC)=CC3=NC(C(=O)CBr)=C2)CN1C(=O)OC(C)(C)C)C(=O)OC.C=C[C@H]1CC1(C)(NC(=O)[C@@H]1C[C@@H](OC2=C3C=CC(OC)=CC3=NC(C3=CSC(NC(C)=O)=N3)=C2)CN1C(=O)OC(C)(C)C)C(=O)OC.CC(=O)NC(N)=O Chemical compound C=C[C@H]1CC1(C)(NC(=O)[C@@H]1C[C@@H](OC2=C3C=CC(OC)=CC3=NC(C(=O)CBr)=C2)CN1C(=O)OC(C)(C)C)C(=O)OC.C=C[C@H]1CC1(C)(NC(=O)[C@@H]1C[C@@H](OC2=C3C=CC(OC)=CC3=NC(C3=CSC(NC(C)=O)=N3)=C2)CN1C(=O)OC(C)(C)C)C(=O)OC.CC(=O)NC(N)=O FMULBMWHXBWWLL-YUAYIRNESA-N 0.000 description 1
- HMEXBCKUJNIROE-IVLGDCGISA-N C=C[C@H]1CC1(C)(NC(=O)[C@@H]1C[C@@H](OC2=C3C=CC(OC)=CC3=NC(C(=O)O)=C2)CN1C(=O)OC(C)(C)C)C(=O)OC.C=C[C@H]1CC1(C)(NC(=O)[C@@H]1C[C@@H](OC2=C3C=CC(OC)=CC3=NC(C(=O)OC)=C2)CN1C(=O)OC(C)(C)C)C(=O)OC Chemical compound C=C[C@H]1CC1(C)(NC(=O)[C@@H]1C[C@@H](OC2=C3C=CC(OC)=CC3=NC(C(=O)O)=C2)CN1C(=O)OC(C)(C)C)C(=O)OC.C=C[C@H]1CC1(C)(NC(=O)[C@@H]1C[C@@H](OC2=C3C=CC(OC)=CC3=NC(C(=O)OC)=C2)CN1C(=O)OC(C)(C)C)C(=O)OC HMEXBCKUJNIROE-IVLGDCGISA-N 0.000 description 1
- XWOUSFJONGYHRE-HHLYKZQOSA-M C=C[C@H]1CC1(C)(NC(=O)[C@@H]1C[C@@H](OC2=C3C=CC(OC)=CC3=NC(C3=CSC(NC(C)=O)=N3)=C2)CN1C(=O)[C@@H](NC(=O)N[C@H](C)C(C)(C)C)C(C)(C)C)C(=O)OC.C=C[C@H]1CC1(C)(NC(=O)[C@@H]1C[C@@H](OC2=C3C=CC(OC)=CC3=NC(C3=CSC(NC(C)=O)=N3)=C2)CN1C(=O)[C@@H](NC(=O)N[C@H](C)C(C)(C)C)C(C)(C)C)C(=O)OC.Cl.[Li]O Chemical compound C=C[C@H]1CC1(C)(NC(=O)[C@@H]1C[C@@H](OC2=C3C=CC(OC)=CC3=NC(C3=CSC(NC(C)=O)=N3)=C2)CN1C(=O)[C@@H](NC(=O)N[C@H](C)C(C)(C)C)C(C)(C)C)C(=O)OC.C=C[C@H]1CC1(C)(NC(=O)[C@@H]1C[C@@H](OC2=C3C=CC(OC)=CC3=NC(C3=CSC(NC(C)=O)=N3)=C2)CN1C(=O)[C@@H](NC(=O)N[C@H](C)C(C)(C)C)C(C)(C)C)C(=O)OC.Cl.[Li]O XWOUSFJONGYHRE-HHLYKZQOSA-M 0.000 description 1
- DAKOBUVUTSAJSI-SDBBMACXSA-N C=C[C@H]1CC1(C)(NC(=O)[C@@H]1C[C@@H](OC2=C3C=CC(OC)=CC3=NC(C3=CSC(NC(C)=O)=N3)=C2)CN1C(=O)[C@@H](NC(=O)N[C@H](C)C(C)(C)C)C(C)(C)C)C(=O)OC.C=C[C@H]1CC1(C)(NC(=O)[C@@H]1C[C@@H](OC2=C3C=CC(OC)=CC3=NC(C3=CSC(NC(C)=O)=N3)=C2)CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C(=O)OC.CC(C)C(C)(C)C.NCl.O=C(OC(Cl)(Cl)Cl)OC(Cl)(Cl)Cl Chemical compound C=C[C@H]1CC1(C)(NC(=O)[C@@H]1C[C@@H](OC2=C3C=CC(OC)=CC3=NC(C3=CSC(NC(C)=O)=N3)=C2)CN1C(=O)[C@@H](NC(=O)N[C@H](C)C(C)(C)C)C(C)(C)C)C(=O)OC.C=C[C@H]1CC1(C)(NC(=O)[C@@H]1C[C@@H](OC2=C3C=CC(OC)=CC3=NC(C3=CSC(NC(C)=O)=N3)=C2)CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C(=O)OC.CC(C)C(C)(C)C.NCl.O=C(OC(Cl)(Cl)Cl)OC(Cl)(Cl)Cl DAKOBUVUTSAJSI-SDBBMACXSA-N 0.000 description 1
- SOVWZIIRORVKFI-HAMUOZRBSA-N C=C[C@H]1C[C@]1(N)C(=O)OCC.C=C[C@H]1C[C@]1(NC(=O)[C@@H]1CC(OC2=CC(C3=CC=CC=C3)=NC3=C2C=C([N+](=O)[O-])C=C3)CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C1CCCCC1)C(=O)O.C=C[C@H]1C[C@]1(NC(=O)[C@@H]1CC(OC2=CC(C3=CC=CC=C3)=NC3=C2C=C([N+](=O)[O-])C=C3)CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C1CCCCC1)C(=O)OCC.C=C[C@H]1C[C@]1(NC(=O)[C@@H]1CC(Oc2cc(-c3ccccc3)nc3ccc([N+](=O)[O-])cc23)CN1)C(=O)OCC.C=C[C@H]1C[C@]1(NC(=O)[C@@H]1CC(Oc2cc(-c3ccccc3)nc3ccc([N+](=O)[O-])cc23)CN1C(=O)OC(C)(C)C)C(=O)OCC.CC(C)(C)OC(=O)N1CC(Oc2cc(-c3ccccc3)nc3ccc([N+](=O)[O-])cc23)C[C@H]1C(=O)O.Cl.Cl Chemical compound C=C[C@H]1C[C@]1(N)C(=O)OCC.C=C[C@H]1C[C@]1(NC(=O)[C@@H]1CC(OC2=CC(C3=CC=CC=C3)=NC3=C2C=C([N+](=O)[O-])C=C3)CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C1CCCCC1)C(=O)O.C=C[C@H]1C[C@]1(NC(=O)[C@@H]1CC(OC2=CC(C3=CC=CC=C3)=NC3=C2C=C([N+](=O)[O-])C=C3)CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C1CCCCC1)C(=O)OCC.C=C[C@H]1C[C@]1(NC(=O)[C@@H]1CC(Oc2cc(-c3ccccc3)nc3ccc([N+](=O)[O-])cc23)CN1)C(=O)OCC.C=C[C@H]1C[C@]1(NC(=O)[C@@H]1CC(Oc2cc(-c3ccccc3)nc3ccc([N+](=O)[O-])cc23)CN1C(=O)OC(C)(C)C)C(=O)OCC.CC(C)(C)OC(=O)N1CC(Oc2cc(-c3ccccc3)nc3ccc([N+](=O)[O-])cc23)C[C@H]1C(=O)O.Cl.Cl SOVWZIIRORVKFI-HAMUOZRBSA-N 0.000 description 1
- NBJXCTLFPNBZSG-POYBYMJQSA-N C=C[C@H]1C[C@]1(N)C(=O)OCC.Cl Chemical compound C=C[C@H]1C[C@]1(N)C(=O)OCC.Cl NBJXCTLFPNBZSG-POYBYMJQSA-N 0.000 description 1
- NQAWKQZMWHNJCT-LEUCUCNGSA-N C=C[C@H]1C[C@]1(N)C(C)=O.S Chemical compound C=C[C@H]1C[C@]1(N)C(C)=O.S NQAWKQZMWHNJCT-LEUCUCNGSA-N 0.000 description 1
- QBDOXRUCHQZZLA-FFAPXJNASA-N C=C[C@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H](O/C2=C/C=C\C3=CC=CC=C32)CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C1CCCCC1)C(=O)O Chemical compound C=C[C@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H](O/C2=C/C=C\C3=CC=CC=C32)CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C1CCCCC1)C(=O)O QBDOXRUCHQZZLA-FFAPXJNASA-N 0.000 description 1
- RWWQZRHLTYGYDH-BUJYAZECSA-N C=C[C@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H](OC/C2=C/C=C\C3=CC=CC=C32)CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C1CCCCC1)C(=O)O Chemical compound C=C[C@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H](OC/C2=C/C=C\C3=CC=CC=C32)CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C1CCCCC1)C(=O)O RWWQZRHLTYGYDH-BUJYAZECSA-N 0.000 description 1
- OETNBTVGWURZOW-PZRGFJITSA-N C=C[C@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H](OC2=CC3=CC=CC=C3C=C2)CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C1CCCCC1)C(=O)O Chemical compound C=C[C@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H](OC2=CC3=CC=CC=C3C=C2)CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C1CCCCC1)C(=O)O OETNBTVGWURZOW-PZRGFJITSA-N 0.000 description 1
- IIJOJBZUPFYRLK-NGMRCMGVSA-N C=C[C@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H](OC2=CC=NC3=CC(Cl)=CC=C32)CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C1CCCCC1)C(=O)OCC Chemical compound C=C[C@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H](OC2=CC=NC3=CC(Cl)=CC=C32)CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C1CCCCC1)C(=O)OCC IIJOJBZUPFYRLK-NGMRCMGVSA-N 0.000 description 1
- ARRIKRYAXVWDPT-UHFFFAOYSA-N C=S(=O)(=O)C1=C(C)N=C(NC(C)=O)S1.C=S(=O)(=O)C1=CC=CC=C1.C=S(=O)(=O)C1=CC=CS1 Chemical compound C=S(=O)(=O)C1=C(C)N=C(NC(C)=O)S1.C=S(=O)(=O)C1=CC=CC=C1.C=S(=O)(=O)C1=CC=CS1 ARRIKRYAXVWDPT-UHFFFAOYSA-N 0.000 description 1
- QUSZWBIQKVYOQE-UHFFFAOYSA-N CC(=O)C1=CC=CC2=CC=CN=C21.CCC1=CC=CC2=CC=CN=C21.O=C(O)C1=CC=CC2=CC=CN=C21.OCC1=CC=CC2=CC=CN=C21 Chemical compound CC(=O)C1=CC=CC2=CC=CN=C21.CCC1=CC=CC2=CC=CN=C21.O=C(O)C1=CC=CC2=CC=CN=C21.OCC1=CC=CC2=CC=CN=C21 QUSZWBIQKVYOQE-UHFFFAOYSA-N 0.000 description 1
- NPDBDJFLKKQMCM-UHFFFAOYSA-N CC(C)(C)C(N)C(=O)O Chemical compound CC(C)(C)C(N)C(=O)O NPDBDJFLKKQMCM-UHFFFAOYSA-N 0.000 description 1
- FPPVFDWOHYWBCY-LFABVHOISA-N CC(C)(C)OC(=O)N1CC(Oc2cc(-c3ccccc3)nc3ccc([N+](=O)[O-])cc23)C[C@H]1C(=O)O Chemical compound CC(C)(C)OC(=O)N1CC(Oc2cc(-c3ccccc3)nc3ccc([N+](=O)[O-])cc23)C[C@H]1C(=O)O FPPVFDWOHYWBCY-LFABVHOISA-N 0.000 description 1
- AGRJUIGAPVULLK-DOMZBBRYSA-N CC(C)(C)OC(=O)N1C[C@H](OC2=CC=NC3=CC(Cl)=CC=C32)C[C@H]1C(=O)O Chemical compound CC(C)(C)OC(=O)N1C[C@H](OC2=CC=NC3=CC(Cl)=CC=C32)C[C@H]1C(=O)O AGRJUIGAPVULLK-DOMZBBRYSA-N 0.000 description 1
- ZSKRGEZVUPKAKC-AEFFLSMTSA-N CC(C)(C)OC(=O)N1C[C@H](OCC2=C3/C=C\C=C/C3=CC=C2)C[C@H]1C(=O)O Chemical compound CC(C)(C)OC(=O)N1C[C@H](OCC2=C3/C=C\C=C/C3=CC=C2)C[C@H]1C(=O)O ZSKRGEZVUPKAKC-AEFFLSMTSA-N 0.000 description 1
- MYNSPTJWBGQDLW-CVEARBPZSA-N CC(C)(C)OC(=O)N1C[C@H](OCC2=CC=CC3=CC=CN=C32)C[C@H]1C(=O)O Chemical compound CC(C)(C)OC(=O)N1C[C@H](OCC2=CC=CC3=CC=CN=C32)C[C@H]1C(=O)O MYNSPTJWBGQDLW-CVEARBPZSA-N 0.000 description 1
- RHDQNZICEQIHNA-NKVVBNORSA-N CC(C)(C)OC(=O)N1C[C@H](OCC2=CC=CC3=CC=CN=C32)C[C@H]1C(=O)O.CCC1C[C@]1(NC(=O)[C@@H]1C[C@@H](OCC2=CC=CC3=CC=CN=C32)CN1C(=O)OC(C)(C)C)C(=O)OC.CCC1C[C@]1(NC(=O)[C@@H]1C[C@@H](OCC2=CC=CC3=CC=CN=C32)CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C1CCCCC1)C(=O)O.CCC1C[C@]1(NC(=O)[C@@H]1C[C@@H](OCC2=CC=CC3=CC=CN=C32)CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C1CCCCC1)C(=O)OC Chemical compound CC(C)(C)OC(=O)N1C[C@H](OCC2=CC=CC3=CC=CN=C32)C[C@H]1C(=O)O.CCC1C[C@]1(NC(=O)[C@@H]1C[C@@H](OCC2=CC=CC3=CC=CN=C32)CN1C(=O)OC(C)(C)C)C(=O)OC.CCC1C[C@]1(NC(=O)[C@@H]1C[C@@H](OCC2=CC=CC3=CC=CN=C32)CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C1CCCCC1)C(=O)O.CCC1C[C@]1(NC(=O)[C@@H]1C[C@@H](OCC2=CC=CC3=CC=CN=C32)CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C1CCCCC1)C(=O)OC RHDQNZICEQIHNA-NKVVBNORSA-N 0.000 description 1
- UQUNEWAHEOPQAH-ZNLDPBMLSA-M CC(C)(C)OC(=O)[N-][C@H](C(=O)O)C(C)(C)C.[H]N(C(=O)[C@@H]1CC(OC2=C3C=CC(OC)=CC3=NC(C3=CC=CC=C3)=C2)CN1C(=O)OC(C)(C)C)C1(C(=O)OC)CCC1.[H]OC(=O)C1(N([H])C(=O)[C@@H]2CC(OC3=C4C=CC(OC)=CC4=NC(C4=CC=CC=C4)=C3)CN2C(=O)[C@@H](N([H])C(=O)OC(C)(C)C)C(C)(C)C)CCC1 Chemical compound CC(C)(C)OC(=O)[N-][C@H](C(=O)O)C(C)(C)C.[H]N(C(=O)[C@@H]1CC(OC2=C3C=CC(OC)=CC3=NC(C3=CC=CC=C3)=C2)CN1C(=O)OC(C)(C)C)C1(C(=O)OC)CCC1.[H]OC(=O)C1(N([H])C(=O)[C@@H]2CC(OC3=C4C=CC(OC)=CC4=NC(C4=CC=CC=C4)=C3)CN2C(=O)[C@@H](N([H])C(=O)OC(C)(C)C)C(C)(C)C)CCC1 UQUNEWAHEOPQAH-ZNLDPBMLSA-M 0.000 description 1
- UOQGCAZWBCCDBH-UHFFFAOYSA-N CC(C)(COC)NC(C)=O Chemical compound CC(C)(COC)NC(C)=O UOQGCAZWBCCDBH-UHFFFAOYSA-N 0.000 description 1
- OSUCFYKEDQWHAJ-UHFFFAOYSA-N CC(C)C1(C(C)C)CC1.CC(C)C1(C(C)C)CCC1 Chemical compound CC(C)C1(C(C)C)CC1.CC(C)C1(C(C)C)CCC1 OSUCFYKEDQWHAJ-UHFFFAOYSA-N 0.000 description 1
- HKZXDFQIKRFLMW-UHFFFAOYSA-N CC(C)C1C=CCCC1 Chemical compound CC(C)C1C=CCCC1 HKZXDFQIKRFLMW-UHFFFAOYSA-N 0.000 description 1
- XVTMZAFEBXBSNY-MMZICYPTSA-N CC(C)N1C[C@@H](O)CC1C(=O)C(C)(C)C.CC[C@@H]1CC(C(=O)C(C)(C)C)N(C(C)C)C1.O[Ar].S[Ar].[Ar] Chemical compound CC(C)N1C[C@@H](O)CC1C(=O)C(C)(C)C.CC[C@@H]1CC(C(=O)C(C)(C)C)N(C(C)C)C1.O[Ar].S[Ar].[Ar] XVTMZAFEBXBSNY-MMZICYPTSA-N 0.000 description 1
- ZSMPXLJQCKPGFF-UHFFFAOYSA-N CC(C)Nc1nc(C)c[s]1 Chemical compound CC(C)Nc1nc(C)c[s]1 ZSMPXLJQCKPGFF-UHFFFAOYSA-N 0.000 description 1
- WRAGCBBWIYQMRF-UHFFFAOYSA-N CC(NC1CCCCC1)=O Chemical compound CC(NC1CCCCC1)=O WRAGCBBWIYQMRF-UHFFFAOYSA-N 0.000 description 1
- UZJLYRRDVFWSGA-UHFFFAOYSA-N CC(NCc1ccccc1)=O Chemical compound CC(NCc1ccccc1)=O UZJLYRRDVFWSGA-UHFFFAOYSA-N 0.000 description 1
- WXPLRSVMGRAIGW-UHFFFAOYSA-N CC(Nc1ncc[s]1)=O Chemical compound CC(Nc1ncc[s]1)=O WXPLRSVMGRAIGW-UHFFFAOYSA-N 0.000 description 1
- VQNGHBQJURBQLF-UHFFFAOYSA-N CC(OC1CSCC1)=O Chemical compound CC(OC1CSCC1)=O VQNGHBQJURBQLF-UHFFFAOYSA-N 0.000 description 1
- AJNCBDSCHMVPMB-UHFFFAOYSA-N CCC.CCC(Br)CBr.CCC1CC1(C)C.CCC1CC1(C)C(=O)O.CCC1CC1(C)C(=O)O.CCC1CC1(C)NC(=O)OCC[Si](C)(C)C Chemical compound CCC.CCC(Br)CBr.CCC1CC1(C)C.CCC1CC1(C)C(=O)O.CCC1CC1(C)C(=O)O.CCC1CC1(C)NC(=O)OCC[Si](C)(C)C AJNCBDSCHMVPMB-UHFFFAOYSA-N 0.000 description 1
- YRWSHDMHSOEHQH-UHFFFAOYSA-N CCC1CC1(C)NC(=O)OCC[Si](C)(C)C.CCC1CC1(NC(=O)OC(C)(C)C)C(=O)O Chemical compound CCC1CC1(C)NC(=O)OCC[Si](C)(C)C.CCC1CC1(NC(=O)OC(C)(C)C)C(=O)O YRWSHDMHSOEHQH-UHFFFAOYSA-N 0.000 description 1
- HBHWFLQOADMYOC-UHFFFAOYSA-N CCC1CC1(NC(=O)OC(C)(C)C)C(=O)O.CCC1CC1(NC(=O)OC(C)(C)C)C(=O)OC Chemical compound CCC1CC1(NC(=O)OC(C)(C)C)C(=O)O.CCC1CC1(NC(=O)OC(C)(C)C)C(=O)OC HBHWFLQOADMYOC-UHFFFAOYSA-N 0.000 description 1
- LSCDFZRKDWDINR-PATORLSPSA-N CCC1CC1(NC(=O)OC(C)(C)C)C(=O)O.CCC1CC1(NC(=O)OC(C)(C)C)C(=O)OCC1=CC=CC=C1.CC[C@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H](OCC2=C3C=CC=CC3=CC=C2)CN1C(=O)OC(C)(C)C)C(=O)OCC1=CC=CC=C1.CC[C@H]1C[C@]1(NC(=O)[C@H]1CC[C@H](OCC2=C3C=CC=CC3=CC=C2)C1)C(=O)O.CC[C@H]1C[C@]1(NC(=O)[C@H]1CC[C@H](OCC2=C3C=CC=CC3=CC=C2)C1)C(=O)OCC1=CC=CC=C1 Chemical compound CCC1CC1(NC(=O)OC(C)(C)C)C(=O)O.CCC1CC1(NC(=O)OC(C)(C)C)C(=O)OCC1=CC=CC=C1.CC[C@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H](OCC2=C3C=CC=CC3=CC=C2)CN1C(=O)OC(C)(C)C)C(=O)OCC1=CC=CC=C1.CC[C@H]1C[C@]1(NC(=O)[C@H]1CC[C@H](OCC2=C3C=CC=CC3=CC=C2)C1)C(=O)O.CC[C@H]1C[C@]1(NC(=O)[C@H]1CC[C@H](OCC2=C3C=CC=CC3=CC=C2)C1)C(=O)OCC1=CC=CC=C1 LSCDFZRKDWDINR-PATORLSPSA-N 0.000 description 1
- HECOVHQHCZEULO-BFFQSRHISA-M CCC1CC1(NC(=O)OC(C)(C)C)C(=O)OC.CCC1C[C@@]1(NC(=O)OC(C)(C)C)C(=O)O.CCC1C[C@@]1(NC(=O)OC(C)(C)C)C(=O)OC.CC[C@H]1C[C@]1(NC(=O)OC(C)(C)C)C(=O)OC.O[Na] Chemical compound CCC1CC1(NC(=O)OC(C)(C)C)C(=O)OC.CCC1C[C@@]1(NC(=O)OC(C)(C)C)C(=O)O.CCC1C[C@@]1(NC(=O)OC(C)(C)C)C(=O)OC.CC[C@H]1C[C@]1(NC(=O)OC(C)(C)C)C(=O)OC.O[Na] HECOVHQHCZEULO-BFFQSRHISA-M 0.000 description 1
- GZEWMAUDHGTNRX-XKZIGAHESA-N CCC1CC1(NC(=O)OCC[Si](C)(C)C)C(=O)OC(C)(C)C.CCC1C[C@@]1(NC(=O)[C@@H]1C[C@@H](OCC2=C3C=CC=CC3=CC=C2)CN1C(=O)OC(C)(C)C)C(=O)OC(C)(C)C.CC[C@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H](OCC2=C3C=CC=CC3=CC=C2)CN1C(=O)OC(C)(C)C)C(=O)OC(C)(C)C Chemical compound CCC1CC1(NC(=O)OCC[Si](C)(C)C)C(=O)OC(C)(C)C.CCC1C[C@@]1(NC(=O)[C@@H]1C[C@@H](OCC2=C3C=CC=CC3=CC=C2)CN1C(=O)OC(C)(C)C)C(=O)OC(C)(C)C.CC[C@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H](OCC2=C3C=CC=CC3=CC=C2)CN1C(=O)OC(C)(C)C)C(=O)OC(C)(C)C GZEWMAUDHGTNRX-XKZIGAHESA-N 0.000 description 1
- XBCXITVNOAZNLZ-PQCOBQOQSA-N CCOC(=O)/C=C(\NC1=CC=CC(OC)=C1)C1=CC=CC=C1.CCOC(=O)CC(=O)C1=CC=CC=C1.COC1=CC(N)=CC=C1.COC1=CC(N/C(=C\C(N)=O)C2=CC=CC=C2)=CC=C1.COC1=CC2=NC(C3=CC=CC=C3)=CC(Cl)=C2C=C1.COC1=CC2=NC(C3=CC=CC=C3)=CC(O)=C2C=C1.[2H]ClP(=O)(Cl)Cl.[Ar] Chemical compound CCOC(=O)/C=C(\NC1=CC=CC(OC)=C1)C1=CC=CC=C1.CCOC(=O)CC(=O)C1=CC=CC=C1.COC1=CC(N)=CC=C1.COC1=CC(N/C(=C\C(N)=O)C2=CC=CC=C2)=CC=C1.COC1=CC2=NC(C3=CC=CC=C3)=CC(Cl)=C2C=C1.COC1=CC2=NC(C3=CC=CC=C3)=CC(O)=C2C=C1.[2H]ClP(=O)(Cl)Cl.[Ar] XBCXITVNOAZNLZ-PQCOBQOQSA-N 0.000 description 1
- OVJVUNNWZDVEQJ-UHFFFAOYSA-N CCOC(=O)CCCN.CCOC(=O)CCCNC(=O)OC1CCC1.O=C(Cl)OC1CCC1.OC1CCC1 Chemical compound CCOC(=O)CCCN.CCOC(=O)CCCNC(=O)OC1CCC1.O=C(Cl)OC1CCC1.OC1CCC1 OVJVUNNWZDVEQJ-UHFFFAOYSA-N 0.000 description 1
- LMGBSTARLBUYON-RXCSQUHRSA-N CC[C@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H](OC/C2=C/C=C\C3=CC=CC=C32)CN1C(=O)[C@@H](NC(=O)OCC(C)C)C(C)C)C(=O)O Chemical compound CC[C@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H](OC/C2=C/C=C\C3=CC=CC=C32)CN1C(=O)[C@@H](NC(=O)OCC(C)C)C(C)C)C(=O)O LMGBSTARLBUYON-RXCSQUHRSA-N 0.000 description 1
- UINIUABSGNQPKG-MTWPPDNHSA-N CC[C@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H](OC/C2=C/C=C\C3=CC=CC=C32)CN1C(=O)[C@@H](NC(=O)OCC(C)C)C1CCCCC1)C(=O)O Chemical compound CC[C@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H](OC/C2=C/C=C\C3=CC=CC=C32)CN1C(=O)[C@@H](NC(=O)OCC(C)C)C1CCCCC1)C(=O)O UINIUABSGNQPKG-MTWPPDNHSA-N 0.000 description 1
- VGRVKVGGUPOCMT-UHFFFAOYSA-N CCc1nc(C)c[s]1 Chemical compound CCc1nc(C)c[s]1 VGRVKVGGUPOCMT-UHFFFAOYSA-N 0.000 description 1
- ZCLBLSZZIRMCLZ-UHFFFAOYSA-N CNC1(CC1)C(O)=O Chemical compound CNC1(CC1)C(O)=O ZCLBLSZZIRMCLZ-UHFFFAOYSA-N 0.000 description 1
- DVMSRJRMSSVDQB-LYMULUNZSA-N CO.COC(=O)C#CC(=O)OC.COC1=CC=CC(N)=C1.[H]/C(C(=O)OC)=C(/NC1=CC(OC)=CC=C1)C(=O)OC Chemical compound CO.COC(=O)C#CC(=O)OC.COC1=CC=CC(N)=C1.[H]/C(C(=O)OC)=C(/NC1=CC(OC)=CC=C1)C(=O)OC DVMSRJRMSSVDQB-LYMULUNZSA-N 0.000 description 1
- ONVVBEMIFUIYEL-RIYBWTSXSA-N COC(=O)C1(N)CCC1.COC(=O)[C@@H]1C[C@@H](OC2=C3C=CC(OC)=CC3=NC(C3=CC=CC=C3)=C2)CN1C(=O)OC(C)(C)C.Cl.[H]N(C(=O)[C@@H]1C[C@@H](OC2=C3C=CC(OC)=CC3=NC(C3=CC=CC=C3)=C2)CN1C(=O)OC(C)(C)C)C1(C(=O)OC)CCC1 Chemical compound COC(=O)C1(N)CCC1.COC(=O)[C@@H]1C[C@@H](OC2=C3C=CC(OC)=CC3=NC(C3=CC=CC=C3)=C2)CN1C(=O)OC(C)(C)C.Cl.[H]N(C(=O)[C@@H]1C[C@@H](OC2=C3C=CC(OC)=CC3=NC(C3=CC=CC=C3)=C2)CN1C(=O)OC(C)(C)C)C1(C(=O)OC)CCC1 ONVVBEMIFUIYEL-RIYBWTSXSA-N 0.000 description 1
- JTNATEINSACWHA-UHFFFAOYSA-N COC(=O)C1(N)CCC1.NC1(C(=O)O)CCC1 Chemical compound COC(=O)C1(N)CCC1.NC1(C(=O)O)CCC1 JTNATEINSACWHA-UHFFFAOYSA-N 0.000 description 1
- SGXOPTPGZBLQAY-UHFFFAOYSA-N COC(C1(CCC1)N)=O Chemical compound COC(C1(CCC1)N)=O SGXOPTPGZBLQAY-UHFFFAOYSA-N 0.000 description 1
- KSUSQDWCKXDQFV-UHFFFAOYSA-N COC(CCNc1c2)c1ccc2Cl Chemical compound COC(CCNc1c2)c1ccc2Cl KSUSQDWCKXDQFV-UHFFFAOYSA-N 0.000 description 1
- RFYVHXAMNWNFNV-GCJKJVERSA-N COC1=CC2=NC(C3=CC=CC=C3)=CC(O[C@@H]3C[C@@H](C(=O)O)N(C(=O)OC(C)(C)C)C3)=C2C=C1 Chemical compound COC1=CC2=NC(C3=CC=CC=C3)=CC(O[C@@H]3C[C@@H](C(=O)O)N(C(=O)OC(C)(C)C)C3)=C2C=C1 RFYVHXAMNWNFNV-GCJKJVERSA-N 0.000 description 1
- PYYVANLRRNVTQS-UHFFFAOYSA-N COc(cc1)cc2c1c(OC)ccn2 Chemical compound COc(cc1)cc2c1c(OC)ccn2 PYYVANLRRNVTQS-UHFFFAOYSA-N 0.000 description 1
- DYBFVMORKXIRJA-UHFFFAOYSA-N COc1c(C=CNC2)c2ccc1 Chemical compound COc1c(C=CNC2)c2ccc1 DYBFVMORKXIRJA-UHFFFAOYSA-N 0.000 description 1
- SLMVMPUVHALQML-UHFFFAOYSA-N COc1nc(-c2ccccc2)nc2c1cccc2 Chemical compound COc1nc(-c2ccccc2)nc2c1cccc2 SLMVMPUVHALQML-UHFFFAOYSA-N 0.000 description 1
- BNYLGFINMVZZGA-UHFFFAOYSA-N CS(c1ccc[s]1)(=O)=O Chemical compound CS(c1ccc[s]1)(=O)=O BNYLGFINMVZZGA-UHFFFAOYSA-N 0.000 description 1
- TUFXENPTHJOHQI-UHFFFAOYSA-N Cc(c(O)ccc1)c1C(I)=O Chemical compound Cc(c(O)ccc1)c1C(I)=O TUFXENPTHJOHQI-UHFFFAOYSA-N 0.000 description 1
- XEQAJBVCRSOQEY-UHFFFAOYSA-N Cc(cc1)cc(C(F)(F)F)c1[N+]([O-])=O Chemical compound Cc(cc1)cc(C(F)(F)F)c1[N+]([O-])=O XEQAJBVCRSOQEY-UHFFFAOYSA-N 0.000 description 1
- ZPTVNYMJQHSSEA-UHFFFAOYSA-N Cc(cc1)ccc1[N+]([O-])=O Chemical compound Cc(cc1)ccc1[N+]([O-])=O ZPTVNYMJQHSSEA-UHFFFAOYSA-N 0.000 description 1
- VJOGRACTRNDJLM-UHFFFAOYSA-N Cc1c[s]c(-c2c[s]c(C)n2)n1 Chemical compound Cc1c[s]c(-c2c[s]c(C)n2)n1 VJOGRACTRNDJLM-UHFFFAOYSA-N 0.000 description 1
- APVQRVSBMIDSFS-UHFFFAOYSA-N Cc1cc(Oc(cc2)ccc2F)ccc1 Chemical compound Cc1cc(Oc(cc2)ccc2F)ccc1 APVQRVSBMIDSFS-UHFFFAOYSA-N 0.000 description 1
- 108090000317 Chymotrypsin Proteins 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 1
- 101710118188 DNA-binding protein HU-alpha Proteins 0.000 description 1
- 241001198387 Escherichia coli BL21(DE3) Species 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 241000710781 Flaviviridae Species 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- 235000008526 Galium odoratum Nutrition 0.000 description 1
- 206010019786 Hepatitis non-A non-B Diseases 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 108010093488 His-His-His-His-His-His Proteins 0.000 description 1
- QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-UWTATZPHSA-N L-Aspartic acid Natural products OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 1
- 125000000998 L-alanino group Chemical group [H]N([*])[C@](C([H])([H])[H])([H])C(=O)O[H] 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 229930182844 L-isoleucine Natural products 0.000 description 1
- 239000004395 L-leucine Substances 0.000 description 1
- 235000019454 L-leucine Nutrition 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 108010028275 Leukocyte Elastase Proteins 0.000 description 1
- 102000016799 Leukocyte elastase Human genes 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- IPCRBOOJBPETMF-UHFFFAOYSA-N N-acetylthiourea Chemical compound CC(=O)NC(N)=S IPCRBOOJBPETMF-UHFFFAOYSA-N 0.000 description 1
- 125000000729 N-terminal amino-acid group Chemical group 0.000 description 1
- 101710144128 Non-structural protein 2 Proteins 0.000 description 1
- 108091092724 Noncoding DNA Proteins 0.000 description 1
- 101710199667 Nuclear export protein Proteins 0.000 description 1
- 102000008021 Nucleoside-Triphosphatase Human genes 0.000 description 1
- 108010075285 Nucleoside-Triphosphatase Proteins 0.000 description 1
- 229910019213 POCl3 Inorganic materials 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 206010033647 Pancreatitis acute Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 108010077895 Sarcosine Proteins 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 239000012505 Superdex™ Substances 0.000 description 1
- 238000006069 Suzuki reaction reaction Methods 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 239000003875 Wang resin Substances 0.000 description 1
- RSBFMCGEQFBZBE-CIRBGYJCSA-N [(1r,2s)-2-ethenyl-1-ethoxycarbonylcyclopropyl]azanium;chloride Chemical compound Cl.CCOC(=O)[C@@]1(N)C[C@H]1C=C RSBFMCGEQFBZBE-CIRBGYJCSA-N 0.000 description 1
- BBAWTPDTGRXPDG-UHFFFAOYSA-N [1,3]thiazolo[4,5-b]pyridine Chemical compound C1=CC=C2SC=NC2=N1 BBAWTPDTGRXPDG-UHFFFAOYSA-N 0.000 description 1
- PHPUAZSMVFYNDC-UHFFFAOYSA-N [C-]#[N+]C1=CC=[C+]([CH2-])C=C1.[C-]#[N+]CC1=CC=C[C+]([CH2-])=C1.[C-]#[N+]CC1=CC=[C+]([CH2-])C=C1.[CH2-][C+]1=CC(OC)=CC=C1.[CH2-][C+]1=CC=C(C)C=C1.[CH2-][C+]1=CC=C(Cl)C=C1.[CH2-][C+]1=CC=C(F)C=C1.[CH2-][C+]1=CC=C(N)C(C)=C1.[CH2-][C+]1=CC=C(NC(C)=O)C=C1.[CH2-][C+]1=CC=C([N+](=O)[O-])C=C1.[CH2-][C+]1=CC=CC(C(C)=O)=C1.[CH2-][C+]1=CC=CC(C)=C1.[CH2-][C+]1=CC=CC(C2=CC=CC=C2)=C1.[CH2-][C+]1=CC=CC(CCO)=C1.[CH2-][C+]1=CC=CC(CO)=C1.[CH2-][C+]1=CC=CC(OC2=CC=C(F)C=C2)=C1.[CH2-][C+]1=CC=CC=C1 Chemical compound [C-]#[N+]C1=CC=[C+]([CH2-])C=C1.[C-]#[N+]CC1=CC=C[C+]([CH2-])=C1.[C-]#[N+]CC1=CC=[C+]([CH2-])C=C1.[CH2-][C+]1=CC(OC)=CC=C1.[CH2-][C+]1=CC=C(C)C=C1.[CH2-][C+]1=CC=C(Cl)C=C1.[CH2-][C+]1=CC=C(F)C=C1.[CH2-][C+]1=CC=C(N)C(C)=C1.[CH2-][C+]1=CC=C(NC(C)=O)C=C1.[CH2-][C+]1=CC=C([N+](=O)[O-])C=C1.[CH2-][C+]1=CC=CC(C(C)=O)=C1.[CH2-][C+]1=CC=CC(C)=C1.[CH2-][C+]1=CC=CC(C2=CC=CC=C2)=C1.[CH2-][C+]1=CC=CC(CCO)=C1.[CH2-][C+]1=CC=CC(CO)=C1.[CH2-][C+]1=CC=CC(OC2=CC=C(F)C=C2)=C1.[CH2-][C+]1=CC=CC=C1 PHPUAZSMVFYNDC-UHFFFAOYSA-N 0.000 description 1
- FAVKJBMIWORATA-UHFFFAOYSA-N [CH2-][C+](=O)C1=C(C)C(O)=CC=C1.[CH2-][C+](=O)C1=CC(O)=CC=C1.[CH2-][C+](=O)C1=CC=CC=C1 Chemical compound [CH2-][C+](=O)C1=C(C)C(O)=CC=C1.[CH2-][C+](=O)C1=CC(O)=CC=C1.[CH2-][C+](=O)C1=CC=CC=C1 FAVKJBMIWORATA-UHFFFAOYSA-N 0.000 description 1
- YIHWDGPNVQNBRR-UHFFFAOYSA-N [CH2-][C+](=O)CC(C)(C)C Chemical compound [CH2-][C+](=O)CC(C)(C)C YIHWDGPNVQNBRR-UHFFFAOYSA-N 0.000 description 1
- YUZFOAMDQINZHP-PGSFDYSTSA-N [CH2-][C+](=O)CC(C)(C)C.[CH2-][C+](=O)CC1CCCCC1.[CH2-][C+](=O)[C@@H](C)C1CCCCC1.[CH2-][C+](=O)[C@@H](CC(=O)O)C1CCCCC1.[CH2-][C+](=O)[C@@H](CC(=O)OCC(C)(C)C)C1CCCCC1.[CH2-][C+](=O)[C@@H](O)C1CCCCC1.[CH2-][C+](C)=O Chemical compound [CH2-][C+](=O)CC(C)(C)C.[CH2-][C+](=O)CC1CCCCC1.[CH2-][C+](=O)[C@@H](C)C1CCCCC1.[CH2-][C+](=O)[C@@H](CC(=O)O)C1CCCCC1.[CH2-][C+](=O)[C@@H](CC(=O)OCC(C)(C)C)C1CCCCC1.[CH2-][C+](=O)[C@@H](O)C1CCCCC1.[CH2-][C+](C)=O YUZFOAMDQINZHP-PGSFDYSTSA-N 0.000 description 1
- XIEBLWACWQPTJC-UHFFFAOYSA-N [CH2-][C+](=O)CC(C)(C)C.[CH2-][C+](=O)OC(C)C(C)(C)C.[CH2-][C+](=O)OC1CCC1.[CH2-][C+](=O)OC1CCCC1.[CH2-][C+](=O)OC1CCCCC1.[CH2-][C+](=O)OCC(C)(C)N Chemical compound [CH2-][C+](=O)CC(C)(C)C.[CH2-][C+](=O)OC(C)C(C)(C)C.[CH2-][C+](=O)OC1CCC1.[CH2-][C+](=O)OC1CCCC1.[CH2-][C+](=O)OC1CCCCC1.[CH2-][C+](=O)OCC(C)(C)N XIEBLWACWQPTJC-UHFFFAOYSA-N 0.000 description 1
- LJMJGVUUHMIYCZ-XYRKCJFDSA-N [CH2-][C+](=O)NC(C)(C)C.[CH2-][C+](=O)NC(C)(C)C(N)=O.[CH2-][C+](=O)NC(C)(C)CC.[CH2-][C+](=O)NC(C)(C)CO.[CH2-][C+](=O)NC(C)(C)COC.[CH2-][C+](=O)NC(C)(CC)CC.[CH2-][C+](=O)NC(C)C.[CH2-][C+](=O)NC1CCCCC1.[CH2-][C+](=O)NCC.[CH2-][C+](=O)N[C@@H](C)C(C)(C)C.[CH2-][C+](=O)N[C@H](C)C(C)(C)C.[CH2-][C+](=O)N[C@H](C)C(N)=O.[CH2-][C+](=O)N[C@H](CC)C(C)(C)C Chemical compound [CH2-][C+](=O)NC(C)(C)C.[CH2-][C+](=O)NC(C)(C)C(N)=O.[CH2-][C+](=O)NC(C)(C)CC.[CH2-][C+](=O)NC(C)(C)CO.[CH2-][C+](=O)NC(C)(C)COC.[CH2-][C+](=O)NC(C)(CC)CC.[CH2-][C+](=O)NC(C)C.[CH2-][C+](=O)NC1CCCCC1.[CH2-][C+](=O)NCC.[CH2-][C+](=O)N[C@@H](C)C(C)(C)C.[CH2-][C+](=O)N[C@H](C)C(C)(C)C.[CH2-][C+](=O)N[C@H](C)C(N)=O.[CH2-][C+](=O)N[C@H](CC)C(C)(C)C LJMJGVUUHMIYCZ-XYRKCJFDSA-N 0.000 description 1
- OCMJRKMNFWDZRT-UHFFFAOYSA-N [CH2-][C+](=O)NC1=C(C)C=CC=C1C.[CH2-][C+](=O)NC1=C(C)C=CC=C1C.[CH2-][C+](=O)NC1=NC=CS1.[CH2-][C+](=O)NCC1=CC=CC=C1 Chemical compound [CH2-][C+](=O)NC1=C(C)C=CC=C1C.[CH2-][C+](=O)NC1=C(C)C=CC=C1C.[CH2-][C+](=O)NC1=NC=CS1.[CH2-][C+](=O)NCC1=CC=CC=C1 OCMJRKMNFWDZRT-UHFFFAOYSA-N 0.000 description 1
- QFDAMVAABYTIFE-UHFFFAOYSA-N [CH2-][C+](=O)NCCC Chemical compound [CH2-][C+](=O)NCCC QFDAMVAABYTIFE-UHFFFAOYSA-N 0.000 description 1
- BSIODQPWRJGQIN-BYZBDTJCSA-N [CH2-][C+](=O)N[C@H](C)C(C)(C)C.[CH2-][C+](=O)N[C@H](C)C(C)(C)C Chemical compound [CH2-][C+](=O)N[C@H](C)C(C)(C)C.[CH2-][C+](=O)N[C@H](C)C(C)(C)C BSIODQPWRJGQIN-BYZBDTJCSA-N 0.000 description 1
- ICKIZHSZTOPNDF-NSMBSDNGSA-N [CH2-][C+](=O)OC1CCSC1.[CH2-][C+](=O)O[C@@H]1CCOC1.[CH2-][C+](=O)O[C@H]1CCOC1 Chemical compound [CH2-][C+](=O)OC1CCSC1.[CH2-][C+](=O)O[C@@H]1CCOC1.[CH2-][C+](=O)O[C@H]1CCOC1 ICKIZHSZTOPNDF-NSMBSDNGSA-N 0.000 description 1
- CXSBDTFAHGEFKC-UHFFFAOYSA-N [CH2-][C+](=S)NC(C)(C)C.[CH2-][C+](=S)NC1CCCCC1 Chemical compound [CH2-][C+](=S)NC(C)(C)C.[CH2-][C+](=S)NC1CCCCC1 CXSBDTFAHGEFKC-UHFFFAOYSA-N 0.000 description 1
- VLAWTOAILWTUJE-UHFFFAOYSA-N [CH2-][C+](C)(C)SCC1=CC=C(C)C=C1.[CH2-][C+](C)(C)SCNC(C)=O.[CH2-][C+](C)CC.[CH2-][C+](C)CC.[CH2-][C+](C)OC.[CH2-][C+](C)OC.[CH2-][C+](C)OC(C)(C)C.[CH2-][C+](C)OCC1=CC=CC=C1.[CH2-][C+](O)C1CCCCC1 Chemical compound [CH2-][C+](C)(C)SCC1=CC=C(C)C=C1.[CH2-][C+](C)(C)SCNC(C)=O.[CH2-][C+](C)CC.[CH2-][C+](C)CC.[CH2-][C+](C)OC.[CH2-][C+](C)OC.[CH2-][C+](C)OC(C)(C)C.[CH2-][C+](C)OCC1=CC=CC=C1.[CH2-][C+](O)C1CCCCC1 VLAWTOAILWTUJE-UHFFFAOYSA-N 0.000 description 1
- SWLGTNLRTUGMHV-UHFFFAOYSA-N [CH2-][C+](C)C1CCCCC1 Chemical compound [CH2-][C+](C)C1CCCCC1 SWLGTNLRTUGMHV-UHFFFAOYSA-N 0.000 description 1
- WFPUXFVBDJXKRP-UHFFFAOYSA-N [CH2-][C+](O)C1CCCCC1 Chemical compound [CH2-][C+](O)C1CCCCC1 WFPUXFVBDJXKRP-UHFFFAOYSA-N 0.000 description 1
- YDWJUTOFAVCQPM-UHFFFAOYSA-N [CH2-][C+]1=CC=C2OCOC2=C1.[CH2-][C+]1=NC(CC)=CS1 Chemical compound [CH2-][C+]1=CC=C2OCOC2=C1.[CH2-][C+]1=NC(CC)=CS1 YDWJUTOFAVCQPM-UHFFFAOYSA-N 0.000 description 1
- GMRODCVDNXSFAA-UHFFFAOYSA-N [CH2-][C+]1=CC=CC(C)=C1 Chemical compound [CH2-][C+]1=CC=CC(C)=C1 GMRODCVDNXSFAA-UHFFFAOYSA-N 0.000 description 1
- WUXSPKVBGCLHTB-UHFFFAOYSA-N [CH2-][C+]1=CC=CN=C1.[CH2-][C+]1=CC=CS1.[CH2-][C+]1=CC=NC=N1.[CH2-][C+]1=CN=CC=N1.[CH2-][C+]1=CSC=N1.[CH2-][C+]1=NC=CS1.[CH2-][NH+]1CCC(C)CC1.[CH2-][NH+]1CCC(OC)CC1.[CH2-][NH+]1CCCCC1.[CH2-][NH+]1CCN(C)CC1.[CH2-][NH+]1CCOCC1 Chemical compound [CH2-][C+]1=CC=CN=C1.[CH2-][C+]1=CC=CS1.[CH2-][C+]1=CC=NC=N1.[CH2-][C+]1=CN=CC=N1.[CH2-][C+]1=CSC=N1.[CH2-][C+]1=NC=CS1.[CH2-][NH+]1CCC(C)CC1.[CH2-][NH+]1CCC(OC)CC1.[CH2-][NH+]1CCCCC1.[CH2-][NH+]1CCN(C)CC1.[CH2-][NH+]1CCOCC1 WUXSPKVBGCLHTB-UHFFFAOYSA-N 0.000 description 1
- JOUFTBKXUSTJIY-UHFFFAOYSA-N [CH2-][C+]1=CN(C(C)(C)C)N=C1 Chemical compound [CH2-][C+]1=CN(C(C)(C)C)N=C1 JOUFTBKXUSTJIY-UHFFFAOYSA-N 0.000 description 1
- HSDMDUXCOMPLBC-UHFFFAOYSA-N [CH2-][CH+]C1=CC=C2OCOC2=C1.[CH2-][CH+]C1=NC=CC=C1 Chemical compound [CH2-][CH+]C1=CC=C2OCOC2=C1.[CH2-][CH+]C1=NC=CC=C1 HSDMDUXCOMPLBC-UHFFFAOYSA-N 0.000 description 1
- PBGVMIDTGGTBFS-UHFFFAOYSA-N [CH2-][CH+]CCC1=CC=CC=C1 Chemical compound [CH2-][CH+]CCC1=CC=CC=C1 PBGVMIDTGGTBFS-UHFFFAOYSA-N 0.000 description 1
- XUGWDICFJDKOST-UHFFFAOYSA-N [CH2-][OH+]C(C)C.[CH2-][OH+]CC.[CH2-][OH+]CC(C)C.[CH2-][OH+]CCC Chemical compound [CH2-][OH+]C(C)C.[CH2-][OH+]CC.[CH2-][OH+]CC(C)C.[CH2-][OH+]CCC XUGWDICFJDKOST-UHFFFAOYSA-N 0.000 description 1
- VMCOXOTYZADDJP-UHFFFAOYSA-N [CH2-][OH+]C1=CC=NC2=C1C=CC(C)=C2 Chemical compound [CH2-][OH+]C1=CC=NC2=C1C=CC(C)=C2 VMCOXOTYZADDJP-UHFFFAOYSA-N 0.000 description 1
- IKSRRQUCMLKLSY-UHFFFAOYSA-N [CH2-][OH+]C1CCCCC1 Chemical compound [CH2-][OH+]C1CCCCC1 IKSRRQUCMLKLSY-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 150000001241 acetals Chemical class 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 201000003229 acute pancreatitis Diseases 0.000 description 1
- 125000002015 acyclic group Chemical group 0.000 description 1
- 150000001263 acyl chlorides Chemical class 0.000 description 1
- 150000001266 acyl halides Chemical class 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 1
- 125000005256 alkoxyacyl group Chemical group 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 150000004808 allyl alcohols Chemical group 0.000 description 1
- BHELZAPQIKSEDF-UHFFFAOYSA-N allyl bromide Chemical compound BrCC=C BHELZAPQIKSEDF-UHFFFAOYSA-N 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- MMCPOSDMTGQNKG-UHFFFAOYSA-N anilinium chloride Chemical compound Cl.NC1=CC=CC=C1 MMCPOSDMTGQNKG-UHFFFAOYSA-N 0.000 description 1
- 229940019748 antifibrinolytic proteinase inhibitors Drugs 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009697 arginine Nutrition 0.000 description 1
- 125000005160 aryl oxy alkyl group Chemical group 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 239000003637 basic solution Substances 0.000 description 1
- VVCLBQFBKZQOAF-NSHDSACASA-N benzyl (2s)-pyrrolidine-2-carboxylate Chemical class O=C([C@H]1NCCC1)OCC1=CC=CC=C1 VVCLBQFBKZQOAF-NSHDSACASA-N 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000005997 bromomethyl group Chemical group 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- MOIPGXQKZSZOQX-UHFFFAOYSA-N carbonyl bromide Chemical compound BrC(Br)=O MOIPGXQKZSZOQX-UHFFFAOYSA-N 0.000 description 1
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 1
- 150000003857 carboxamides Chemical class 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- AEULIVPVIDOLIN-UHFFFAOYSA-N cep-11981 Chemical compound C1=C2C3=C4CNC(=O)C4=C4C5=CN(C)N=C5CCC4=C3N(CC(C)C)C2=CC=C1NC1=NC=CC=N1 AEULIVPVIDOLIN-UHFFFAOYSA-N 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229960002376 chymotrypsin Drugs 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 229910052681 coesite Inorganic materials 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- GBRBMTNGQBKBQE-UHFFFAOYSA-L copper;diiodide Chemical compound I[Cu]I GBRBMTNGQBKBQE-UHFFFAOYSA-L 0.000 description 1
- 229910052906 cristobalite Inorganic materials 0.000 description 1
- 239000010779 crude oil Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 150000001930 cyclobutanes Chemical class 0.000 description 1
- KTHXBEHDVMTNOH-UHFFFAOYSA-N cyclobutanol Chemical compound OC1CCC1 KTHXBEHDVMTNOH-UHFFFAOYSA-N 0.000 description 1
- LWABFMLTBBNLTA-UHFFFAOYSA-N cyclobutyl carbamate Chemical compound NC(=O)OC1CCC1 LWABFMLTBBNLTA-UHFFFAOYSA-N 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 150000001942 cyclopropanes Chemical class 0.000 description 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000000326 densiometry Methods 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- AQEFLFZSWDEAIP-UHFFFAOYSA-N di-tert-butyl ether Chemical compound CC(C)(C)OC(C)(C)C AQEFLFZSWDEAIP-UHFFFAOYSA-N 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- BGRWYRAHAFMIBJ-UHFFFAOYSA-N diisopropylcarbodiimide Natural products CC(C)NC(=O)NC(C)C BGRWYRAHAFMIBJ-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- CLPHAYNBNTVRDI-UHFFFAOYSA-N ditert-butyl propanedioate Chemical compound CC(C)(C)OC(=O)CC(=O)OC(C)(C)C CLPHAYNBNTVRDI-UHFFFAOYSA-N 0.000 description 1
- NLEBIOOXCVAHBD-QKMCSOCLSA-N dodecyl beta-D-maltoside Chemical compound O[C@@H]1[C@@H](O)[C@H](OCCCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 NLEBIOOXCVAHBD-QKMCSOCLSA-N 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 239000012039 electrophile Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 229940125532 enzyme inhibitor Drugs 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- RSBFMCGEQFBZBE-HNJRQZNRSA-N ethyl (1s,2s)-1-amino-2-ethenylcyclopropane-1-carboxylate;hydrochloride Chemical compound Cl.CCOC(=O)[C@]1(N)C[C@H]1C=C RSBFMCGEQFBZBE-HNJRQZNRSA-N 0.000 description 1
- NBJXCTLFPNBZSG-UHFFFAOYSA-N ethyl 1-amino-2-ethenylcyclopropane-1-carboxylate Chemical compound CCOC(=O)C1(N)CC1C=C NBJXCTLFPNBZSG-UHFFFAOYSA-N 0.000 description 1
- QUGJYNGNUBHTNS-UHFFFAOYSA-N ethyl 2-(benzhydrylideneamino)acetate Chemical compound C=1C=CC=CC=1C(=NCC(=O)OCC)C1=CC=CC=C1 QUGJYNGNUBHTNS-UHFFFAOYSA-N 0.000 description 1
- UREBWPXBXRYXRJ-UHFFFAOYSA-N ethyl acetate;methanol Chemical compound OC.CCOC(C)=O UREBWPXBXRYXRJ-UHFFFAOYSA-N 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000010265 fast atom bombardment Methods 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 230000008570 general process Effects 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 229960002743 glutamine Drugs 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 108700012707 hepatitis C virus NS3 Proteins 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 150000002431 hydrogen Chemical group 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 150000002463 imidates Chemical class 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007919 intrasynovial administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 150000002513 isocyanates Chemical class 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 108010026228 mRNA guanylyltransferase Proteins 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 229910000000 metal hydroxide Inorganic materials 0.000 description 1
- GRWIABMEEKERFV-UHFFFAOYSA-N methanol;oxolane Chemical compound OC.C1CCOC1 GRWIABMEEKERFV-UHFFFAOYSA-N 0.000 description 1
- HRDXJKGNWSUIBT-UHFFFAOYSA-N methoxybenzene Chemical group [CH2]OC1=CC=CC=C1 HRDXJKGNWSUIBT-UHFFFAOYSA-N 0.000 description 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
- LSHLWAMYTKXJPL-HCSZTWNASA-N methyl (1r,2s)-1-amino-2-ethenylcyclopropane-1-carboxylate;hydrochloride Chemical compound Cl.COC(=O)[C@@]1(N)C[C@H]1C=C LSHLWAMYTKXJPL-HCSZTWNASA-N 0.000 description 1
- MMSKTMKTGVHMAV-PRHODGIISA-N methyl (1r,2s)-2-ethenyl-1-[(2-methylpropan-2-yl)oxycarbonylamino]cyclopropane-1-carboxylate Chemical compound CC(C)(C)OC(=O)N[C@]1(C(=O)OC)C[C@H]1C=C MMSKTMKTGVHMAV-PRHODGIISA-N 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 1
- YRCHYHRCBXNYNU-UHFFFAOYSA-N n-[[3-fluoro-4-[2-[5-[(2-methoxyethylamino)methyl]pyridin-2-yl]thieno[3,2-b]pyridin-7-yl]oxyphenyl]carbamothioyl]-2-(4-fluorophenyl)acetamide Chemical compound N1=CC(CNCCOC)=CC=C1C1=CC2=NC=CC(OC=3C(=CC(NC(=S)NC(=O)CC=4C=CC(F)=CC=4)=CC=3)F)=C2S1 YRCHYHRCBXNYNU-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 210000004897 n-terminal region Anatomy 0.000 description 1
- 239000006225 natural substrate Substances 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229940127073 nucleoside analogue Drugs 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000033116 oxidation-reduction process Effects 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 238000005897 peptide coupling reaction Methods 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 150000003053 piperidines Chemical class 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000002064 post-exposure prophylaxis Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000004237 preparative chromatography Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 150000003147 proline derivatives Chemical class 0.000 description 1
- UFUASNAHBMBJIX-UHFFFAOYSA-N propan-1-one Chemical group CC[C]=O UFUASNAHBMBJIX-UHFFFAOYSA-N 0.000 description 1
- VVWRJUBEIPHGQF-UHFFFAOYSA-N propan-2-yl n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)N=NC(=O)OC(C)C VVWRJUBEIPHGQF-UHFFFAOYSA-N 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000011945 regioselective hydrolysis Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 229940043230 sarcosine Drugs 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- DVWOYOSIEJRHKW-UIRZNSHLSA-M sodium (2S)-2-[[(2S)-2-[[(4,4-difluorocyclohexyl)-phenylmethoxy]carbonylamino]-4-methylpentanoyl]amino]-1-hydroxy-3-[(3S)-2-oxopyrrolidin-3-yl]propane-1-sulfonate Chemical compound FC1(CCC(CC1)C(OC(=O)N[C@H](C(=O)N[C@H](C(S(=O)(=O)[O-])O)C[C@H]1C(NCC1)=O)CC(C)C)C1=CC=CC=C1)F.[Na+] DVWOYOSIEJRHKW-UIRZNSHLSA-M 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 125000003003 spiro group Chemical group 0.000 description 1
- 239000012258 stirred mixture Substances 0.000 description 1
- 229910052682 stishovite Inorganic materials 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 150000003871 sulfonates Chemical class 0.000 description 1
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- NYBWUHOMYZZKOR-UHFFFAOYSA-N tes-adt Chemical class C1=C2C(C#C[Si](CC)(CC)CC)=C(C=C3C(SC=C3)=C3)C3=C(C#C[Si](CC)(CC)CC)C2=CC2=C1SC=C2 NYBWUHOMYZZKOR-UHFFFAOYSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 150000003536 tetrazoles Chemical class 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 150000007979 thiazole derivatives Chemical class 0.000 description 1
- 150000003548 thiazolidines Chemical class 0.000 description 1
- HNKJADCVZUBCPG-UHFFFAOYSA-N thioanisole Chemical compound CSC1=CC=CC=C1 HNKJADCVZUBCPG-UHFFFAOYSA-N 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- 150000003585 thioureas Chemical class 0.000 description 1
- 206010043778 thyroiditis Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000003146 transient transfection Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- ZGYICYBLPGRURT-UHFFFAOYSA-N tri(propan-2-yl)silicon Chemical compound CC(C)[Si](C(C)C)C(C)C ZGYICYBLPGRURT-UHFFFAOYSA-N 0.000 description 1
- 229910052905 tridymite Inorganic materials 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 1
- XZZNDPSIHUTMOC-UHFFFAOYSA-N triphenyl phosphate Chemical compound C=1C=CC=CC=1OP(OC=1C=CC=CC=1)(=O)OC1=CC=CC=C1 XZZNDPSIHUTMOC-UHFFFAOYSA-N 0.000 description 1
- UCPYLLCMEDAXFR-UHFFFAOYSA-N triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 description 1
- 238000001665 trituration Methods 0.000 description 1
- 229960004441 tyrosine Drugs 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 230000008957 viral persistence Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 238000002424 x-ray crystallography Methods 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P13/00—Preparation of nitrogen-containing organic compounds
- C12P13/02—Amides, e.g. chloramphenicol or polyamides; Imides or polyimides; Urethanes, i.e. compounds comprising N-C=O structural element or polyurethanes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/081—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P41/00—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture
- C12P41/003—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture by ester formation, lactone formation or the inverse reactions
- C12P41/005—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture by ester formation, lactone formation or the inverse reactions by esterification of carboxylic acid groups in the enantiomers or the inverse reaction
Abstract
-
- B is H, a C6 or C10 aryl, C7-16 aralkyl; Het or (lower alkyl)-Het, all of which optionally substituted with C1-6 alkyl; C1-6 alkoxy; C1-6 alkanoyl; hydroxy; hydroxyalkyl; halo; haloalkyl; nitro; cyano; cyanoalkyl; amino optionally substituted with C1-6 alkyl; amido; or (lower alkyl)amide; or
- B is an acyl derivative of formula R4—C(O)—; a carboxyl of formula R4—O—C(O)—; an amide of formula R4—N(R5)—C(O)—; a thioamide of formula R4—N(R5)—C(S)—; or a sulfonyl of formula R4—SO2; R5 is H or C1-6 alkyl; and
- Y is H or C1-6 alkyl;
- R3 is C1-8 alkyl, C3-7 cycloalkyl, or C4-10 alkylcycloalkyl, all optionally substituted with hydroxy, C1-6 alkoxy, C1-6 thioalkyl, amido, (lower alkyl)amido, C6 or C10 aryl, or C7-16 aralkyl;
- R2 is CH2—R20, NH—R20, O—R20 or S—R20, wherein R20 is a saturated or unsaturated C3-7 cycloalkyl or C4-10 (alkylcycloalkyl), all of which being optionally mono-, di- or tri-substituted with R21,
- or R20 is a C6 or C10 aryl or C7-14 aralkyl optionally substituted, or R20 is Het or (lower alkyl)-Het, both optionally substituted, Het or (lower alkyl)-Het; carboxyl; carboxy(lower alkyl); C6 or C10 aryl, C7-14 aralkyl or Het, said aryl, aralkyl or Het being optionally substituted; and
- R1 is H; C1-6 alkyl, C3-7 cycloalkyl, C2-6 alkenyl, or C2-6 alkynyl, all optionally substituted with halogen; or a pharmaceutically acceptable salt or ester thereof.
Description
This application is a continuation of U.S. application Ser. No. 09/849,057, filed on May 4, 2001, U.S. Pat. No. 6,410,531 which is a divisional of U.S. application Ser. No. 09/368,866, filed on Aug. 5, 1999, U.S. Pat. No. 6,323,180 which claims the benefit of U.S. Provisional Application No. 60/095,931, filed Aug. 10, 1998, and U.S. Provisional Application No. 60/132,386, filed May 4, 1999. All of the aforementioned applications are herein incorporated by reference.
The present invention relates to compounds, process for their synthesis, compositions and methods for the treatment of hepatitis C virus (HCV) infection. In particular, the present invention provides novel peptide analogs, pharmaceutical compositions containing such analogs and methods for using these analogs in the treatment of HCV infection. The present invention also provides processes and intermediates for the synthesis of these peptide analogs.
Hepatitis C virus (HCV) is the major etiological agent of post-transfusion and community-acquired non-A non-B hepatitis worldwide. It is estimated that over 150 million people worldwide are infected by the virus. A high percentage of carriers become chronically infected and many progress to chronic liver disease, so-called chronic hepatitis C. This group is in turn at high risk for serious liver disease such as liver cirrhosis, hepatocellular carcinoma and terminal liver disease leading to death. The mechanism by which HCV establishes viral persistence and causes a high rate of chronic liver disease has not been thoroughly elucidated. It is not known how HCV interacts with and evades the host immune system. In addition, the roles of cellular and humoral immune responses in protection against HCV infection and disease have yet to be established. Immunoglobulins have been reported for prophylaxis of transfusion-associated viral hepatitis, however, the Center for Disease Control does not presently recommend immunoglobulins treatment for this purpose. The lack of an effective protective immune response is hampering the development of a vaccine or adequate post-exposure prophylaxis measures, so in the near-term, hopes are firmly pinned on antiviral interventions.
Various clinical studies have been conducted with the goal of identifying pharmaceutical agents capable of effectively treating HCV infection in patients afflicted with chronic hepatitis C. These studies have involved the use of interferon-alpha, alone and in combination with other antiviral agents. Such studies have shown that a substantial number of the participants do not respond to these therapies, and of those that do respond favorably, a large proportion were found to relapse after termination of treatment.
Until recently, interferon (IFN) was the only available therapy of proven benefit approved in the clinic for patients with chronic hepatitis C. However the sustained response rate is low, and interferon treatment also induces severe side-effects (i.e. retinopathy, thyroiditis, acute pancreatitis, depression) that diminish the quality of life of treated patients. Recently, interferon in combination with ribavirin has been approved for patients non-responsive to IFN alone. However, the side effects caused by IFN are not alleviated with this combination therapy.
Therefore, a need exists for the development of effective antiviral agents for treatment of HCV infection that overcomes the limitations of existing pharmaceutical therapies.
HCV is an enveloped positive strand RNA virus in the Flaviviridae family. The single strand HCV RNA genome is approximately 9500 nucleotides in length and has a single open reading frame (ORF) encoding a single large polyprotein of about 3000 amino acids. In infected cells, this polyprotein is cleaved at multiple sites by cellular and viral proteases to produce the structural and non-structural (NS) proteins. In the case of HCV, the generation of mature nonstructural proteins (NS2, NS3, NS4A, NS4B, NS5A, and NS5B) is effected by two viral proteases. The first one, as yet poorly characterized, cleaves at the NS2-NS3 junction; the second one is a serine protease contained within the N-terminal region of NS3 (henceforth referred to as NS3 protease) and mediates all the subsequent cleavages downstream of NS3, both in cis, at the NS3-NS4A cleavage site, and in trans, for the remaining NS4A-NS4B, NS4B-NS5A, NS5A-NS5B sites. The NS4A protein appears to serve multiple functions, acting as a cofactor for the NS3 protease and possibly assisting in the membrane localization of NS3 and other viral replicase components. The complex formation of the NS3 protein with NS4A seems necessary to the processing events, enhancing the proteolytic efficiency at all of the sites. The NS3 protein also exhibits nucleoside triphosphatase and RNA helicase activities. NS5B is a RNA-dependent RNA polymerase that is involved in the replication of HCV.
A general strategy for the development of antiviral agents is to inactivate virally encoded enzymes that are essential for the replication of the virus. In this vein, patent application WO 97/06804 describes the (−) enantiomer of the nucleoside analogue cytosine-1,3-oxathiolane (also known as 3TC) as active against HCV. This compound, although reported as safe in previous clinical trials against HIV and HBV, has yet to be clinically proven active against HCV and its mechanism of action against the virus has yet to be reported.
Intense efforts to discover compounds which inhibit the NS3 protease or RNA helicase of HCV have led to the following disclosures:
-
- U.S. Pat. No. 5,633,388 describes heterocyclic-substituted carboxamides and analogues as being active against HCV. These compounds are directed against the helicase activity of the NS3 protein of the virus but clinical tests have not yet been reported.
- A phenanthrenequinone has been reported by Chu et al., (Tel. Lett., (1996), 7229-7232) to have activity against the HCV NS3 protease in vitro. No further development on this compound has been reported.
- A paper presented at the Ninth International Conference on Antiviral Research, Urabandai, Fukyshima, Japan (1996) (Antiviral Research, (1996), 30, 1, A23 (abstract 19)) reports thiazolidine derivatives to be inhibitory to the HCV protease.
Several studies have reported compounds inhibitory to other serine proteases, such as human leukocyte elastase. One family of these compounds is reported in WO 95/33764 (Hoechst Marion Roussel, 1995). The peptides disclosed in this application are morpholinylcarbonyl-benzoyl-peptide analogues that are structurally different from the peptides of the present invention.
-
- WO 98/17679 from Vertex Pharmaceuticals Inc. discloses inhibitors of serine protease, particularly, Hepatitis C virus NS3 protease. These inhibitors are peptide analogues based on the NS5A/5B natural substrate. Although several tripeptides are disclosed, all of these peptide analogues contain C-terminal activated carbonyl function as an essential feature. These analogues were also reported to be active against other serine protease and are therefore not specific for HCV NS3 protease.
- Hoffman LaRoche has also reported hexapeptides that are proteinase inhibitors useful as antiviral agents for the treatment of HCV infection. These peptides contain an aldehyde or a bororric acid at the C-terminus.
- Steinkahler et al. and Ingallinella et al, have published on NS4A-4B product inhibition (Biochemistry (1998), 37, 8899-8905 and 8906-8914). However, the peptides and peptide analogues presented do not include nor do they lead to the design of the peptides of the present invention.
One advantage of the present invention is that it provides tripeptides that are inhibitory to the NS3 protease of the hepatitis C virus.
A further advantage of one aspect of the present invention resides in the fact that these peptides specifically inhibit the NS3 protease and do not show significant inhibitory activity at concentrations up to 300 μM against other serine proteases such as human leukocyte elastase (HLE), porcine pancreatic elastase (PPE), or bovine pancreatic chymotrypsin, or cysteine proteases such as human liver cathepsin B (Cat B).
A further advantage of the present invention is that it provides small peptides of low molecular weight that may be capable of penetrating cell membranes and may be active in cell culture and in vivo with good pharmacokinetic profile.
Included in the scope of the invention are racemates, diastereoisomers and optical isomers of a compound of formula (I):
wherein
wherein
-
- B is H, a C6 or C10 aryl, C7-16 aralkyl; Het or (lower alkyl)-Het, all of which optionally substituted with C1-6 alkyl; C1-6 alkoxy; C1-6 alkanoyl; hydroxy; hydroxyalkyl; halo; haloalkyl; nitro; cyano; cyanoalkyl; amino optionally substituted with C1-6 alkyl; amido; or (lower alkyl)amide;
- or B is an acyl derivative of formula R4—C(O)—; a carboxyl of formula R4—O—C(O)—; an amide of formula R4—N(R5)—C(O)—; a thioamide of formula R4—N(R5)—C(S)—; or a sulfonyl of formula R4—SO2 wherein
- R4 is
- (i) C1-10 alkyl optionally substituted with carboxyl, C1-6 alkanoyl, hydroxy, C1-6 alkoxy, amino optionally mono- or di-substituted with C1-6 alkyl, amido, or (lower alkyl) amide;
- (ii) C3-7 cycloalkyl, C3-7 cycloalkoxy, or C4-10 alkylcycloalkyl, all optionally substituted with hydroxy, carboxyl, (C1-6 alkoxy)carbonyl, amino optionally mono- or di-substituted with C1-6 alkyl, amido, or (lower alkyl) amide;
- (iii) amino optionally mono- or di-substituted with C1-6 alkyl; amido; or (lower alkyl)amide;
- (iv) C6 or C10 aryl or C7-16 aralkyl, all optionally substituted with C1-6 alkyl, hydroxy, amido, (lower alkyl)amide, or amino optionally mono- or di-substituted with C16 alkyl; or
- (v) Het or (lower alkyl)-Het, both optionally substituted with C1-6 alkyl, hydroxy, amido, (lower alkyl) amide, or amino optionally mono- or di-substituted with C1-6 alkyl;
- R5 is H or C1-6 alkyl;
- with the proviso that when R4 is an amide or a thioamide, R4 is not (ii) a cycloalkoxy; and
- Y is H or C1-6 alkyl;
- R3 is C1-8 alkyl, C3-7 cycloalkyl, or C4-10 alkylcycloalkyl, all optionally substituted with hydroxy, C1-6 alkoxy, C1-6 thioalkyl, amido, (lower alkyl) amido, C6 or C10 aryl, or C7-16 aralkyl;
- R2 is CH2—R20, NH—R20, O—R20 or S—R20, wherein R20 is a saturated or unsaturated C3-7 cycloalkyl or C4-10(alkylcycloalkyl), all of which being optionally mono-, di- or tri-substituted with R21,
- or R20 is a C6 or C10 aryl or C7-14 aralkyl, all optionally mono-, di- or tri-substituted with R21,
- or R20 is Het or (lower alkyl)-Het, both optionally mono-, di- or tri-substituted with R21,
- wherein each R21 is independently C1-6 alkyl; C1-6 alkoxy; lower thioalkyl; sulfonyl; NO2; OH; SH; halo; haloalkyl; amino optionally mono- or di-substituted with C1-6 alkyl, C6 or C10 aryl, C7-14 aralkyl, Het or (lower alkyl)-Het;
- amido optionally mono-substituted with C1-6 alkyl, C6 or C10 aryl, C7-14 aralkyl, Het or (lower alkyl)-Het;
- carboxyl; carboxy(lower alkyl); C6 or C10 aryl, C7-14 aralkyl or Het, said aryl, aralkyl or Het being optionally substituted with R22;
- wherein R22 is C1-6 alkyl; C3-7 cycloalkyl; C1-6 alkoxy; amino optionally mono- or di-substituted with C1-6 alkyl; sulfonyl; (lower alkyl)sulfonyl; NO2; OH; SH; halo; haloalkyl; carboxyl; amide; (lower alkyl)amide; or Het optionally substituted with C1-6 alkyl
- R1 is H, C1-6 alkyl, C3-7 cycloalkyl, C2-6 alkenyl, or C2-6 alkynyl, all optionally substituted with halogen;
or a pharmaceutically acceptable salt or ester thereof.
Included within the scope of this invention is a pharmaceutical composition comprising an anti-hepatitis C virally effective amount of a compound of formula I, or a therapeutically acceptable salt or ester thereof, in admixture with a pharmaceutically acceptable carrier medium or auxiliary agent.
An important aspect of the invention involves a method of treating a hepatitis C viral infection in a mammal by administering to the mammal an anti-hepatitis C virally effective amount of the compound of formula I, or a therapeutically acceptable salt or ester thereof or a composition as described above.
Another important aspect involves a method of inhibiting the replication of hepatitis C virus by exposing the virus to a hepatitis C viral NS3 protease inhibiting amount of the compound of formula I, or a therapeutically acceptable salt or ester thereof or a composition as described above.
Still another aspect involves a method of treating a hepatitis C viral infection in a mammal by administering thereto an anti-hepatitis C virally effective amount of a combination of the compound of formula I, or a therapeutically acceptable salt or ester thereof. According to one embodiment, the pharmaceutical compositions of this invention comprise an additional immunomodulatory agent. Examples of additional immunomodulatory agents include but are not limited to, α-, β-, and δ-interferons.
Definitions
As used herein, the following definitions apply unless otherwise noted: With reference to the instances where (R) or (S) is used to designate the configuration of a substituent, e.g. R1 of the compound of formula I, the designation is done in the context of the compound and not in the context of the substituent alone.
The natural amino acids, with exception of glycine, contain a chiral carbon atom. Unless otherwise specifically indicated, the compounds containing natural amino acids with the L-configuration are preferred. However, applicants contemplate that when specified, some amino acids of the formula I can be of either D- or L-configuration or can be mixtures of D- and L-isomers, including racemic mixtures. The designation “P1, P2 and P3” as used herein refer to the position of the amino acid residues starting from the C-terminus end of the peptide analogues and extending towards the N-terminus [i.e. P1 refers to position 1 from the C-terminus, P2: second position from the C-terminus, etc.) (see Berger A. & Schechter I., Transactions of the Royal Society London series (1970), B257, 249-264].
The abbreviations for the α-amino acids used in this application are set forth in Table A.
TABLE A | |||
Amino Acid | Symbol | ||
1-aminocyclopropyl-carboxylic acid | Acca | ||
Alanine | Ala | ||
Aspartic acid | Asp | ||
Cysteine | Cys | ||
Cyclohexylglycine (also named: 2-amino-2- | Chg | ||
cyclohexylacetic acid) | |||
Glutamic acid | Glu | ||
Isoleucine | Ile | ||
Leucine | Leu | ||
Phenyalanine | Phe | ||
Proline | Pro | ||
Valine | Val | ||
tert-Butylglycine | Tbg | ||
As used herein the term “1-aminocyclopropyl-carboxylic acid” (Acca) refers to a compound of formula:
The term “residue” with reference to an amino acid or amino acid derivative means a radical derived from the corresponding α-amino acid by eliminating the hydroxyl of the carboxy group and one hydrogen of the α-amino group. For instance, the terms Gln, Ala, Gly, Ile, Arg, Asp, Phe, Ser, Leu, Cys, Asn, Sar and Tyr represent the “residues” of L-glutamine, L-alanine, glycine, L-isoleucine, L-arginine, L-aspartic acid, L-phenylalanine, L-serine, L-leucine, L-cysteine, L-asparagine, sarcosine and L-tyrosine, respectively.
The term “side chain” with reference to an amino acid or amino acid residue means a group attached to the α-carbon atom of the α-amino acid. For example, the R-group side chain for glycine is hydrogen, for alanine it is methyl, for valine it is isopropyl. For the specific R-groups or side chains of the α-amino acids reference is made to A. L. Lehninger's text on Biochemistry (see chapter 4).
The term “halo” as used herein means a halogen substituent selected from bromo, chloro, fluoro or iodo.
The term “C1-6 alkyl” or “(lower)alkyl” as used herein, either alone or in combination with another substituent, means acyclic, straight or branched chain alkyl substituents containing from 1 to six carbon atoms and includes, for example, methyl, ethyl, propyl, butyl, tert-butyl, hexyl, 1-methylethyl, 1-methylpropyl, 2-methylpropyl, 1,1-dimethylethyl.
The term “C3-7 cycloalkyl” as used herein, either alone or in combination with another substituent, means a cycloalkyl substituent containing from three to seven carbon atoms and includes cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl. This term also includes “spiro”-cyclic group such as spiro-cyclopropyl or spiro-cyclobutyl:
The term “C4-10 (alkylcycloalkyl)” as used herein means a cycloalkyl radical containing from three to seven carbon atoms linked to an alkyl radical, the linked radicals containing up to ten carbon atoms; for example, cyclopropylmethyl, cyclopentylethyl, cyclohexylmethyl, cyclohexylethyl or cycloheptylethyl.
The term “C2-10 alkenyl” as used herein, either alone or in combination with another radical, means an alkyl radical as defined above containing from 2 to 10 carbon atoms, and further containing at least one double bond. For example alkenyl includes allyl and vinyl.
The term “C1-6 alkanoyl” as used herein, either alone or in combination with another radical, means straight or branched 1-oxoalkyl radicals containing one to six carbon atoms and includes formyl, acetyl, 1-oxopropyl (propionyl), 2-methyl-1-oxopropyl, 1-oxohexyl and the like.
The term “C1-6 alkoxy” as used herein, either alone or in combination with another radical, means the radical —O(C1-6 alkyl) wherein alkyl is as defined above containing up to six carbon atoms. Alkoxy includes methoxy, ethoxy, propoxy, 1-methylethoxy, butoxy and 1,1-dimethylethoxy. The latter radical is known commonly as tert-butoxy.
The term “C3-7 cycloalkoxy” as used herein, either alone or in combination with another radical, means a C3-7 cycloalkyl group linked to an oxygen atom, such as, for example:
The term “C6 or C10 aryl” as used herein, either alone or in combination with another radical, means either an aromatic monocyclic group containing 6 carbon atoms or an aromatic bicyclic group containing 10 carbon atoms. For example, aryl includes phenyl, 1-naphthyl or 2-naphthyl.
The term “C7-16 aralkyl” as used herein, either alone or in combination with another radical, means a C6 or C10 aryl as defined above linked to an alkyl group, wherein alkyl is as defined above containing from 1 to 6 carbon atoms. C7-16 aralkyl includes for example benzyl, butylphenyl, and 1-naphthylmethyl.
The term “amino aralkyl” as used herein, either alone or in combination with another radical, means an amino group substituted with a C7-16 aralkyl group, such as, for example, the amino aralkyl:
The term “(lower alkyl)amide” as used herein, either alone or in combination with another radical, means an amide mono-substituted with a C1-6 alkyl, such as:
The term “carboxy(lower)alkyl” as used herein, either alone or in combination with another radical, means a carboxyl group (COOH) linked through a (lower)alkyl group as defined above and includes for example butyric acid.
The term “heterocycle” or “Het” as used herein, either alone or in combination with another radical, means a monovalent radical derived by removal of a hydrogen from a five-, six-, or seven-membered saturated or unsaturated (including aromatic) heterocycle containing from one to four heteroatoms selected from nitrogen, oxygen and sulfur. Furthermore, “Het” as used herein, means a heterocyclic as defined above fused to one or more other cycle, be it a heterocycle or any other cycle. Examples of suitable heterocycles include: pyrrolidine, tetrahydrofuran, thiazolidine, pyrrole, thiophene, diazepine, 1H-imidazole, isoxazole, thiazole, tetrazole, piperidine, 1,4-dioxane, 4-morpholine, pyridine, pyrrolidine, thiazolo[4,5-b]-pyridine, quinoline, or indole, or the following heterocycles:
The term “(lower alkyl)-Het” as used herein, means a heterocyclic radical as defined above linked through a chain or branched alkyl group, wherein alkyl is as defined above containing from 1 to 6 carbon atoms. Examples of (lower alkyl)-Het include:
The term “pharmaceutically acceptable ester” as used herein, either alone or in combination with another substituent, means esters of the compound of formula I in which any of the carboxyl functions of the molecule, but preferably the carboxy terminus, is replaced by an alkoxycarbonyl function:
in which the R moiety of the ester is selected from alkyl (e.g. methyl, ethyl, n-propyl, t-butyl, n-butyl); alkoxyalkyl (e.g. methoxymethyl); alkoxyacyl (e.g. acetoxymethyl); aralkyl (e.g. benzyl); aryloxyalkyl (e.g. phenoxymethyl); aryl (e.g. phenyl), optionally substituted with halogen, C1-4 alkyl or C1-4 alkoxy. Other suitable prodrug esters can be found in Design of prodrugs, Bundgaard, H. Ed. Elsevier (1985) incorporated herewith by reference. Such pharmaceutically acceptable esters are usually hydrolyzed in vivo when injected in a mammal and transformed into the acid form of the compound of formula I.
in which the R moiety of the ester is selected from alkyl (e.g. methyl, ethyl, n-propyl, t-butyl, n-butyl); alkoxyalkyl (e.g. methoxymethyl); alkoxyacyl (e.g. acetoxymethyl); aralkyl (e.g. benzyl); aryloxyalkyl (e.g. phenoxymethyl); aryl (e.g. phenyl), optionally substituted with halogen, C1-4 alkyl or C1-4 alkoxy. Other suitable prodrug esters can be found in Design of prodrugs, Bundgaard, H. Ed. Elsevier (1985) incorporated herewith by reference. Such pharmaceutically acceptable esters are usually hydrolyzed in vivo when injected in a mammal and transformed into the acid form of the compound of formula I.
With regard to the esters described above, unless otherwise specified, any alkyl moiety present advantageously contains 1 to 16 carbon atoms, particularly 1 to 6 carbon atoms. Any aryl moiety present in such esters advantageously comprises a phenyl group.
In particular the esters may be a C1-16 alkyl ester, an unsubstituted benzyl ester or a benzyl ester substituted with at least one halogen, C1-6 alkyl, C1-6 alkoxy, nitro or trifluoromethyl.
The term “pharmaceutically acceptable salt” as used herein includes those derived from pharmaceutically acceptable bases. Examples of suitable bases include choline, ethanolamine and ethylenediamine. Na+, K+, and Ca++ salts are also contemplated to be within the scope of the invention (also see Pharmaceutical salts, Birge, S. M. et al., J. Pharm. Sci., (1977), 66, 1-19, incorporated herein by reference).
Preferred Embodiments
Included within the scope of this invention are compounds of formula I wherein Preferably, B is a C6 or C10 aryl or C7-16 aralkyl, all optionally substituted with C1-6 alkyl, C1-6 alkoxy, C1-6 alkanoyl, hydroxy, hydroxyalkyl, halo, haloalkyl, nitro, cyano, cyanoalkyl, amido, (lower alkyl) amido, or amino optionally substituted with C1-6 alkyl; or
B is preferably Met or (lower alkyl)-Het, all optionally substituted with C1-6 alkyl, C1-6 alkoxy, C1-6 alkanoyl, hydroxy, hydroxyalkyl, halo, haloalkyl, nitro, cyano, cyanoalkyl, amido, (lower alkyl)amido, or amino optionally substituted with C1-6 alkyl.
Alternatively, B is preferably R4—SO2 wherein R4 is preferably C1-6 alkyl; amido; (lower alkyl)amide; C6 or C10 aryl, C7-4 aralkyl or Het, all optionally substituted with C1-6 alkyl.
Alternatively, B is preferably an acyl derivative of formula R4—C(O)— wherein R4 is preferably
-
- (i) C1-10 alkyl optionally substituted with carboxyl, hydroxy or C1-6 alkoxy, amido, (lower alkyl)amide, or amino optionally mono- or di-substituted with C1-6 alkyl;
- (ii) C3-7 cycloalkyl or C4-10 alkylcycloalkyl, both optionally substituted with hydroxy, carboxyl, (C1-6 alkoxy) carbonyl, amido, (lower alkyl)amide, or amino optionally mono- or di-substituted with C1-6 alkyl;
- (iv) C6 or C10 aryl or C7-16 aralkyl, all optionally substituted with C1-6 alkyl, hydroxy, amido, (lower alkyl) amide, or amino optionally substituted with C1-6 alkyl;
- (v) Het or (lower alkyl)-Het, both optionally substituted with C1-6 alkyl, hydroxy, amino optionally substituted with C1-6 alkyl, amido, (lower alkyl)amide, or amino optionally substituted with C1-6 alkyl.
Alternatively, B is preferably a carboxyl of formula R4—O—C(O)—, wherein R4 is preferably
-
- (i) C1-10 alkyl optionally substituted with carboxyl, C1-6 alkanoyl, hydroxy, C1-6 alkoxy, amino optionally mono- or di-substituted with C1-6 alkyl, amido or (lower alkyl)amide;
- (ii) C3-7 cycloalkyl, C4-10 alkylcycloalkyl, all optionally substituted with carboxyl, (C1-6 alkoxy)carbonyl, amino optionally mono- or di-substituted with C1-6 alkyl, amido or (lower alkyl)amide;
- (iv) C6 or C10 aryl or C7-16 aralkyl optionally substituted with C1-6 alkyl, hydroxy, amido, (lower alkyl)amido, or amino optionally mono- or di-substituted with C1-6 alkyl; or
- (v) Het or (lower alkyl)-Het, both optionally substituted with C1-6 alkyl, hydroxy, amino optionally mono- or di-substituted with C1-6 alkyl, amido or (lower alkyl) amido.
Alternatively, B is preferably an amide of formula R4—N(R5)—C(O)— wherein R4 is preferably
-
- (i) C1-10 alkyl optionally substituted with carboxyl, C1-6 alkanoyl, hydroxy, C1-6 alkoxy, amido, (lower alkyl) amido, or amino optionally mono- or di-substituted with C1-6 alkyl;
- (ii) C3-7 cycloalkyl or C4-10 alkylcycloalkyl, all optionally substituted with carboxyl, (C1-6 alkoxy)carbonyl, amido, (lower alkyl)amido, or amino optionally mono- or di-substituted with C1-6 alkyl;
- (iii) amino optionally mono- or di-substituted with C1-3 alkyl;
- (iv) C6 or C10 aryl or C7-16 aralkyl, all optionally substituted with C1-6 alkyl, hydroxy, amido, (lower alkyl) amide, or amino optionally substituted with C1-6 alkyl; or
- (v) Het or (lower alkyl)-Het, both optionally substituted with C1-6 alkyl, hydroxy, amino optionally substituted with C1-6 alkyl, amido or (lower alkyl)amide; and
- R5 is preferably H or methyl.
Alternatively, B is a preferably thioamide of formula R4—NH—C(S)—; wherein R4 is preferably
-
- (i) C1-10 alkyl optionally substituted with carboxyl, C1-6 alkanoyl or C1-6 alkoxy;
- (ii) C3-7 cycloalkyl or C4-10 alkylcycloalkyl, all optionally substituted with carboxyl, (C1-6 alkoxy)carbonyl, amino or amido.
More preferably, B is a C6 or C10 aryl optionally substituted with C1-6 alkyl, C1-6 alkoxy, C1-6 alkanoyl, hydroxy, hydroxyalkyl, halo, haloalkyl, nitro, cyano, cyanoalkyl, amido, (lower alkyl)amide, or amino optionally mono- or di-substituted with C1-6 alkyl, such that B is for example:
or B is more preferably Het optionally substituted with C1-6 alkyl, C1-6 alkoxy, C1-6 alkanoyl, hydroxy, halo, amido, (lower alkyl)amide, or amino optionally mono- or di-substituted with C1-6 alkyl, such that B is for example:
or B is more preferably Het optionally substituted with C1-6 alkyl, C1-6 alkoxy, C1-6 alkanoyl, hydroxy, halo, amido, (lower alkyl)amide, or amino optionally mono- or di-substituted with C1-6 alkyl, such that B is for example:
Alternatively, B is more preferably R4—SO2 wherein R4 is preferably C6 or C10 aryl, a C7-14 aralkyl or Het all optionally substituted with C1-6 alkyl; amido, (lower alkyl) amide, such that B is, for example:
Alternatively, B is more preferably an acyl derivative of formula R4—C(O)— wherein R4 is preferably
-
- (i) C1-10 alkyl optionally substituted with carboxyl, hydroxy or C1-6 alkoxy; or
- (ii) C3-7 cycloalkyl or C4-10 alkylcycloalkyl, both optionally substituted with hydroxy, carboxyl, (C1-6 alkoxy) carbonyl, such that B is, for example:
or R4 is preferably - (iv) C6 or C10 aryl or C7-16 aralkyl, all optionally substituted with C1-6 alkyl, hydroxy, such that B is for example:
or R4 is preferably - (v) Het optionally substituted with C1-6 alkyl, hydroxy, amido or amino, such that B is for example:
Alternatively, B is more preferably a carboxyl of formula R4—O—C(O)—, wherein R4 is preferably
-
- (i) C1-10 alkyl optionally substituted with carboxyl, C1-6 alkanoyl, hydroxy, C1-6 alkoxy or amido, (lower alkyl) amide, amino optionally mono- or di-substituted with C1-6 alkyl;
- (ii) C3-7 cycloalkyl, C4-10 alkylcycloalkyl, all optionally substituted with carboxyl, (C1-6 alkoxy)carbonyl, amido, (lower alkyl)amide, amino optionally mono- or di-substituted with C1-6 alkyl, such that B is for example:
or R4 is preferably - (iv) C6 or C10 aryl or C7-16 aralkyl, all optionally substituted with C1-6 alkyl, hydroxy, amino optionally substituted with C1-6 alkyl; or
- (v) Het or (lower alkyl)-Het, both optionally substituted with C1-6 alkyl, hydroxy, amido, or amino optionally mono-substituted with C1-6 alkyl, such that B is for example:
Alternatively, B is more preferably an amide of formula R4—N(R5)—C(O)— wherein R4 is preferably
-
- (i) C1-10 alkyl optionally substituted with carboxyl, C1-6 alkanoyl, hydroxy, C1-6 alkoxy, amido, (lower alkyl) amide, amino optionally mono- or di-substituted with C1-6 alkyl;
- (ii) C3-7 cycloalkyl or C4-10 alkylcycloalkyl, all optionally substituted with carboxyl, (C1-6 alkoxy)carbonyl, amido, (lower alkyl)amide, amino optionally mono- or di-substituted with C1-6 alkyl; and
- R5 is H or methyl, such that B is for example:
or R4 is preferably - (iii) amino optionally mono- or di-substituted with C1-3 alkyl, such that B is for example:
or R4 is preferably - (iv) C6 or C10 aryl or C7-16 aralkyl, all optionally substituted with C1-6 alkyl, hydroxy, amino or amido optionally substituted with C1-6 alkyl; or
- (v) Het optionally substituted with C1-6 alkyl, hydroxy, amino or amido, such that B is for example:
Alternatively, B is more preferably a thioamide of formula R4—NH—C(S)—; wherein R4 is preferably
-
- R4 is (i) C1-10 alkyl; or (ii) C3-7 cycloalkyl, such that B is for example:
- R4 is (i) C1-10 alkyl; or (ii) C3-7 cycloalkyl, such that B is for example:
Most preferably, B is an amide of formula R4—NH—C(O)— wherein R4 is preferably
-
- (i) C1-10 alkyl optionally substituted with carboxyl, C1-6 alkanoyl, hydroxy, C1-6 alkoxy amido, (lower alkyl) amide, amino optionally mono- or di-substituted with C1-6 alkyl;
- (ii) C3-7 cycloalkyl or C4-10 alkylcycloalkyl, all optionally substituted with carboxyl, (C1-6 alkoxy)carbonyl, amido, (lower alkyl)amide, amino optionally mono- or di-substituted with C1-6 alkyl;
or R4 is preferably - (iv) C6 or C10 aryl or C7-16 aralkyl optionally substituted with C1-6 alkyl, hydroxy, amino or amido, such that B is for example:
Preferably, Y is H or methyl. More preferably, Y is H.
Preferably, R3 is C1-8 alkyl, C3-7 cycloalkyl, or C4-10 alkylcycloalkyl, all optionally substituted with hydroxy, C1-6 alkoxy, C1-6 thioalkyl, acetamido, C6 or C10 aryl, or C7-16 aralkyl, such that B is for example:
Most preferably, R3 is the side chain of Tbg, Chg or Val.
Included within the scope of the invention are compounds of formula I wherein, preferably, R2 is S—R20 or O—R20 wherein R20 is preferably a C6 or C10 aryl, C7-16 aralkyl, Het or —CH2—Het, all optionally mono-, di- or tri-substituted with R21.
-
- Preferably, R21 is C1-6 alkyl; C1-6 alkoxy; lower thioalkyl; amino or amido optionally mono-or di-substituted with C1-6 alkyl, C6 or C10 aryl, C7-16 aralkyl, Het or (lower alkyl)-Het; NO2; OH; halo; trifluoromethyl; carboxyl; C6 or C10 aryl, C7-16 aralkyl, or Het, said aryl, aralkyl or Het being optionally substituted with R22. More preferably, R21 is C1-6 alkyl; C1-6 alkoxy; amino; di(lower alkyl) amino; (lower alkyl)amide; C6 or C10 aryl, or Het, said aryl or Het being optionally substituted with R22.
- Preferably, R22 is C1-6 alkyl; C3-7 cycloalkyl; C1-6 alkoxy; amino; mono- or di-(lower alkyl)amino; (lower alkyl)amide; sulfonylalkyl; NO2; OH; halo; trifluoromethyl; carboxyl or Het. More preferably, R22 is C1-6 alkyl; C3-7 cycloalkyl; C1-6 alkoxy; amino; mono- or di(lower alkyl)amino; amido; (lower alkyl)amide; halo; trifluoromethyl or Het. Most preferably, R22 is C1-6 alkyl; C1-6 alkoxy; halo; amino optionally mono- or di-substituted with lower alkyl; amido; (lower alkyl)amide; or Het. Even most preferably, R22 is methyl; ethyl; isopropyl; tert-butyl; methoxy; chloro; amino optionally mono- or di-substituted with lower alkyl; amido, (lower alkyl) amide; or (lower alkyl) 2-thiazole.
- Preferably, R21 is C1-6 alkyl; C1-6 alkoxy; lower thioalkyl; amino or amido optionally mono-or di-substituted with C1-6 alkyl, C6 or C10 aryl, C7-16 aralkyl, Het or (lower alkyl)-Het; NO2; OH; halo; trifluoromethyl; carboxyl; C6 or C10 aryl, C7-16 aralkyl, or Het, said aryl, aralkyl or Het being optionally substituted with R22. More preferably, R21 is C1-6 alkyl; C1-6 alkoxy; amino; di(lower alkyl) amino; (lower alkyl)amide; C6 or C10 aryl, or Het, said aryl or Het being optionally substituted with R22.
More preferably, R2 is 1-naphthylmethoxy; 2-naphthylmethoxy; benzyloxy, 1-naphthyloxy; 2-naphthyloxy; or quinolinoxy unsubstituted, mono- or di-substituted with R21 as defined above. Most preferably, R2 is 1-naphtylmethoxy; or quinolinoxy unsubstituted, mono- or di-substituted with R21 as defined above, such that R2 is for example:
More preferably, R21A is C1-6 alkyl such as isopropyl, tert-butyl or cyclohexyl; C1-6 alkoxy such as methoxy,
lower thioalkyl such as
halo such as chloro;
amino optionally mono-substituted with C1-6 alkyl; or C6 or C10 aryl, such that R21A is for example: dimethylamino, Ph—N(Me)—;
unsubstituted C6 or C10 aryl, C7-16 aralkyl, such as for example phenyl or
or R21A is more preferably Het optionally substituted with R22 wherein R22 is C1-6 alkyl, C1-6 alkoxy, amido, (lower alkyl)amide, amino optionally mono- or di-substituted with C1-6 alkyl, or Het, such that R21A is for example:
lower thioalkyl such as
halo such as chloro;
amino optionally mono-substituted with C1-6 alkyl; or C6 or C10 aryl, such that R21A is for example: dimethylamino, Ph—N(Me)—;
unsubstituted C6 or C10 aryl, C7-16 aralkyl, such as for example phenyl or
or R21A is more preferably Het optionally substituted with R22 wherein R22 is C1-6 alkyl, C1-6 alkoxy, amido, (lower alkyl)amide, amino optionally mono- or di-substituted with C1-6 alkyl, or Het, such that R21A is for example:
Most preferably, R21A is C6, C10 aryl or Het, all optionally substituted with R22 as defined above, such that R21A is for example:
Even most preferably, R2 is:
wherein R22A is preferably C1-6 alkyl (such as methyl); C1-6 alkoxy (such as methoxy); or halo (such as chloro); R22B is preferably C1-6 alkyl, amino optionally mono-substituted with C1-6 alkyl, amido, or (lower alkyl)amide; and R21B is preferably C1-6 alkyl, C1-6 alkoxy, amino, di(lower alkyl) amino, (lower alkyl)amide, NO2, OH, halo, trifluoromethyl, or carboxyl. More preferably, R21B is C1-6 alkoxy, or di(lower alkyl)amino. Most preferably, R21B is methoxy.
wherein R22A is preferably C1-6 alkyl (such as methyl); C1-6 alkoxy (such as methoxy); or halo (such as chloro); R22B is preferably C1-6 alkyl, amino optionally mono-substituted with C1-6 alkyl, amido, or (lower alkyl)amide; and R21B is preferably C1-6 alkyl, C1-6 alkoxy, amino, di(lower alkyl) amino, (lower alkyl)amide, NO2, OH, halo, trifluoromethyl, or carboxyl. More preferably, R21B is C1-6 alkoxy, or di(lower alkyl)amino. Most preferably, R21B is methoxy.
As described hereinabove the P1 segment of the compounds of formula I is a cyclobutyl or cyclopropyl ring, both optionally substituted with R1.
Preferably, R1 is H, C1-3 alkyl, C3-5 cycloalkyl, or C2-4 alkenyl optionally substituted with halo. More preferably R1 is ethyl, vinyl, cyclopropyl, 1 or 2-bromoethyl or 1 or 2-bromovinyl. Most preferably, R1 is vinyl.
When R1 is not H, then P1 is preferably a cyclopropyl system of formula:
wherein C1 and C2 each represent an asymmetric carbon atom at positions 1 and 2 of the cyclopropyl ring. Notwithstanding other possible asymmetric centers at other segments of the compounds of formula I, the presence of these two asymmetric centers means that the compounds of formula I can exist as racemic mixtures of diastereoisomers. As illustrated in the examples hereinafter, the racemic mixtures can be prepared and thereafter separated into individual optical isomers, or these optical isomers can be prepared by chiral synthesis.
wherein C1 and C2 each represent an asymmetric carbon atom at positions 1 and 2 of the cyclopropyl ring. Notwithstanding other possible asymmetric centers at other segments of the compounds of formula I, the presence of these two asymmetric centers means that the compounds of formula I can exist as racemic mixtures of diastereoisomers. As illustrated in the examples hereinafter, the racemic mixtures can be prepared and thereafter separated into individual optical isomers, or these optical isomers can be prepared by chiral synthesis.
Hence, the compound of formula I can exist as a racemic mixture of diastereoisomers at carbon 1 but wherein R1 at carbon 2 is orientated syn to the carbonyl at position 1, represented by the radical:
or the compound of formula I can exist as a racemic mixture of diastereoisomers wherein R1 at position 2 is orientated anti to the carbonyl at position 1, represented by the radical:
or the compound of formula I can exist as a racemic mixture of diastereoisomers wherein R1 at position 2 is orientated anti to the carbonyl at position 1, represented by the radical:
In turn, the racemic mixtures can be separated into individual optical isomers. A most interesting finding of this invention pertains to the addition of a R1 substituent on the carbon 2 as well as the spatial orientation of the P1 segment. The finding concerns the configuration of the asymmetric carbon 1. A preferred embodiment is one wherein R1 is not H and carbon 1 has the R configuration.
More explicitly, the introduction of a substituent (R1) at C2 has an impact on the potency when R1 is introduced in a way that C1 has the R configuration. For example compounds 901 (1R,2S) and 203 (1R,2R) have activities of 25 and 82 nM respectively. When compared to the unsubstituted cyclopropyl compound 111 (475 nM), a substantial increase in potency is observed. Moreover, as shown for compounds 901 and 203 when carbon 1 has the R configuration, HCV NS3 protease inhibition is further enhanced by the configuration of the substituent R1 (e.g. alkyl or alkylene) at carbon 2 of the cyclopropyl ring, e.g. the compound that possesses R1 “syn” to the carboxyl has greater potency (25 nM) than the “anti” enantiomer (82 nM). We can see the effect of the R vs. S configuration at C1 by comparing compounds 801(1R,2S) and its corresponding (1S,2S) isomer which have potencies of 6 nM and >10 μM respectively, a difference of over 1500 fold!!
Therefore a most preferred compound is an optical isomer having the R1 substituent and the carbonyl in a syn orientation in the following absolute configuration:
In the case where R1 is ethyl, for example, the asymmetric carbon atoms at positions 1 and 2 have the R,R configuration.
Included within the scope of this invention are compounds of formula I wherein
-
- B is a C6 or C10 aryl or C7-16 aralkyl, all optionally substituted with C1-6 alkyl, C1-6 alkoxy, C1-6 alkanoyl, hydroxy, hydroxyalkyl, halo, haloalkyl, nitro, cyano, cyanoalkyl, amido, (lower alkyl)amido, or amino optionally substituted with C1-6 alkyl; or
- Het or (lower alkyl)-Het, all optionally substituted with C1-6 alkyl, C1-6 alkoxy, C1-6 alkanoyl, hydroxy, hydroxyalkyl, halo, haloalkyl, nitro, cyano, cyanoalkyl, amido, (lower alkyl)amido, or amino optionally substituted with C1-6 alkyl, or
- B is R4—SO2 wherein R4 is preferably amido; (lower alkyl)amide; C6 or C10 aryl, C7-14 aralkyl or Het, all optionally substituted with C1-6 alkyl, or
- B is an acyl derivative of formula R4—C(O)— wherein R4 is
- (i) C1-10 alkyl optionally substituted with carboxyl, hydroxy or C1-6 alkoxy, amido, (lower alkyl)amide, or amino optionally mono- or di-substituted with C1-6 alkyl;
- (ii) C3-7 cycloalkyl or C4-10 alkylcycloalkyl, both optionally substituted with hydroxy, carboxyl, (C1-6 alkoxy)carbonyl, amido, (lower alkyl)amide, or amino optionally mono- or di-substituted with C1-6 alkyl;
- (iv) C6 or C10 aryl or C7-16 aralkyl, all optionally substituted with C1-6 alkyl, hydroxy, amido, (lower alkyl)amide, or amino optionally substituted with C1-6 alkyl;
- (v) Het or (lower alkyl)-Het, both optionally substituted with C1-6 alkyl, hydroxy, amino optionally substituted with C1-6 alkyl, amido, (lower alkyl)amide, or amino optionally substituted with C1-6 alkyl, or
- B is a carboxyl of formula R4—O—C(O)—, wherein R4 is
- (i) C1-10 alkyl optionally substituted with carboxyl, C1-6 alkanoyl, hydroxy, C1-6 alkoxy, amino optionally mono- or di-substituted with C1-6 alkyl, amido or (lower alkyl)amide;
- (ii) C3-7 cycloalkyl, C4-10 alkylcycloalkyl, all optionally substituted with carboxyl, (C1-6 alkoxy) carbonyl, amino optionally mono- or di-substituted with C1-6 alkyl, amido or (lower alkyl)amide;
- (iv) C6 or C10 aryl or C7-16 aralkyl optionally substituted with C1-6 alkyl, hydroxy, amido, (lower alkyl) amido, or amino optionally mono- or di-substituted with C1-6 alkyl; or
- (v) Het or (lower alkyl)-Het, both optionally substituted with C1-6 alkyl, hydroxy, amino optionally mono- or di-substituted with C1-6 alkyl, amido or (lower alkyl) amido, or
- B is an amide of formula R4—N(R5)—C(O)— wherein R4 is
- (i) C1-10 alkyl optionally substituted with carboxyl, C1-6 alkanoyl, hydroxy, C1-6 alkoxy, amido, (lower alkyl)amido, or amino optionally mono- or di-substituted with C1-6 alkyl;
- (ii) C3-7 cycloalkyl or C4-10 alkylcycloalkyl, all optionally substituted with carboxyl, (C1-6 alkoxy) carbonyl, amido, (lower alkyl)amido, or amino optionally mono- or di-substituted with C1-6 alkyl;
- (iii) amino optionally mono- or di-substituted with C1-3 alkyl;
- (iv) C6 or C10 aryl or C7-16 aralkyl, all optionally substituted with C1-6 alkyl, hydroxy, amido, (lower alkyl)amide, or amino optionally substituted with C1-6 alkyl; or
- (v) Het or (lower alkyl)-Het, both optionally substituted with C1-6 alkyl, hydroxy, amino optionally substituted with C1-6 alkyl, amido or (lower alkyl)amide; and
- R5 is preferably H or methyl, or
- B is thioamide of formula R4—NH—C(S)—; wherein R4 is
- (i) C1-10 alkyl optionally substituted with carboxyl, C1-6 alkanoyl or C1-6 alkoxy;
- (ii) C3-7 cycloalkyl or C4-10 alkylcycloalkyl, all optionally substituted with carboxyl, (C1-6 alkoxy) carbonyl, amino or amido;
- Y is H or methyl;
- R3 is C1-8 alkyl, C3-7 cycloalkyl, or C4-10 alkylcycloalkyl, all optionally substituted with hydroxy, C1-6 alkoxy, C1-6 thioalkyl, acetamido, C6 or C10 aryl, or C7-16 aralkyl;
- R2 is S—R20 or O—R20 wherein R20 is preferably a C6 or C10 aryl, C7-16 aralkyl, Het or —CH2—Het, all optionally mono-, di- or tri-substituted with R21, wherein
- R21 is C1-6 alkyl; C1-6 alkoxy; lower thioalkyl; amino or amido optionally mono- or di-substituted with C1-6 alkyl, C6 or C10 aryl, C7-16 aralkyl, Het or (lower alkyl)-Het; NO2; OH; halo; trifluoromethyl; carboxyl; C6 or C10 aryl, C7-16 aralkyl, or Het, said aryl, aralkyl or Het being optionally substituted with R22, wherein
- R22 is C1-6 alkyl; C3-7 cycloalkyl; C1-6 alkoxy; amino; mono- or di-(lower alkyl)amino; (lower alkyl)amide; sulfonylalkyl; NO2; OH; halo; trifluoromethyl; carboxyl or Het; or
- R21 is C1-6 alkyl; C1-6 alkoxy; lower thioalkyl; amino or amido optionally mono- or di-substituted with C1-6 alkyl, C6 or C10 aryl, C7-16 aralkyl, Het or (lower alkyl)-Het; NO2; OH; halo; trifluoromethyl; carboxyl; C6 or C10 aryl, C7-16 aralkyl, or Het, said aryl, aralkyl or Het being optionally substituted with R22, wherein
- R2 is selected from the group consisting of:
- or R2 is 1-naphthylmethoxy; 2-naphthylmethoxy; benzyloxy, 1-naphthyloxy; 2-naphthyloxy; or quinolinoxy unsubstituted , mono- or di-substituted with R21 as defined above;
- the P1 segment is a cyclobutyl or cyclopropyl ring, both optionally substituted with R1, wherein R1 is H, C1-3 alkyl, C3-5 cycloalkyl, or C2-4 alkenyl optionally substituted with halo, and said R1 at carbon 2 is orientated syn to the carbonyl at position 1, represented by the radical:
Included within the scope of this invention are compounds of formula I wherein B is a C6 or C10 aryl optionally substituted with C1-6 alkyl, C1-6 alkoxy, C1-6 alkanoyl, hydroxy, hydroxyalkyl, halo, haloalkyl, nitro, cyano, cyanoalkyl, amido, (lower alkyl)amide, or amino optionally mono- or di-substituted with C16 alkyl; or B is Het optionally substituted with C1-6 alkyl, C1-6 alkoxy, C1-6 alkanoyl, hydroxy, halo, amido, (lower alkyl)amide, or amino optionally mono- or di-substituted with C1-6 alkyl; or B is R4—SO2 wherein R4 is C6 or C10 aryl, a C7-14 aralkyl or Het all optionally substituted with C1-6 alkyl; amido, (lower alkyl)amide; or B is an acyl derivative of formula R4—C(O)— wherein R4 is
-
- (i) C1-10 alkyl optionally substituted with carboxyl, hydroxy or C1-6 alkoxy; or
- (ii) C3-7 cycloalkyl or C4-10 alkylcycloalkyl, both optionally substituted with hydroxy, carboxyl, (C1-6 alkoxy) carbonyl; or
- (iv) C6 or C10 aryl or C7-16 aralkyl, all optionally substituted with C1-6 alkyl, hydroxy; or
- (v) Het optionally substituted with C1-6 alkyl, hydroxy, amido or amino;
or B is a carboxyl of formula R4—O—C(O)—, wherein R4 is - (i) C1-10 alkyl optionally substituted with carboxyl, C1-6 alkanoyl, hydroxy, C1-6 alkoxy or amido, (lower alkyl) amide, amino optionally mono- or di-substituted with C1-6 alkyl;
- (ii) C3-7 cycloalkyl, C4-10 alkylcycloalkyl, all optionally substituted with carboxyl, (C1-6 alkoxy)carbonyl, amido, (lower alkyl)amide, amino optionally mono- or di-substituted with C1-6 alkyl; or
- (iv) C6 or C10 aryl or C7-16 aralkyl, all optionally substituted with C1-6 alkyl, hydroxy, amino optionally substituted with C1-6 alkyl; or
- (v) Het or (lower alkyl)-Het, both optionally substituted with C1-6 alkyl, hydroxy, amido, or amino optionally mono-substituted with C1-6 alkyl;
or B is an amide of formula R4—N(R5)—C(O)— wherein R4 is - (i) C1-10 alkyl optionally substituted with carboxyl, C1-6 alkanoyl, hydroxy, C1-6 alkoxy, amido, (lower alkyl) amide, amino optionally mono- or di-substituted with C1-6 alkyl;
- (ii) C3-7 cycloalkyl or C4-10 alkylcycloalkyl, all optionally substituted with carboxyl, (C1-6 alkoxy)carbonyl, amido, (lower alkyl)amide, amino optionally mono- or di-substituted with C1-6 alkyl; and R5 is H or methyl; or
R4 is - (iii) amino optionally mono- or di-substituted with C1-3 alkyl; or
- (iv) C6 or C10 aryl or C7-16 aralkyl, all optionally substituted with C1-6 alkyl, hydroxy, amino or amido optionally substituted with C1-6 alkyl; or
- (v) Het optionally substituted with C1-6 alkyl, hydroxy, amino or amido; or
B is a thioamide of formula R4—NH—C(S)—; wherein R4 is: - (i) C1-10 alkyl; or (ii) C3-7 cycloalkyl; or
B is an amide of formula R4—NH—C(O)— wherein R4 is - (i) C1-10 alkyl optionally substituted with carboxyl, C1-6 alkanoyl, hydroxy, C1-6 alkoxy amido, (lower alkyl) amide, amino optionally mono- or di-substituted with C1-6 alkyl;
- (ii) C3-7 cycloalkyl or C4-10 alkylcycloalkyl, all optionally substituted with carboxyl, (C1-6 alkoxy)carbonyl, amido, (lower alkyl)amide, amino optionally mono- or di-substituted with C1-6 alkyl;
- (iv) C6 or C1-10 aryl or C7-16 aralkyl optionally substituted with C1-6 alkyl, hydroxy, amino or amido;
- Y is H;
- R3 is the side chain of tert-butylglycine (Tbg), Ile, Val, Chg or:
- R2 is 1-naphtylmethoxy; or quinolinoxy unsubstituted, mono- or di-substituted with R21 as defined above, or
- R2 is:
- wherein R21A is C1-6 alkyl; C1-6 alkoxy; C6, C10 aryl or Het; lower thioalkyl; halo; amino optionally mono-substituted with C1-6 alkyl; or C6,C10 aryl, C7-10 aralkyl or Het, optionally substituted with R22 wherein R22 is C1-6 alkyl, C1-6 alkoxy, amido, (lower alkyl)amide, amino optionally mono- or di-substituted with C1-6 alkyl, or Het;
- P1 is a cyclopropyl ring wherein carbon 1 has the R configuration,
- and R1 is ethyl, vinyl, cyclopropyl, 1 or 2-bromoethyl or 1 or 2-bromovinyl.
-
- B is tert-butoxycarbonyl (Boc) or
- R3 is the side chain of Tbg, Chg or Val;
- R2 is:
- wherein R22A is C1-6 alkyl (such as methyl); C1-6 alkoxy (such as methoxy); or halo (such as chloro); R22B is C1-6 alkyl, amino optionally mono-substituted with C1-6 alkyl, amido, or (lower alkyl)amide; and R21B is C1-6 alkyl, C1-6 alkoxy, amino, di(lower alkyl)amino, (lower alkyl)amide, NO2, OH, halo, trifluoromethyl, or carboxyl;
- and P1 is:
Finally, included within the scope of this invention is each compound of formula I as presented in Tables 1 to 10.
According to an alternate embodiment, the pharmaceutical compositions of this invention may additionally comprise another anti-HCV agent. Examples of anti-HCV agents include, α- or β-interferon, ribavirin and amantadine.
According to another alternate embodiment, the pharmaceutical compositions of this invention may additionally comprise other inhibitors of HCV protease.
According to yet another alternate embodiment, the pharmaceutical compositions of this invention may additionally comprise an inhibitor of other targets in the HCV life cycle, including but not limited to, helicase, polymerase, metalloprotease or internal ribosome entry site (IRES).
The pharmaceutical compositions of this invention may be administered orally, parenterally or via an implanted reservoir. Oral administration or administration by injection is preferred. The pharmaceutical compositions of this invention may contain any conventional non-toxic pharmaceutically-acceptable carriers, adjuvants or vehicles. In some cases, the pH of the formulation may be adjusted with pharmaceutically acceptable acids, bases or buffers to enhance the stability of the formulated compound or its delivery form. The term parenteral as used herein includes subcutaneous, intracutaneous, intravenous, intramuscular, infra-articular, intrasynovial, intrasternal, intrathecal, and intralesional injection or infusion techniques.
The pharmaceutical compositions may be in the form of a sterile injectable preparation, for example, as a sterile injectable aqueous or oleaginous suspension. This suspension may be formulated according to techniques known in the art using suitable dispersing or wetting agents (such as, for example Tween 80) and suspending agents.
The pharmaceutical compositions of this invention may be orally administered in any orally acceptable dosage form including, but not limited to, capsules, tablets, and aqueous suspensions and solutions. In the case of tablets for oral use, carriers which are commonly used include lactose and corn starch. Lubricating agents, such as magnesium stearate, are also typically added. For oral administration in a capsule form, useful diluents include lactose and dried corn starch. When aqueous suspensions are administered orally, the active ingredient is combined with emulsifying and suspending agents. If desired, certain sweetening and/or flavoring and/or coloring agents may be added.
Other suitable vehicles or carriers for the above noted formulations and compositions can be found in standard pharmaceutical texts, e.g. in “Remington's Pharmaceutical Sciences”, The Science and Practice of Pharmacy, 19th Ed. Mack Publishing Company, Easton, Pa., (1995).
Dosage levels of between about 0.01 and about 100 mg/kg body weight per day, preferably between about 0.5 and about 75 mg/kg body weight per day of the protease inhibitor compounds described herein are useful in a monotherapy for the prevention and treatment of HCV mediated disease. Typically, the pharmaceutical compositions of this invention will be administered from about 1 to about 5 times per day or alternatively, as a continuous infusion. Such administration can be used as a chronic or acute therapy. The amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration. A typical preparation will contain from about 5% to about 95% active compound (w/w). Preferably, such preparations contain from about 20% to about 80% active compound.
As the skilled artisan will appreciate, lower or higher doses than those recited above may be required. Specific dosage and treatment regimens for any particular patient will depend upon a variety of factors, including the activity of the specific compound employed, the age, body weight, general health status, sex, diet, time of administration, rate of excretion, drug combination, the severity and course of the infection, the patient's disposition to the infection and the judgment of the treating physician. Generally, treatment is initiated with small dosages substantially less than the optimum dose of the peptide. Thereafter, the dosage is increased by small increments until the optimum effect under the circumstances is reached. In general, the compound is most desirably administered at a concentration level that will generally afford antivirally effective results without causing any harmful or deleterious side effects.
When the compositions of this invention comprise a combination of a compound of formula I and one or more additional therapeutic or prophylactic agent, both the compound and the additional agent should be present at dosage levels of between about 10 to 100%, and more preferably between about 10 and 80% of the dosage normally administered in a monotherapy regimen.
When these compounds or their pharmaceutically acceptable salts are formulated together with a pharmaceutically acceptable carrier, the resulting composition may be administered in vivo to manimals, such as man, to inhibit HCV NS3 protease or to treat or prevent HCV virus infection. Such treatment may also be achieved using the compounds of this invention in combination with agents which include, bus are not limited to: immunomodulatory agents, such as α-, β-, or γ-interferons; other antiviral agents such as ribavirin, amantadine; other inhibitors of HCV NS3 protease; inhibitors of other targets in the HCV life cycle, which include but not limited to, helicase, polymerase, metalloprotease, or internal ribosome entry site (IRES); or combinations thereof. The additional agents may be combined with the compounds of this invention to create a single dosage form. Alternatively these additional agents may be separately administered to a mammal as part of a multiple dosage form.
Accordingly, another embodiment of this invention provides methods of inhibiting HCV NS3 protease activity in mammals by administering a compound of the formula I, wherein the substituents are as defined above.
In a preferred embodiment, these methods are useful in decreasing HCV NS3 protease activity in a mammal, If the pharmaceutical composition comprises only a compound of this invention as the active component, such methods may additionally comprise the step of administering to said mammal an agent selected from an immunomodulatory agent, an antiviral agent, a HCV protease inhibitor, or an inhibitor of other targets in the HCV life cycle such as helicase, polymerase, or metallo protease or IRES. Such additional agent may be administered to the mammal prior to, concurrently with, or following the administration of the compositions of this invention.
In an alternate preferred embodiment, these methods are useful for inhibiting viral replication in a mammal. Such methods are useful in treating or preventing HCV disease. If the pharmaceutical composition comprises only a compound of this invention as the active component, such methods may additionally comprise the step of administering to said mammal an agent selected from an immunomodulatory agent, an antiviral agent, a HCV protease inhibitor, or an inhibitor of other targets in the HCV life cycle. Such additional agent may be administered to the mammal prior So, concurrently with, or following the administration of the composition according to this invention.
The compounds set forth herein may also be used as laboratory reagents. The compounds of this invention may also be used to treat or prevent viral contamination of materials and therefore reduce the risk of viral infection of laboratory or medical personnel or patients who come in contact with such materials (e.g. blood, tissue, surgical instruments and garments, laboratory instruments and garments, and blood collection apparatuses and materials).
The compounds set forth herein may also be used as research reagents. The compounds of this invention may also be used as positive control to validate surrogate cell-based assays or in vitro or in vivo viral replication assays.
Process
The compounds of the present invention were synthesized according to a general process as illustrated in scheme I (wherein CPG is a carboxyl protecting group and APG is an amino protecting group):
Briefly, the P1, P2, and P3 can be linked by well known peptide coupling techniques. The P1, P2, and P3 groups may be linked together in any order as long as the final compound corresponds to peptides of Formula I. For example, P3 can be linked to P2-P1;
or P1 linked to P3-P2.
Generally, peptides are elongated by deprotecting the α-amino group of the N-terminal residue and coupling the unprotected carboxyl group of the next suitably N-protected amino acid through a peptide linkage using the methods described. This deprotection and coupling procedure is repeated until the desired sequence is obtained. This coupling can be performed with the constituent amino acids in stepwise fashion, as depicted in Scheme I, or by solid phase peptide synthesis according to the method originally described in Merrifield, J. Am. Chem. Soc., (1963), 85, 2149-2154, the disclosure of which is hereby incorporated by reference. Coupling between two amino acids, an amino acid and a peptide, or two peptide fragments can be carried out using standard coupling procedures such as the azide method, mixed carbonic-carboxylic acid anhydride (isobutyl chloroformate) method, carbodiimide (dicyclohexylcarbodiimide, diisopropylcarbodiimide, or water-soluble carbodiimide) method, active ester (p-nitrophenyl ester, N-hydroxysuccinic imido ester) method, Woodward reagent K-method, carbonyldimidazole method, phosphorus reagents or oxidation-reduction methods. Some of these methods (especially the carbodiimide method) can be enhanced by adding 1-hydroxybenzotriazole. These coupling reactions can be performed in either solution (liquid phase) or solid phase.
More explicitly, the coupling step involves the dehydrative coupling of a free carboxyl of one reactant with the free amino group of the other reactant in the presence of a coupling agent to form a linking amide bond. Descriptions of such coupling agents are found in general textbooks on peptide chemistry, for example, M. Bodanszky, “Peptide Chemistry”, 2nd rev ed., Springer-Verlag, Berlin, Germany, (1993). Examples of suitable coupling agents are N,N′-dicyclohexylcarbodiimide, 1-hydroxybenzotriazole in the presence of N,N′-dicyclohexylcarbodiimide or N-ethyl-N′-[(3-dimethylamino)propyl]carbodiimide. A practical and useful coupling agent is the commercially available (benzotriazol-1-yloxy)tris-(dimethylamino)phosphonium hexafluorophosphate, either by itself or in the presence of 1-hydroxybenzotriazole. Another practical and useful coupling agent is commercially available 2-(1H-benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium tetrafluoroborate. Still another practical and useful coupling agent is commercially available O-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate.
The coupling reaction is conducted in an inert solvent, e.g. dichloromethane, acetonitrile or dimethylformamide. An excess of a tertiary amine, e.g. diisopropylethylamine, N-methylmorpholine or N-methylpyrrolidine, is added to maintain the reaction mixture at a pH of about 8. The reaction temperature usually ranges between 0° C. and 50° C. and the reaction time usually ranges between 15 min and 24 h.
When a solid phase synthetic approach is employed, the C-terminal carboxylic acid is attached to an insoluble carrier (usually polystyrene). These insoluble carriers contain a group that will react with the carboxylic group to form a bond that is stable to the elongation conditions but readily cleaved later. Examples of which are: chloro- or bromomethyl resin, hydroxymethyl resin, trytil resin and 2-methoxy-4-alkoxy-benzylaloconol resin.
Many of these resins are commercially available with the desired C-terminal amino acid already incorporated. Alternatively, the amino acid can be incorporated on the solid support by known methods (Wang, S.-S., J. Am. Chem. Soc., (1973), 95, 1328; Atherton, E.; Shepard, R. C. “Solid-phase peptide synthesis; a practical approach” IRL Press: Oxford, (1989); 131-148). In addition to the foregoing, other methods of peptide synthesis are described in Stewart and Young, “Solid Phase Peptide Synthesis”, 2nd ed., Pierce Chemical Co., Rockford, Ill. (1984); Gross, Meienhofer, Udenfriend, Eds., “The Peptides: Analysis, Synthesis, Biology”, Vol. 1, 2, 3, 5, and 9, Academic Press, New-York, (1980-1987); Bodansky et al., “The Practice of Peptide Synthesis” Springer-Verlag, New-York (1984), the disclosures of which are hereby incorporated by reference.
The functional groups of the constituent amino acids generally must be protected during the coupling reactions to avoid formation of undesired bonds. The protecting groups that can be used are listed in Greene, “Protective Groups in Organic Chemistry”, John Wiley & Sons, New York (1981) and “The Peptides: Analysis, Synthesis, Biology”, Vol. 3, Academic Press, New York (1981), the disclosures of which are hereby incorporated by reference.
The α-carboxyl group of the C-terminal residue is usually protected as an ester (CPG) that can be cleaved to give the carboxylic acid. Protecting groups that can be used include: 1) alkyl esters such as methyl, trimethylsilylethyl and t-butyl, 2) aralkyl esters such as benzyl and substituted benzyl, or 3) esters that can be cleaved by mild base treatment or mild reductive means such as trichloroethyl and phenacyl esters. The α-amino group of each amino acid to be coupled to the growing peptide chain must be protected (APG). Any protecting group known in the art can be used. Examples of such groups include: 1) acyl groups such as formyl, trifluoroacetyl, phthalyl, and p-toluenesulfonyl; 2) aromatic carbamate groups such as benzyloxycarbonyl (Cbz or Z) and substituted benzyloxycarbonyls, and 9-fluorenylmethyloxycarbonyl (Fmoc); 3) aliphatic carbamate groups such as tert-butyloxycarbonyl (Boc), ethoxycarbonyl, diisopropylmethoxycarbonyl, and allyloxycarbonyl; 4) cyclic alkyl carbamate groups such as cyclopentyloxycarbonyl and adamantyloxycarbonyl; 5) alkyl groups such as triphenylmethyl and benzyl; 6) trialkylsilyl such as trimethylsilyl; and 7) thiol containing groups such as phenylthiocarbonyl and dithiasuccinoyl. The preferred α-amino protecting group is either Boc or Fmoc. Many amino acid derivatives suitably protected for peptide synthesis are commercially available.
The α-amino protecting group of the newly added amino acid residue is cleaved prior to the coupling of the next amino acid. When the Boc group is used, the methods of choice are trifluoroacetic acid, neat or in dichloromethane, or HCl in dioxane or in ethyl acetate. The resulting ammonium salt is then neutralized either prior to the coupling or in situ with basic solutions such as aqueous buffers, or tertiary amines in dichloromethane or acetonitrile or dimethylformamide. When the Fmoc group is used, the reagents of choice are piperidine or substituted piperidine in dimethylformamide, but any secondary amine can be used. The deprotection is carried out at a temperature between 0° C. and room temperature (RT) usually 20-22° C.
Any of the amino acids having side chain functionalities must be protected during the preparation of the peptide using any of the above-described groups. Those skilled in the art will appreciate that the selection and use of appropriate protecting groups for these side chain functionalities depend upon the amino acid and presence of other protecting groups in the peptide. The selection of such protecting groups is important in that the group must not be removed during the deprotection and coupling of the α-amino group.
For example, when Boc is used as the α-amino protecting group, the following side chain protecting group are suitable: p-toluenesulfonyl (tosyl) moieties can be used to protect the amino side chain of amino acids such as Lys and Arg; acetamidomethyl, benzyl (Bn), or t-butylsulfonyl moieties can be used to protect the sulfide containing side chain of cysteine; benzyl (Bn) ethers can be used to protect the hydroxy containing side chains of serine, threonine or hydroxyproline; and benzyl esters can be used to protect the carboxy containing side chains of aspartic acid and glutamic acid.
When Fmoc is chosen for the α-amine protection, usually tert-butyl based protecting groups are acceptable. For instance, Boc can be used for lysine and arginine, tert-butyl ether for serine, threonine and hydroxyproline, and tert-butyl ester for aspartic acid and glutamic acid. Triphenylmethyl (Trityl) moiety can be used to protect the sulfide containing side chain of cysteine.
Once the elongation of the peptide is completed all of the protecting groups are removed. When a liquid phase synthesis is used, the protecting groups are removed in whatever manner is dictated by the choice of protecting groups. These procedures are well known to those skilled in the art.
When a solid phase synthesis is used, the peptide is cleaved from the resin simultaneously with the removal of the protecting groups. When the Boc protection method is used in the synthesis, treatment with anhydrous HF containing additives such as dimethyl sulfide, anisole, thioanisole, p-cresol at 0° C. is the preferred method for cleaving the peptide from the resin. The cleavage of the peptide can also be accomplished by other acid reagents such as trifluoromethanesulfonic acid/trifluoroacetic acid mixtures. If the Fmoc protection method is used, the N-terminal Fmoc group is cleaved with reagents described earlier. The other protecting groups and the peptide are cleaved from the resin using solution of trifluoroacetic acid and various additives such as anisole, etc.
1. Synthesis of Capping Group B
Different capping groups B are introduced in the following manner:
1.1) When B is an Aryl, Aralkyl; the Arylated Amino Acids were Prepared by One of the Three Methods Below
-
- a) Direct nucleophilic displacement on a fluoro-nitro aryl moiety:
Briefly, 4-fluoro-3-nitrobenzotrifluoride (a) was reacted with L-amino acid - (b) in the presence of a base such as potassium carbonate at 80° C. to yield the desired N-aryl amino acid (c);
- b) Copper catalyzed couplings according to Ma et al. (J. Am. Chem. Soc. 1998, 120, 12459-12467):
Briefly, bromo-4-fluorobenzene (d) was reacted with L-amino acid (b) in the presence of a base such as potassium carbonate and a catalytic amount of copper iodide at 90° C. to yield the desired N-aryl amino acid (e); or - c) Nucleophilic displacement of a triflate by an aniline:
Briefly, o-anisidine (f) was reacted with triflate (g) in the presence of a base such as 2,6-lutidine at 90° C. to give benzyl ester (h). Hydrogenation with 10% Pd/C yielded the desired N-aryl amino acid (i).
1.2) When B is an Aminothiazole Derivative - a) The Fmoc-thiocyanate prepared according to Kearney et al., 1998, J. Org. Chem, 63, 196, was reacted with a protected P3 residue or the whole peptide or a peptide segment to provide the thiourea.
- b) The thiourea derivative is reacted with an appropriate bromoketone to provide the corresponding thiazole derivative.
1.3) When B is R4—C(O)—, R4—S(O)2
- a) Direct nucleophilic displacement on a fluoro-nitro aryl moiety:
Protected P3 or the whole peptide or a peptide segment is coupled to an appropriate acyl chloride or sulfonyl chloride respectively, that is either commercially available or for which the synthesis is well known in the art.
1.4) When B is R4O—C(O)—
Protected P3 or the whole peptide or a peptide segment is coupled to an appropriate chloroformate that is either commercially available or for which the synthesis is well known in the art. For Boc-derivatives (Boc)2O is used.
-
- a) Cyclobutanol is treated with phosgene to furnish the corresponding chloroformate.
- b) The chloroformate is treated with the desired NH2-tripeptide in the presence of a base such as triethylamine to afford the cyclobutylcarbamate.
1.5) When B is R4—N(R5).C(O)—, or R4—NH—C(S)—, protected P3 or the whole peptide or a peptide segment is treated with phosgene followed by amine as described in SynLett. Feb 1995; (2); 142-144
2. Synthesis of P2 Moieties
2.1 Synthesis of Precursors
A) Synthesis of Haloarylmethane Derivatives
The preparation of halomethyl-8-quinoline Ild was done according to the procedure of K. N. Campbell et al., J. Amer. Chem. Soc., (1946), 68, 1844.
Briefly, 8-quinoline carboxylic acid IIa was converted to the corresponding alcohol IIe by reduction of the corresponding acyl halide IIb with a reducing agent such as lithium aluminium hydride. Treatment of alcohol IIb with the appropriate hydrohaloacid gives the desired halo derivative IId. A specific embodiments of this process is presented in Example 1.
Synthesis of Aryl Alcohol Derivatives
2-phenyl-4-hydroxyquinoline derivatives IIIc were prepared according to Giardina et al. (J. Med. Chem., (1997), 40, 1794-1807).
Briefly, benzoylacetamide (IIIa) was condensed with the appropriate aniline (IIIb) and the imine obtained was cyclized with polyphosphoric acid to give the corresponding 2-phenyl-4-hydroxyquinoline (IIIc). A specific embodiment of this process is presented in Example 2.
Or alternatively, the process can be carried out in a different manner: Benzoylethyl ester (IIIa) was condensed with the appropriate aniline (IIIb) in the presence of acid and the imine obtained was cyclized by heating at 260-280° C. to give the corresponding 2-phenyl-4-hydroxyquinoline (IIIc). A specific embodiments of this process is presented in Example 3 (compound 3e).
2.2. Synthesis of P2
A) The synthesis of 4-substituted proline (wherein R2 is attached to the ring via a carbon atom) (with the stereochemistry as shown):
is done as shown in Scheme IV according to the procedures described by J. Ezquerra et al. (Tetrahedron, (1993), 38, 8665-8678) and C. Pedregal et al. (Tetrahedron Lett., (1994), 35, 2053-2056).
Briefly, Boc-pyroglutamic acid is protected as a benzyl ester. Treatment with a strong base such as lithium diisopropylamide followed by addition of an alkylating agent (Br—R20 or I—R20) gives the desired compounds IVe after reduction of the amide and deprotection of the ester.
is done as shown in Scheme IV according to the procedures described by J. Ezquerra et al. (Tetrahedron, (1993), 38, 8665-8678) and C. Pedregal et al. (Tetrahedron Lett., (1994), 35, 2053-2056).
Briefly, Boc-pyroglutamic acid is protected as a benzyl ester. Treatment with a strong base such as lithium diisopropylamide followed by addition of an alkylating agent (Br—R20 or I—R20) gives the desired compounds IVe after reduction of the amide and deprotection of the ester.
B) The synthesis of O-substituted-4-(R)-hydroxyproline:
may be carried out using the different processes described below.
may be carried out using the different processes described below.
-
- 1) When R20 is aryl, aralkyl, Het or (lower alkyl)-Het, the process can be carried out according to the procedure described by E. M. Smith et al. (J. Med. Chem. (1988), 31, 875-885). Briefly, commercially available Boc-4 (R)-hydroxyproline is treated with a base such as sodium hydride or potassium tert-butoxide and the resulting alkoxide reacted with halo-R20 (Br—R20, I—R20, etc.) to give the desired compounds. Specific embodiments of this process are presented in Examples 4, 5 and 7.
- 2) Alternatively, when R30 is aryl or Het, the compounds can also be prepared via a Mitsunobu reaction (Mitsunobu (1981), Synthesis, January, 1-28; Rano et al., (1995), Tet. Lett. 36(22), 3779-3792; Krchnak et al., (1995), Tet. Lett. 36(5), 62193-6196; Richter et al., (1994), Tet. Lett. 35(27), 4705-4706).
- Briefly, commercially available Boc-4(S)-hydroxyproline methyl ester is treated with the appropriate aryl alcohol or thiol in the presence of triphenylphosphine and diethylazodicarboxylate (DEAD) and the resulting ester is hydrolyzed to the acid. Specific embodiments of this process are presented in Examples 6 and 8.
- Alternatively, the Mitsunobu reaction can be carried out in solid phase (Scheme V). The 96-well block of the Model 396 synthesizer (advanced ChemTech) is provided with aliquots of resin-bound compound (Va) and a variety of aryl alcohols or thiols and appropriate reagents are added. After incubation, each resin-bound product (Vb) is washed, dried, and cleaved from the resin.
- A Suzuki reaction (Miyaura et al., (1981), Synth. Comm. 11, 513; Sato et al., (1989), Chem. Lett., 1405; Watanabe et al., (1992), Synlett., 207; Takayuki et al., (1993), J. Org. Chem. 58, 2201; Frenette et al., (1994), Tet. Lett. 35(49), 9177-9180; Guiles et al., (1996), J. Org. Chem. 61, 5169-5171) can also be used to further functionalize the aryl substituent.
3. Synthesis of P1 Moieties
3.1 Synthesis of the 4 Possible Isomers of 2-substituted 1-aminocyclopropyl Carboxylic Acid
-
- a) Briefly, di-protected malonate VIa and 1,2-dihaloalkane VIb or cyclic sulfate VIc (synthesized according to K. Burgess and Chun-Yen KE (Synthesis, (1996), 1463-1467) are reacted under basic conditions to give the diester VId.
- b) A regioselective hydrolysis of the less hindered ester is performed to give the acid VIe.
- c) This acid VIe is subjected to a Curtius rearrangement to give a racemic mixture of 1-aminocyclopropylcarboxylic acid derivatives VIf with R1 being syn to the carboxyl group. A specific embodiment for this synthesis is presented in Example 9.
- d, e) Alternatively, selective ester formation from the acid VIe with an appropriate halide (P*Cl) or alcohol (P*OH) forms diester VIg in which the P* ester is compatible with the selective hydrolysis of the P ester. Hydrolysis of P ester provides acid VIh.
- f) A Curtius rearrangement on VIh gives a racemic mixture of 1-aminocyclopropylcarboxylic acid derivatives VIi with R1 group being anti to the carboxyl group. A specific embodiment for this synthesis is presented in Example 14.
An alternative synthesis for the preparation of derivatives VIIf (when R1 is vinyl and syn to the carboxyl group) is described below.
Treatment of commercially available or easily obtainable imines VIIa with 1,4-dihalobutene VIIb in presence of a base produces, after hydrolysis of the resulting imine VIIc, VIId having the allyl substituent syn to the carboxyl group. Specific embodiments of this process are presented in Example 15 and 19.
Resolution of all of the above enantiomeric mixtures at carbon 1 (VIe and VIId) can be carried out via:
1) enzymatic separation (Examples 13, 17 and 20);
2) crystallization with a chiral acid (Example 18); or
3) chemical derivatization (Example 10).
Following resolution, determination of the absolute stereochemistry can be carried out as presented in Example 11.
Enantiomeric resolution and stereochemistry determination can be carried out in the same manner for the enantiomeric mixtures at carbon 1 wherein the substituent at C2 is anti to the carboxyl group (VIi).
3.2 Synthesis of 1-aminocyclobutyl Carboxylic Acid
The synthesis of 1,1-aminocyclobutanecarboxylic acid is carried out according to “Kavin Douglas; Ramaligam Kondareddiar; Woodard Ronald, Synth. Commun. (1985), 15 (4), 267-72.
Briefly, treatment of compound VIIIa with a base in the presence of VIIIb gives the corresponding cyclobutyl derivative VIIIc. Hydrolysis of the isocyanate and ester groups of VIIIc under acidic conditions (HCl) yields the hydrochloride salt of the 1-amino-cyclobutylcarboxylic acid VIIId. The carboxylic acid is later esterified under methanol in HCl. A specific embodiment of this esterification is described in Example 21.
3.3 Synthesis of 2-substituted 1-aminocyclobutyl Carboxylic Acid
3.3 Synthesis of 2-substituted 1-aminocyclobutyl Carboxylic Acid
-
- a) A protected glycine ester derivative such as imine IXa is alkylated with an homoallylic electrophile IXb using an appropriate base such as a metal hydride, hydroxide or alkoxide. Useful leaving groups in IXb include halogens (X=Cl, Br, I) or sulfonate esters (mesylate, tosylate or triflate). The allylic alcohol functionality in IXb is protected with hydroxyl protecting groups well known in the art (e.g. acetate, silyl, acetals).
- b) In a second step, the hydroxyl function of monoalkylated derivative IXc is de-protected and converted to a suitable electrophilic function X such as described above for compound IXb.
- c) Cyclization of IXd to cyclobutane derivative IXe is carried out by treatment with a base (metal hydrides, alkoxides), followed by hydrolysis using aqueous mineral acids and neutralization with a mild base. At this stage, syn and anti-isomers of IXe can be separated by flash chromatography.
- d) Optionally, the double bond in IXe can also be hydrogenated under standard conditions to yield the corresponding saturated derivative IXf.
The invention further comprises a process for the preparation of a peptide analog of formula (I) wherein P1 is a substituted aminocyclopropyl carboxylic acid residue, comprising the step of:
-
- coupling a peptide selected from the group consisting of: APG-P3-P2; or APG-P2;
- with a P1 intermediate of formula:
- wherein R1 is C1-6 alkyl, cycloalkyl or C2-6 alkenyl, all optionally substituted with halogen, CPG is a carboxyl protecting group and APG is an amino protecting group and P3 and P2 are as defined above.
The invention further comprises a process for the preparation of: 1)a serine protease inhibitor peptide analog, or 2) a HCV NS3 protease inhibitor peptide analog, this process comprising the step of:
-
- coupling a (suitably protected) amino acid, peptide or peptide fragment with a P1 intermediate of formula:
- wherein R1 is C1-6 alkyl, C3-7 cycloalkyl or C2-6 alkenyl, all optionally substituted with halogen, and CPG is a carboxyl protecting group.
- coupling a (suitably protected) amino acid, peptide or peptide fragment with a P1 intermediate of formula:
The invention therefore comprises a process for the preparation of: 1) a protease inhibitor peptide analog, or 2) a serine protease inhibitor peptide analog, this process comprising the step of:
-
- coupling a (suitably protected) amino acid, peptide or peptide fragment with an intermediate of formula:
- wherein CPG is a carboxyl protecting group.
- coupling a (suitably protected) amino acid, peptide or peptide fragment with an intermediate of formula:
The invention also comprises the use of a P1 intermediate of formula:
wherein R1 is C1-6 alkyl, cycloalkyl or C2-6 alkenyl, all optionally substituted with halogen, for the preparation of: 1)a serine protease inhibitor peptide analog, or 2) a HCV NS3 protease inhibitor peptide analog.
wherein R1 is C1-6 alkyl, cycloalkyl or C2-6 alkenyl, all optionally substituted with halogen, for the preparation of: 1)a serine protease inhibitor peptide analog, or 2) a HCV NS3 protease inhibitor peptide analog.
The invention also comprises the use of an intermediate of formula:
wherein CPG is a carboxyl protecting group, for the preparation of: 1) a protease inhibitor peptide analog, or 2) a serine protease inhibitor peptide analog.
wherein CPG is a carboxyl protecting group, for the preparation of: 1) a protease inhibitor peptide analog, or 2) a serine protease inhibitor peptide analog.
The invention also comprises the use of a P1 intermediate of formula:
wherein R1 is C1-6 alkyl, cycloalkyl or C2-6 alkenyl, all optionally substituted with halogen, for the preparation of a compound of formula I as defined above.
wherein R1 is C1-6 alkyl, cycloalkyl or C2-6 alkenyl, all optionally substituted with halogen, for the preparation of a compound of formula I as defined above.
-
- R21A is C1-6 alkyl; C1-6 alkoxy; lower thioalkyl; halo; amino optionally mono-substituted with C1-6 alkyl; C6, C10 aryl, C7-16 aralkyl or Het, said aryl, aralkyl or Het optionally substituted with R22 wherein R22 is C1-6 alkyl, C1-6 alkoxy, amido, (lower alkyl)amide, amino optionally mono- or di-substituted with C1-6 alkyl, or Het, and
- R21B is C1-6 alkyl, C1-6 alkoxy, amino, di(lower alkyl) amino, (lower alkyl)amide, NO2, OH, halo, trifluoromethyl, or carboxyl;
for the synthesis of 1) a serine protease inhibitor peptide analog, 2) a HCV NS3 protease inhibitor peptide analog, or 3) a peptide analog of formula I as defined above.
The present invention is illustrated in further detail by the following non-limiting examples.
Temperatures are given in degrees Celsius. Solution percentages express a weight to volume relationship, and solution ratios express a volume to volume relationship, unless stated otherwise. Nuclear magnetic resonance (NMR) spectra were recorded on a Bruker 400 MHz spectrometer; the chemical shifts (δ) are reported in parts per million. Flash chromatography was carried out on silica gel (SiO2) according to Still's flash chromatography technique (W. C. Still et al., J. Org. Chem., (1978), 43, 2923).
Abbreviations used in the examples include Bn: benzyl; Boc: tert-butyloxycarbonyl {Me3COC(O)}; BSA: bovine serum albumin; CHAPS: 3-[(3-cholamidopropyl)-dimethylammonio]-1-propanesulfonate; DBU: 1,8-diazabicyclo[5.4.0]undec-7-ene; CH2Cl2=DCM: methylene chloride; DEAD: diethylazodicarboxylate; DIAD: diisopropylazodicarboxylate; DIEA: diisopropylethylamine; DIPEA: diisopropylethylamine; DMAP: dimethylaminopyridine; DCC: 1,3-dicyclohexylcarbodiimide; DME: 1,2-dimethyoxyethane; DMF: dimethylformamide; DMSO: dimethylsulfoxide; DTT: dithiothreitol or threo-1,4-dimercapto-2,3-butanediol; DPPA: diphenylphosphoryi azide; EDTA: ethylenediaminetetraacetic acid; Et: ethyl; EtOH: ethanol; EtOAc: ethyl acetate; Et2O: diethyl ether; HATU: [O-7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate]; HPLC: high performance liquid chromatography; MS: mass spectrometry (MALDI-TOF: Matrix Assisted Laser Disorption Ionization-Time of Flight, FAB: Fast Atom Bombardment); LAH: lithium aluminum hydride; Me: methyl; MeOH: methanol; MES: (2-{N-morpholino}ethane-sulfonic acid); NaHMDS: sodium bis(trimethylsilyl)amide; NMM: N-methylmorpholine; NMP: N-methylpyrrolidine; Pr: propyl; Succ: 3-carboxypropanoyl; PNA: 4-nitrophenylamino or p-nitroanilide; TBAF: tetra-n-bulylammonium fluoride; TBTU: 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate; TCEP: tris(2-carboxyethyl) phosphine hydrochloride; TFA; trifluoroacetic acid; THF: tetrahydrofuran; TIS: triisopropylsilane; TLC: thin layer chromatography; TMSE: trimethylsilylethyl; Tris/HCl: tris(hydroxymethyl)aminomethane hydrochloride.
To commercially available 8-quinoline carboxylic acid (2.5 g, 14.4 mmol) was added neat thionyl chloride (10 ml, 144 mmol). This mixture was heated at 80° C. for 1 h before the excess thionyl chloride was distilled off under reduced pressure. To the resulting brownish solid was added absolute EtOH (15 mL) which was heated at 80° C. for 1 h before being concentrated in vacuo. The residue was partitioned between EtOAc and saturated aqueous NaHCO3, and the organic phase dried (MgSO4), filtered and concentrated to give a brownish oil (2.8 g). This material (ca. 14.4 mmol) was added dropwise over 35 min to a LAH (0.76 g, 20.2 mmol)/Et2O suspension which was cooled to −60° C. The reaction mixture was slowly warmed to −35° C. over 1.5 h before the reaction was complete. The reaction was quenched with MgSO4.10H2O slowly over 30 min and then wet THF. The mixture was partitioned between Et2O and 10% aqueous NaHCO3. The organic phase was dried (MgSO4), filtered and concentrated to give a yellowish solid (2.31 g, 80% over 2 steps) corresponding to the alcohol. The alcohol (2.3 g, 11.44 mmol) was dissolved in AcOH/HBr (20 mL, 30% solution from Aldrich) and heated at 70° C. for 2.5 h. The mixture was concentrated in vacuo to dryness, partitioned between EtOAc (100 mL) and saturated aqueous NaHCO3 before being dried (MgSO4), filtered and concentrated to give the desired compound (1) as a brownish solid (2.54 g, 100%).
Commercially available ethyl benzoylacetate (6.00 g, 31.2 mmol) was heated at 85° C. (sealed tube) in 75 mL of 30% NH4OH for 2 hours. The solid formed upon cooling was filtered and refluxed in water for 2 hours. The solution was extracted three times with CH2Cl2. The organic layers were combined, dried over MgSO4, filtered and concentrated. The yellow residue was flash chromatographed on silica gel, eluting with EtOAc:hexane (3:7), to give the corresponding amide as a white solid, 1.60 g, 31% yield.
This amide (250 mg, 1.53 mmol) was refluxed using a Dean-Stark apparatus with aniline (143 mg, 1.53 mmol) and aniline.HCl (10 mg, 0.08 mmol) in toluene (10 mL) for 16 h. The solution was concentrated to afford a brown oil that was mixed with polyphosphoric acid (2 g) and heated at 135° C. for 20 min. The reaction mixture was poured into water and adjusted to pH 8 with 5 M NaOH. The aqueous suspension was extracted twice with ethyl acetate. The organic layers were combined, washed with brine, dried over MgSO4, filtered and concentrated. The residue was flash chromatographed on silica gel, eluting with 3% MeOH in ethyl acetate, to give 2-phenyl-4-hydroxyquinoline (2), 67 mg, 20% yield.
1H NMR (DMSO-d6) δ8.11 (d, J=7 Hz, 1 H), 7.86-7.83 (m, 2 H), 7.77 (d, J=8 Hz, 1 H), 7.68 (dd, J=8, 7 Hz, 1 H), 7.61-7.58 (m, 3 H), 7.35 (dd, J=8, 7 Hz, 1 H), 6.34 (s, 1 H).
A solution of ethyl benzoylacetate (b) (100.0 g, 0.52 mol), m-anisidine (a) (128.1 g, 1.04 mol) and 4 N HCl/dioxane (5.2 mL) in toluene (1.0 L) was refluxed for 6.25 h in a Dean-Stark apparatus. The cooled toluene solution was successively washed with aqueous 10% HCl (2×300 mL), 1 N NaOH (2×300 mL), H2O (300 mL) and brine (150 mL). The toluene phase was dried (MgSO4), filtered and concentrated under reduced pressure to give a 1.2:1.0 mixture of ester c and amide d (144.6 g, 45%/38% crude yield) as a dark brown oil. The crude oil was heated to 280° C. for 80 min while distilling generated EtOH. The cooled dark solid obtained was triturated with CH2Cl2 (200 mL). The suspension was filtered and the resulting solid washed with CH2Cl2 to give e (22.6 g, 17% from a) as a beige solid: 1H NMR (DMSO-d6) δ8.00 (d, J=9.0 Hz, 1H), 7.81-7.82 (m, 2H), 7.57-7.59 (m, 3H), 7.90 (d, J=2.2 Hz, 1H), 6.94 (dd, J=9.0, 2.2 Hz, 1H), 6.26 (s, 1H), 3.87 (s, 3H).
A suspension of c (8.31 g, 33.1 mmol) in POCl3 (90 mL) was heated to reflux for 2 h (clear solution obtained upon heating). The reaction mixture was concentrated under reduced pressure. The residue was partitioned between 1 N NaOH (exothermic, 10 N NaOH added to maintain high pH) and EtOAc (500 mL). The organic layer was washed with H2O (100 mL) and brine (100 mL) then was dried (MgSO4), filtered and concentrated under reduced pressure to give 3 (8.60 g, 96%) as a pale yellow solid:
1H NMR (DMSO-d6) δ8.28-8.30 (m, 2H), 8.20 (s, 1H), 8.10 (d, J=9.1 Hz, 1H), 7.54-7.58 (m, 3H), 7.52 (d, J=2.5 Hz, 1H), 7.38 (dd, J=9.1, 2.5 Hz, 1H), 3.98 (s, 3H). This reaction was repeated three times and gave always 96-98% yield which is significantly higher that the 68% yield reported in J. Med. Chem. 1997, 40, 1794.
Commercially available Boc-4(R)-hydroxyproline (5.00 g, 21.6 mmol) was dissolved in THF (100 mL) and cooled to 0° C. Sodium hydride (60% dispersion in oil, 1.85 g, 45.4 mmol) was added portionwise over 10 minutes and the suspension was stirred at RT for 1 h. Then, 1-(bromomethyl) n2aphthalene (8.00 g, 36.2 mmol) (prepared as described in E. A. Dixon et al. Can. J. Chem., (1981), 59, 2629-2641) was added and the mixture was heated at reflux for 18 h. The mixture was poured into water (300 mL) and washed with hexane. The aqueous layer was acidified with 10% aqueous HCl and extracted twice with ethyl acetate. The organic layers were combined and washed with brine, dried (MgSO4), filtered and concentrated. The residue was purified by flash chromatography (49:49:2 hexane: ethyl acetate:acetic acid) to give the title compound as a colorless oil (4.51 g, 56% yield). 1H NMR (DMSO-d6) indicated the presence of two rotamers: δ8.05 (m, 1H), 7.94 (m, 1H), 7.29 (d, J=14 Hz, 1H), 7.55-7.45 (m, 4H), 4.96 (m, 2H), 4.26 (br. s, 1H), 4.12 (dd, J=J=8 Hz, 1H), 3.54-3.42 (m, 2H), 2.45-2.34 (m, 1H), 2.07-1.98 (m, 1H) 1.36 (s, (3/9) 9H), 1.34 (s, (6/9) 9H).
Boc-4(R)-hydroxyproline (1.96 g, 8.5 mmol) in anhydrous THF (20 mL) was added to a suspension of NaH (1.4 g, 60% in oil, 34 mmol) in THF (100 mL). This mixture was stirred 30 min before bromomethyl-8-quinoline from Example 1 (2.54 g, 11.44 mmol) was added in THF (30 mL). The reaction mixture was heated at 70° C. (5 h) before the excess NaH was destroyed carefully with wet THF. The reaction was concentrated in vacuo and the resulting material was dissolved in EtOAc and H2O. The basic aqueous phase was separated and acidified with 10% aqueous HCl to pH −5 before being extracted with EtOAc (150 mL). The organic phase was dried (MgSO4), filtered and concentrated to give a brown oil. Purification by flash chromatography (eluent: 10% MeOH/CHCl3) gave the desired compound (5) as a pale yellow solid (2.73 g, 86%). HPLC (97.5%); 1H-NMR (DMSO-d6) shows rotamer populations in a 6:4 ratio, δ12-11.4 (bs, 1H), 8.92 (2×d, J=4.14 and 4.14 Hz, 1H), 8.38 (2×d, J=8.27 and 8.27 Hz, 1H), 7.91 (d, J=7.94 Hz, 1H, 7.77 (d, J=7.0Hz, 1H), 7.63-7.54 (m, 2H), 5.14 (2×s, 2H), 4.32-4.29 (m, 1H), 4.14-4.07 (m, 1H), 3.52-3.44 (m, 2H), 2.43-2.27 (m, 1H), 2.13-2.04 (m, 1H), 1.36 and 1.34 (2×s, 9H).
Commercially available Boc-4(S)-hydroxyproline methyl ester (500 mg, 2.04 mmol) and 7-chloro-4-hydroxyquinoline (440 mg, 2.45 mmol) were placed in dry THF (10 mL) at 0° C. Triphenylphosphine (641 mg, 2.95 mmol) was added, followed by slow addition of DIAD (426 mg, 2.45 mmol). The mixture was stirred at RT for 20 h. The reaction mixture was then concentrated, taken up in ethyl acetate and extracted three times with HCl 1N. The aqueous phase was basified with Na2CO3 and extracted twice with ethyl acetate. The organic layers were combined, dried over MgSO4, filtered and concentrated to give a yellow oil. The oil was purified by flash chromatography to give the methyl ester as a white solid, 498 mg, 58% yield. This methyl ester (400 mg, 0.986 mmol) was hydrolyzed with 1M aqueous sodium hydroxide (1.7 mL, 1.7 mmol) in methanol (4 mL), at 0° C., for 3 h. The solution was concentrated to remove the methanol and neutralized with 1M aqueous HCl. The suspension was concentrated to dryness and taken up in methanol (20 mL), the salts were filtered off and the filtrate concentrated to give the desired compound (6) as a white solid, 387 mg, quant. yield.
1H NMR (DMSO-d6) (ca. 1:1 mixture of rotamers) δ8.74 (d, J=5 Hz, 1 H), 8.13-8.09 (m, 1 H), 7.99 and 7.98 (s, 1 H), 7.58 (d, J=9 Hz, 1 H), 7.02 (d, J=5 Hz, 1 H), 5.26-5.20 (m, 1 H), 4.10-4.01 (m, 1 H), 3.81-3.72 (m, 1 H), 3.59 (dd, J=12, 10 Hz, 1 H), 2.41-2.31 (m, 2 H), 1.34 and 1.31 (s, 9H).
Potassium tert-butoxide (8.16 g, 72.7 mmol) was added in small portions, over 15 min, to a solution of Boc-4(R)-hydroxy proline (6.73 g, 29.1 mmol) in DMSO (83 mL) maintained at 25° C. The mixture was stirred at 25° C. for 1.5 h. Chloro-2-phenyl-7-methoxyquinoline 3 (8.61 g, 32.0 mmol) was added in 4 portions over 15 min to the reaction mixture. The reaction mixture was stirred at 25° C. for 19 h. The resulting suspension was poured in H2O (650 mL) and the mixture was washed with Et2O (3×150 mL) to remove excess chloroquinoline (EtOAc was later found to be more efficient). The aqueous layer was acidified with aqueous 1 N HCl (38 mL of calculated 1.5 equiv. required, 43.6 mL) to pH 4-5. The white solid that precipitated was recovered by filtration. The moist solid was dried under reduced pressure over P2O5 to give the proline derivative 7 (12.6 g, 91%, contains 2.3% w/w of DMSO) as a beige solid:
1H NMR (DMSO-d6) δ(2:1 mixture of rotamers) 8.27 (d, J=7.0 Hz, 2H), 8.00, 7.98 (2d, J=9.2, ˜9.2 Hz, 1H), 7.48-7.56 (m, 3H), 7.45, 7.43 (2s, 1H), 7.39 (d, J=2.5 Hz, 1H), 7.17 (dd, J=9.2, 2.5 Hz, 1H), 5.53-5.59 (m, 1H), 4.34-4.41 (m, 1H), 3.93 (s, 3H), 3.76 (broad s, 2H), 2.63-2.73 (m, 1H), 2.32-2.43 (m, 1H), 1.36, 1.33 (2s, 9H).
Diethyl azodicarboxylate (0.77 mL, 4.89 mmol) was added dropwise to a stirred solution of triphenylphosphine (1.28 g, 4.88 mmol) in 15 mL of tetrahydrofuran at 0° C. After 30 min. of stirring under nitrogen a solution of Boc-4(S)-hydroxyproline methyl ester (1.00 g, 4.08 mmol) was added in 5 mL of tetrahydrofuran followed by a suspension of commercially available 6-nitro-2-phenyl-4-quinolinol (1.30 g, 4.88 mmol) in 10 mL of the same solvent. The red mixture was stirred for 15 min. at 0° C. and at RT overnight. The solvent was evaporated in vacuo. The remaining oil was diluted in ethyl acetate and washed twice with sodium bicarbonate, once with water and once with brine. The organic layer was dried (MgSO4), filtered and evaporated in vacuo. The residue was chromatographed over silica gel (70:30 v/v, hexanes-ethyl acetate) affording the desired methyl ester as a light yellow solid (1.70 g, 85%).
1H NMR(CDCl3) rotamers=3:7 δ9.03 (d, J=2.5 Hz, 1H), 8.46 (dd, J=9, 2.5 Hz, 1H), 8.18 (d, J=9 Hz, 1H), 8.14-8.07 (m, 2H), 7.59-7.50 (m, 3H), 7.19 (s, 1H), 5.39-5.30 (m, 1H), 4.67 (t, J=8 Hz, 0.3H), 4.61 (t, J=8 Hz, 0.7H), 4.07-4.01 (m, 2H), 3.81 (s, 3H), 2.89-2.73 (m, 1H), 2.55-2.47 (m, 1H), 1.49 (s, 2.7H), 1.45 (s, 6.3H).
To a solution of the methyl ester (503 mg, 1.02 mmol) in a mixture of THF; H2O (10:4 mL) was added lithium hydroxide monohydrate (85 mg, 2.05 mmol). 2 mL of MeOH was added in order to get an homogeneous solution. A white precipitate resulted within 30 min. The resulting suspension was stirred at RT for an additional 6 h. The reaction mixture was diluted with an aqueous solution of citric acid 10% and extracted with ethyl acetate. The organic layer was dried (MgSO4), filtered and evaporated in vacuo to afford 416 mg (85%) of the desired acid (8).
1H NMR (DMSO-d6): δ8.92-8.87 (m, 1H), 8.47 (dd, J=9, 3Hz, 1H), 8.38-8.32 (m, 2H), 8.19 (d, J=9 Hz, 1H), 7.77 (s, 1H), 7.62-7.55 (m, 3H), 5.73-5.66 (m, 1H), 4.41 (t, J=8 Hz, 1H), 3.89-3.76 (m, 2H), 2.83-2.72 (m, 1H), 2.47-2.35 (m, 1H), 1.38 (s, 9H).
a) To a suspension of benzyltriethylammonium chloride (21.0 g, 92.19 mmol) in a 50% aqueous NaOH solution (92.4 g in 185 mL H2O) were successively added di-tert-butylmalonate (20.0 g, 92.47 mmol) and 1,2-dibromobutane (30.0 g, 138.93 mmol). The reaction mixture was vigorously stirred overnight at RT, a mixture of ice and water was then added. The crude product was extracted with CH2Cl2 (3×) and sequentially washed with water (3×) and brine. The organic layer was dried (MgSO4), filtered and concentrated. The residue was flash chromatographed (7 cm, 2 to 4 % Et2O in hexane) to afford the desired cyclopropane derivative 9c (19.1 g, 70.7 mmol, 76% yield). 1H NMR (CDCl3) δ1.78-1.70 (m, 1H), 1.47 (s, 9H), 1.46 (s, 9H), 1.44-1.39 (m, 1H), 1.26-1.64 (m, 3H), 1.02 (t, 3H, J=7.6 Hz).
b) To a suspension of potassium tert-butoxide (6.71 g, 59.79 mmol, 4.4 eq.) in dry ether (100 mL) at 0° C. was added H2O (270 μL, 15.00 mmol, 1.1 eq.). After 5 min diester 9c (3.675 g, 13.59 mmol) in ether (10 mL) was added to the suspension. The reaction mixture was stirred overnight at RT, then poured in a mixture of ice and water and washed with ether (3×). The aqueous layer was acidified with a 10% aq. citric acid solution at 0° C. and extracted with AcOEt (3×). The combined organic layer was successively washed with water (2×) and brine. After the usual treatment (Na2SO4, filtration, concentration), the desired acid 9d was isolated as a pale yellow oil (1.86 g, 8.68 mmol, 64% yield). 1H NMR (CDCl3) δ2.09-2.01 (m, 1H), 1.98 (dd, J=3.8, 9.2 Hz, 1H), 1.81-1.70 (m, 1H), 1.66 (dd, J=3.0, J=8.2 Hz, 1H), 1.63-1.56 (m, 1H), 1.51 (s, 9H), 1.0 (t, J=7.3 Hz, 3H).
c) To the acid 9d (2.017 g, 9.414 mmol) in dry benzene (32 mL) were successively added Et3N (1.50 mL, 10.76 mmol, 1.14 eq.) and DPPA (2.20 mL, 10.21 mmol, 1.08 eq.). The reaction mixture was refluxed for 3.5 h then 2-trimethylsilylethanol (2.70 mL, 18.84 mmol, 2.0 eq.) was added. The reflux was maintained overnight then the reaction mixture was diluted with Et2O and successively washed with a 10% aqueous citric acid solution, water, saturated aqueous NaHCO3, water (2×) and brine. After the usual treatment (MgSO4, filtration, concentration) the residue was purified by flash chromatography (5 cm, 10% AcOEt-hexane) to afford the desired carbamate 9e (2.60 g, 7.88 mmol, 84% yield) as a pale yellow oil. MS (FAB) 330 (MH+); 1H NMR (CDCl3) δ5.1 (bs, 1H), 4.18-4.13 (m, 2H), 1.68-1.38 (m, 4H), 1.45 (s, 9H), 1.24-1.18 (m, 1H), 1.00-0.96 (m, 5H), 0.03 (s, 9H).
d) To carbamate 9e (258 mg, 0.783 mmol) was added a 1.0 M TBAF solution in THF (940 μL, 0.94 mmol, 1.2 eq.). After 4.5 h an additional amount of 1.0 M TBAF was added (626 μL, 0.63 mmol, 0.8 eq.). The reaction mixture was stirred overnight at RT, refluxed for 30 min and then diluted with AcOEt. The solution was successively washed with water (2×) and brine. After the usual treatment (MgSO4, filtration and concentration) the desired amine 9f was isolated (84 mg, 0.453 mmol, 58% yield) as a pale yellow liquid. 1H NMR (CDCl3) δ1.96 (bs, 2H), 1.60-1.40 (m, 2H), 1.47 (s, 9H), 1.31-1.20 (m, 1H), 1.14 (dd, J=4.1, 7.3 Hz, 1H), 1.02 (dd, J=4.1, 9.2 Hz, 1H), 0.94 (t, J=7.3 Hz, 3H).
Compound 9e from Example 9 (8.50 g, 25.86 mmol) was treated with 1M TBAF/THF (26 mL) at reflux for 45 min. The cooled reaction mixture was diluted with EtOAc, washed with water (3×) and brine (1×), then, dried (MgSO4), filtered and evaporated to provide the free amine as a light yellow oil. The free amine was dissolved in anhydrous CH2Cl2 (120 mL), NMM (8.5 mL, 77.57 mmol), compound 4 (Example 4) (10.08 g, 27.15 mmol) and HATU (11.79 g, 31.03 mmol) were added successively. The reaction mixture was stirred at RT overnight, then worked up as described previously. The crude diastereomeric mixture was separated by flash chromatography (eluent-hexane:Et2O ; 25:75) to provide the dipeptide 10a (the less polar eluting spot) as a white foam (4.42 g; 64% of the theoretical yield) and 10b (the more polar eluting spot) as an ivory foam (4 g., 57% of theoretical yield). At this time both isomers were separated but the absolute stereochemistry was still not known.
Prof. A. Charette, from the University of Montreal, provided compound 11a having the absolute stereochemistry as shown, which was determined by X-ray crystallography (J. Am. Chem. Soc., 1995, 117, 12721). Compound 11a (13.2 mg, 0.046 mmol) was dissolved in 1M HCl/EtOAc (240 μL) and stirred approximately 48 hours. The mixture was evaporated to dryness to provide compound 11b as a light yellow paste and was coupled to compound 4 (18 mg, 0.049 mmol) as described in Example 10, using NMM (20.3 μL, 0.185 mmol) and HATU (21.1 mg, 0.056 mmol) in CH2C2. The crude material was purified by flash chromatography (eluent-hexane:Et2O; 50:50) to provide the dipeptide 11c as an oil (7.7 mg; 31%). By TLC, HPLC and NMR comparison, dipeptide 11c, was found to be identical to the less polar compound 10a obtained in Example 10, thus identifying the absolute stereochemistry of 10a as (1R,2R).
The carbamate 9e from Example 9 (2.6 g, 7.88 mmol) was stirred for 40 min in TFA at 0° C. The mixture was then concentrated and diluted with THF (10 mL). An aqueous NaOH solution (700 mg, 17.5 mmol in 8.8 mL of H2O) was added followed by a THF (13 mL) solution of (Boc)2O(2.06 g, 9.44 mmol, 1.2 eq.). The reaction mixture was stirred overnight at RT(the pH was maintained at 8 by adding a 10% aqueous NaOH solution when needed), then diluted with H2O, washed with Et2O (3×) and acidified at 0° C. with a 10% aq. citric acid solution. The aqueous layer was extracted with EtOAc (3×) and successively washed with H2O (2×) and brine. After the usual treatment (MgSO4, filtration and concentration) the desired Boc-protected amino acid (12a) (788 mg, 3.44 mmol, 44% yield) was isolated. 1H NMR (CDCl3) δ5.18 (bs, 1H), 1.64-1.58 (m, 2H), 1.55-1.42 (m, 2H), 1.45 (s, 9H), 1.32-1.25 (m, 1H), 0.99 (t, 3H, J=7.3 Hz).
The Boc derivative 12a (0.30 g, 1.31 mmol) was dissolved in Et2O (10 mL) and treated with freshly prepared diazomethane in Et2O at 0° C. until the yellow color of a slight excess of diazomethane remained. After stirring for 20 min at RT the reaction mixture was concentrated to dryness to give 12b as a clear colorless oil (0.32 g, 100%). 1H NMR (CDCl3) δ5.1 (bs, 1H), 3.71 (s, 3H), 1.62-1.57 (m, 2H), 1.55 (s, 9H), 1.53-1.43 (m, 1H), 1.28-1.21 (m, 2H), 0.95 (t, J=7.3 Hz, 3H).
a) The enantiomeric mixture of (1S, 2R)/(1R, 2R) 1-Boc-amino-2-ethylcarboxylic acid methyl ester of Example 10 (0.31 g, 1.27 mmol) was dissolved in acetone (3 mL) and then diluted with water (7 mL) while being rapidly stirred. The pH of the solution was adjusted to 7.5 with 0.05M aqueous NaOH before Alcalaseo® [2.4L extract from Novo Nordisk Industrials] (300 mg) was added. During incubation pH was stabilized with NaOH and a pH stat was set up to monitor the addition of the NaOH solution. After 40 h the mixture was diluted with EtOAc and H2O (with 5 mL sat. NaHCO3) and the phases separated. The aqueous phase was acidified with 10% aqueous HCl and extracted with EtOAc, dried (MgSO4), filtered and concentrated to give acid 13a (48.5 mg). The absolute stereochemistry was determined using the correlation described in Examples 10 and 11.
b) Treatment of an aliquot of acid 13a with diazomethane in Et2O to give the methyl ester followed by analysts by HPLC using a chiral column [Chiralcel® OD-H, 2.5% Isopropanol/hexane, isocratic] showed a 51:1 ratio of the (S,R) isomer.
c) To 9d (1.023 g, 4.77 mmol) in CH3CN (25 mL) were successively added DBU (860 μL, 5.75 mmol, 1.2 eq.) and allyl bromide (620 μL, 7.16 mmol, 1.5 eq.). The reaction mixture was stirred for 4 h at RT and then concentrated. The residue was diluted with Et2O and successively washed with a 10% aq. citric acid solution (2×), H2O, saturated aqueous NaHCO3, H2O (2×) and brine. After the usual treatment (MgSO4, filtration and concentration) the desired ester 14a was isolated (1.106 g, 3.35 mmol, 91% yield) as a colorless oil. MS (FAB) 255 (MH+); 1H NMR (CDCl3) γ5.96-5.86 (m, 1H), 5.37-5.22 (m, 2H), 4.70-4.65 (m, 1H), 4.57-4.52 (m, 1H), 1.87-1.79 (m, 1H), 1.47 (s, 9H), 1.45-1.40 (m, 1H), 1.33-1.24 (m, 3H), 1.03 (t, J=7.3 Hz, 3H).
d) To ester 14a (1.106 g, 4.349 mmol) in dry CH2Cl2 (5 mL) at RT was added TFA (5 mL). The reaction mixture was stirred for 1.5 h and then concentrated to afford 14b (854 mg, 4.308 mmol, 99 % yield). MS (FAB) 199 (MH+); 1H NMR (CDCl3) δ5.99-5.79 (m, 1H), 5.40-5.30 (m, 2H), 4.71-4.62 (m, 2H), 2.22-2.00 (m, 2H), 1.95-1.88 (m, 1H), 1.84-1.57 (m, 2H), 0.98 (t, J=7.3 Hz, 3H).
e) To acid 14b (853 mg, 4.30 mmol) in dry benzene (14.8 mL) were successively added Et3N (684 μL, 4.91 mmol, 1.14 eq.) and DPPA (992 μL, 4.60 mmol, 1.07 eq.). The reaction mixture was refluxed for 4.5 h then 2-trimethylsilylethanol (1.23 mL, 8.58 mmol, 2.0 eq.) was added. The reflux was maintained overnight then the reaction mixture was diluted with Et2O and successively washed with a 10% aqueous citric acid solution, water, saturated aq. NaHCO3, water (2×) and brine. After the usual treatment (MgSO4, filtration, concentration) the residue was flash chromatographed (5 cm, 10 to 15 % AcOEt-hexane) to afford carbamate 14c (1.212 g, 3.866 mmol, 90% yield) as a pale yellow oil. MS (FAB) 314 (MH+); 1H NMR (CDCl3) δ5.93-5.84 (m, 1H), 5.32-5.20 (m, 2H), 5.05 (bs, 1H), 4.60-4.56 (m, 2H), 4.20-4.11 (m, 2H), 1.71-1.60 (m, 3H), 1.39-1.22 (m, 1H), 1.03 (t, J=7.6 Hz, 3H), 0.96-0.86 (m, 1H), 0.04 (s, 9H).
f) To carbamate 14c (267 mg, 0.810 mmol) was added a 1.0 M TBAF solution in THF (1.62 mL, 1.62 mmol, 2.0 eq.). The reaction mixture was stirred overnight at RT, refluxed for 30 min and then diluted with AcOEt. The solution was successively washed with water (2×) and brine. After the usual treatment (MgSO4, filtration and concentration) the desired amine 14d was isolated (122 mg, 0.721 mmol, 89% yield) as a pale yellow liquid. 1H NMR (CDCl3) δ5.94-5.86 (m,1H), 5.31-5.22 (m, 2H), 4.58 (d, J=5.7 Hz, 2H), 1.75 (bs, 2H), 1.61-1.53 (m, 2H), 1.51-1.42 (m, 2H), 1.00 (t, J=7.3 Hz, 3H), 0.70-0.62 (m, 1H).
a) To a THF solution (180 mL) of potassium tert-butoxide (4.62 g, 41.17 mmol, 1.1 eq.) at −78° C. was added commercially available imine 15a (10.0 g, 37.41 mmol) in THF (45 mL). The reaction mixture was warmed to 0° C. and stirred at this temperature for 40 min. The mixture was then cooled back to −78° C. for the addition of 1,4-dibromobutene 15b (8.0 g, 37.40 mmol) and then stirred at 0° C. for 1 h and cooled back to −78° C. for the addition of potassium tert-butoxide (4.62 g, 41.17 mmol, 1.1 eq.). The reaction mixture was finally stirred one more hour at 0° C. and concentrated to yield compound 15c. b, c, d) 15c was taken up in Et2O (265 mL) and treated with a 1N aq. HCl solution (106 mL). After 3.5 h at RT, the layers were separated and the aqueous layer was washed with Et2O (2×) and basified with a saturated aq. NaHCO3 solution. The desired amine was extracted with Et2O (3×) and the combined organic extract was washed with brine. After the usual treatment (MgSO4, filtration and concentration) the residue was treated with a 4N HCl solution in dioxane (187 mL, 748 mmol). After concentration, hydrochloride sail 15d was isolated as a brown solid (2.467 g, 12.87 mmol, 34% yield). 1H NMR (CDCl3) δ9.17 (bs, 3H), 5.75-5.66 (m, 1H), 5.39 (d, J=17.2 Hz, 1H), 5.21 (d, J=10.2 Hz, 1H), 4.35-4.21 (m, 2H), 2.77-2.70 (m, 1H), 2.05 (dd, J=6.4, 10.2 Hz, 1H), 1.75 (dd, J=6.4, 8.3 Hz, 1H),1.33 (t, J=7.0 Hz, 3H).
The hydrochloride salt 15d (1.0 g, 5.2 mmol) and (Boc)2O (1.2 g, 5.7 mmol) were dissolved in THF (30 mL) and heated with DMAP (0.13 g, 1.04 mmol, 0.2 equiv.) and diisopropylethylamine (2.8 mL, 15.6 mmol). The reaction mixture was stirred 24 h before being diluted with EtOAc (40 mL) and washed successively with sat. NaHCO3 (aq), 5% aqueous HCl, and sat. brine. The organic phase was dried (MgSO4), filtered and concentrated to give after purification by flash chromatography (15% EtOAc/hexane), 16a (0.29 g, 23%). 1H NMR (CDCl3) δ5.80-5.72 (m, 1H), 5.29-5.25 (dd, J=17.2, 17.2 Hz, 1H), 5.24-5.1 (bs, 1H), 5.10 (dd, J=9.2, 9.2 Hz, 1H), 4.22-4.13 (m, 2H), 2.15-2.04 (m, 1H), 1.85-1.73 (bs, 1H), 155-1.5 (m, 1H), 1.49 (s, 9H), 1.26 (t, J=7.3 Hz, 3H).
a) Racemic derivative 17a (0.29 g, 1.14 mmol) was dissolved in acetone (5 mL) and diluted with H2O (10 mL). The pH was adjusted with 0.2N aqueous NaOH to 7.2 before Alcalase® was added (300 mg). To keep the pH constant during incubation, a NaOH solution was added by a pH stat titrator over 9 days until the theoretical amount of base had been added. Following acid/base extraction as described in Example 13, the unhydrolyzed ester (0.15 g, 100%) and the hydrolyzed material (0.139 g, 95%) were isolated. Analysis of the unhydrolyzed ester by HPLC using a chiral column showed a ratio of 43:1 of the desired compound 17c that was assigned the (R,S) stereochemistry based on chemical correlation as described in Examples 10 and 11.
Conditions for HPLC analysis: Chiralcel® OD-H (4.6 mm×25 cm), isocratic conditions using a mobile phase of 2.5% isopropanol/hexane.
To a solution of crude racemic (1S,2S and 1R, 2S) ethyl 1-amino-2-vinylcyclopropyl carboxylate [obtained from N-(diphenylmethylene)glycine ethyl ester (25.0 g, 93.5 mol) as described in Example 15] in EtOAc (800 mL) was added dibenzoyl-D-tartaric acid (33.5 g, 93.5 mol). The mixture was heated to reflux, left at RT for 15 min then cooled to 0° C. A white solid was obtained after 30 min. The solid was filtered, washed with EtOAc (100 mL) and air-dried. The solid was suspended in acetone (70 mL), sonicated and filtered (3×). The solid was next recrystallized twice in hot acetone (crop A). The mother liquors were concentrated and the residue was recrystallized three times in hot acetone (crop A). The two crops of the amorphous white solids of dibenzoyl-D-tartaric acid salt were combined (5.53 g) and suspended in a mixture of Et2O (250 mL) and saturated NaHCO3 solution (150 mL). The organic layer was washed with brine, dried (MgSO4) and filtered. The filtrate was diluted with 1 N HCl/Et2O (100 mL) and concentrated under reduced pressure. The oily residue was evaporated with CCl4 to afford ethyl 1 (R)-amino-2(S)-vinyl cyclopropanecarboxylate hydrochloride (940 mg, 11% yield) as a white hygroscopic solid: [α]D 25+39.5° C. (c 1.14 MeOH); [α]365 25+88.5° C. (c 1.14 MeOH); 1H NMR (DMSO-d6) δ9.07 (broad s, 2H), 5.64 (ddd, J=17.2, 10.4, 8.7 Hz, 1H), 5.36 (dd, J=17.2, 1.6 Hz, 1H), 5.19 (dd, J=10.4, 1.6 Hz, 1H), 4.24-4.16 (m, 2H), 2.51-2.45 (m, peaks hindered by DMSO, 1H), 1.84 (dd, J=10.0, 6.0 Hz, 1H), 1.64 (dd, J=8.3, 6.0 Hz, 1H), 1.23 (t, J=7.1 Hz, 3H); MS (ESI) m/z 156 (MH)+; the enantiomeric purity was determined to be 91% ee by HPLC analysis (CHIRALPAK AS® column, Hex:i-PrOH) of the Boc derivative.
Glycine ethyl ester hydrochloride 19a (1519.2 g, 10.88 mole, 1.0 equiv) was suspended in tert-butylmethyl ether (8 L). Benzaldehyde (1155 g, 10.88 mole, 1 equiv) and anhydrous sodium sulfate (773 g, 5.44 mole, 05 equiv) were added and the mixture cooled to 5° C. in an ice-water bath. Triethylamine (2275 mL, 16.32 mole, 1.5 equiv) was added dropwise over 15 min (use 0.5 L of tert-butylmethyl ether for rinses) and the mixture stirred for 40 h at room temperature. The reaction was then quenched by addition of ice-cold water (5 L) and the organic layer was separated. The aqueous phase was extracted with tert-butylmethyl ether (1 L) and the combined organic phases washed with a mixture of saturated NaHCO3 (400 mL) and water (1.6 L), and then brine. The solution was dried over MgSO4, concentrated under reduced pressure and the residual yellow oil dried to constant weight under vacuum. Imine 19b was obtained as a thick yellow oil that solidifies at −20° C. (2001 g, 96% yield): 1H NMR (CDCl3, 400 MHz) δ8.30 (s, 1H), 7.79 (m, 2H), 7.48-7.39 (m, 3H), 4.40 (d, J=1.3 Hz, 2H), 4.24 (q, J=7 Hz, 2H), 1.31 (t, J=7 Hz, 3H).
Lithium tert-butoxide (4.203 g, 52.5 mmol, 2.1 equiv) was suspended in dry toluene (60 mL). Imine 19b (5.020 g, 26.3 mmol, 1.05 equiv) and dibromide 19c (5.348 g, 25 mmol, 1 equiv) were dissolved in dry toluene (30 mL) and this solution added dropwise over 30 min to the stirred solution of LiOtBu at room temperature. After completion, the deep red mixture was stirred for an additional 10 min and quenched by addition of water (50 mL) and tert-butylmethyl ether (TBME, 50 mL). The aqueous phase was separated and extracted a second time with TBME (50 mL). The organic phases were combined, 1 N HCl (60 mL) was added and the mixture stirred at room temperature for 2 h. The organic phase was separated and extracted with water (40 mL). The aqueous phases were then combined, saturated with salt (35 g) and TBME (50 mL) was added. The stirred mixture was then basified to pH 13-14 by careful addition of 10 N NaOH. The organic layer was separated and the aqueous phase extracted with TBME (2×50 mL). The organic extracts containing free amine 19d were combined and ditertbutyldicarbonate (5.46 g, 25 mmol, 1 equiv) was added. After stirring overnight at room temperature, TLC showed some unreacted free amine. Additional ditertbutyldicarbonate (1.09 g, 5 mmol, 0.2 equiv) was added and the mixture refluxed for 2 h, at which point, TLC analysis indicated complete conversion of 19d to carbamate 19e. The solution was cooled to room temperature, dried over MgSO4 and concentrated under reduced pressure. The residue was purified by flash chromatography using 10% then 20% EtOAc/hexane as eluent. Purified 19e was obtained as a clear yellow oil which slowly solidifies under vacuum (4.014 g, 63% yield).
1H NMR (CDCl3, 400 MHz) δ5.77 (ddd, J=17, 10, 9 Hz, 1H), 5.28 (dd, J=17, 1.5 Hz, 1H), 5.18 (broad s, 1H), 5.11 (dd J=10, 1.5 Hz, 1H), 4.24-4.09 (m, 2H), 2.13 (q, J=8.5 Hz, 1H), 1.79 (broad m, 1H), 1.46 (m, 1H), 1.45 (s, 9H), 1.26 (t, J=7 Hz, 3H).
Ethyl ester 19e (10.807 g, 42.35 mmol) was dissolved in dry methanol (50 mL) and a solution of sodium methoxide in MeOH (25% w/w, 9.7 mL, 42 mmol, 1 equivalent) was added. The mixture was heated at 50° C. for 2 h, at which point TLC analysis indicated complete trans-esterification (19e Rf0.38, 19f Rf0.34 in 20% EtOAc/hexane). The reaction mixture was cooled to room temperature and acidified to pH 4 using 4N HCl in dioxane. Precipitated NaCl was removed by filtration (use tert-butylmethyl ether for washings) and volatiles removed under reduced pressure. Tert-butylmethyl ether (100 mL) was added to the residue and solids removed by filtration. Evaporation of the filtrate under reduced pressure and drying under vacuum gave pure methyl ester 19f (10.11 g, 99% yield).
1H NMR (CDCl3, 400 MHz) δ5.75 (ddd, J=17, 10, 9 Hz, 1H), 5.28 (dd, J=17, 1 Hz, 1H), 5.18 (broad s, 1H), 5.11 (ddd, J=10, 1.5, 0.5 Hz, 1H), 3.71 (s, 3H), 2.14 (q, J=9 Hz, 1H), 1.79 (broad m, 1H), 1.50 (broad m, 1H), 1.46 (s, 9H).
Racemic ester 19f (0.200 g, 0.83 mmol) was dissolved in acetone (3 mL) and water (7 mL) was added. 0.05 M NaOH (1 drop) was added to bring the pH of the solution to ˜8 and then Alcalase® 2.4 L (Novo Nordisk Biochem, 0.3 g in one mL of water) was added. The mixture was stirred vigorously at room temperature, maintaining the pH of the solution at 8 using an automatic titrator. At beginning of day 4 and 5 of stirring at pH 8, additional enzyme solution was added (2×0.3 g). After a total of 5 days, a total of 8.3 mL of 0.05 M NaOH was consumed. The reaction mixture was diluted with EtOAc and water and the organic phase separated. After washing with brine, the organic extract was dried (MgSO4) and concentrated under vacuum. Compound 20a (0.059 g, 30% yield) was obtained as a clear oil: 1H NMR identical to that of compound 19f. HPLC (Chiralcel ODH, 4.6×250 mm, isocratic 1% EtOH in hexane, 0.8 mL/min flow rate): (1 R,2S)-2 Rt 19.3 min (97%); (1S,2R)-2 R, 17.0 min (3%).
Compound 20a (39.96 g, 165.7 mmol) was dissolved in dioxane (25 mL) and the solution added dropwise with stirring to 4 N HCl in dioxane (Aldrich, 250 mL). After 45 min, TLC analysis indicated complete deprotection. Volatiles were removed under reduced pressure, and the residue co-evaporated twice with MeOH (2×100 mL). Ether (300 mL) and MeOH (10 mL) were added to the brown, oily residue and the mixture stirred overnight at room temperature resulting in the precipitation of a semi-solid. Additional MeOH (15 mL) was added and stirring continued for 6 h, at which point a yellowish solid was collected by filtration. The product was washed with 5% MeOH in ether (50 mL) and ether (2×50 mL), and dried in vacuo to give compound 20b as a yellowish solid (22.60 g, 76% yield). Filtrates (including washings) were evaporated in vacuum to give additional 20b as a brown oil (7.82 g, 26% yield). Both fractions were pure enough for use in the synthesis of HCV protease inhibitors: [α]D 25+38.2° (c 1.0, MeOH). 1H NMR (400 MHz, DMSO-d6) δ9.15 (broad s, 3H), 5.65 (ddd, J=17, 10, 9 Hz, 1H), 5.36 (dd, J=17, 1.5 Hz, 1H), 5.19 (dd, J=10, 1.5 Hz, 1H), 3.74 (s, 3H), 2.50 (q, overlap with DMSO signal, J=9 Hz, 1H), 1.86 (dd, J=10, 6 Hz, 1H), 1.64 (dd, J=8, 6 Hz, 1H).
1,1-aminocyclobutanecarboxylic acid was prepared according to Kavin Douglas; Ramaligam Kondareddiar; Woodard Ronald, Synth. Commun. (1985), 15 (4), 267-72. The amino acid salt (21a) (1.00 g., 6.6 mmoles) was stirred in dry methanol (40 ml) at −20° C. and mixture saturated with dry hydrogen chloride to yield (21b). Stirring of this mixture was continued for 4 h. The hot solution was filtered and filtrate concentrated (Rotavap, 30° C.) to leave a residue which upon trituration in ethyl ether afforded a white powder (0.907 g., 83% ) after filtration and drying. 1H NMR (400 MHz, D2) δ CH3O (3H, s, 3.97 ppm); CH2 (2H, m, 2.70-2.77 ppm); CH2 (2H, m, 2.45-2.53 ppm) and CH2 (2H, m, 2.14-2.29 ppm).
The synthesis was done on a parallel synthesizer model ACT396 from Advanced ChemTech® with the 96 well block. Typically, 24 peptides were synthesized in parallel using standard solid-phase techniques. The starting (Fmoc-amino)cyclopropane (optionally substituted) carboxylic acid-Wang resin were prepared by the DCC/DMAP coupling method (Atherton, E; Scheppard, R. C. Solid Phase Peptide Synthesis, a Practical Approach; JRL Press: Oxford (1989); pp 131-148).
Each well was loaded with 100 mg of the starting resin (approximately 0.05 mmol). The resins were washed successively with 1.5 mL portions of NMP (1×) and DMF (3×). The Fmoc protecting group was removed by treatment with 1.5 mL of a 25% v/v solution of piperidine in DMF for 20 minutes. The resins were washed with 1.5 mL portions of DMF (4×), MeOH (3×) and DMF (3×). The coupling was done in DMF (350 μL), using 400 μL (0.2 mmol) of a 0.5M solution of Fmoc-amino acid/HOBt hydrate in DMF, 400 μL (0.4 mmol) of a 1M solution of DIPEA in DMF and 400 μL (0.2 mmol) of a 0.5M solution of TBTU in DMF. After shaking for 1 hour, the wells were drained, the resins were washed with 1.5 mL of DMF and the coupling was repeated once more under the same conditions. The resins were then washed as described above and the cycle was repeated with the next amino acid.
The capping groups were introduced in two ways:
-
- 1. In the form of a carboxylic acid using the protocol described above (for example acetic acid) or,
- 2. As an acylating agent such as an anhydride or an acid chloride. The following example illustrates the capping with succinic anhydride: After the Fmoc deprotection and subsequent washing protocol, DMF was added (350 μL), followed by 400 μL each of a DMF solution of succinic anhydride (0.5 M, 0.2 mmol) and DIPEA (1.0 M, 0.4 mmol). The resins were stirred for 2 h and a recoupling step was performed. At the end of the synthesis the resin was washed with 1.5 mL portions of DCM (3×), MeOH (3×), DCM (3×), and were dried under vacuum for 2 h. The cleavage from the resin and concomitant side chain deprotection was effected by the addition of 1.5 mL of a mixture of TEA, H2O, DTT and TIS (92.5: 2.5: 2.5: 2.5). After shaking for 2.5 h, the resin was filtered and washed with 1.5 mL of DCM. The filtrates were combined and concentrated by vacuum centrifugation. Each compound was purified by preparative reversed phase HPLC using a C18 column (22 mm by 500 mm). The product-containing fractions were identified by MALDI-TOF mass spectrometry, combined and lyophilized.
The reactants, i.e. a free amine (1 eq.) (or its hydrochloride salt) and the free carboxylic acid (1 eq.) were dissolved in CH2Cl2, CH3CN or DMF. Under a nitrogen atmosphere, four equivalents of N-methylmorpholine and 1.05 equivalents of the coupling agent were added to the stirred solution. After 20 min, one equivalent of the second reactant, i.e. a free carboxylic acid was added. (Practical and efficient coupling reagents for this purpose are (benzotriazol-1-yloxy)tris-(dimethylamino)phosphonium hexafluorophosphate (HOBT) or preferably 2-(1H-benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium tetrafluoroborate (TBTU) or O-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium tetrafluoroborate (HATU). The reaction was monitored by TLC. After completion of the reaction, the solvent was evaporated under reduced pressure. The residue was dissolved in EtOAc. The solution was washed successively with 10% aqueous citric acid, saturated aqueous NaHCO3 and brine. The organic phase was dried (MgSO4), filtered and concentrated under reduced pressure. When the residue was purified, it was done by flash chromatography as defined above.
a) The (R,R) isomer of Boc-Et-Acca-OMe 13c (0.12 g, 0.49 mmol) obtained from enzymatic resolution (Example 13) was treated with 4N HCl/dioxane (45 min) before being concentrated in vacuo to give a white solid. To this HCl salt (ca. 0.49 mmol) was added TBTU (0.17 g, 0.54 mmol), the Boc-4(R)-(8-quinoline-methyloxy) proline 5 (from Example 5) (0.18 g, 0.49 mmol) and DIPEA (0.3 mL, 1.7 mmol) in MeCN (10 mL). The mixture was stirred at RT for 3.5 h before being concentrated in vacuo. The resulting material was dissolved in EtOAc and washed sequentially with saturated aqueous NaHCO3 and brine. Dried (MgSO4), filtered and concentrated to give 24b a white solid (0.122 g, 50%).
b) 24b (0.12 g, 0.25 mmol) was treated at RT with 4N HCl/dioxane (30 min) before being concentrated in vacuo. The resulting hydrochloride salt (ca. 0.25 mmol) was treated with Boc-Chg-OH.H2O (75 mg, 0.27 mmol),TBTU (87 mg, 0.27 mmol) in MeCN (10 mL) and finally at 0° C. with DIPEA (0.15 mL, 0.87 mmol). The residue was diluted with EtOAc, sequentially washed with saturated aqueous NaHCO3, and brine, dried (MgSO4), filtered and concentrated to give 24c as an off white solid (0.2 g). This material (0.14 g) was dissolved in DMSO and purified by preparative HPLC to give 24c as a white solid after lyophilization (35 mg, 33%). HPLC (98%); MS (FAB) m/z: 637.3 (MH+); HRMS calcd for C35H48N4O7 (MH+) 637.36011: found 637.36250; 1H-NMR (DMSO-d6) shows a rotamer population, δ8.91 (2×d, J=4.1 and 4.1 Hz, 1H), 8.40-8.36 (m, 2H), 7.90 (d, J=7.6 Hz, 1H), 7.77 (d, J=7.0 Hz, 1H), 7.6-7.54 (m, 2H), 6.80 (d, J=8.6 Hz, 1H), 5.18 and 5.16 (2×s, 2H), 4.40 (bs, 1H), 4.31 (t, J=8.3 Hz, 1H), 4.12 (d, J=11.44 Hz, 1H), 4.03 (t, J=7.9 Hz, 1H), 3.78-3.72 (m, 1H), 3.56 (s, 3H), 2.35-2.27 (m, 1H), 2.06-1.97 (m, 1H), 1.71-1.55 (m, 10H), 1.53-1.38 (m, 2H), 1.26 (s, 9H), 1.18-1.06 (m, 2H), 1.02-0.93 (m, 2H), 0.89 (t, J=7.3 Hz, 3H).
Compound 304
c) To 24c (30 mg, ca. 0.047 mmol) was added MeOH (1 mL), THF (1 mL), and lithium hydroxide monohydrate (12 mg, 0.29 mmol) in H2O (1 mL). The clear solution was stirred rapidly for 48 h before being concentrated in vacuo. The crude peptide was dissolved in DMSO and purified by preparative HPLC to give compound 304 as a white solid after lyophilization (21 mg, 72%). HPLC (99%); MS (FAB) m/z: (MH+) 623.3; HRMS calcd for C34H46N4O7 (MH+) 623.34448, found: 623.34630, 1HNMR (DMSO-d6) shows a rotamer population of 1:1, δ8.90 (2×d, J=4.1 Hz, 1H), 8.37 (d, J=8.3 Hz, 1H), 8.26 (s, 1H), 7.89 (d, J=8.3 Hz, 1H), 7.77 (d, J=6.7 Hz, 1H), 7.6-7.53 (m, 2H), 6.88 and 6.79 (2×d, J=8.6 and 7.9 Hz, 1H), 5.17 and 5.16 (2×s, 2H), 4.43-4.35 (bs, 1H), 4.29 (t, J=8.3 Hz, 1H), 3.82-3.71 (m, 1H), 2.35-2.27 (m, 1H), 2.06-1.97 (m, 1H), 1.72-1.53 (m, 10H), 1.52-1.44 (m, 2H), 1.37 and 1.29 (2×s, 9H), 1.18-1.05 (m, 3H), 1.0-0.94 (m,1H), 0.91 (t, J=7.3 Hz, 3H).
a) Compound 25a (=12a) (282 mg, 1.23 mmol) was suspended in anhydrous CH3CN (6 mL). DBU (221 μL, 1.48 mmol) and benzylbromide (161 μL, 1.35 mmol) were added successively and the reaction mixture was stirred overnight at RT. The mixture was concentrated, the resulting oil was diluted with EtOAc and 10% aq. citric acid and successively washed with 10% citric acid (2×), saturated aq. NaHCO3 (2×), water (2×) and brine (1×). The EtOAc layer was dried (MgSO4), filtered and evaporated to dryness. The crude colorless oil was purified by flash chromatography (eluent—hexane: EtOAc; 95:5 to 90:10) to provide the benzylated product 25b as a colorless oil (368 mg; 93%).
MS (FAB) 318.2 MH− 320.2 MH+ 342.2 (M+Na)+
1H NMR (CDCl3) δ7.37-7.28 (m, 5H), 5.22-5.10 (m, 1H), 5.19 (d, J=12 Hz, 1H), 5.16 (d, J=12 Hz, 1H), 1.60-1.40 (m, 4H), 1.39 (s, 9H), 1.31-1.22 (m, 1H) 0.91 (t, J=7.5, 14.5 Hz, 3H).
b) Compound 25b (368 mg, 1.15 mmol) was treated with 4N HCl/dioxane (6 mL) as described previously. The crude hydrochloride salt was coupled to compound 4 (from Example 4) (470.8 mg, 1.27 mmol) with NMM (507 μL, 4.61 mmol) and HATU (instead of TBTU, 525.6 mg, 1.38 mmol) in CH2Cl2 (6 mL) as described in Example 22 to yield the crude racemic dipeptide as an orange oil. The crude material was purified by flash chromatography (eluent—hexane: Et2O; 50:50) to provide the pure dipeptide 25c (the less polar eluting spot) as a white foam (223 mg; 68% of the theoretical yield).
MS 571.4 MH− 573.3 MH+ 595.3 (M+Na)+
1H NMR (CDCl3), ca.1:1 mixture of rotamers, δ8.03 (b d, J=8 Hz, 1H), 7.86 (b d, J=7.5 Hz, 1H), 7.82 (b d, J=6.5 Hz, 1H), 7.61 (b s, 0.5H), 7.57-7.40(m, 4H), 7.31-7.21 (m, 5H), 6.48 (b s, 0.5H), 5.22-5.11 (m, 1H), 5.08-4.81 (m, 3H), 4.41-3.74 (m, 3H), 3.49-3.18 (m, 1H), 2.76-1.90 (m, 2H), 1.69-1.48 (m, 3H), 1.40 (s, 9H), 140-1.23 (m, 2H), 0.92 (t, J=7.5, 15 Hz, 3H).
c) The dipeptide 25c (170.1 mg, 0.297 mmol) was treated with 4N HCl/dioxane (2mL) as described previously. The crude hydrochloride salt was coupled to Boc-Chg-OH (84.1 mg ,0.327 mmol) with NMM (130.7 μL , 1.19 mmol) and HATU (instead of TBTU, 135.5 mg; 0.356 mmol) in CH2Cl2 (2 mL) for 2.75 h at RT then worked up as described previously to provide the crude tripeptide 25d as an ivory foam (ca. 211.4 mg; 100%).
MS (FAB) 712.5 MH+
Compound 301
d) The crude tripeptide 25d (ca. 15.4 mg, 0.022 mmol) was dissolved in absolute ethanol (2 mL) and an estimated amount (tip of spatula) of both 10% Pd/C catalyst and ammonium acetate were added. The mixture was hydrogenated overnight under a hydrogen filled balloon at RT and atmospheric pressure. The reaction mixture was filtered through a 0.45 μm Millex® filter, evaporated to dryness then diluted with EtOAc and 10% aqueous citric acid, and washed again with 10% aqueous citric acid (1×), water (2×) and brine (1×). The organic layer was dried (MgSO4), filtered, evaporated to dryness and lyophilized to provide the tripeptide 301 as a white amorphous solid (11.0 mg; 82%).
MS (FAB) 622.5 MH+ 644.5 (M+Na)+
1H NMR (DMSO), ca.1:4 mixture of rotamers, δ8.54 & 8.27 (s, 1H),8.06-7.99 (m, 1H), 7.96-7.91 (m, 1H), 7.87 (d, J=8 Hz, 1H), 7.57-7.42 (m, 4H), 6.81 (d, J=8 Hz, 1H), 4.99 (d, J=12 Hz, 1H), 4.88 (d, J=12 Hz, 1H), 4.46-1.19 (m, 2H), 4.17-4.02 (m, 2H), 3.88-3.67 (m, 1H), 2.28-2.19 (m, 1H), 2.05-1.93 (m, 1H), 1.73-1.43 (m, 8H), 1.32-1.07 (m, 6H), 1.28 (s, 9H), 1.03-0.85 (m, 2H), 0.91 (t, J=7.5, 15 Hz, 3H).
a) The acid 26a (180 mg, 0.500 mmol) and the amine 15d (96 mg, 0.500 mmole) were coupled using TBTU (192 mg, 0.600 mmol) and DIPEA (226 mg, 1.75 mmol) in CH2Cl2 (10 mL) for 20 h. The reaction mixture was concentrated, taken up in ethyl acetate, washed twice with sat. NaHCO3 and once with brine. The organic layer was dried on MgSO4, filtered and concentrated to give 26c as a brown oil, used without purification in the next step.
b, c) The crude compound 26c (ca. 0.500 mmol) was stirred for 30 min in HCl 4N/dioxane (4 mL) and concentrated to dryness. The solid was taken up in CH2Cl2 (10 mL) and DIPEA (226 mg, 1.75 mmol) was added followed by Boc-Chg-OH monohydrate (138 mg, 0.500 mmol) and TBTU (192 mg, 0.600 mmol). The solution was stirred at RT for 5 h. The reaction mixture was concentrated, taken up in ethyl acetate, washed twice with sat. NaHCO3 and once with brine. The organic layer was dried on MgSO4, filtered and concentrated to give a brown oil, purified by flash chromatography to give 26d as a yellow oil, 204 mg, 64% over two couplings.
1H NMR (CDCl3) δ8.77-8.74 (m, 1 H), 8.14 (d, J=8 Hz, 1 H), 8.02 (d, J=9 Hz, 1 H), 7.69 (dd, J=9, 7 Hz, 1 H), 7.52 (d, J=5 Hz, 1 H), 7.47 (dd, J=8, 7 Hz, 1 H), 6.78 (d, J=5 Hz, 1 H), 5.80-5.70 (m, 1 H), 5.35-5.27 (m, 2 H), 5.14-5.07 (m, 2 H), 4.89-4.83 (m, 1 H), 4.39-4.32 (m, 1 H), 4.30-4.24 (m, 1 H), 4.20-4.07 (m, 2 H), 4.00-3.92 (m, 1 H), 3.04-2.92 (m, 1 H), 2.39-2.29 (m, 1 H), 2.16-2.04 (m, 1 H), 1.91-1.83 (m, 1 H), 1.82-1.62 (m, 7 H), 1.45-1.35 (m, 9 H), 1.27-1.07 (m, 8 H).
d) 26d (136 mg, 0.214 mmole) was dissolved in THF (4 mL) and MeOH (2 mL). An aqueous solution (2 mL) of LiOH hydrate (72 mg, 1.72 mmol) was added and the reaction mixture was stirred at RT for 20 h. The solution was concentrated and purified by preparative HPLC to give compound 306 (the less polar isomer) as a white solid (25 mg).
Compound 306: MS(FAB) 607.4 (MH+)
1H NMR (DMSO-d6) δ9.16 (d, J=6 Hz, 1 H), 8.55 (s, 1 H), 8.35 (d, J=8 Hz, 1 H), 8.12 (d, J=9 Hz, 1 H), 8.05 (dd, J=8, 7 Hz, 1 H), 7.76 (dd, J=8, 7 Hz, 1 H), 7.59 (d, J=6 Hz, 1 H), 7.02 (d, J=8 Hz, 1 H), 5.75-5.66 (m, 2 H), 5.19 (d, J=18 Hz, 1 H), 5.07 (d, J=10 Hz, 1 H), 4.55 (d, J=12 Hz, 1 H), 4.43 (dd, J=10, 8 Hz, 1 H), 4.03 (d, J=10 Hz, 1 H), 3.87-3.83 (m, 1 H), 2.66-2.59 (m, 1 H), 2.36-2.30 (m, 1 H), 1.98 (dd, J=18, 9 Hz, 1 H), 1.75-1.56 (m, 8 H), 1.38-1.35 (m, 1 H), 1.25-1.22 (m, 1 H), 1.09 (s, 9 H), 1.12-0.95 (m, 3 H).
c) A solution of the acid (8) from Example 8 (505 mg, 105 mmol) in 5 mL of dichloromethane was treated with TBTU (376 mg, 1.17 mmol). The HCl salt of the (R,S) vinyl AccaOEt (18) (from Example 18) (279 mg, 1.46 mmol), in 7 mL of dichloromethane containing (0.60 mL, 5.46 mmol) of N-methyl morpholine, was added to the previous solution of the activated ester. The resulting solution was stirred at RT overnight. The solvent was evaporated in vacuo. The residue diluted with ethyl acetate, was washed twice with a saturated solution of sodium bicarbonate and once with brine. The organic layer was dried (MgSO4) filtered and evaporated in vacuo. The residue was chromatographed over silica gel (60:40 v/v, hexanes-ethyl acetate) to afford 173 mg (27%) of the dipeptide 27c.
d, e) A solution of the dipeptide 27c (70 mg, 0.114 mmol) in 3 mL of hydrogen chloride 4.0 M solution in 1,4-dioxane was stirred at RT for 1 h (a precipitated came out from the reaction after 10 min). The solvent was removed in vacuo. The amine hydrochloride salt 27d (0.114 mmol), diluted in 1.5 mL of acetonitrile, was neutralized by addition of 65 μL (0.591 mmol) of N-methyl morpholine. A solution of the Boc ChgOH.H2O (39 mg, 0.142 mmol) in 1.5 mL of acetonitrile was treated with TBTU (46 mg, 0.143 mmol) and then added to the previous solution of the amine. The resulting solution was stirred at RT (for 2 days). The solvent was removed in vacuo. The residue, diluted with ethyl acetate, was washed twice with a saturated solution of sodium bicarbonate and once with brine. The organic layer was dried (MgSO4), filtered and evaporated in vacuo. 86 mg (100%) of tripeptide 27e was obtained. This crude compound was used in the next reaction without farther purification.
i) To a solution of tripeptide 27e (86 mg, 0.114 mmol) in 5 mL of a mixture THF:H2O (2.5:1) was added lithium hydroxide monohydrate (22 mg, 0.524 mmol). An additional 0.25 mL of MeOH was added in order to get an homogeneous solution. The resulting solution was stirred at RT overnight before the solvent was evaporated in vacuo. The residue was partitioned between water and EtOAc. The aqueous layer was acidified with 1M HCl and then extracted twice with ethyl acetate. The desired compound has been found in the ethyl acetate coming from the first basic extraction. This organic layer was dried (MgSO4), filtered and evaporated in vacuo to afford 69 mg of the crude acid, which was purified by preparatory HPLC. The compound was dissolved in MeOH (4 mL) and injected onto an equilibrated Whatman Partisil 10-ODS-3 (2.2×50 cm) C18 reverse phase column. (λ=230 nm, solvent A=0.06% TEA/H2O, solvent B=0.06% TFA/CH3CN). Purification program: 20% to 70% of solvent B in 60 min. Fractions were analyzed by analytical HPLC. Appropriate fractions were collected and lyophilized to provide 50 mg (60%) of the desired tripeptide 307 as a white amorphous solid.
Compound 307: 1H NMR (DMSO-d6) rotamers ˜2:8 δ8.86 (d, J=2.5 Hz, 1H), 8.85 (s, 0.2H), 8.64 (s, 0.8H), 8.49 (dd, J=9.5, 3 Hz, 0.2H), 8.45 (dd, J=9.2 Hz, 0.8H), 8.39-8.33 (m, 2H), 8.20 (d, J=9.5 Hz, 0.2H), 8.18 (d, J=9.5 Hz, 0.8H), 7.81 (s, 0.2H), 7.78 (s, 0.8H), 7.64-7.56 (m, 3H), 6.87 (d, J=8 Hz, 0.8H), 6.36 (d, J=9 Hz, 0.2H), 5.82-5.67 (m, 2H), 5.27-5.17 (m, 1H), 5.09-5.03 (m, 1H), 4.73 (t, J=8 Hz, 0.2H), 4.55 (dd, J=10, 7.5 Hz, 0.8H), 4.49-4.40 (m, 1H), 4.00-3.95 (m, 1H), 3.83-3.76 (m, 1H), 2.87-2.80 (m, 0.2H), 2.69-2.62 (m, 0.8H), 2.39-2.26 (m, 1H), 2.08-2.00 (m, 1H), 1.75-1.41 (m, 7H), 1.37 (s, 1.8H), 1.32-1.27 (m, 1H), 1.17-0.82 (m, 5H), 0.94 (s, 7.2H).
Compound 311 was prepared using the process described in Example 24 but using the appropriate building blocks.
Compound 310 1H NMR (DMSO-d6) δ8.98 (d, J=6 Hz, 1 H), 8.52 (s, 1 H), 8.24 (d, J=9 Hz, 1 H), 8.08 (d, J=2 Hz, 1 H), 7.63 (d, J=9 Hz, 1 H), 7.37 (d, J=6 Hz, 1 H), 6.98 (d, J=8 Hz, 1 H), 5.75-5.66 (m, 1 H), 5.57 (br s, 1H), 5.24-5.19 (m, 1 H), 5.08-5.01 (m, 1 H), 4.57-4.40 (m, 2 H), 4.00-3.96 (m, 1 H), 3.82 (dd, J=9, 8 Hz, 1 H), 2.59-2.54 (in, 1 H), 2.32-2.26 (m, 1 H), 1.99 (dd, J=17, 9 Hz, 1 H), 1.74-1.55 (m, 8 H), 1.37 (s, 1 H), 1.26-1.22 (m, 1 H), 1.14-1.08 (m, 9 H), 1.02-0.91 (m, 3 H).
Compound 302 was prepared using the process described in Example 27 but using the appropriate building blocks.
1H NMR (DMSO-d6) δ8.34 (s, 1 H), 8.04-8.01 (m, 1 H), 7.94-7.92 (m, 1 H), 7.87 (d, J=8 Hz, 1 H), 7.54-7.50 (m, 3 H), 7.45 (dd, J=17, 8 Hz, 1 H), 7.22 (d, J=8 Hz, 1 H), 4.94 (dd, J=55, 12 Hz, 2 H), 4.34 (s, 1 H), 4.27 (dd, J=8, 8 Hz, 1 H), 4.16 (d, J=11 Hz, 1 H), 4.07 (dd, J=8, 8 Hz, 1 H), 3.72-3.65 (m, 2 H), 3.59-3.54 (m, 1 H), 2.24-2.18 (m, 1 H), 2.02-1.95 (m, 2 H), 1.75-1.70 (m, 1 H), 1.53-1.44 (m, 2 H), 1.32-1.27 (m, 1 H), 1.21-1.17 (m, 1 H), 0.96-0.85 (m, 10 H), 0.80-0.77 (m, 5 H), 0.62-0.57 (m, 1 H).
Compound 308 was prepared using the process described in Example 27 but using the appropriate building blocks.
1H NMR (DMSO-d6) rotamers=2:8 δ8.77 (s, 0.2H), 8.45 (s, 0.8H), 8.13 (d, J=8.5 Hz, 0.8H), 8.03 (d, J=8.5 Hz, 0.2H), 7.89-7.83 (m, 1H), 7.55-7.37 (m, 4H), 7.05-6.59 (m, 1H), 6.95 (d, J=8 Hz, 0.8H), 6.26 (d, J=8.5 Hz, 0.2H), 5.81-5.64 (m, 1 H), 5.33-5.28 (m, 1H), 5.26-5.15 (m, 1H), 5.08-5.02 (m, 1H), 4.60 (t, J=7.5 Hz, 0.2H), 4.38-4.27 (m, 1.8H), 4.09-3.91 (m, 1.8H), 3.74 (dd, J=12.5, 4 Hz, 0.2H), 2.69-2.60 (m, 0.2H), 2.50-2.40 (m, 1H), 2.36-2.28 (m, 0.2H), 2.23-2.14 (m, 0.8H), 2.05-1.97 (m, 0.8H), 1.76-1.44 (m, 7H), 1.37 (s, 1.8H), 1.29 (s, 7.2H), 1.28-1.20 (m, 1H), 1.16-0.88 (m, 5H).
Compound 309 was prepared using the process described in Example 27 but using the appropriate building blocks.
1H NMR (DMSO-d6) rotamers=2:8 δ8.75 (s, 0.2H), 8.50 (s, 0.8H), 7.89-7.78 (m, 3H), 7.50-7.44 (m, 1H), 7.42-7.32 (m, 2H), 7.17-7.09 (m, 0.8H) 7.08-7.03 (m, 0.2H), 6.79 (d, J=8.5 Hz, 0.8H), 6.33 (d, J=9 Hz, 0.2H), 5.81-5.65 (m, 1H), 5.30-5.16 (m, 2H), 5.10-5.02 (m, 1H), 4.56 (t, J=7.5 Hz, 0.2H), 4.33 (t, J=8 Hz, 0.8H), 4.10-3.90 (m, 2.8H), 3.74-3.68 (m, 0.2H), 2.45-2.37 (m, 1H), 2.34-2.17 (m, 1H), 2.05-1.97 (m, 1H), 1.76-1.48 (m, 7H), 1.37 (s, 1.8H), 1.23 (s, 7.2H), 1.21-0.88 (m, 6H).
Compound 305 was prepared using the process described in Example 27 but using the appropriate building blocks.
1H NMR (DMSO-d6) rotamers (1:9) δ8.68 (s, 0.1H), 8.43 (s, 0.9H), 8.04-8.00 (m, 1H), 7.95-7.91 (m, 1H), 7.87 (d, J=8.5 Hz, 1H), 7.57-7.49 (m, 3H), 7.47-7.42 (m, 1H), 6.82 (d, J=8.5 Hz, 0.9H), 6.21 (d, J=8.5 Hz, 0.1H), 5.80-5.64 (m, 1H), 5.21 (dd, J=17, 2 Hz, 0.1H), 5.18 (dd, J=17, 2 Hz, 0.9H), 5.06 (dd, J=10.5, 2 Hz, 1H), 5.02-4.85 (m, 2H), 4.43 (t, J=7.5 Hz, 0.1H), 4.34 (br s, 1H), 4.23 (t, J=8.5 Hz, 0.9H), 4.16-4.05 (m, 1.8H), 3.89-3.82 (m, 0.2H), 3.74 (dd, J=11, 3.5 Hz, 0.9H), 3.53 (dd, J=12.5, 4 Hz, 0.1H), 2.30-2.21 (m, 1H), 2.02-1.94 (m, 2H), 1.74-1.38 (m, 7H), 1.36 (s, 0.9H), 1.28 (s, 8.1H), 1.25-0.87 (m, 6H).
Compound 303 was prepared using the process described in Example 27 but using the appropriate building blocks.
1H NMR (DMSO-d6) δ8.29 (s, 1 H), 8.04-8.01 (m, 1 H), 7.94-7.92 (m, 1 H), 7.87 (d, J=8 Hz, 1 H), 7.56-7.52 (m, 3 H), 7.46 (dd,J=8, 7 Hz, 1 H), 7.19 (d, J=9 Hz, 1H), 5.01 (d, J=12 Hz, 1 H), 4.86 (d, J=12 Hz, 1 H), 4.34 (br. s, 1 H), 4.24 (t, J=8 Hz, 1 H), 4.18-4.09 (m, 2 H), 3.74-3.53 (m, 3 H), 2.24-2.18 (m, 1 H), 2.04-1.95 (m, 1 H), 1.74-1.45 (m, 10 H), 1.31-1.13 (m, 4 H), 0.96-0.86 (m, 7 H), 0.79-0.76 (m, 5 H).
a) Coupling of P2 with P1
The methyl ester derivative of 7 (34a) (170 mg, 0.355 mmole) was stirred in 50% THF-methanol (4 ml) and aqueous LiOH (1M, 1 ml) at RT for 1 h. The solution was concentrated (Rotavap, 30° C.) and residue acidified to pH 6 and solution lyophilized. The resulting powder was stirred in dry DMF (3 ml) in the presence of DIEA (0.4 ml) followed by the successive addition of 1,1-aminocyclobutylcarboxylic acid methyl ester hydrochloride (34b) (140 mg, 0.845 mmole) and TBTU (134 mg, 0.417 mmole). After stirring for 18 h at RT, the mixture was purified by flash chromatography on silica gel (230-400 Mesh) using 1:2 ethyl acetate-hexane to afford an orange oil (98 mg, 90% purity by HPLC).
b) Coupling of P1-P2 with P3
b) Coupling of P1-P2 with P3
The dipeptide 34b (97 mg, 90%, 0.155 mmole) was stirred in 4N HCl-dioxane (5 ml) during 1 h at RT . The solution was then concentrated to dryness (Rotavap, high vacuum) to afford a beige solid. This material was stirred in dry DMF (2 ml) at RT in the presence of DIEA (0.4 ml) followed by addition of L-Boc-Tbg (80 mg, 0.35 mmole) and TBTU (112 mg, 0.35 mmole). After stirring 2 days at RT, the solution was poured in ethyl acetate to generate the free base using 5% aqueous potassium carbonate. The organic phase was worked up to give a yellow oily residue. The material was purified by flash chromatography on silica gel column (230-400 Mesh) using 1:2 & 3:1 v/v ethyl acetate: hexane to afford 40 mg of an oil, homogeneous by HPLC.
The methyl ester (40 mg) was finally saponified in 1N potassium hydroxide (2 ml) in methanol (4 ml) by stirring at RT during 3 h. The mixture was concentrated (Rotavap, 30° C.) and acidified to pH 4 with 2N hydrochloric acid. This mixture was purified by preparative HPLC on C18 column using a gradient of 0-50% aqueous acetonitrile (0.1% TFA) at 220 nm. The fractions were pooled, concentrated to half volume and lyophilized to afford 403 as a white fluffy solid (10 mg).
1H NMR (400 M Hz, DMSO-d6) δ Mixture of rotamers: NH+ (1H, s, 8.6 ppm), CH (3H, m, 8.2 ppm), Ph (5H, broad s, 7.66 & 7.53 ppm), CH (1H, broad, 7.22 ppm), NH (1H, d, J=7.6 Hz, 6.71 ppm), CHO (1H, broad s, 5.76 ppm), CH (2H, m, 4.58-4.49 ppm), CH (1H, m, 4.04 ppm), CH3O (3H, s, 3.97 ppm), CH (1H, d, 3.86 ppm), CH (7H, very broad, 1.8-2.6 ppm), Boc group (9H, s, 1.25 ppm) and t-butyl group (9H, s, 0.97 ppm).
MS. showed M+H+ at m/e 675 (100%).
HPLC peak 98% at 18.9 min.
A solution of m-anisidine (35a) (9.15 mL, 81.4 mmoles) and dimethylacetylene-dicarboxylate (35b) (10.0 mL, 81.3 mmoles) in 160 mL of methanol is heated under reflux for 2 h. The solvent is removed in vacuo and the residue purified by a flash column chromatography (90:10 hexanes-ethyl acetate). Compound 35c (17.0 g, 79% yield) is obtained as an orange oil.
1H NMR (CDCl3) δ9.62 (broad s, 1H), 7.17 (dd, J=7 and 8.5 Hz, 1H), 6.66-6.62 (m, 1H), 6.49-6.45 (m, 2H), 5.38 (s, 1H), 3.77 (s, 3H), 3.74 (s, 3H), 3.71 (s, 3H).
Diphenylether (50 mL) is heated in a sand bath up to an internal temperature of =250°. Diester adduct (35c) (7.5 g, 28.3 mmoles), dissolved in 5 mL of diphenyl ether, is added within 2 min to the boiling solvent. The heating is maintained for 5 min and the reaction mixture is then allowed to cool down to room temperature. Rapidly a beige solid precipitated out. The solid is filtered and then triturated with methanol. To yield 4.1 g (62% yield) of the desired compound 35d.
1H NMR (DMSO-d6) δ7.97 (d, J=9 Hz, 1H), 7.40 (d, J=2 Hz, 1H), 6.96 (dd, J=9 and 2 Hz, 1H), 6.55 (s, 1H), 3.95 (s, 3H), 3.84 (s, 3H).
A solution of cis-4-hydroxy-L-proline derivative (35e) (1.71 g, 5.33 mmoles), 4-hydroxyquinoline derivative (35f) (1.25 g, 5.36 mmoles) and triphenylphosphine (2.80 g, 10.68 mmoles) in 75 mL of THF is cooled down to 0° for the addition drop to drop (=1 h) of DEAD (1.70 mL, 10.80 mmoles). The reaction mixture was then allowed to warm up slowly to room temperature and the stirring was continued overnight. The solvent is removed in vacuo and the residue purified by a flash column chromatography (70:30 ehtylacetate-hexanes). Compound 35g (0.7 g of pure compound 35g, and 1.8 g of compound 35g contaminated with =50% of triphenylphosphate oxide) is obtained as a white solid.
1H NMR (CDCl3) rotamers (4:6) δ8.04 (d, J=9 Hz, 1H), 7.54 (d, J=2.5 Hz, 1H), 7.40-7.32 (m, 6H), 7.23 (dd, J=9 and 2.5 Hz, 1H), 5.33-5.13 (m, 3H), 4.66 (t, J=7.5 Hz, 0.4 H), 4.54 (t, J=8 Hz, 0.6 H), 4.07 (s, 3H), 3.94 (s, 3H), 4.04-3.80 (m, 2H), 2.78-2.65 (m, 1H), 2.47-2.34 (m, 1H), 1.45 (s, 3.6H), 1.37 (s, 5.4H).
To proline benzyl ester derivative (35g) (0.70 g, 1.31 mmoles) in solution in a mixture of methanol-ethyl acetate (10 mL—10 mL) is added 100 mg of 10% Pd/C. The resulting suspension is stirred at room temperature under hydrogen atmosphere for 1½ h. The catalyst is then filtered on a Millex-HV Millipore (0.45 μm filter unit) and the solvents are evaporated in vacuo. Quantitative yield of the desired acid 35h (0.59 g) is obtained.
1H NMR: (CDCl3) rotamers 70:30 δ8.06 (d, J=9.5 Hz, 0.3 H), 8.01 (d, J=9 Hz, 0.7 H), 7.56 (d, J=2 Hz, 1H), 7.44 (broad s, 0.7 H), 7.41 (broad s, 0.3 H), 7.24 (dd, J=9 and 2.5 Hz, 1H), 5.31-5.25 (m, 1H), 4.67 (t, J=7.5 Hz, 0.7 H), 4.55 (t, J=7.5 Hz, 0.3 H), 4.08 (s, 3H), 3.95 (s, 3H), 4.04-3.80 (m, 2H), 2.83-2.72 (m, 1H), 2.71-2.47 (m, 1H), 1.46 (s, 9H).
The salt of the amine 35i (215 mg, 1.21 mmoles) in 7 mL of acetonitrile is treated with 0.95 mL of DIEA (5.45 mmoles). This solution is then added to a solution of acid 35h (590 mg, 1.32 mmoles) and TBTU (389 mg, 1.21 mmoles) in 5 mL of CH3CN the resulting solution is stirred at room temperature overnight. The solvent is removed in vacuo and the residue is diluted with ethylacetate and washed twice with a saturated solution of sodium bicarbonate once with brine and dried over MgSO4. The solvent is removed in vacuo and the residue is purified by flash column chromatography (75:25 AcOEt-hexanes) to afford 527 mg (70% yield) of the desired dipeptide (35j).
1H NMR: (CDCl3) δ8.01 (d, J=9 Hz, 1H), 7.55 (d, J=2.5 Hz, 1H), 7.45 (s, 1H), 7.22 (dd, J=9 and 2.5 Hz, 1H), 5.81-5.71 (m, 1H), 5.36-5.28 (m, 2H), 5.18-5.12 (m, 1H), 4.61-4.45 (m, 1H), 4.07 (s, 3H), 3.94 (s, 3H), 3.91-3.74 (m, 2H), 3.72 (s, 3H), 2.99-2.84 (m, 1H), 2.49-2.34 (m, 1H), 2.20-2.08 (m, 1H), 1.97-1.84 (m, 1H), 1.58-1.52 (m, 1H), 1.44 (s, 9H).
The diester 35j (716 mg, 1.25 mmoles) in solution in a mixture of THF:MeoH (1.5 mL—1.5 mL) is cooled to 0° before being treated with an aqueous solution of NaOH 1M (1.25 mL, 1.25 mmoles). After 1 h of stirring at 0°, 3 drops of glacial acetic acid are added to neutralize the NaOH. The solvents are removed in vacuo and the compound is dried on the pump for a few hours.
A solution of the acid 35k sodium salt (1.25 mmoles) and Et3N (0.19 mL, 1.36 mmoles) in 8 mL of THF is cooled to 0° and isobutyl chloroformate (0.18 mL, 1.39 mmoles) is added. After 40 min diazomethane (9 mL, 6.30 mmoles) is added and the resulting solution is stirred at 0° for 30 min and at room temperature for 2 h. The solvents are removed in vacuo. The residue, diluted with ethyl acetate, is washed twice with a saturated solution of NaHCO3 once with brine and dried over MgSO4, the solvent is evaporated under vacuo and the residue is purified by flash column chromatography (50:50 Hexanes/AcOEt) to afford 378 mg (52% yield) of the expected diazoketone 351.
1H NMR: (CDCl3) δ8.00 (d, J=9 Hz, 1H), 7.42 (s, 1H), 7.35 (d, J=2.5 Hz, 1H), 7.20 (dd, J=9 and 2.5 Hz, 1H), 6.92 (s, 1H), 5.81-5.71 (m, 1H), 5.35-5.28 (m, 3H), 5.17-5.13 (m, 1H), 4.61-4.40 (m, 1H), 3.97 (s, 3H), 3.96-3.74 (m, 2H), 3.72 (s, 3H), 2.94-2.38 (m, 2H), 2.18-2.06 (m, 1H), 1.98-1.84 (m, 1H), 1.57-1.52 (m, 1H), 1.42 (s, 9H).
To a cooled (0°) solution of the diazoketone 351 (0.37 g, 0.642 mmoles) in 15 mL of THF is added 0.25 mL of HBr 48%. The resulting yellow solution is stirred at 0° for 1 h. The reaction mixture is partitioned between ethyl acetate and a saturated solution of NaHCO3. The organic phase is washed one more time with NaHCO3 and dried with NaSO4. After evaporation of the solvents in vacuo, 0.36 g (90% yield) of the α-bromoketone 35m is isolated.
The α-bromoketone 35m (170 mg, 0.271 mmoles) in 10 mL of isopropanol is treated with 1-acetyl-2-thiourea (64 mg, 0.542 mmoles). The resulting solution is heated at 75° for 1 h. The solvent is removed in vacuo. The residue is diluted with ethyl acetate and washed twice with a saturated solution of NaHCO3, once with brine and dried with MgSO4. Evaporation of the solvent in vacuo afforded 182 mg (>100%) of crude material 35n.
The dipeptide 35n (145 mg, 0.223 mmoles) is treated with 3 mL of a 4M solution of HCl in dioxane. The resulting solution is stirred at room temperature for 1 h. The solvents are removed in vacuo and the residue is dried over the pump.
The salt of the amine 35o in 5 mL of CH3CN is treated with 195 μL (1,12 mmoles) of DIEA. This solution is then added to the solution of the Boc-tert-butylglycine (103 mg, 0.446 mmoles) and HATU (186 mg, 0.489 mmoles) in 3 mL of CH3CN. The reaction mixture is stirred at room temperature overnight. The CH3CN is evaporated in vacuo. The residue diluted with ethyl acetate is washed twice with a saturated solution of NaHCO3, once with brine and dried with MgSO4. After removal of the solvent, 274 mg of the crude tripeptide 35p is obtained (>100%).
The tripeptide 35p (56 mg, 0.0733 mmoles), in 4 mL of a 4M solution of HCl in dioxane, is stirred at room temperature for 2 h. The solvent is removed in vacuo and the residue dried over the pump.
The salt of the amine obtained is dissolved in 4 mL of CH2Cl2 and treated with 0.13 mL of DIBA (0.746 mmoles) followed by 26 mg of triphosgene (0.0876 mmoles). After 3 h incubation, 1,2,2-trimethylpropylamine (20 mg, 0.146 mmoles) is added (synthesized as described in Moss N., Gauthier J., Ferland J. M., February 1995, SynLett. (2), 142-144). The ice bath is removed and the reaction mixture is stirred at room temperature overnight. The CH2Cl2 is evaporated in vacuo. The residue, diluted with ethyl acetate is washed twice with a saturated solution of NaHCO3, once with brine and dried with MgSO4 to afford 60 mg (≈100%) of the desired urea 35q.
A solution of methyl ester 35q (57 mg, 0.0721 mmoles) in a mixture of THF:H2O (2.5 mL:1 mL) is treated with solid LiOH.H2O (25 mg, 0.595 mmoles) and 1 mL of MeOH is added in order to clarify the solution. After stirring for 4 h at room temperature, the reaction is neutralized by addition of a 1M solution of HCl. The solvents are removed in vacuo and the residue is purified by a preparative chromatography. The compound dissolved in 2.5 mL of MeOH, is injected into an equilibrated Whatman Partisil 10-ODS-3 (2.2×50 cm) C18 reverse phase column. Purification program: Linear Gradient at 20 mL/nm, λ220 nm, inject at 10% A up to 60% A in 60 min. A:0.06% TFA/CH3CN; B:0.06%; TFA/H2O. Fractions were analyzed by analytical HPLC. The product collected was lyophilized to provide 15 mg of compound 333 as an off white solid (27% yield).
1H NMR: (DMSO-d6) δ8.88 (s, 0.2H), 8.84 (d, J=4.5 Hz, 0.2H), 8.68 (d, J=8.5 Hz, 0. H), 8.56 (s, 0.8H), 8.40-8.13 (m, 1.5H), 7.96 (d, J=9.0 Hz, 0.2H), 7.72-7.44 (m, 2.4H), 7.35-7.09 (m, 1.2H), 6.98 (d, J=9 Hz, 0.2H), 6.15 (d, J=9 Hz, 0.2H), 6.06 (d, J=9 Hz, 0.8H), 5.93 (d, J=9.5 Hz, 0.24H), 5.86 (d, J=9 Hz, 0.8H), 5.79-5.67 (m, 1H), 5.69-5.44 (m, 1H), 5.24-5.14 (m, 1H), 5.09-5.01 (m, 1H), 4.50-4.35 (m, 2H), 4.24 (d, J=9.0 Hz, 0.2H), 4.20 (d, J=9.0 Hz, 0.8H), 4.06-3.98 (m, 2H), 3.95 (s, 3H), 3.77-3.60 (m, 2H), 2.58-2.50 (m, 1H), 2.33-2.28 (m, 1H), 2.22 (s, 2.4H), 2.21 (s, 0.6H), 2.02 (q, J=9 Hz, 1H), 1.56-1.38 (m, 1H), 1.28-1.22 (m, 1H), 0.97 (s, 9H), 0.83 (d, J=6 Hz, 3H), 0.72 (s, 9H).
MS(FAB) 778.3 (m+H)+, 776.3 (M−H).
Serum from an HCV-infected patient was obtained through an external collaboration (Bernard Willems MD, Hôpital St-Luc, Montréal, Canada and Dr. Donald Murphy, Laboratoire de Santé Publique du Québec, Ste-Anne de Bellevue, Canada). An engineered full-length cDNA template of the HCV genome was constructed from DNA fragments obtained by reverse transcription-PCR (RT-PCR) of serum RNA and using specific primers selected on the basis of homology between other genotype 1b strains. From the determination of the entire genomic sequence, a genotype 1b was assigned to the HCV isolate according to the classification of Simmonds et al. (J. Clin. Microbiol., (1993), 31, p.1493-1503). The amino acid sequence of the nonstructural region, NS2-NS4B, was shown to be greater than 93% identical to HCV genotype 1b (BK, JK and 483 isolates) and 88% identical to HCV genotype 1a (HCV-1 isolate). A DNA fragment encoding the polyprotein precursor (NS3/NS4A/NS4B/NS5A/NS5B) was generated by PCR and introduced into eukaryotic expression vectors. After transient transfection, the polyprotein processing mediated by the HCV NS3 protease was demonstrated by the presence of the mature NS3 protein using Western blot analysis. The mature NS3 protein was not observed with expression of a polyprotein precursor containing the mutation S1165A, which inactivates the NS3 protease, confirming the functionality of the HCV NS3 protease.
The DNA fragment encoding the recombinant HCV NS3 protease (amino acid 1027 to 1206) was cloned in the pET11d bacterial expression vector. The NS3 protease expression in E. coli BL21(DE3)pLysS was induced by incubation with 1 mM IPTG for 3 h at 22° C. A typical fermentation (18 L) yielded approximately 100 g of wet cell paste. The cells were resuspended in lysis buffer (3.0 mL/g) consisting of 25 mM sodium phosphate, pH 7.5, 10% glycerol (v/v), 1 mM EDTA, 0.01% NP-40 and stored at −80° C. Cells were thawed and homogenized following the addition of 5 mM DTT. Magnesium chloride and DNase were then added to the homogenate at final concentrations of 20 mM and 20 μg/mL respectively. After a 25 min incubation at 4° C., the homogenate was sonicated and centrifuged at 15000×g for 30 min at 4° C. The pH of the supernatant was then adjusted to 6.5 using a 1M sodium phosphate solution.
An additional gel filtration chromatography step was added to the 2 step purification procedure described in WO 95/22985 (incorporated herein by reference). Briefly, the supernatant from the bacterial extract was loaded on a SP HiTrap column (Pharmacia) previously equilibrated at a flow rate of 2 mL/min in buffer A (50 mM sodium phosphate, pH 6.5, 10% glycerol, 1 mM EDTA, 5 mM DTT, 0.01% NP-40). The column was then washed with buffer A containing 0.15 M NaCl and the protease eluted by applying 10 column volumes of a linear 0.15 to 0.3 M NaCl gradient. NS3 protease-containing fractions were pooled and diluted to a final NaCl concentration of 0.1 M. The enzyme was farther purified on a HiTrap Heparin coiumn (Pharmacia) equilibrated in buffer B (25 mM sodium phosphate, pH 7.5, 10% glycerol, 5 mM DTT, 0.01% NP-40). The sample was loaded at a flow rate of 3 mL/min. The column was then washed with buffer B containing 0.15 M NaCl at a flow rate of 1.5 mL/min. Two step washes were performed in the presence of buffer B containing 0.3 or 1M NaCl. The protease was recovered in the 0.3M NaCl wash, diluted 3-fold with buffer B, reapplied on the HiTrap Heparin column and eluted with buffer B containing 0.4 M NaCl. Finally, the NS3 protease-containing fractions were applied on a Superdex 75 HiLoad 16/60 column (Pharmacia) equilibrated in buffer B containing 0.3 M NaCl. The purity of the HCV NS3 protease obtained from the pooled fractions was judged to be greater than 95% by SDS-PAGE followed by densitometry analysis.
The enzyme was stored at −80° C. and was thawed on ice and diluted just prior to use.
The enzyme was cloned, expressed and prepared according to the protocol described in Example 36. The enzyme was stored at −80° C., thawed on ice and diluted just prior to use in the assay buffer containing the NS4A cofactor peptide.
The substrate used for the NS3 protease/NS4A cofactor peptide radiometric assay, DDIVPC-SMSYTW, is cleaved between the cysteine and the serine residues by the enzyme. The sequence DDIVPC-SMSYTW corresponds to the NS5A/NS5B natural cleavage site in which the cysteine residue in P2 has been substituted for a proline. The peptide substrate DDIVPC-SMSYTW and the tracer biotin-DDIVPC-SMS[125I-Y]TW are incubated with the recombinant NS3 protease and the NS4A peptide cofactor KKGSVVIVGRIILSGRK (molar ratio enzyme:cofactor 1:100) in the absence or presence of inhibitors. The separation of substrate from products is performed by adding avidin-coated agarose beads to the assay mixture followed by filtration. The amount of SMS[125I-Y]TW product found in the filtrate allows for the calculation of the percentage of substrate conversion and of the percentage of inhibition.
A. Reagents
- Tris and Tris-HCl (UltraPure) were obtained from Gibco-BRL. Glycerol (UltraPure), MES and BSA were purchased from Sigma. TCEP was obtained from Pierce, DMSO from Aldrich and NaOH from Anachemia.
- Assay buffer: 50 mM Tris HCl, pH 7.5, 30% (w/v) glycerol, 1 mg/mL BSA, 1 mM TCEP (TCEP added just prior to use from a 1 M stock solution in water).
- Substrate: DDIVPCSMSYTW, 25 μM final concentration (from a 2 mM stock solution in DMSO stored at −20° C. to avoid oxidation).
- Tracer: reduced mono iodinated substrate biotin DDIVPC SMS[125I Y]TW (˜1 nM final concentration).
- HCV NS3 protease type 1b, 25 nM final concentration (from a stock solution in 50 mM sodium phosphate, pH 7.5, 10% glycerol, 300 mM NaCl, 5 mM DTT, 0.01% NP-40).
- NS4A Cofactor peptide: KKGSVV1VGRIILSGRK, 2.5 μM final concentration (from a 2 mM stock solution in DMSO stored at −20° C.).
B. Protocol
The assay was performed in a 96-well polystyrene plate from Costar. Each well contained:
- 20 μL substrate/tracer in assay buffer;
- 10 μL±inhibitor in 20% DMSO/assay buffer;
- 10 μL NS3 protease 1b/NS4 cofactor peptide (molar ratio 1:100).
Blank (no inhibitor and no enzyme) and control (no inhibitor) were also prepared on the same assay plate.
The enzymatic reaction was initiated by the addition of the enzyme/NS4A peptide solution and the assay mixture was incubated for 40 min at 23° C. under gentle agitation. Ten (10) μL of 0.5N NaOH were added and 10 μL 1 M MES, pH 5.8 were added to quench the enzymatic reaction.
Twenty (20) μL of avidin-coated agarose beads (purchased from Pierce) were added in a Millipore MADP N65 filtration plate. The quenched assay mixture was transferred to the filtration plate, and incubated for 60 min at 23° C. under gentle agitation.
The plates were filtered using a Millipore MultiScreen Vacuum Manifold Filtration apparatus, and 40 μL of the filtrate was transferred in an opaque 96-well plate containing 60 μL of scintillation fluid per well.
The filtrates were counted on a Packard TopCount instrument using a 125I-liquid protocol for 1 minute.
The % inhibition was calculated with the following equation:
100−[(countsinh−countsblank)/(countsctl−countsblank)×100]
100−[(countsinh−countsblank)/(countsctl−countsblank)×100]
A non-linear curve fit with the Hill model was applied to the inhibition-concentration data, and the 50% effective concentration (IC50) was calculated by the use of SAS software (Statistical Software System; SAS Institute, Inc. Cary, N.C.).
The NS2-NS5B-3′ non coding region was cloned by RT-PCR into the pCR®3 vector (Invitrogen) using RNA extracted from the serum of an HCV genotype 1b infected individual (provided by Dr. Bernard Wiilems, Hôpital St-Luc, Montréal, Québec, Canada). The NS3-NS4A DNA region was then subcloned by PCR into the pFastBac™ HTa baculovirus expression vector (Gibco/BRL). The vector sequence includes a region encoding a 28-residue N-terminal sequence which contains a hexahistidine tag. The Bac-to-Bac™ baculovirus expression system (Gibco/BRL) was used to produce the recombinant baculovirus. The full length mature NS3 and NS4A heterodimer protein (His-NS3-NS4AFL) was expressed by infecting 106 Sf21 cells/mL with the recombinant baculovirus at a multiplicity of infection of 0.1-0.2 at 27° C. The infected culture was harvested 48 to 64 h later by centrifugation at 4° C. The cell pellet was homogenized in 50 mM NaPO4, pH 7.5, 40% glycerol (w/v), 2 mM β-mercaptoethanol, in presence of a cocktail of protease inhibitors. His-NS3-NS4AFL was then extracted from the cell lysate with 1.5% NP-40, 0.5% Triton X-100, 0.5M NaCl, and a DNase treatment. After ultracentrifugation, the soluble extract was diluted 4-fold and bound on a Pharmacia Hi-Trap Ni-chelating column. The His-NS3-NS4AFL was eluted in a >90% pure form (as judged by SDS-PAGE), using a 50 to 400 mM imidazole gradient. The His-NS3-NS4AFL was stored at −80° C. in 50 mM sodium phosphate, pH 7.5, 10% (w/V) glycerol, 0.5 M NaCl, 0.25 M imidazole, 0.1% NP-40. It was thawed on ice and diluted just prior to use. The protease activity of His-NS3-NS4AFL was assayed in 50 mM Tris-HCl, pH 8.0, 0.25 M sodium citrate, 0.01% (w/v) n-dodecyl-β-D-maltoside, 1 mM TCEP. Five (5) μM of the internally quenched substrate anthranilyl-DDIVPAbu[C(O)—O]-AMY(3-NO2)TW-OH in presence of various concentrations of inhibitor were incubated with 1.5 nM of His-NS3-NS4AFL for 45 min at 23° C. The final DMSO concentration did not exceed 5.25%. The reaction was terminated with the addition of 1M MES, pH 5.8. Fluorescence of the N-terminal product was monitored on a Perkin-Elmer LS-50B fluorometer equipped with a 96-well plate reader (excitation wavelength: 325 nm; emission wavelength: 423 nm).
The % inhibition was calculated with the following equation:
100−[(countsinh−countsblank)/(countsctl−countsblank)×100]
A non-linear curve fit with the Hill model was applied to the inhibition-concentration data, and the 50% effective concentration (IC50) was calculated by the use of SAS software (Statistical Software System; SAS Institute, Inc. Cary, N.C.).
100−[(countsinh−countsblank)/(countsctl−countsblank)×100]
A non-linear curve fit with the Hill model was applied to the inhibition-concentration data, and the 50% effective concentration (IC50) was calculated by the use of SAS software (Statistical Software System; SAS Institute, Inc. Cary, N.C.).
NS3 Protease Cell-based Assay
This assay was done with Huh-7 cells, a human cell line derived from a hepatoma, co-transfected with 2 DNA constructs:
-
- one expressing a polyprotein comprising the HCV non-structural proteins fused to tTA in the following order: NS3-NS4A-NS4B-NS5A-tTA (called NS3);
- the other expressing the reporter protein, secreted alkaline phosphatase, under the control of tTA (called SEAP).
The polyprotein must be cleaved by the NS3 protease for the mature proteins to be released. Upon release of the mature proteins, it is believed that the viral proteins will form a complex at the membrane of the endoplasmic reticulum while tTA will migrate to the nucleus and transactivate the SEAP gene. Therefore, reduction of NS3 proteolytic activity should lead to reduction of mature tTA levels and concomitant decrease in SEAP activity.
To control for other effects of the compounds, a parallel transfection was done where a construct expressing tTA alone (called tTA) was co-transfected with the SEAP construct such that SEAP activity is independent of NS3 proteolytic activity. Protocol of the assay: Huh-7 cells, grown in CHO-SFMII+10% FCS (fetal calf serum), were co-transfected with either NS3 and SEAP or tTA and SEAP, using the FuGene protocol (Boehringer Mannheim). After 5 h at 37°, the cells were washed, trypsinized and plated (at 80000 cells/well) in 96-well plates containing a range of concentrations of the compounds to be tested. After a 24-h incubation period, an aliquot of the medium was drawn and the SEAP activity in this aliquot was measured with the Phospha-Light kit (Tropix).
Analysis of the percent inhibition of SEAP activity with respect to compound concentration was performed with the SAS software to obtain the EC50.
The toxicity of the compound (TC50) was then assessed using the MTT assay as follows:
- 20 μL of a MTT solution (5 mg/ml medium) was added per well and incubated at 37° for 4 hrs;
- the medium was removed and 50 μl of 0.01N HCl+10% Triton X-100 was added;
- after shaking at RT for at least 1 hr, the OD of each well was read at 595 nm wavelength.
The TC50 was calculated in the same way as the EC50.
Specificity Assays
The specificity of the compounds was determined against a variety of serine proteases: human leukocyte elastase, porcine pancreatic elastase and bovine pancreatic α-chymotrypsin and one cysteine protease: human liver cathepsin B. In all cases a 96-well plate format protocol using a calorimetric p-nitroaniline (pNA) substrate specific for each enzyme was used. Each assay included a 1 h enzyme-inhibitor pre-incubation at 30° C. followed by addition of substrate and hydrolysis to ≈30% conversion as measured on a UV Thermomax® micropiate reader. Substrate concentrations were kept as low as possible compared to KM to reduce substrate competition. Compound concentrations varied from 300 to 0.06 μM depending on their potency.
The final conditions for each assay were as follows:
-
- 50 mM Tris-HCl pH 8, 0.5 M Na2SO4, 50 mM NaCl, 0.1 mM EDTA, 3% DMSO, 0.01% Tween-20 with;
- [100 μM Succ-AAPF-pNA and 250 pM α-chymotrypsin], [133 μM Succ-AAA-pNA and 8 nM porcine elastase], [133 μM Succ-AAV-pNA and 8 nM leukocyte elastase]; or
- [100 mM NaHPO4 pH 6, 0.1 mM EDTA, 3% DMSO, 1 mM TCEP, 0.01% Tween-20, 30 μM Z-FR-pNA and 5 nM cathepsin B (the stock enzyme was activated in buffer containing 20 mM TCEP before use)].
A representative example is summarized below for porcine pancreatic elastase: In a polystyrene flat-bottom 96-well plate wore added using a Biomek liquid handler (Beckman):
-
- 40 μL of assay buffer (50 mM Tris-HCl pH 8, 50 mM NaCl, 0.1 mM EDTA);
- 20 μL of enzyme solution (50 mM Tris-HCl pH 8, 50 mM NaCl, 0.1 mM EDTA, 0.02% Tween-20, 40 nM porcine pancreatic elastase); and
- 20 μL of inhibitor solution (50 mM Tris-HCl, pH 8, 50 mM NaCl, 0.1 mM EDTA, 0.02% Tween-20, 1.5 mM−0.3 μM inhibitor, 15% v/v DMSO).
After 60 min pre-incubation at 30° C., 20 μL of substrate solution (50 mM Tris-HCl, pH 8, 0.5 M NaSO4, 50 mM NaCl, 0.1 mM EDTA, 665 μM Succ-AAA-pNA) were added to each well and the reaction was further incubated at 30° C. for 60 min after which time the absorbance was read on the UV Thermomax® plate reader. Rows of wells were allocated for controls (no inhibitor) and for blanks (no inhibitor and no enzyme).
The sequential 2-fold dilutions of the inhibitor solution were performed on a separate plate by the liquid handler using 50 mM Tris-HCl pH 8, 50 mM NaCl, 0.1 mM EDTA, 0.02% Tween-20, 15% DMSO. All other specificity assays were performed in a similar fashion.
The percentage of inhibition was calculated using the formula:
[1-((UVinh−UVblank)/(UVctl−UVblank))]×100
[1-((UVinh−UVblank)/(UVctl−UVblank))]×100
A non-linear curve fit with the Hill model was applied to the inhibition-concentration data, and the 50% effective concentration (IC50) was calculated by the use of SAS software (Statistical Software System; SAS Institute, Inc., Cary, N.C.).
The following tables list compounds representative of the invention. Compounds of the invention were assayed either in one or both of the assays of Examples 37 and 38 and were found to be active with IC50 below 50 μM.
Activity in Cells and Specificity
Representative compounds of the invention were also tested in the surrogate cell-based assay of Example 39, and in one or several assays of Example 40. For example, compound 601 from Table 6 was found to have an IC50 of 50 nM in the assay of Example 37 and 30 nM in the assay of Example 38. The EC50 as determined by the assay of Example 39 is 8.2 μM. In the specificity assays of Example 40, the same compound was found to have the following activity: HLE>75 μCM; PPE>75 μM; α-Chym.>75 μM; Cat. B>75 μM. These results indicate that this family of compounds is highly specific for the NS3 protease and at least certain members of this family are active in a surrogate cell-based assay.
The following abbreviations are used within the present tables:
MS: Mass spectrometric data; Ac: acetyl; Bn: benzyl; Boc: tert-butyloxycarbonyl; cHex: cyclohexyl; Chg: cyclohexylglycine (2-amino-2-cyclohexyl-acetic acid); iPr: isopropyl; O-Bn: benzyloxy; Ph: phenyl: t-Bu: tert-butyl; Tbg: tert-butylglycine; 1- or 2-Np; 1- or 2-naphthyl; 1- or 2-NpCH2O: 1, or 2-naphthylmethoxy.
TABLE 1 |
|
Tab 1 | IC50 | ||||
Cpd # | B | R3 | R2 | MS | (μM) |
101 | Boc | cHex | —O—CH2-1-naphthyl | 594 | 43 |
102 |
|
cHex | —O—CH2-1-naphthyl | 632 | 45 |
103 |
|
cHex | —O—CH2-1-naphthyl | 642 | 42 |
104 |
|
cHex | —O—CH2-1-naphthyl | 728 | 29.5 |
105 |
|
cHex | —O—CH2-1-naphthyl | 619 | 47 |
106 | Boc | cHex |
|
702 | 2.8 |
107 |
|
cHex | —O—CH2-1-naphthyl | 720 M + Na+ | 34 |
108 | Boc | iPr |
|
662 | 8.9 |
109 | acetyl | cHex |
|
644 | 6.3 |
110 | Boc | i-Pr |
|
575.3 | 9.7 |
111 | Boc | t-Bu |
|
661.3 | 0.475 |
TABLE 2 |
|
Table 2 | R1 | IC50 | ||||
Cpd # | B | R3 | R2 | anti to carboxy | MS | (μM) |
201 | Boc | cyclohexyl | —O—CH2-1-naphthyl | ethyl | 622 | 15 |
(one isomer) | ||||||
202 | Boc | cyclohexyl | —O—CH2-1-naphthyl | ethyl | 622 | 40 |
(other isomer) | ||||||
203 | Boc | t-Bu |
|
vinyl 1R, 2R | 687.5 | 0.082 |
TABLE 3 |
|
Table 3 | R1 | IC50 | ||||
Cpd # | B | R3 | R2 | syn to carboxyl | MS | (μM) |
301 | Boc | cHex | —O—CH2-1-naphthyl | ethyl | 622 | 7.7 |
302 |
|
iPr | —O—CH2-1-naphthyl | ethyl | 582 | 12.5 |
303 |
|
cHex | —O—CH2-1-naphthyl | ethyl | 622 | 11 |
304 | Boc | cHex |
|
ethyl | 623 | 32 |
305 | Boc | cHex | —O—CH2-1-naphthyl | vinyl | 620 | 3.2 |
306 | Boc | cHex |
|
vinyl | 607 | 0.8 |
307 | Boc | cHex |
|
vinyl | 728 | 0.27 |
308 | Boc | cHex |
|
vinyl | 606 | 1.6 |
309 | Boc | cHex |
|
vinyl | 606 | 5 |
310 | Boc | cHex |
|
vinyl | 607 | 2.5 |
311 | Boc | cHex |
|
vinyl | 641 | 0.56 |
312 | Boc | cHex |
|
vinyl | 607 | 8.5 |
313 | Boc | cHex |
|
vinyl | 621 | 2.5 |
314 | Boc | cHex |
|
vinyl | 683 | 0.14 |
315 | Boc | cHex |
|
vinyl | 698 | 0.66 |
316 | Acetyl | cHex |
|
vinyl | 625 | 1.9 |
317 | Boc | cHex |
|
vinyl | 740 | 0.32 |
318 | CF3—C(O)— | i-Pr |
|
vinyl | 639.3 | 0.83 |
319 |
|
cHex |
|
vinyl | 732.3 | 1.2 |
320 |
|
cHex |
|
vinyl | 704.3 | 0.65 |
321 | Boc | t-Bu |
|
vinyl | 658.7 | 0.19 |
322 | Boc | t-Bu |
|
vinyl | 717.6 | 1.95 |
323 | Boc | t-Bu |
|
|
672.4 | 0.64 |
324 | Boc | t-Bu |
|
vinyl | 727.5 | 0.05 |
325 | Boc | t-Bu |
|
|
701.4 | 0.153 |
326 | Boc | t-Bu |
|
vinyl | 708.3 | 0.32 |
327 |
|
t-Bu |
|
vinyl | 610.3 | 0.045 |
328 | Boc | t-Bu |
|
vinyl | 615.3 | 3.2 |
329 | Boc | t-Bu |
|
vinyl | 685.3 | 0.36 |
330 | Boc | t-Bu |
|
vinyl | 627.5 | 6 |
331 |
|
t-Bu |
|
vinyl | 656.5 | 0.071 |
332 | Boc | t-Bu |
|
ethyl | 689.3 | 0.13 |
333 |
|
t-Bu |
|
vinyl | 778.3 | 0.003 |
334 |
|
t-Bu |
|
vinyl | 764.4 | 0.007 |
TABLE 4 |
|
Table 4 | IC50 | |||||
Cpd # | B | R3 | R2 | R1 | MS | (μM) |
401 | Boc | i-Pr |
|
H | 589.1 | 5.8 |
402 | Boc | t-Bu |
|
H | 603.6 | 7.9 |
403 | Boc | t-Bu |
|
H | 675.4 | 0.132 |
404 | Boc | t-Bu |
|
3-(═CH2) | 687.1 | 0.6 |
405 | Boc | t-Bu |
|
2-vinyl | 702.3 | 0.220 |
406 | Boc | t-Bu |
|
2-Et | 703.3 | 0.4 |
TABLE 5 |
|
Table 5 | IC50 | ||||
Cpd # | R3 | MS | (μM) | ||
501 | t-Bu | 581.3 | 0.4 | ||
502 | H | 539.2 | 6.2 | ||
503 |
|
625.3 | 0.79 | ||
504 |
|
582.6 | 2.6 | ||
505 |
|
583.2 | 0.79 | ||
506 |
|
659.2 | 1.3 | ||
507 |
|
670.2 | 0.98 | ||
508 |
|
703.3 | 3.1 | ||
509 |
|
581.3 | 0.377 | ||
510 |
|
581.2 | 0.255 | ||
511 |
|
637.2 | 2.1 | ||
TABLE 6 |
|
Table 6 | |||||
Cpd # | R3 | R21A | R21B | MS | IC50 (μM) |
601 | i-Pr | Ph | 7-OMe | 673.3 | 0.05 |
602 | t-Bu | Ph | 8-OMe, 7-OMe | 717.2 | 0.041 |
603 | i-Pr | Ph | 7-ethyl | 671.2 | 0.195 |
604 | t-Bu | — | 7-OMe | 611.2 | 0.073 |
605 | t-Bu | Ph | 7-O-iPr | 715.3 | 0.195 |
606 | t-Bu | — | 7-Cl | 615.2 | 0.48 |
607 | iPr | — | 7-Cl | 601.2 | 0.45 |
608 | CH2-iPr | — | 7-Cl | 615.3 | 1.45 |
609 | t-Bu |
|
— | 680.2 | 1.7 |
610 | t-Bu | Cl | — | 613.3 | 0.25 |
611 | t-Bu | Ph | 7-N(Me)2 | 700.5 | 0.035 |
612 | t-Bu |
|
— | 666.4 | 0.278 |
613 | t-Bu |
|
— | 650.4 | 1.0 |
614 | t-Bu |
|
— | 664.5 | 2.2 |
615 | t-Bu | — | 7-N(Me)2 | 624.5 | 0.16 |
616 | t-Bu |
|
— | 678.4 (M − H)+ | 0.087 |
617 | t-Bu |
|
— | 664.5 | 0.345 |
618 | t-Bu |
|
— | 638.5 | 2.3 |
619 | t-Bu |
|
— | 700.5 | 3.0 |
620 | t-Bu |
|
— | 679.5 | 0.72 |
621 | t-Bu |
|
— | 678.3 | 0.058 |
622 | t-Bu |
|
— | 625.4 | 0.16 |
623 | t-Bu | MeO— | — | 611.3 | 0.20 |
624 | t-Bu | (Me2)N— | — | 624.4 | 1.30 |
625 | t-Bu | Ph | 7-S(Me) | 703.4 | 0.16 |
626 | t-Bu | Ph | 7-Br | 737.3 | 0.24 |
627 | t-Bu | Ph | 7-F | 675.3 | 0.33 |
628 | t-Bu |
|
7-N(Me)2 | 764.2 | 0.011 |
629 | t-Bu |
|
7-N(Me)2 | 764.3 | 0.02 |
630 | t-Bu |
|
7-N(Et)2 | 792.3 | 0.043 |
TABLE 7 |
|
Table 7 | ||||
Cpd # | R3 | R21A | MS | IC50 (μM) |
701 | t-Bu |
|
691.3 | 0.028 |
702 | t-Bu |
|
713.4 | 0.10 |
703 | t-Bu |
|
655.3 | 0.047 |
704 | t-Bu |
|
728.4 | 0.24 |
705 | t-Bu |
|
696.4 | 0.13 |
706 | t-Bu |
|
693.3 | 0.032 |
707 | t-Bu |
|
694.3 | 0.023 |
708 | t-Bu | Ph-N(Me)— | 716.4 | 0.15 |
709 | t-Bu |
|
709.2 | 0.021 |
710 | t-Bu | HOOC— | 655.3 | 0.685 |
711 | t-Bu |
|
708.2 | 0.016 |
712 | t-Bu | (Me)2N— | 654.3 | 0.10 |
713 | t-Bu |
|
692.3 (M − H)− | 0.026 |
714 | t-Bu |
|
722.3 | 0.012 |
715 | t-Bu |
|
688.3 | 0.031 |
716 | t-Bu |
|
688.3 | 0.079 |
717 | t-Bu |
|
723.3 | 0.028 |
718 | t-Bu | NH2 | 626.3 | 0.16 |
719 | t-Bu |
|
751.2 | 0.018 |
720 | t-Bu |
|
733.4 | 0.03 |
721 | t-Bu |
|
724.1 | 0.045 |
722 | t-Bu |
|
737.3 | 0.048 |
723 | t-Bu |
|
791.4 | 0.047 |
724 | t-Bu |
|
708.4 | 0.075 |
725 | t-Bu |
|
689.4 | 0.046 |
726 | t-Bu | i-Pr | 653.3 | 0.25 |
727 | t-Bu |
|
688.3 | 0.07 |
728 | t-Bu |
|
786.1 | 0.022 |
729 | t-Bu |
|
689.3 | 0.2 |
730 | t-Bu |
|
669.2 | 0.042 |
731 | t-Bu |
|
669.2 | 0.031 |
732 | t-Bu |
|
791.0 | 0.02 |
733 | t-Bu |
|
765.3 | 0.028 |
734 | t-Bu |
|
671.3 | 0.044 |
735 | t-Bu |
|
683.3 | 0.058 |
736 | t-Bu | t-Bu | 667.4 | 0.25 |
737 | t-Bu | cHex | 693.4 | 0.11 |
TABLE 8 |
|
Table 8 | IC50 | ||||
Cpd # | B | R3 | R22 | MS | (μM) |
801 |
|
t-Bu | — | 686.7 | 0.006 |
802 |
|
t-Bu | — | 727.7 | 0.024 |
803 |
|
t-Bu | — | 685.7 | 0.12 |
804 |
|
t-Bu | — | 711.7 | 0.032 |
805 | Ac | t-Bu | — | 629.6 | 0.083 |
806 |
|
t-Bu | — | 725.7 | 0.036 |
807 |
|
t-Bu | — | 672.4 | 0.01 |
808 |
|
t-Bu | — | 712.4 | 0.008 |
809 |
|
i-Pr | — | 649.3 | 0.071 |
810 |
|
t-Bu | — | 749.3 | 0.45 |
811 | Boc | t-Bu | 4-Cl | 721.3 | 0.04 |
812 |
|
t-Bu | — | 706.2 | 0.013 |
813 |
|
t-Bu | — | 702.2 | 0.02 |
814 | Boc | t-Bu | 2-Cl | 721.3 | 0.13 |
815 | Boc | t-Bu | 3-Cl | 721.3 | 0.16 |
816 |
|
t-Bu | — | 658.3 | 0.032 |
817 |
|
t-Bu | — | 720.2 | 0.017 |
818 |
|
t-Bu | — | 728.3 | 0.019 |
819 |
|
i-Pr | — | 762.3 | 0.32 |
820 |
|
i-Pr | — | 733.2 | 0.063 |
821 |
|
i-Pr | — | 679.1 | 0.12 |
822 |
|
i-Pr | — | 663.3 | 0.05 |
823 | Boc | t-Bu | 2-OMe | 717.2 | 0.107 |
824 | Boc | t-Bu | 3-OMe | 719.2 | 0.07 |
825 | Boc | t-Bu | 4-OMe | 719.2 | 0.024 |
826 |
|
i-Pr | — | 663.3 | 0.78 |
827 |
|
t-Bu | — | 673.2 | 0.27 |
828 |
|
i-Pr | — | 691.3 | 0.10 |
829 |
|
t-Bu | — | 734.3 | 0.057 |
830 |
|
t-Bu | — | 645.3 | 0.111 |
831 |
|
t-Bu | — | 701.3 | 0.015 |
832 |
|
t-Bu | — | 801.3 | 0.11 |
833 |
|
t-Bu | — | 715.2 | 0.015 |
834 |
|
i-Pr | — | 663.3 | 0.074 |
835 |
|
t-Bu | — | 702.5 | 0.007 |
836 |
|
i-Pr | — | 694.4 | 0.13 |
837 |
|
i-Pr | — | 683.3 | 0.098 |
838 |
|
i-Pr | — | 679.1 | 0.094 |
839 |
|
i-Pr | — | 674.5 | 0.10 |
840 |
|
i-Pr | — | 667.4 | 0.081 |
841 | Boc | t-Bu | 2-Me | 701.5 | 0.24 |
842 | Boc | t-Bu | 3-Me | 701.5 | 0.073 |
843 | Boc | t-Bu | 4-Me | 701.5 | 0.053 |
844 |
|
t-Bu | 4-OMe | 716.6 | 0.006 |
845 |
|
i-Pr | — | 706.9 | 0.18 |
846 |
|
i-Pr | — | 693.4 | 0.104 |
847 | Boc | cHex | — | 713.4 | 0.037 |
848 | Boc |
|
— | 687.5 | 0.093 |
849 | Boc |
|
— | 701.5 | 0.110 |
850 | Boc |
|
— | 731.5 | 0.063 |
851 | Boc |
|
— | 689.5 | 0.12 |
852 | Boc |
|
— | 689.5 | 0.05 |
853 | Boc |
|
— | 765.5 | 0.17 |
854 |
|
i-Pr | — | 723.4 (M − H)+ | 0.37 |
855 |
|
i-Pr | — | 693.3 | 0.075 |
856 |
|
i-Pr | — | 688.3 | 0.11 |
857 |
|
t-Bu | — | 716.4 | 0.011 |
858 |
|
t-Bu | — | 700.4 | 0.205 |
859 |
|
i-Pr | — | 655.4 | 0.83 |
860 |
|
i-Pr | — | 759.3 | 0.24 |
861 |
|
i-Pr | — | 688.3 | 0.17 |
862 |
|
i-Pr | — | 685.3 | 0.23 |
863 |
|
i-Pr | — | 699.4 | 0.30 |
864 |
|
i-Pr | — | 667.3 | 0.45 |
865 |
|
t-Bu | — | 701.4 | 0.02 |
866 |
|
t-Bu | — | 702.4 | 0.20 |
867 |
|
t-Bu | — | 701.3 | 0.051 |
868 |
|
t-Bu | — | 713.3 | 0.03 |
869 |
|
t-Bu | — | 699.4 | 0.014 |
870 |
|
t-Bu | — | 700.4 | 0.009 |
871 |
|
t-Bu | — | 714.3 | 0.011 |
872 |
|
t-Bu | — | 714.4 | 0.005 |
873 |
|
t-Bu | — | 714.3 | 0.019 |
TABLE 9 |
|
Table 9 | IC50 | ||||
Cpd # | B | MS | (μM) | ||
901 | Boc | 685.3 | 0.025 | ||
902 |
|
825.4 | 0.042 | ||
903 |
|
769.3 | 0.005 | ||
904 |
|
707.3 | 0.095 | ||
905 |
|
685.2 | 0.029 | ||
906 |
|
728.2 | 0.014 | ||
907 |
|
717.2 | 0.025 | ||
908 |
|
691.2 | 0.072 | ||
909 |
|
727.2 | 0.036 | ||
910 |
|
715.3 | 0.056 | ||
911 |
|
721.3 | 0.039 | ||
912 |
|
733.2 | 0.034 | ||
913 |
|
713.3 | 0.030 | ||
914 |
|
805.3 | 0.031 | ||
915 |
|
692.2 | 0.026 | ||
916 |
|
680.3 | 0.3 | ||
Claims (96)
wherein
B is H, a C6 or C10 aryl, C7-16 aralkyl; Het or (lower alkyl)-Het, all of which optionally substituted with C1-6 alkyl; C1-6 alkoxy; C1-6 alkanoyl; hydroxy; hydroxyalkyl; halo; haloalkyl; nitro; cyano; cyanoalkyl; amino optionally substituted with C1-6 alkyl; amido; or (lower alkyl)amide;
or B is an acyl derivative of formula R4—C(O)—; a carboxyl derivative of formula R4—O—C(O)—; an amide derivative of formula R4—N(R5)—C(O)—; a thioamide derivative of formula R4—N(R5)—C(S)—; or a sulfonyl derivative of formula R4—SO2 wherein
R4 is
(i) C1-10 alkyl optionally substituted with carboxyl, C1-6 alkanoyl, hydroxy, C1-6 alkoxy, amino optionally mono- or di-substituted with C1-6 alkyl, or amido, or (lower alkyl) amide ; and when B is R4 —O—C(O)—; R 4 —N(R 5)—C(O)—; R 4 N(R 5)—C(S)—; or R 4 —SO 2 , then R 4 may additionally be selected from C 1-10 alkyl substituted with (lower alkyl) amide;
(ii) C3-7 cycloalkyl, or C3-7 cycloalkoxy, or C4-10 alkylcycloalkyl, all optionally substituted with hydroxy, carboxyl, (C1-6 alkoxy)carbonyl, amino optionally mono- or di-substituted with C1-6 alkyl, amido, or (lower alkyl) amide; or R4 is C 4-10 alkylcycloalkyl, optionally substituted with hydroxy, carboxyl, (C 1-6 alkoxy)carbonyl, amino optionally mono- or di-substituted with C 1-6 alkyl, or amido; and when B is R 4 —O—C(O)—; R 4 —N(R 5)—C(O)—; R 4 —N(R 5)—C(S)—; or R 4 —SO 2 , then R 4 may additionally be C 4-10 alkylcycloalkyl substituted with (lower alkyl) amide;
(iii) amino optionally mono- or di-substituted with C1-6 alkyl; amido; or (lower alkyl)amide;
(iv) C6 or C10 aryl or C7-16 aralkyl, all optionally substituted with C1-6 alkyl, hydroxy, amido, (lower alkyl)amide, or amino optionally mono- or di-substituted with C1-6 alkyl; or
(v) Het or (lower alkyl)-Het, both optionally substituted with C1-6 alkyl, hydroxy, amido, (lower alkyl) amide, or amino optionally mono- or di-substituted with C1-6 alkyl;
R5 is H or C1-6 alkyl;
with the proviso that when B is a carboxyl derivative, an amide derivative or a thioamide derivative, R4 is not a cycloalkoxy;
Y is H or C1-6 alkyl;
R3 is C1-8 alkyl, C3-7 cycloalkyl, or C4-10 alkylcycloalkyl, all optionally substituted with hydroxy, C1-6 alkoxy, C1-6 thioalkyl, amido, (lower alkyl)amido, C6 or C10 aryl, or C7-16 aralkyl;
R2 is CH2—R20, NH—R20, O—R20 or S—R20, wherein R20 is a saturated or unsaturated C3-7 cycloalkyl or C4-10(alkylcycloalkyl), all of which being optionally mono-, di- or tri-substituted with R21,
or R20 is a C6 or C10 aryl or C7-14 aralkyl, all optionally mono-, di- or tri-substituted with R21,
or R20 is Het or (lower alkyl)-Het, both optionally mono-, di- or tri-substituted with R21, provided that Het is not pyridinyl or quinolyl in these instances,
wherein each R21 is independently C1-6 alkyl; C1-6 alkoxy; lower thioalkyl; sulfonyl; NO2; OH; SH; halo; haloalkyl; amino optionally mono- or di-substituted with C1-6 alkyl, C6 or C10 aryl, C7-14 aralkyl, Het or (lower alkyl)-Het; amido optionally mono-substituted with C1-6 alkyl, C6 or C10 aryl, C7-14 aralkyl, Het or (lower alkyl)-Het; carboxyl; carboxy(lower alkyl); C6 or C10 aryl, C7-14 aralkyl or Het, said aryl, aralkyl or Het being optionally substituted with R22;
wherein R22 is C1-6 alkyl; C3-7 cycloalkyl; C1-6 alkoxy; amino optionally mono- or di-substituted with C1-6 alkyl; sulfonyl; (lower alkyl)sulfonyl; NO2; OH; SH; halo; haloalkyl; carboxyl; amide amido; (lower alkyl)amide; or Het optionally substituted with C1-6 alkyl;
R1 is H; C1-6 alkyl, C3-7 cycloalkyl, C2-6 alkenyl, or C2-6 alkynyl, all optionally substituted with halogen;
or a pharmaceutically acceptable salt or ester thereof;
wherein “Het” is defined as a five-, six-, or seven-membered saturated or unsaturated, aromatic or non-aromatic, heterocycle containing from one to four heteroatoms selected from nitrogen, oxygen and sulfur, wherein said heterocycle is optionally fused to a benzene ring.
2. A compound of formula I according to claim 1 , wherein
B is a C6 or C10 aryl or C7-16 aralkyl, all optionally substituted with C1-6 alkyl, C1-6 alkoxy, C1-6 alkanoyl, hydroxy, hydroxyalkyl, halo, haloalkyl, nitro, cyano, cyanoalkyl, amido, (lower alkyl)amido, or amino optionally substituted with C1-6 alkyl; or
B is Het or (lower alkyl)-Het, all optionally substituted with C1-6 alkyl, C1-6 alkoxy, C1-6 alkanoyl, hydroxy, hydroxyalkyl, halo, haloalkyl, nitro, cyano, cyanoalkyl, amido, (lower alkyl)amido, or amino optionally substituted with C1-6 alkyl.
3. A compound of formula I according to claim 1 , wherein B is R4—SO2 wherein R4 is C1-6 alkyl; amido; (lower alkyl)amide; C6 or C10 aryl, C7-14 aralkyl or Het, all optionally substituted with C1-6 alkyl.
4. A compound of formula I according to claim 1 , wherein B is an acyl derivative of formula R4—C(O)— wherein R4 is
(i) C1-10 alkyl optionally substituted with carboxyl, hydroxy, or C1-6 alkoxy, amido, (lower alkyl)amide, or amino optionally mono- or di-substituted with C1-6 alkyl;
(ii) C3-7 cycloalkyl or C4-10 alkylcycloalkyl, both optionally substituted with hydroxy, carboxyl, (C1-6 alkoxy)carbonyl, amido, (lower alkyl)amide, or amino optionally mono- or di-substituted with C1-6 alkyl; or C4-10 alkylcycloalkyl, optionally substituted with hydroxy, carboxyl, (C 1-6 alkoxy)carbonyl, amino optionally mono- or di-substituted with C 1-6 alkyl, or amido;
(iv) C6 or C10 aryl or C7-16 aralkyl, all optionally substituted with C1-6 alkyl, hydroxy, amido, (lower alkyl)amide, or amino optionally mono- or di-substituted with C1-6 alkyl; or
(v) Het or (lower alkyl)-Het, both optionally substituted with C1-6 alkyl, hydroxy, amino optionally mono- or di-substituted with C1-6 alkyl, amido, or (lower alkyl)amide, or amino optionally substituted with C1-6 alkyl .
5. A compound of formula I according to claim 1 , wherein B is a carboxyl derivative of formula R4—O—C(O)—, wherein R4 is
(i) C1-10 alkyl optionally substituted with carboxyl, C1-6 alkanoyl, hydroxy, C1-6 alkoxy, amino optionally mono- or di-substituted with C1-6 alkyl, amido or (lower alkyl)amide;
(ii) C3-7 cycloalkyl, or C4-10 alkylcycloalkyl, all optionally substituted with carboxyl, (C1-6 alkoxy)carbonyl, amino optionally mono- or di-substituted with C1-6 alkyl, amido or (lower alkyl)amide;
(iv) C6 or C10 aryl or C7-16 aralkyl optionally substituted with C1-6 alkyl, hydroxy, amido, (lower alkyl)amido, or amino optionally mono- or di-substituted with C1-6 alkyl; or
(v) Het or (lower alkyl)-Het, both optionally substituted with C1-6 alkyl, hydroxy, amino optionally mono- or di-substituted with C1-6 alkyl, amido or (lower alkyl)amido.
6. A compound of formula I according to claim 1 , wherein B is an amide derivative of formula R4—N(R5)—C(O)— wherein R4 is
(i) C1-10 alkyl optionally substituted with carboxyl, C1-6 alkanoyl, hydroxy, C1-6 alkoxy, amido, (lower alkyl)amido, or amino optionally mono- or di-substituted with C1-6 alkyl;
(ii) C3-7 cycloalkyl or C4-10 alkylcycloalkyl, all optionally substituted with carboxyl, (C1-6 alkoxy)carbonyl, amido, (lower alkyl)amido, or amino optionally mono- or di-substituted with C1-6 alkyl;
(iii) amino optionally mono- or di-substituted with C1-3 alkyl;
(iv) C6 or C10 aryl or C7-16 aralkyl, all optionally substituted with C1-6 alkyl, hydroxy, amido, (lower alkyl) amide, or amino optionally substituted with C1-6 alkyl; or
(v) Het or (lower alkyl)-Het, both optionally substituted with C1-6 alkyl, hydroxy, amino optionally substituted with C1-6 alkyl, amido or (lower alkyl)amide; and
R5 is H or methyl.
7. A compound of formula I according to claim 1 , wherein B is a thioamide derivative of formula R4—NH—C(S)—; wherein R4 is
(i) C1-10 alkyl optionally substituted with carboxyl, C1-6 alkanoyl or C1-6 alkoxy;
(ii) C3-7 cycloalkyl or C4-10 alkylcycloalkyl, all optionally substituted with carboxyl, (C1-6 alkoxy)carbonyl, amino or amido.
8. A compound of formula I according to claim 2 , wherein B is a C6 or C10 aryl optionally substituted with C1-6 alkyl, C1-6 alkoxy, C1-6 alkanoyl, hydroxy, hydroxyalkyl, halo, haloalkyl, nitro, cyano, cyanoalkyl, amido, (lower alkyl)amide, or amino optionally mono- or di-substituted with C1-6 alkyl.
9. A compound of formula I according to claim 2 , wherein B is Het optionally substituted with C1-6 alkyl, C1-6 alkoxy, C1-6 alkanoyl, hydroxy, halo, amido, (lower alkyl)amide, or amino optionally mono- or di-substituted with C1-6 alkyl.
10. A compound of formula I according to claim 4 , wherein B is an acyl derivative of formula R4—C(O)— wherein R4 is
(i) C1-10 alkyl optionally substituted with carboxyl, hydroxy or C1-6 alkoxy; or
(ii) C3-7 cycloalkyl or C4-10 alkylcycloalkyl, both optionally substituted with hydroxy, carboxyl, or (C1-6 alkoxy)carbonyl, or
(iv) C6 or C10 aryl or C7-16 aralkyl, all both optionally substituted with C1-6 alkyl, or hydroxy, or
(v) Het optionally substituted with C1-6 alkyl, hydroxy, amido or amino.
11. A compound of formula I according to claim 5 , wherein B is a carboxyl derivative of formula R4—O—C(O)—, wherein R4 is
(i) C1-10 alkyl optionally substituted with carboxyl, C1-6 alkanoyl, hydroxy, C1-6 alkoxy or , amido, (lower alkyl)amide, or amino optionally mono- or di-substituted with C1-6 alkyl;
(ii) C3-7 cycloalkyl, or C4-10 alkylcycloalkyl, all both optionally substituted with carboxyl, (C1-6 alkoxy)carbonyl, amido, (lower alkyl)amide, or amino optionally mono- or di-substituted with C1-6 alkyl, or
(iv) C6 or C10 aryl or C7-16 aralkyl, all both optionally substituted with C1-6 alkyl, hydroxy, or amino optionally substituted with C1-6 alkyl; or
(v) Het or (lower alkyl)-Het, both optionally substituted with C1-6 alkyl, hydroxy, amido, or amino optionally mono-substituted with C1-6 alkyl.
12. A compound of formula I according to claim 6 , wherein B is an amide derivative of formula R4—N(R5)—C(O)— wherein R4 is
(i) C1-10 alkyl optionally substituted with carboxyl, C1-6 alkanoyl, hydroxy, C1-6 alkoxy, amido, (lower alkyl)amide, or amino optionally mono- or di-substituted with C1-6 alkyl;
(ii) C3-7 cycloalkyl or C4-10 alkylcycloalkyl, all both optionally substituted with carboxyl, (C1-6 alkoxy)carbonyl, amido, (lower alkyl)amide, or amino optionally mono- or di-substituted with C1-6 alkyl;
(iii) amino optionally mono- or di-substituted with C1-3 alkyl, or
(iv) C6 or C10 aryl or C7-16 aralkyl, all optionally substituted with C1-6 alkyl, hydroxy, amino or amido optionally substituted with C1-6 alkyl; or
(v) Het optionally substituted with C1-6 alkyl, hydroxy, amino or amido, and R5 is H.
13. A compound of formula I according to claim 7 , wherein B is a thioamide derivative of formula R4—NH—C(S)—; wherein R4 is (i) C1-10 alkyl; or (ii) C3-7 cycloalkyl.
14. A compound of formula I according to claim 12 , wherein B is an amide derivative of formula R4—NH—C(O)— wherein R4 is
(i) C1-10 alkyl optionally substituted with carboxyl, C1-6 alkanoyl, hydroxy, C1-6 alkoxy, amido, (lower alkyl)amide, or amino optionally mono- or di-substituted with C1-6 alkyl;
(ii) C3-7 cycloalkyl or C4-10 alkylcycloalkyl, all both optionally substituted with carboxyl, (C1-6 alkoxy)carbonyl, amido, (lower alkyl)amide, or amino optionally mono- or di-substituted with C1-6 alkyl; or
(iv) C6 or C10 aryl or C7-16 aralkyl, both optionally substituted with C1-6 alkyl, hydroxy, amino or amido.
16. A compound of formula I according to claim 1 , wherein Y is H or methyl.
17. A compound of formula I according to claim 16 , wherein Y is H.
18. A compound of formula I according to claim 1 , wherein R3 is C1-8 alkyl, C3-7 cycloalkyl, or C4-10 alkylcycloalkyl, all optionally substituted with hydroxy, C1-6 alkoxy, C1-6 thioalkyl, acetamido, C6 or C10 aryl, or C7-16 aralkyl, .
20. A compound of formula I according to claim 19 , wherein R3 is the side chain of Tbg, Chg or Val.
21. A compound of formula I according to claim 1 , wherein R2 is S—R20 or O—R20 wherein R20 is a C6 or C10 aryl, C7-16 C7-14 aralkyl, Het or —CH2—Het, all optionally mono-, di- or tri-substituted with R21, wherein
R21 is C1-6 alkyl; C1-6 alkoxy; lower thioalkyl; amino or amido optionally mono-or di-substituted mono-substituted with C1-6 alkyl, C6 or C10 aryl, C7-16 C7-14 aralkyl, Het or (lower alkyl)-Het; NO2; OH; halo; trifluoromethyl; carboxyl; C6 or C10 aryl, C7-16 C7-14 aralkyl, or Het, said aryl, aralkyl or Het being optionally substituted with R22, wherein
R22 is C1-6 alkyl; C3-7 cycloalkyl; C1-6 alkoxy; amino; mono- or di-(lower alkyl)amino; amido; (lower alkyl)amide; sulfonylalkyl; NO2; OH; halo; trifluoromethyl; carboxyl or Het.
22. A compound of formula I according to claim 21 , wherein R21 is C1-6 alkyl; C1-6 alkoxy; amino; di(lower alkyl)amino; (lower alkyl)amide; C6 or C10 aryl, or Het, said aryl or Het being optionally substituted with R22, wherein R22 is C1-6 alkyl; C3-7 cycloalkyl; C1-6 alkoxy; amino; mono- or di(lower alkyl)amino; amido; (lower alkyl)amide; halo; trifluoromethyl or Het.
23. A compound of formula I according to claim 22 , wherein R22 is C1-6 alkyl; C1-6 alkoxy; halo; amino optionally mono- or di-substituted with lower alkyl; amido; (lower alkyl)amide; or Het.
24. A compound of formula I according to claim 23 , wherein R22 is methyl; ethyl; isopropyl; tert-butyl; methoxy; chloro; amino optionally mono- or di-substituted with lower alkyl; amido, (lower alkyl)amide; or (lower alkyl) 2-thiazole.
26. A compound of formula I according to claim 21 , wherein R2 is 1-naphthylmethoxy; 2-naphthylmethoxy; benzyloxy, 1-naphthyloxy; or 2-naphthyloxy; or quinolinoxy unsubstituted , mono- or di-substituted with R21 as defined in claim 21 .
27. A compound of formula I according to claim 26 , wherein R2 is 1-naphtylmethoxy; or quinolinoxy 1-naphthylmethoxy unsubstituted, mono- or di-substituted with R21 as defined in claim 26 .
wherein
R21A is C1-6 alkyl; C1-6 alkoxy; lower thioalkyl; halo; amino optionally mono-substituted with C1-6 alkyl; or C6, C10 aryl, C7-16 aralkyl, or Het, said aryl, aralkyl or Het optionally substituted with R22 wherein R22 is C1-6 alkyl, C1-6 alkoxy, amido, (lower alkyl)amide, amino optionally mono- or di-substituted with C1-6 alkyl, or Het; and
R21B is C1-6 alkyl, C1-6 alkoxy, amino, di(lower alkyl)amino, (lower alkyl)amide, NO2, OH, halo, trifluoromethyl, or carboxyl.
30. A compound of formula I according to claim 29 , wherein R21A is C6, C10 aryl or Het, all optionally substituted with R22 as defined in claim 29 .
wherein R22B is C1-6 alkyl, amino optionally mono-substituted with C1-6 alkyl, amido, or (lower alkyl)amide; and R21B is C1-6 alkyl, C1-6 alkoxy, amino, di(lower alkyl) amino, (lower alkyl)amide, NO2, OH, halo, trifluoromethyl, or carboxyl.
34. A compound of formula I according to claim 32 or 33 , wherein R21B is C1-6 alkoxy, or di(lower alkyl)amino.
35. A compound of formula I according to claim 32 or, 33, wherein R21B is methoxy.
36. A compound of formula I according to claim 1 , wherein R1 is H, C1-3 alky C1-3 alkyl, C3-5 cycloalkyl, or C2-4 alkenyl, all optionally substituted with halo.
38. A compound of formula I according to claim 37 , wherein R1 is vinyl.
43. A compound of formula I according to claim 42 , wherein R1 is ethyl, hence the asymmetric carbon atoms at positions 1 and 2 have the R,R configuration.
44. A compound of formula I according to claim 42 , wherein R1 is vinyl, hence the asymmetric carbon atoms at positions 1 and 2 have the R,S configuration.
45. A compound of formula I according to claim 1 , wherein
B is a C6 or C10 aryl or C7-16 aralkyl, all optionally substituted with C1-6 alkyl, C1-6 alkoxy, C1-6 alkanoyl, hydroxy, hydroxyalkyl, halo, haloalkyl, nitro, cyano, cyanoalkyl, amido, (lower alkyl)amido, or amino optionally substituted with C1-6 alkyl; or
B is Het or (lower alkyl)-Het, all optionally substituted with C1-6 alkyl, C1-6 alkoxy, C1-6 alkanoyl, hydroxy, hydroxyalkyl, halo, haloalkyl, nitro, cyano, cyanoalkyl, amido, (lower alkyl)amido, or amino optionally substituted with C1-6 alkyl, or
B is R4—SO2 wherein R4 is preferably amido; (lower alkyl)amide; C6 or C10 aryl, C7-14 aralkyl or Het, all optionally substituted with C1-6 alkyl, or
B is an acyl derivative of formula R4—C(O)— wherein R4 is
(i) C1-10 alkyl optionally substituted with carboxyl, hydroxy or , C1-6 alkoxy, amido, (loweralkyl)amide, or amino optionally mono- or di-substituted with C1-6 alkyl;
(ii) C3-7 cycloalkyl or C4-10 alkylcycloalkyl, both optionally substituted with hydroxy, carboxyl, (C1-6 alkoxy)carbonyl, amido, (lower alkyl)amide, or amino optionally mono- or di-substituted with C1-6 alkyl; or C4-10 alkylcycloalkyl, optionally substituted with hydroxy, carboxyl, (C 1-6 alkoxy)carbonyl, amido or amino optionally mono- or di-substituted with C 1-6 alkyl,
(iv) C6 or C10 aryl or C7-16 aralkyl, all optionally substituted with C1-6 alkyl, hydroxy, amido, (lower alkyl)amide, or amino optionally mono- or di-substituted with C1-6 alkyl; , or
(v) Het or (lower alkyl)-Het, both optionally substituted with C1-6 alkyl, hydroxy, amino optionally substituted with C1-6 alkyl, amido, (lower alkyl)amide, or amino optionally mono- or di-substituted with C1-6 alkyl, or
B is a carboxyl derivative of formula R4—O—C(O)—, wherein R4 is
(i) C1-10 alkyl optionally substituted with carboxyl, C1-6 alkanoyl, hydroxy, C1-6 alkoxy, amino optionally mono- or di-substituted with C1-6 alkyl, amido or (lower alkyl)amide;
(ii) C3-7 cycloalkyl, or C4-10 alkylcycloalkyl, all optionally substituted with carboxyl, (C1-6 alkoxy)carbonyl, amino optionally mono- or di-substituted with C1-6 alkyl, amido or (lower alkyl)amide;
(iv) C6 or C10 aryl or C7-16 aralkyl, all optionally substituted with C1-6 alkyl, hydroxy, amido, (lower alkyl)amido, or amino optionally mono- or di-substituted with C1-6 alkyl; or
(v) Het or (lower alkyl)-Het, both optionally substituted with C1-6 alkyl, hydroxy, amino optionally mono- or di-substituted with C1-6 alkyl, amido, or (lower alkyl)amido, or
B is an amide derivative of formula R4—N(R5)—C(O)— wherein R4 is
(i) C1-10 alkyl optionally substituted with carboxyl, C1-6 alkanoyl, hydroxy, C1-6 alkoxy, amido, (lower alkyl)amido, or amino optionally mono- or di-substituted with C1-6 alkyl;
(ii) C3-7 cycloalkyl or C4-10 alkylcycloalkyl, all optionally substituted with carboxyl, (C1-6 alkoxy)carbonyl, amido, (lower alkyl)amido, or amino optionally mono- or di-substituted with C1-6 alkyl;
(iii) amino optionally mono- or di-substituted with C1-3 alkyl; or
(iv) C6 or C10 aryl or C7-16 aralkyl, all optionally substituted with C1-6 alkyl, hydroxy, amido, (lower alkyl)amide, or amino optionally mono- or di-substituted with C1-6 alkyl; or
(v) Het or (lower alkyl)-Het, both optionally substituted with C1-6 alkyl, hydroxy, amino optionally mono- or di-substituted with C1-6 alkyl, amido or (lower alkyl)amide; and
R5 is H or methyl, or
B is a thioamide derivative of formula R4—NH—C(S)—; wherein R4 is:
(i) C1-10 alkyl optionally substituted with carboxyl, C1-6 alkanoyl or C1-6 alkoxy; or
(ii) C3-7 cycloalkyl or C4-10 alkylcycloalkyl, all optionally substituted with carboxyl, (C1-6 alkoxy)carbonyl, amino or amido;
Y is H or methyl;
R3 is C1-6 alkyl, C3-7 cycloalkyl, or C4-10 alkylcycloalkyl, all optionally substituted with hydroxy, C1-6 alkoxy, C1-6 thioalkyl, acetamido, C6 or C10 aryl, or C7-16 aralkyl;
R2 is S—R20 or O—R20 wherein R20 is a C6 or C10 aryl, C7-16 aralkyl, Het or —CH2-Het, all optionally mono-, di- or tri-substituted with R21, provided that Het is not pyridinyl or quinolyl in these instances, wherein
R21 is C1-6 alkyl; C1-6 alkoxy; lower thioalkyl; amino or amido optionally mono- or di-substituted mono-substituted with C1-6 alkyl, C6 or C10 aryl, C7-16 C7-14 aralkyl, Het or (lower alkyl)-Het; NO2; OH; halo; trifluoromethyl; carboxyl; C6 or C10 aryl, C7-16 aralkyl, or Het, said aryl, aralkyl or Het being optionally substituted with R22, wherein
R22 is C1-6 alkyl; C3-7 cycloalkyl; C1-6 alkoxy; amino; mono- or di-(lower alkyl)amino; (lower alkyl)amide; sulfonylalkyl; NO2; OH; halo; trifluoromethyl; carboxyl or Het; or
or R2 is 1-naphthylmethoxy; 2-naphthylmethoxy; benzyloxy; 1-naphthyloxy; or 2-naphthyloxy; or quinolinoxy unsubstituted, mono- or di-substituted with R21, as defined above; and
P1 is:
or a pharmaceutically acceptable salt or ester thereof.
46. A compound of formula I according to claim 45 , wherein B is a C6 or C10 aryl optionally substituted with C1-6 alkyl, C1-6 alkoxy, C1-6 alkanoyl, hydroxy, hydroxyalkyl, halo, haloalkyl, nitro, cyano, cyanoalkyl, amido, (lower alkyl)amide, or amino optionally mono- or di-substituted with C1-6 alkyl; or B is Het optionally substituted with C1-6 alkyl, C1-6 alkoxy, C1-6 alkanoyl, hydroxy, halo, amido, (lower alkyl)amide, or amino optionally mono- or di-substituted with C1-6 alkyl; or B is R4—SO2 wherein R4 is C6 or C10 aryl, a C7-14 aralkyl or Het all optionally substituted with C1-6 alkyl; amido, (lower alkyl)amide; or B is an acyl derivative of formula R4—C(O)— wherein R4 is
(i) C1-10 alkyl optionally substituted with carboxyl, hydroxy or C1-6 alkoxy; or
(ii) C3-7 cycloalkyl or C4-10 alkylcycloalkyl, both optionally substituted with hydroxy, carboxyl, or (C1-6 alkoxy)carbonyl; or
(iv) C6 or C10 aryl or C7-16 aralkyl, all optionally substituted with C1-6 alkyl, or hydroxy; or
(v) Het optionally substituted with C1-6 alkyl, hydroxy, amido or amino; or B is a carboxyl derivative of formula R4—O—C(O)—, wherein R4 is
(i) C1-10 alkyl optionally substituted with carboxyl, C1-6 alkanoyl, hydroxy, C1-6 alkoxy, or amido, (lower alkyl)amide, or amino optionally mono- or di-substituted with C1-6 alkyl;
(ii) C3-7 cycloalkyl, or C4-10 alkylcycloalkyl, all optionally substituted with carboxyl, (C1-6 alkoxy)carbonyl, amido, (lower alkyl)amide, or amino optionally mono- or di-substituted with C1-6 alkyl; or
(iv) C6 or C10 aryl or C7-16 aralkyl, all optionally substituted with C1-6 alkyl, hydroxy, oramino optionally substituted with C1-6 alkyl; or
(v) Het or (lower alkyl)-Het, both optionally substituted with C1-6 alkyl, hydroxy, amido, or amino optionally mono-substituted with C1-6 alkyl;
or B is an amide derivative of formula R4—N(R5)—C(O)— wherein R4 is
(i) C1-10 alkyl optionally substituted with carboxyl, C1-6 alkanoyl, hydroxy, C1-6 alkoxy, amido, (lower alkyl)amide, or amino optionally mono- or di-substituted with C1-6 alkyl;
(ii) C3-7 cycloalkyl or C4-10 alkylcycloalkyl, all optionally substituted with carboxyl, (C1-6 alkoxy)carbonyl, amido, (lower alkyl)amide, or amino optionally mono- or di-substituted with C1-6 alkyl; and R5 is H or methyl; or
R4 is
(iii) amino optionally mono- or di-substituted with C1-3 alkyl; or
(iv) C6 or C10 aryl or C7-16 aralkyl, all optionally substituted with C1-6 alkyl, hydroxy, amino or amido optionally substituted with C1-6 alkyl; or
(v) Het optionally substituted with C1-6 alkyl, hydroxy, amino or amido; or
B is a thioamide derivative of formula R4—NH—C(S)—; wherein R4 is:
(i) C1-10 alkyl; or (ii) C3-7 cycloalkyl; or
Y is H;
R2 is 1-naphtylmethoxy; or quinolinoxy 1-aphthylmethoxy unsubstituted, mono- or di-substituted with R21 as defined above, or
wherein R21A is C1-6 alkyl; C1-6 alkoxy; C6, C10 aryl or Het; lower thioalkyl; halo; amino optionally mono-substituted with C1-6 alkyl; or C6, C10 aryl, C7-16 aralkyl or Het, optionally substituted with R22 wherein R22 is C1-6 alkyl, C1-6 alkoxy, amido, (lower alkyl)amide, amino optionally mono- or di-substituted with C1-6 alkyl, or Het; and R21B is C1-6 alkyl, C1-6 alkoxy, amino, di(lower alkyl)amino, (lower alkyl)amide, NO2, OH, halo, trifluoromethyl, or carboxyl;
R1 is ethyl, vinyl, cyclopropyl, 1 or 2-bromoethyl or 1 or 2-bromovinyl.
47. A compound of formula I according to claim 46 , wherein
B is an amide derivative of formula R4—NH—C(O)— wherein R4 is
i) C1-10 alkyl optionally substituted with carboxyl, C1-6 alkanoyl, hydroxy, C1-6 alkoxy, amido, (lower alkyl)amide, or amino optionally mono- or di-substituted with C1-6 alkyl;
(ii) C3-7 cycloalkyl or C4-10 alkylcycloalkyl, all optionally substituted with carboxyl, (C1-6 alkoxy)carbonyl, amido, (lower alkyl)amide, or amino optionally mono- or di-substituted with C1-6 alkyl; or
(iv) C6 or C10 aryl or C7-16 aralkyl optionally substituted with C1-6 alkyl, hydroxy, amino or amido;
R3 is the side chain of Tbg, Chg or Val;
wherein B, R3, R2 are as defined below:
Tab 1
Cpd # B R3 R2
101 Boc cHex —O—CH2-1-naphthyl;
102 cHex —O—CH2-1-naphthyl;
103 cHex —O—CH2-1-naphthyl;
104 cHex —O—CH2-1-naphthyl;
105 cHex —O—CH2-1-naphthyl;
106 Boc cHex
107 cHex —O—CH2-1-naphthyl;
108 Boc iPr
109 acetyl cHex
110 Boc i-Pr
and 111 Boc t-Bu
!
49. Compound #111 according to claim 48 .
51. Compound #203 according to claim 49 .
wherein B, R3, R2 and R1 are as defined below:
Table 3 R1
Cpd # B R3 R2 syn to carboxyl
301 Boc cHex —O—CH2-1-naphthyl ethyl;
302 iPr —O—CH2-1-naphthyl ethyl;
303 cHex —O—CH2-1-naphthyl ethyl;
304 Boc cHex ethyl;
305 Boc cHex —O—CH2-1-naphthyl vinyl;
306 Boc cHex vinyl;
307 Boc cHex vinyl;
308 Boc cHex vinyl;
309 Boc cHex vinyl;
310 Boc cHex vinyl;
311 Boc cHex vinyl;
312 Boc cHex vinyl;
313 Boc cHex vinyl;
314 Boc cHex vinyl;
315 Boc cHex vinyl;
316 Acetyl cHex vinyl;
317 Boc cHex vinyl;
318 CF3—C(O)— i-Pr vinyl;
319 cHex vinyl;
320 cHex vinyl;
321 Boc t-Bu vinyl;
322 Boc t-Bu vinyl;
323 Boc t-Bu
324 Boc t-Bu vinyl;
325 Boc t-Bu
326 Boc t-Bu vinyl;
327 t-Bu Vinyl;
328 Boc t-Bu vinyl;
329 Boc t-Bu vinyl;
330 Boc t-Bu vinyl;
331 t-Bu Vinyl;
332 Boc t-Bu ethyl;
333 t-Bu vinyl;
and 334 t-Bu vinyl .
!
53. A compound according to claim 52 , selected from the group consisting of compound #307, 314, 317, 319, 321, 324, 325, and 326, 327, 329, 331, 332, 333, and 334 .
55. A compound according to claim 54 , selected from the group consisting of compound #:403, 405, and 406.
57. A compound according to claim 56 , selected from the group consisting of compound #: 501, 509, and 510.
wherein R3, R21A and R21B are as defined below:
Table 6
Cpd # R3 R21A R21B
601 i-Pr Ph 7-OMe;
602 t-Bu Ph 8-OMe, 7-OMe;
603 i-Pr Ph 7-ethyl;
604 t-Bu — 7-OMe;
605 t-Bu Ph 7-O-iPr;
606 t-Bu — 7-Cl;
607 i-Pr — 7-Cl;
608 CH2-iPr — 7-Cl;
609 t-Bu —;
610 t-Bu Cl —;
611 t-Bu Ph 7-N(Me)2;
612 t-Bu —;
613 t-Bu —;
614 t-Bu —;
615 t-Bu — 7-N(Me)2;
616 t-Bu —;
617 t-Bu —;
618 t-Bu —;
619 t-Bu —;
620 t-Bu —;
621 t-Bu —;
622 t-Bu —;
623 t-Bu MeO— —;
624 t-Bu (Me2)N— —;
625 t-Bu Ph 7-S(Me);
626 t-Bu Ph 7-Br;
627 t-Bu Ph 7-F;
628 t-Bu 7-N(Me)2;
629 t-Bu 7-N(Me)2;
and 630 t-Bu 7-N(Et)2;
!
59. A compound according to claim 58 , selected from the group consisting of compound #: 601, 602, 603, 604, 605, 606, 607, 610, 611, 612, 615, 616, 617, 620, 621, 622, 625, 626, 627, 628, 629, and 630.
wherein R3 and R21A are as defined below:
Table 7
Cpd # R3 R21A
701 t-Bu
702 t-Bu
703 t-Bu
704 t-Bu
705 t-Bu
706 t-Bu
707 t-Bu
708 t-Bu Ph-N(Me)—;
709 t-Bu
710 t-Bu HOOC—;
711 t-Bu
712 t-Bu (Me)2N;
713 t-Bu
714 t-Bu
715 t-Bu
716 t-Bu
717 t-Bu
718 t-Bu NH2;
719 t-Bu
720 t-Bu
721 t-Bu
722 t-Bu
723 t-Bu
724 t-Bu
725 t-Bu
726 t-Bu i-Pr;
727 t-Bu
728 t-Bu
729 t-Bu
730 t-Bu
731 t-Bu
732 t-Bu
733 t-Bu
734 t-Bu
735 t-Bu
736 t-Bu t-Bu;
and 737 t-Bu CHex.
!
61. A compound according to claim 60 , selected from the group consisting of compound #: 701, 702, 703, 704, 705, 706, 707, 708, 709, and 711 to 737.
62. A compound according to claim 45 represented by the formula:
Table 8
Cpd # B R3 R22
801 t-Bu —;
802 t-Bu —;
803 t-Bu —;
804 t-Bu —;
805 Ac t-Bu —;
806 t-Bu —;
807 t-Bu —;
808 t-Bu —;
809 i-Pr —;
810 t-Bu —;
811 Boc t-Bu 4-Cl;
812 t-Bu —;
813 t-Bu —;
814 Boc t-Bu 2-Cl;
815 Boc t-Bu 3-Cl;
816 t-Bu —;
817 t-Bu —;
818 t-Bu —;
819 i-Pr —;
820 i-Pr —;
821 i-Pr —;
822 i-Pr —;
823 Boc t-Bu 2-OMe;
824 Boc t-Bu 3-OMe;
825 Boc t-Bu 4-OMe;
826 i-Pr —;
827 t-Bu —;
828 i-Pr —;
829 t-Bu —;
830 t-Bu —;
831 t-Bu —;
832 t-Bu —;
833 t-Bu —;
834 i-Pr —;
835 t-Bu —;
836 i-Pr —;
837 i-Pr —;
838 i-Pr —;
839 i-Pr —;
840 i-Pr —;
841 Boc t-Bu 2-Me;
842 Boc t-Bu 3-Me;
843 Boc t-Bu 4-Me;
844 t-Bu 4-OMe;
845 i-Pr —;
846 i-Pr —;
847 Boc cHex —;
848 Boc —;
849 Boc —;
850 Boc —;
851 Boc —;
852 Boc —;
853 Boc —;
854 i-Pr —;
855 i-Pr —;
856 i-Pr —;
857 t-Bu —;
858 t-Bu —;
859 i-Pr —;
860 i-Pr —;
861 i-Pr —;
862 i-Pr —;
863 i-Pr —;
864 i-Pr —;
865 t-Bu —;
866 t-Bu —;
867 t-Bu —;
868 t-Bu —;
869 t-Bu —;
870 t-Bu —;
871 t-Bu —;
872 t-Bu —;
and 873 t-Bu —.
!
63. A compound according to claim 62 , selected from the group consisting of compound #: 801 to 825, 827 to 858, and 860 to 873.
66. A pharmaceutical composition comprising an anti-hepatitis C virally effective amount of a compound of formula I according to claim 1 , or a therapeutically acceptable salt or ester therof, in admixture with a pharmaceutically acceptable carrier medium or auxiliary agent.
67. A method of treating a hepatitis C viral infection in a mammal comprising administering to the mammal an anti-hepatitis C virally effective amount of the compound of formula I according to claim 1 , or a therapeutically acceptable salt or ester thereof.
68. A method of treating a hepatitis C viral infection in a mammal comprising administering to the mammal an anti-hepatitis C virally effective amount of the composition according to claim 66 .
69. A method of inhibiting the replication of hepatitis C virus comprising exposing the virus to a hepatitis C viral NS3 protease inhibiting amount of the compound of formula I according to claim 1 , or a therapeutically acceptable salt or ester thereof.
70. A method of treating a hepatitis C viral infection in a mammal comprising administering thereto an anti-hepatitis C virally effective amount of a combination of the compound of formula I according to claim 1 , or a therapeutically acceptable salt or ester thereof with another anti-HCV agent.
71. A method according to claim 70 , wherein said other anti-HCV agent is selected from the group consisting of: α- or β-interferon, ribavirin and amantadine.
72. A method according to claim 70 , wherein said other anti-HCV agent comprises an inhibitor or other targets in the HCV life cycle, selected from: helicase, polymerase, metalloprotease or IRES.
73. A process for the preparation of a peptide analog compound of formula (I) according to claim 1 wherein P1 is a substituted aminocyclopropyl carboxylic acid residue as shown for the P1 part of formula (I), comprising the step of:
coupling a peptide selected from the group consisting of: APG-P3-P2; or and APG-P2;
74. A process for the preparation of: a peptide analog compound of formula (I) according to claim 1 , this process comprising the step of:
76. A process according to claim 73 , 74 or 75 wherein said carboxyl protecting group (CPG) is selected from the group consisting of: alkyl esters, aralkyl esters, and esters being cleavable by mild base treatment or mild reductive means.
77. Method of preparing a composition for treating a hepatitis C viral infection in a mammal comprising combining an anti-hepatitis C virally effective amount of the compound of formula I according to claim 1 , or a therapeutically acceptable salt or ester thereof, with a pharmaceutically acceptable carrier medium or auxiliary agent.
78. Method of preparing a composition for inhibiting the replication of hepatitis C virus comprising combining a hepatitis C viral NS3 protease inhibiting amount of the compound of formula I according to claim 1 , or a therapeutically acceptable salt or ester thereof, with a pharmaceutically acceptable carrier medium or auxiliary agent.
79. Method of preparing a composition for treating a hepatitis C viral infection in a mammal comprising combining an anti-hepatitis C virally effective amount of a combination of the compound of formula I according to claim 1 , or a therapeutically acceptable salt or ester thereof, and an interferon with a pharmaceutically acceptable carrier medium or auxiliary agent.
wherein
R21A is C1-6 alkyl; C1-6 alkoxy; lower thioalkyl; halo; amino optionally mono-substituted with C1-6 alkyl; or C6, C10 aryl, C7-16 aralkyl, or Het, said aryl, aralkyl or Het optionally substituted with R22 wherein R22 is C1-6 alkyl, C1-6 alkoxy, amido, (lower alkyl)amide, amino optionally mono- or di-substituted with C1-6 alkyl, or Het; and
R21B is C1-6 alkyl, C1-6 alkoxy, amino, di(lower alkyl) amino, (lower alkyl)amide, NO2, OH, halo, trifluoromethyl, or carboxyl;
R1 is ethyl, vinyl, cyclopropyl, 1 or 2-bromoethyl or 1 or 2-bromovinyl;
APG is an amino protecting group selected from: 1) acyl groups, 2) aromatic carbamate groups, 3) aliphatic carbamate groups, 4) cyclic alkyl carbamate groups, 5) alkyl groups, 6) trialkylsilyl, and 7) thiol containing groups; and
CPG is a carboxyl protecting group selected from: alkyl esters, aralkyl esters, and esters being cleavable by mild base treatment or mild reductive means.
81. The compound according to claim 80 , wherein said carboxyl protecting group is selected from: methyl, trimethylsilylethyl, t-butyl, benzyl, substituted benzyl, trichloroethyl and phenacyl esters.
82. The compound according to claim 80 , wherein said amino protecting group is selected from: formyl, trifluoroacetyl, phthalyl, p-toluenesulfonyl, as benzyloxycarbonyl, substituted benzyloxycarbonyl, 9-fluorenylmethyloxycarbonyl, tert-butyloxycarbonyl, ethoxycarbonyl, diisopropylmethoxycarbonyl, allyloxycarbonyl, cyclopentyloxycarbonyl, adamantyloxycarbonyl, triphenylmethyl, benzyl, trimethylsilyl, phenylthiocarbonyl and dithiasuccinoyl.
83. The compound according to claim 80 , wherein said amino protecting group is selected from: tert-butyloxycarbonyl and 9-fluorenylmethyloxycarbonyl.
84. A compound of formula I according to claim 80 , wherein R21A is C6, C10 aryl or Het, all optionally substituted with R22 as defined in claim 80 .
wherein
R22A is C1-6 alkyl; C1-6 alkoxy; or halo; and R21B is C1-6 alkyl, C1-6 alkoxy, amino, di(lower alkyl)amino, (lower alkyl)amide, NO2, OH, halo, trifluoromethyl, or carboxyl;
R1 is ethyl, vinyl, cyclopropyl, 1 or 2-bromoethyl or 1 or 2-bromovinyl;
APG is an amino protecting group selected from: 1) acyl groups, 2) aromatic carbamate groups, 3) aliphatic carbamate groups, 4) cyclic alkyl carbamate groups, 5) alkyl groups, 6) trialkylsilyl, and 7) thiol containing groups; and
CPG is a carboxyl protecting group selected from: alkyl esters, aralkyl esters, and esters being cleavable by mild base treatment or mild reductive means.
wherein R22B is C1-6 alkyl, amino optionally mono-substituted with C1-6 alky, amido, or (lower alkyl)amide; and R21B is C1-6 alkyl, C1-6 alkoxy, amino, di(lower alkyl) amino, (lower alkyl)amide, NO2, OH, halo, trifluoromethyl, or carboxyl.
88. A compound of formula I according to claim 86 or 87 , wherein R21B is C1-6 alkoxy, or di(lower alkyl)amino.
89. A compound of formula I according to claim 86 or 87 , wherein R21B is methoxy.
90. A compound of formula I according to claim 80 , wherein R1 is vinyl.
95. A compound of formula I according to claim 94 , wherein R1 is ethyl, hence the asymmetric carbon atoms at positions 1 and 2 have the R,R configuration.
96. A compound of formula I according to claim 94 , wherein R1 is vinyl, hence the asymmetric carbon atoms at positions 1 and 2 have the R,S configuration.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/119,609 USRE42164E1 (en) | 1998-08-10 | 2008-05-13 | Hepatitis C inhibitor tri-peptides |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US9593198P | 1998-08-10 | 1998-08-10 | |
US13238699P | 1999-05-04 | 1999-05-04 | |
US09/368,866 US6323180B1 (en) | 1998-08-10 | 1999-08-05 | Hepatitis C inhibitor tri-peptides |
US09/849,057 US6410531B1 (en) | 1998-08-10 | 2001-05-04 | Hepatitis C inhibitor tri-peptides |
US10/091,293 US6534523B1 (en) | 1998-08-10 | 2002-03-05 | Hepatitis C inhibitor tri-peptides |
US12/119,609 USRE42164E1 (en) | 1998-08-10 | 2008-05-13 | Hepatitis C inhibitor tri-peptides |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/091,293 Reissue US6534523B1 (en) | 1998-08-10 | 2002-03-05 | Hepatitis C inhibitor tri-peptides |
Publications (1)
Publication Number | Publication Date |
---|---|
USRE42164E1 true USRE42164E1 (en) | 2011-02-22 |
Family
ID=26790767
Family Applications (11)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/368,866 Expired - Lifetime US6323180B1 (en) | 1998-08-10 | 1999-08-05 | Hepatitis C inhibitor tri-peptides |
US09/660,030 Expired - Lifetime US6268207B1 (en) | 1998-08-10 | 2000-09-12 | Enzymatic resolution of 1-amino-2-vinylcyclopropyl caboxylic acid methyl ester |
US09/675,398 Ceased US6329379B1 (en) | 1998-08-10 | 2000-09-29 | Hepatitis C inhibitor tri-peptides |
US09/703,751 Ceased US6329417B1 (en) | 1998-08-10 | 2000-11-01 | Hepatitis C inhibitor tri-pepitides |
US09/827,976 Expired - Lifetime US6420380B2 (en) | 1998-08-10 | 2001-04-06 | Hepatitis C inhibitor tri-peptides |
US09/849,057 Expired - Lifetime US6410531B1 (en) | 1998-08-10 | 2001-05-04 | Hepatitis C inhibitor tri-peptides |
US10/091,293 Ceased US6534523B1 (en) | 1998-08-10 | 2002-03-05 | Hepatitis C inhibitor tri-peptides |
US11/241,899 Expired - Lifetime USRE40525E1 (en) | 1998-08-10 | 2005-09-30 | Hepatitis C inhibitor tri-peptides |
US12/042,627 Expired - Lifetime USRE41894E1 (en) | 1998-08-10 | 2008-03-05 | Hepatitis C inhibitor tri-peptides |
US12/118,926 Expired - Lifetime USRE41356E1 (en) | 1998-08-10 | 2008-05-12 | Hepatitis C inhibitor tri-peptides |
US12/119,609 Expired - Lifetime USRE42164E1 (en) | 1998-08-10 | 2008-05-13 | Hepatitis C inhibitor tri-peptides |
Family Applications Before (10)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/368,866 Expired - Lifetime US6323180B1 (en) | 1998-08-10 | 1999-08-05 | Hepatitis C inhibitor tri-peptides |
US09/660,030 Expired - Lifetime US6268207B1 (en) | 1998-08-10 | 2000-09-12 | Enzymatic resolution of 1-amino-2-vinylcyclopropyl caboxylic acid methyl ester |
US09/675,398 Ceased US6329379B1 (en) | 1998-08-10 | 2000-09-29 | Hepatitis C inhibitor tri-peptides |
US09/703,751 Ceased US6329417B1 (en) | 1998-08-10 | 2000-11-01 | Hepatitis C inhibitor tri-pepitides |
US09/827,976 Expired - Lifetime US6420380B2 (en) | 1998-08-10 | 2001-04-06 | Hepatitis C inhibitor tri-peptides |
US09/849,057 Expired - Lifetime US6410531B1 (en) | 1998-08-10 | 2001-05-04 | Hepatitis C inhibitor tri-peptides |
US10/091,293 Ceased US6534523B1 (en) | 1998-08-10 | 2002-03-05 | Hepatitis C inhibitor tri-peptides |
US11/241,899 Expired - Lifetime USRE40525E1 (en) | 1998-08-10 | 2005-09-30 | Hepatitis C inhibitor tri-peptides |
US12/042,627 Expired - Lifetime USRE41894E1 (en) | 1998-08-10 | 2008-03-05 | Hepatitis C inhibitor tri-peptides |
US12/118,926 Expired - Lifetime USRE41356E1 (en) | 1998-08-10 | 2008-05-12 | Hepatitis C inhibitor tri-peptides |
Country Status (43)
Families Citing this family (423)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR9712544B1 (en) | 1996-10-18 | 2013-10-22 | SERINE PROTEASE INHIBITORS, PHARMACEUTICAL COMPOSITION UNDERSTANDING THE SAME AND ITS USES | |
US6767991B1 (en) | 1997-08-11 | 2004-07-27 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis C inhibitor peptides |
US6323180B1 (en) * | 1998-08-10 | 2001-11-27 | Boehringer Ingelheim (Canada) Ltd | Hepatitis C inhibitor tri-peptides |
UA74546C2 (en) * | 1999-04-06 | 2006-01-16 | Boehringer Ingelheim Ca Ltd | Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition |
US6608027B1 (en) | 1999-04-06 | 2003-08-19 | Boehringer Ingelheim (Canada) Ltd | Macrocyclic peptides active against the hepatitis C virus |
SK18862001A3 (en) * | 1999-06-25 | 2002-11-06 | Basf Aktiengesellschaft | Corynebacterium glutamicum genes encoding metabolic pathway proteins |
EP1268525B1 (en) | 2000-04-05 | 2008-12-31 | Schering Corporation | Macrocyclic ns3-serine protease inhibitors of hepatitis c virus comprising n-cyclic p2 moieties |
AR030558A1 (en) | 2000-04-19 | 2003-08-27 | Schering Corp | MACROCICLIC COMPOUNDS, WHICH INCLUDE ENANTIOMERS, STEROISOMERS, ROTAMERS AND TAUTOMEROS, SALTS AND PHARMACEUTICALLY ACCEPTABLE SOLVATOS, PHARMACEUTICAL COMPOSITION, A METHOD FOR THE PREPARATION AND THE USE OF SUCH COMPUTERS FOR THE INHIBITION, THE SERIES |
AU2001259511A1 (en) * | 2000-05-05 | 2001-11-20 | Smith Kline Beecham Corporation | Novel anti-infectives |
PE20011350A1 (en) | 2000-05-19 | 2002-01-15 | Vertex Pharma | PROPHARMAC OF AN INHIBITOR OF INTERLEUKIN-1ß CONVERTER ENZYME (ICE) |
RU2003105221A (en) | 2000-07-21 | 2004-09-20 | Шеринг Корпорейшн (US) | NEW PEPTIDES AS INHIBITORS OF NS3-SERIN PROTEASES OF HEPATITIS C VIRUS |
AR029851A1 (en) | 2000-07-21 | 2003-07-16 | Dendreon Corp | NEW PEPTIDES AS INHIBITORS OF NS3-SERINA PROTEASA DEL VIRUS DE HEPATITIS C |
AR034127A1 (en) | 2000-07-21 | 2004-02-04 | Schering Corp | IMIDAZOLIDINONES AS INHIBITORS OF NS3-SERINA PROTEASA OF THE HEPATITIS C VIRUS, PHARMACEUTICAL COMPOSITION, A METHOD FOR THEIR PREPARATION, AND THE USE OF THE SAME FOR THE MANUFACTURE OF A MEDICINAL PRODUCT |
AU2001276988B2 (en) | 2000-07-21 | 2007-01-25 | Dendreon Corporation | Peptides as NS3-serine protease inhibitors of hepatitis C virus |
SV2003000617A (en) | 2000-08-31 | 2003-01-13 | Lilly Co Eli | INHIBITORS OF PROTEASA PEPTIDOMIMETICA REF. X-14912M |
US6846806B2 (en) | 2000-10-23 | 2005-01-25 | Bristol-Myers Squibb Company | Peptide inhibitors of Hepatitis C virus NS3 protein |
BR0115447A (en) | 2000-11-20 | 2005-10-18 | Bristol Myers Squibb Co | Hepatitis C Tripeptide Inhibitors |
WO2002048172A2 (en) | 2000-12-12 | 2002-06-20 | Schering Corporation | Diaryl peptides as ns3-serine protease inhibitors of hepatits c virus |
RS50236B (en) | 2001-01-22 | 2009-07-15 | Merck & Co.Inc., | Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase |
NZ530000A (en) | 2001-07-11 | 2007-03-30 | Vertex Pharma | Peptidomimetic bridged bicyclic serine protease inhibitors |
WO2003024747A1 (en) | 2001-09-14 | 2003-03-27 | Honda Giken Kogyo Kabushiki Kaisha | Front grill impact-absorbing structure for a vehicle |
MXPA04003825A (en) * | 2001-10-24 | 2004-07-08 | Vertex Pharma | Inhibitors of serine protease, particularly hepatitis c virus ns3-ns4a protease, incorporating a fused ring system. |
JP2005511572A (en) * | 2001-11-02 | 2005-04-28 | グラクソ グループ リミテッド | Acyl dihydropyrrole derivatives as HCV inhibitors |
US6867185B2 (en) * | 2001-12-20 | 2005-03-15 | Bristol-Myers Squibb Company | Inhibitors of hepatitis C virus |
MXPA04007163A (en) | 2002-01-23 | 2004-10-29 | Schering Corp | Proline compounds as ns3-serine protease inhibitors for use in treatment of hepatites c virus infection. |
US7119072B2 (en) * | 2002-01-30 | 2006-10-10 | Boehringer Ingelheim (Canada) Ltd. | Macrocyclic peptides active against the hepatitis C virus |
US6642204B2 (en) * | 2002-02-01 | 2003-11-04 | Boehringer Ingelheim International Gmbh | Hepatitis C inhibitor tri-peptides |
US7091184B2 (en) * | 2002-02-01 | 2006-08-15 | Boehringer Ingelheim International Gmbh | Hepatitis C inhibitor tri-peptides |
CA2370396A1 (en) * | 2002-02-01 | 2003-08-01 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis c inhibitor tri-peptides |
CA2369970A1 (en) * | 2002-02-01 | 2003-08-01 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis c inhibitor tri-peptides |
WO2003087092A2 (en) | 2002-04-11 | 2003-10-23 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly hepatitis c virus ns3 - ns4 protease |
MY140680A (en) * | 2002-05-20 | 2010-01-15 | Bristol Myers Squibb Co | Hepatitis c virus inhibitors |
AU2003301959A1 (en) * | 2002-05-20 | 2004-06-03 | Bristol-Myers Squibb Company | Substituted cycloalkyl p1' hepatitis c virus inhibitors |
ATE503764T1 (en) * | 2002-05-20 | 2011-04-15 | Bristol Myers Squibb Co | HEPATITIS C VIRUS INHIBITORS |
ATE481106T1 (en) * | 2002-05-20 | 2010-10-15 | Bristol Myers Squibb Co | HETEROCYCLIC SULFONAMIDE HEPATITIS C VIRUS INHIBITORS |
KR100457857B1 (en) * | 2002-05-23 | 2004-11-18 | (주) 비엔씨바이오팜 | 2-[2-(3-Indolyl)ethylamino]pyridine derivatives, its preparation and antiviral pharmaceutical composition comprising the same |
RS114004A (en) | 2002-06-28 | 2007-02-05 | Idenix (Cayman) Limited, | Modified 2' and 3'-nucleoside produgs for treating flaviridae infections |
US20040033959A1 (en) * | 2002-07-19 | 2004-02-19 | Boehringer Ingelheim Pharmaceuticals, Inc. | Pharmaceutical compositions for hepatitis C viral protease inhibitors |
AU2003261434A1 (en) * | 2002-08-12 | 2004-02-25 | Bristol-Myers Squibb Company | Iminothiazolidinones as inhibitors of hcv replication |
EP1408031A1 (en) * | 2002-10-09 | 2004-04-14 | 3 D Gene Pharma | Pyrolidine derivatives useful in treatment of hepatitis C virus infection |
EP1554274B1 (en) * | 2002-10-24 | 2008-12-24 | Glaxo Group Limited | 1-acyl-pyrrolidine derivatives for the treatment of viral infections |
US20050075279A1 (en) * | 2002-10-25 | 2005-04-07 | Boehringer Ingelheim International Gmbh | Macrocyclic peptides active against the hepatitis C virus |
US7601709B2 (en) | 2003-02-07 | 2009-10-13 | Enanta Pharmaceuticals, Inc. | Macrocyclic hepatitis C serine protease inhibitors |
CA2516016C (en) * | 2003-03-05 | 2012-05-29 | Boehringer Ingelheim International Gmbh | Hepatitis c inhibiting compounds |
DE602004029866D1 (en) * | 2003-03-05 | 2010-12-16 | Boehringer Ingelheim Pharma | PEPTIDE ANALOGUE WITH INHIBITORAL EFFECT ON HEPATITIS C |
KR100960802B1 (en) * | 2003-03-08 | 2010-06-01 | 주식회사유한양행 | Ns3 protease inhibitors for the treatment of hepatitis c virus infection |
US7148347B2 (en) * | 2003-04-10 | 2006-12-12 | Boehringer Ingelheim International Gmbh | Process for preparing macrocyclic compounds |
WO2004094452A2 (en) * | 2003-04-16 | 2004-11-04 | Bristol-Myers Squibb Company | Macrocyclic isoquinoline peptide inhibitors of hepatitis c virus |
US6846836B2 (en) | 2003-04-18 | 2005-01-25 | Bristol-Myers Squibb Company | N-substituted phenylurea inhibitors of mitochondrial F1F0 ATP hydrolase |
JP4778893B2 (en) | 2003-04-18 | 2011-09-21 | エナンタ ファーマシューティカルズ インコーポレイテッド | Quinoxalinyl macrocyclic hepatitis C serine protease inhibitor |
US7176208B2 (en) | 2003-04-18 | 2007-02-13 | Enanta Pharmaceuticals, Inc. | Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors |
CN1791599A (en) * | 2003-05-21 | 2006-06-21 | 贝林格尔.英格海姆国际有限公司 | Hepatitis c inhibitor compounds |
EP2345661A1 (en) | 2003-05-30 | 2011-07-20 | Pharmasset, Inc. | Modified fluorinated nucleoside analogues |
US7273851B2 (en) * | 2003-06-05 | 2007-09-25 | Enanta Pharmaceuticals, Inc. | Tri-peptide hepatitis C serine protease inhibitors |
WO2004113365A2 (en) * | 2003-06-05 | 2004-12-29 | Enanta Pharmaceuticals, Inc. | Hepatitis c serine protease tri-peptide inhibitors |
US7125845B2 (en) * | 2003-07-03 | 2006-10-24 | Enanta Pharmaceuticals, Inc. | Aza-peptide macrocyclic hepatitis C serine protease inhibitors |
DK1658302T3 (en) | 2003-07-25 | 2010-11-22 | Idenix Pharmaceuticals Inc | Purine nucleoside analogues for the treatment of diseases caused by Flavirividae, including hepatitis C |
JP4527722B2 (en) | 2003-08-26 | 2010-08-18 | シェーリング コーポレイション | Novel peptidomimetic NS3-serine protease inhibitor of hepatitis C virus |
US8025899B2 (en) | 2003-08-28 | 2011-09-27 | Abbott Laboratories | Solid pharmaceutical dosage form |
US8377952B2 (en) | 2003-08-28 | 2013-02-19 | Abbott Laboratories | Solid pharmaceutical dosage formulation |
MY148123A (en) | 2003-09-05 | 2013-02-28 | Vertex Pharma | Inhibitors of serine proteases, particularly hcv ns3-ns4a protease |
CA2536182C (en) * | 2003-09-22 | 2012-07-24 | Boehringer Ingelheim International Gmbh | Macrocyclic peptides active against the hepatitis c virus |
JP4525982B2 (en) | 2003-09-26 | 2010-08-18 | シェーリング コーポレイション | Macrocyclic inhibitor of NS3 serine protease of hepatitis C virus |
KR20060130027A (en) | 2003-10-10 | 2006-12-18 | 버텍스 파마슈티칼스 인코포레이티드 | Inhibitors of serine proteases, particularly hcv ns3-ns4a protease |
RS20060259A (en) | 2003-10-14 | 2008-08-07 | Intermune Inc., | Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of hcv replication |
US7491794B2 (en) * | 2003-10-14 | 2009-02-17 | Intermune, Inc. | Macrocyclic compounds as inhibitors of viral replication |
US7494660B2 (en) | 2003-10-27 | 2009-02-24 | Vertex Pharmaceuticals Incorporated | HCV NS3-NS4A protease resistance mutants |
WO2005043118A2 (en) | 2003-10-27 | 2005-05-12 | Vertex Pharmaceuticals Incorporated | Drug discovery method |
EP1944042A1 (en) | 2003-10-27 | 2008-07-16 | Vertex Pharmceuticals Incorporated | Combinations for HCV treatment |
US20050119318A1 (en) * | 2003-10-31 | 2005-06-02 | Hudyma Thomas W. | Inhibitors of HCV replication |
US7132504B2 (en) | 2003-11-12 | 2006-11-07 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
MXPA06005683A (en) * | 2003-11-20 | 2006-12-14 | Schering Corp | Depeptidized inhibitors of hepatitis c virus ns3 protease. |
US7135462B2 (en) | 2003-11-20 | 2006-11-14 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7309708B2 (en) | 2003-11-20 | 2007-12-18 | Birstol-Myers Squibb Company | Hepatitis C virus inhibitors |
EP1699558B1 (en) * | 2003-12-08 | 2009-03-11 | Boehringer Ingelheim International GmbH | Removal of ruthenium by-product by supercritical fluid processing |
CN1901971A (en) | 2003-12-15 | 2007-01-24 | 日本烟草产业株式会社 | Cyclopropane compounds and pharmaceutical use thereof |
GB0500020D0 (en) | 2005-01-04 | 2005-02-09 | Novartis Ag | Organic compounds |
ES2358333T3 (en) | 2004-01-21 | 2011-05-09 | Boehringer Ingelheim International Gmbh | MACROCYCLIC PEPTIDES WITH ACTION AGAINST THE VIRUS OF HEPATITIS C. |
AR048401A1 (en) | 2004-01-30 | 2006-04-26 | Medivir Ab | HCV SERINE-PROTEASA NS3 INHIBITORS |
SE0400199D0 (en) * | 2004-01-30 | 2004-01-30 | Medivir Ab | HCV Protease Inhibitors |
AU2005212257A1 (en) | 2004-02-04 | 2005-08-25 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease |
US20050182252A1 (en) | 2004-02-13 | 2005-08-18 | Reddy K. R. | Novel 2'-C-methyl nucleoside derivatives |
EP1718608B1 (en) | 2004-02-20 | 2013-07-17 | Boehringer Ingelheim International GmbH | Viral polymerase inhibitors |
DE602005013922D1 (en) | 2004-02-24 | 2009-05-28 | Japan Tobacco Inc | CONDENSED HETEROTETRACYCLIC COMPOUNDS AND THEIR USE AS HCV POLYMERASE INHIBITOR |
US20070049593A1 (en) | 2004-02-24 | 2007-03-01 | Japan Tobacco Inc. | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor |
BRPI0508095A (en) | 2004-02-27 | 2007-07-17 | Schering Corp | compounds as inhibitors of hepatitis c virus ns3 serine protease |
KR20060124725A (en) | 2004-02-27 | 2006-12-05 | 쉐링 코포레이션 | Inhibitors of hepatitis c virus ns3 protease |
US7635694B2 (en) | 2004-02-27 | 2009-12-22 | Schering Corporation | Cyclobutenedione-containing compounds as inhibitors of hepatitis C virus NS3 serine protease |
JP2007525521A (en) * | 2004-02-27 | 2007-09-06 | シェーリング コーポレイション | Cyclobutenedione-containing compounds as inhibitors of hepatitis C virus NS3 serine protease |
NZ549223A (en) * | 2004-02-27 | 2010-10-29 | Schering Corp | Sulfur compounds as inhibitors of hepatitis C virus NS3 serine protease |
US7816326B2 (en) | 2004-02-27 | 2010-10-19 | Schering Corporation | Sulfur compounds as inhibitors of hepatitis C virus NS3 serine protease |
WO2005087730A1 (en) | 2004-02-27 | 2005-09-22 | Schering Corporation | 3,4-(cyclopentyl)-fused proline compounds as inhibitors of hepatitis c virus ns3 serine protease |
AU2005222056A1 (en) | 2004-02-27 | 2005-09-22 | Schering Corporation | Novel compounds as inhibitors of hepatitis C virus NS3 serine protease |
SI2399915T1 (en) * | 2004-03-12 | 2015-05-29 | Vertex Pharmaceuticals Incorporated | Process and intermediates for the preparation of aspartic acetal caspase inhibitors |
JP4654239B2 (en) | 2004-03-15 | 2011-03-16 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Method for preparing macrocyclic dipeptide suitable for treatment of hepatitis C virus infection |
EA012389B1 (en) * | 2004-03-30 | 2009-10-30 | Интермун, Инк. | Macrocyclic compounds as inhibitors of viral replication |
KR20070011451A (en) | 2004-05-05 | 2007-01-24 | 예일 유니버시티 | Novel antiviral helioxanthin analogs |
US7399749B2 (en) | 2004-05-20 | 2008-07-15 | Schering Corporation | Substituted prolines as inhibitors of hepatitis C virus NS3 serine protease |
EP1753775B1 (en) * | 2004-05-25 | 2012-12-26 | Boehringer Ingelheim International GmbH | Process for preparing acyclic hcv protease inhibitors |
EP1758453B1 (en) | 2004-06-15 | 2014-07-16 | Merck Sharp & Dohme Corp. | C-purine nucleoside analogs as inhibitors of rna-dependent rna viral polymerase |
CA2571079A1 (en) | 2004-06-24 | 2006-02-02 | Merck & Co., Inc. | Nucleoside aryl phosphoramidates for the treatment of rna-dependent rna viral infection |
US7705146B2 (en) * | 2004-06-28 | 2010-04-27 | Boehringer Ingelheim International Gmbh | Hepatitis C inhibitor peptide analogs |
BRPI0513426A (en) | 2004-07-16 | 2007-11-27 | Gilead Sciences Inc | Amino Acid Preparation Process Useful in the Preparation of Peptide Receptor Modulators |
UY29016A1 (en) * | 2004-07-20 | 2006-02-24 | Boehringer Ingelheim Int | ANALOGS OF INHIBITING DIPEPTIDES OF HEPATITIS C |
CA2573346C (en) * | 2004-07-20 | 2011-09-20 | Boehringer Ingelheim International Gmbh | Hepatitis c inhibitor peptide analogs |
CN101023094B (en) * | 2004-07-21 | 2011-05-18 | 法莫赛特股份有限公司 | Preparation of alkyl-substituted 2-deoxy-2-fluoro-d-ribofuranosyl pyrimidines and purines and their derivatives |
US7597884B2 (en) | 2004-08-09 | 2009-10-06 | Alios Biopharma, Inc. | Hyperglycosylated polypeptide variants and methods of use |
WO2006020580A2 (en) * | 2004-08-09 | 2006-02-23 | Alios Biopharma Inc. | Synthetic hyperglycosylated, protease-resistant polypeptide variants, oral formulations and methods of using the same |
WO2006026352A1 (en) | 2004-08-27 | 2006-03-09 | Schering Corporation | Acylsulfonamide compounds as inhibitors of hepatitis c virus ns3 serine protease |
AU2005285045B2 (en) * | 2004-09-14 | 2011-10-13 | Gilead Pharmasset Llc | Preparation of 2'fluoro-2'- alkyl- substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives |
WO2006030892A1 (en) * | 2004-09-17 | 2006-03-23 | Nippon Shinyaku Co., Ltd. | Process for production of heterocyclic compounds |
MX2007003812A (en) | 2004-10-01 | 2007-05-24 | Vertex Pharma | Hcv ns3-ns4a protease inhibition. |
US7659263B2 (en) | 2004-11-12 | 2010-02-09 | Japan Tobacco Inc. | Thienopyrrole compound and use thereof as HCV polymerase inhibitor |
US7323447B2 (en) | 2005-02-08 | 2008-01-29 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
WO2006096652A2 (en) | 2005-03-08 | 2006-09-14 | Boehringer Ingelheim International Gmbh | Process for preparing macrocyclic compounds |
AU2006242475B2 (en) | 2005-05-02 | 2011-07-07 | Merck Sharp & Dohme Corp. | HCV NS3 protease inhibitors |
US7592336B2 (en) * | 2005-05-10 | 2009-09-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
EA016071B1 (en) | 2005-05-13 | 2012-01-30 | Вирокем Фарма Инк. | Compounds and methods for the treatment or prevention of flavivirus infections |
WO2006130666A2 (en) * | 2005-06-02 | 2006-12-07 | Schering Corporation | Medicaments and methods combining a hcv protease inhibitor and an akr competitor |
US20070237818A1 (en) * | 2005-06-02 | 2007-10-11 | Malcolm Bruce A | Controlled-release formulation of HCV protease inhibitor and methods using the same |
AU2006252519B2 (en) | 2005-06-02 | 2012-08-30 | Merck Sharp & Dohme Corp. | HCV protease inhibitors in combination with food |
AU2006252553B2 (en) * | 2005-06-02 | 2012-03-29 | Merck Sharp & Dohme Corp. | Combination of HCV protease inhibitors with a surfactant |
KR20080033274A (en) | 2005-06-17 | 2008-04-16 | 노파르티스 아게 | Use of sanglifehrin in hcv |
US7608592B2 (en) | 2005-06-30 | 2009-10-27 | Virobay, Inc. | HCV inhibitors |
TWI449711B (en) * | 2005-06-30 | 2014-08-21 | Virobay Inc | Hcv inhibitors |
US7601686B2 (en) | 2005-07-11 | 2009-10-13 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
EP1910378B1 (en) * | 2005-07-20 | 2012-06-20 | Boehringer Ingelheim International GmbH | Hepatitis c inhibitor peptide analogs |
US7470664B2 (en) * | 2005-07-20 | 2008-12-30 | Merck & Co., Inc. | HCV NS3 protease inhibitors |
EP2305695A3 (en) | 2005-07-25 | 2011-07-27 | Intermune, Inc. | Macrocyclic inhibitors of Hepatitis C virus replication |
JP5230417B2 (en) | 2005-07-29 | 2013-07-10 | テイボテク・フアーマシユーチカルズ | Macrocycle inhibitor of hepatitis C virus |
TWI383980B (en) * | 2005-07-29 | 2013-02-01 | Tibotec Pharm Ltd | Macrocylic inhibitors of hepatitis c virus |
TWI382025B (en) | 2005-07-29 | 2013-01-11 | Tibotec Pharm Ltd | Macrocylic inhibitors of hepatitis c virus |
DK1919898T3 (en) | 2005-07-29 | 2011-05-02 | Tibotec Pharm Ltd | Macrocyclic inhibitors of hepatitis C virus |
CN101273030B (en) | 2005-07-29 | 2012-07-18 | 泰博特克药品有限公司 | Macrocyclic inhibitors of hepatitis C virus |
PE20070343A1 (en) | 2005-07-29 | 2007-05-12 | Medivir Ab | MACRO CYCLIC INHIBITORS OF HEPATITIS C VIRUS |
PE20070210A1 (en) | 2005-07-29 | 2007-04-16 | Tibotec Pharm Ltd | MACROCYCLIC COMPOUNDS AS INHIBITORS OF HEPATITIS C VIRUS |
EP1913015B1 (en) | 2005-07-29 | 2013-12-11 | Janssen R&D Ireland | Macrocyclic inhibitors of hepatitis c virus |
PE20070211A1 (en) | 2005-07-29 | 2007-05-12 | Medivir Ab | MACROCYCLIC COMPOUNDS AS INHIBITORS OF HEPATITIS C VIRUS |
AU2006275605B2 (en) * | 2005-08-01 | 2011-01-06 | Merck Sharp & Dohme Corp. | Macrocyclic peptides as HCV NS3 protease inhibitors |
NZ565540A (en) * | 2005-08-02 | 2011-06-30 | Vertex Pharma | Inhibitors of serine proteases |
EP1915054A4 (en) | 2005-08-09 | 2010-09-01 | Merck Sharp & Dohme | Ribonucleoside cyclic acetal derivatives for the treatment of rna-dependent rna viral infection |
JP5015154B2 (en) | 2005-08-12 | 2012-08-29 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Viral polymerase inhibitor |
US8399615B2 (en) | 2005-08-19 | 2013-03-19 | Vertex Pharmaceuticals Incorporated | Processes and intermediates |
EP2364970A1 (en) | 2005-08-19 | 2011-09-14 | Vertex Pharmaceuticals Incorporated | Processes and intermediates |
AR055395A1 (en) | 2005-08-26 | 2007-08-22 | Vertex Pharma | INHIBITING COMPOUNDS OF THE ACTIVITY OF SERINA PROTEASA NS3-NS4A OF HEPATITIS C VIRUS |
US7964624B1 (en) | 2005-08-26 | 2011-06-21 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases |
ES2364426T3 (en) | 2005-09-09 | 2011-09-02 | Boehringer Ingelheim International Gmbh | METAL PROCESS WITH CLOSURE OF THE RING FOR THE PREPARATION OF MACROCYCLIC PEPTIDES. |
BRPI0617274A2 (en) | 2005-10-11 | 2011-07-19 | Intermune Inc | compounds and methods for inhibiting hepatitis c viral replication |
US7772183B2 (en) | 2005-10-12 | 2010-08-10 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7741281B2 (en) | 2005-11-03 | 2010-06-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7705138B2 (en) | 2005-11-11 | 2010-04-27 | Vertex Pharmaceuticals Incorporated | Hepatitis C virus variants |
EP1951748B1 (en) | 2005-11-11 | 2013-07-24 | Vertex Pharmaceuticals, Inc. | Hepatitis c virus variants |
WO2007076034A2 (en) * | 2005-12-21 | 2007-07-05 | Abbott Laboratories | Anti-viral compounds |
CA2633760A1 (en) | 2005-12-21 | 2007-07-05 | Abbott Laboratories | Anti-viral compounds |
EP2345652A1 (en) | 2005-12-21 | 2011-07-20 | Abbott Laboratories | Antiviral compounds |
WO2007081517A2 (en) | 2005-12-21 | 2007-07-19 | Abbott Laboratories | Anti-viral compounds |
US7816348B2 (en) | 2006-02-03 | 2010-10-19 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
JP5436864B2 (en) | 2006-02-27 | 2014-03-05 | バーテックス ファーマシューティカルズ インコーポレイテッド | Co-crystal containing VX-950 and pharmaceutical composition containing the same |
CA2645072A1 (en) | 2006-03-08 | 2007-09-13 | Achillion Pharmaceuticals, Inc. | Substituted aminothiazole derivatives with anti-hcv activity |
EP1993994A2 (en) | 2006-03-16 | 2008-11-26 | Vertex Pharmceuticals Incorporated | Deuterated hepatitis c protease inhibitors |
CN101466727B (en) | 2006-04-11 | 2012-10-17 | 诺瓦提斯公司 | Hcv/hiv inhibitor and their uses |
GB0609492D0 (en) * | 2006-05-15 | 2006-06-21 | Angeletti P Ist Richerche Bio | Therapeutic agents |
RU2419626C2 (en) | 2006-05-23 | 2011-05-27 | Айрм Ллк | Compounds and compositions as canal activating protease inhibitors |
US8268776B2 (en) | 2006-06-06 | 2012-09-18 | Enanta Pharmaceuticals, Inc. | Macrocylic oximyl hepatitis C protease inhibitors |
US20080187516A1 (en) * | 2006-06-06 | 2008-08-07 | Ying Sun | Acyclic oximyl hepatitis c protease inhibitors |
US9526769B2 (en) | 2006-06-06 | 2016-12-27 | Enanta Pharmaceuticals, Inc. | Macrocylic oximyl hepatitis C protease inhibitors |
US7728148B2 (en) * | 2006-06-06 | 2010-06-01 | Enanta Pharmaceuticals, Inc. | Acyclic oximyl hepatitis C protease inhibitors |
GB0612423D0 (en) * | 2006-06-23 | 2006-08-02 | Angeletti P Ist Richerche Bio | Therapeutic agents |
UY30437A1 (en) * | 2006-06-26 | 2008-01-31 | Enanta Pharm Inc | QUINOXALINIL MACROCECLIC INHIBITORS OF SERINE PROTEASE VIRUS OF HEPATITIS C |
RU2008152171A (en) | 2006-07-05 | 2010-08-10 | Интермьюн, Инк. (Us) | NEW HEPATITIS C VIRAL REPLICATION INHIBITORS |
EP2049474B1 (en) | 2006-07-11 | 2015-11-04 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
US7718612B2 (en) * | 2007-08-02 | 2010-05-18 | Enanta Pharmaceuticals, Inc. | Pyridazinonyl macrocyclic hepatitis C serine protease inhibitors |
US20090035267A1 (en) * | 2007-07-31 | 2009-02-05 | Moore Joel D | Acyclic, pyridazinone-derived hepatitis c serine protease inhibitors |
US7635683B2 (en) * | 2006-08-04 | 2009-12-22 | Enanta Pharmaceuticals, Inc. | Quinoxalinyl tripeptide hepatitis C virus inhibitors |
US7687459B2 (en) * | 2006-08-11 | 2010-03-30 | Enanta Pharmaceuticals, Inc. | Arylalkoxyl hepatitis C virus protease inhibitors |
US20080038225A1 (en) * | 2006-08-11 | 2008-02-14 | Ying Sun | Triazolyl acyclic hepatitis c serine protease inhibitors |
US7605126B2 (en) | 2006-08-11 | 2009-10-20 | Enanta Pharmaceuticals, Inc. | Acylaminoheteroaryl hepatitis C virus protease inhibitors |
US7582605B2 (en) * | 2006-08-11 | 2009-09-01 | Enanta Pharmaceuticals, Inc. | Phosphorus-containing hepatitis C serine protease inhibitors |
EP1886685A1 (en) | 2006-08-11 | 2008-02-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods, uses and compositions for modulating replication of hcv through the farnesoid x receptor (fxr) activation or inhibition |
US20090098085A1 (en) * | 2006-08-11 | 2009-04-16 | Ying Sun | Tetrazolyl acyclic hepatitis c serine protease inhibitors |
WO2008022006A2 (en) * | 2006-08-11 | 2008-02-21 | Enanta Pharmaceuticals, Inc. | Arylalkoxyl hepatitis c virus protease inhibitors |
AU2007284027A1 (en) | 2006-08-17 | 2008-02-21 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
CA2666814A1 (en) * | 2006-08-21 | 2008-05-29 | United Therapeutics Corporation | Combination therapy for treatment of viral infections |
JP2010507656A (en) * | 2006-10-24 | 2010-03-11 | メルク エンド カムパニー インコーポレーテッド | HCV NS3 protease inhibitor |
US8138164B2 (en) * | 2006-10-24 | 2012-03-20 | Merck Sharp & Dohme Corp. | HCV NS3 protease inhibitors |
US8309540B2 (en) * | 2006-10-24 | 2012-11-13 | Merck Sharp & Dohme Corp. | HCV NS3 protease inhibitors |
KR101615500B1 (en) | 2006-10-27 | 2016-04-27 | 머크 샤프 앤드 돔 코포레이션 | HCV NS3 protease inhibitors |
ES2444575T3 (en) * | 2006-10-27 | 2014-02-25 | Merck Sharp & Dohme Corp. | HCV NS3 protease inhibitors |
US8343477B2 (en) | 2006-11-01 | 2013-01-01 | Bristol-Myers Squibb Company | Inhibitors of hepatitis C virus |
US20080108632A1 (en) * | 2006-11-02 | 2008-05-08 | Taigen Biotechnology Co., Ltd. | Hcv protease inhibitors |
US7772180B2 (en) * | 2006-11-09 | 2010-08-10 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
RS52874B (en) | 2006-11-15 | 2013-12-31 | Vertex Pharmaceuticals Incorporated | Thiophene analogues for the treatment or prevention of flavivirus infections |
US7763584B2 (en) | 2006-11-16 | 2010-07-27 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8003604B2 (en) | 2006-11-16 | 2011-08-23 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7888464B2 (en) | 2006-11-16 | 2011-02-15 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
AR064258A1 (en) | 2006-11-17 | 2009-03-25 | Tibotec Pharm Ltd | HEPATITIS C VIRUS MACROCICLIC INHIBITORS |
US20100081672A1 (en) * | 2006-12-07 | 2010-04-01 | Schering Corporation | Ph sensitive matrix formulation |
GB0625345D0 (en) * | 2006-12-20 | 2007-01-31 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
WO2008075103A1 (en) * | 2006-12-20 | 2008-06-26 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa | Antiviral indoles |
GB0625349D0 (en) * | 2006-12-20 | 2007-01-31 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
EP2094276A4 (en) * | 2006-12-20 | 2011-01-05 | Abbott Lab | Anti-viral compounds |
WO2008074035A1 (en) * | 2006-12-27 | 2008-06-19 | Abbott Laboratories | Hcv protease inhibitors and uses thereof |
WO2008095058A1 (en) * | 2007-02-01 | 2008-08-07 | Taigen Biotechnology Co. Ltd. | Hcv protease inhibitors |
NZ579295A (en) | 2007-02-27 | 2012-03-30 | Vertex Pharma | Inhibitors of serine proteases |
SI2114924T1 (en) | 2007-02-27 | 2012-06-29 | Vertex Pharma | Co-crystals and pharmaceutical compositions comprising the same |
WO2008106167A1 (en) * | 2007-02-28 | 2008-09-04 | Conatus Pharmaceuticals, Inc. | Combination therapy comprising matrix metalloproteinase inhibitors and caspase inhibitors for the treatment of liver diseases |
PL2144604T3 (en) * | 2007-02-28 | 2012-02-29 | Conatus Pharmaceuticals Inc | Methods for the treatment of chronic viral hepatitis C using RO 113-0830 |
CA2681624A1 (en) * | 2007-03-23 | 2009-01-15 | Schering Corporation | P1-nonepimerizable ketoamide inhibitors of hcv ns3 protease |
US7964580B2 (en) | 2007-03-30 | 2011-06-21 | Pharmasset, Inc. | Nucleoside phosphoramidate prodrugs |
US20080292587A1 (en) * | 2007-04-26 | 2008-11-27 | Ying Sun | Oximyl dipeptide hepatitis c protease inhibitors |
US20080267917A1 (en) * | 2007-04-26 | 2008-10-30 | Deqiang Niu | N-functionalized amides as hepatitis c serine protease inhibitors |
US20080317712A1 (en) * | 2007-04-26 | 2008-12-25 | Deqiang Niu | Arylpiperidinyl and arylpyrrolidinyl tripeptide hepatitis c serine protease inhibitors |
US8377872B2 (en) | 2007-04-26 | 2013-02-19 | Enanta Pharmaceuticals, Inc. | Cyclic P3 tripeptide hepatitis C serine protease inhibitors |
US7910587B2 (en) * | 2007-04-26 | 2011-03-22 | Enanta Pharmaceuticals, Inc. | Quinoxalinyl dipeptide hepatitis C virus inhibitors |
US20090155209A1 (en) * | 2007-05-03 | 2009-06-18 | Blatt Lawrence M | Novel macrocyclic inhibitors of hepatitis c virus replication |
ES2381410T3 (en) | 2007-05-04 | 2012-05-28 | Vertex Pharmceuticals Incorporated | Combination therapy for the treatment of HCV infections |
KR20120011093A (en) * | 2007-05-09 | 2012-02-06 | 화이자 인코포레이티드 | Substituted heterocyclic derivatives and compositions and their pharmaceutical use as antibacterials |
EP2185524A1 (en) | 2007-05-10 | 2010-05-19 | Intermune, Inc. | Novel peptide inhibitors of hepatitis c virus replication |
GB0709791D0 (en) * | 2007-05-22 | 2007-06-27 | Angeletti P Ist Richerche Bio | Antiviral agents |
CA2692145C (en) * | 2007-06-29 | 2015-03-03 | Gilead Sciences, Inc. | Antiviral compounds |
AP2874A (en) | 2007-06-29 | 2014-03-31 | Gilead Sciences Inc | Antiviral compounds |
CA2693533A1 (en) * | 2007-07-17 | 2009-01-22 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa | Macrocyclic indole derivatives for the treatment of hepatitis c infections |
WO2009010804A1 (en) * | 2007-07-19 | 2009-01-22 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Macrocyclic compounds as antiviral agents |
EP2188274A4 (en) | 2007-08-03 | 2011-05-25 | Boehringer Ingelheim Int | Viral polymerase inhibitors |
CN101835774B (en) | 2007-08-30 | 2014-09-17 | 弗特克斯药品有限公司 | Co-crystals and pharmaceutical compositions comprising the same |
GB0718575D0 (en) | 2007-09-24 | 2007-10-31 | Angeletti P Ist Richerche Bio | Nucleoside derivatives as inhibitors of viral polymerases |
US8419332B2 (en) * | 2007-10-19 | 2013-04-16 | Atlas Bolt & Screw Company Llc | Non-dimpling fastener |
US20090111757A1 (en) * | 2007-10-25 | 2009-04-30 | Taigen Biotechnology Co., Ltd. | Hcv protease inhibitors |
US8383583B2 (en) | 2007-10-26 | 2013-02-26 | Enanta Pharmaceuticals, Inc. | Macrocyclic, pyridazinone-containing hepatitis C serine protease inhibitors |
WO2009064955A1 (en) | 2007-11-14 | 2009-05-22 | Enanta Pharmaceuticals, Inc. | Macrocyclic tetrazolyl hepatitis c serine protease inhibitors |
WO2009070689A1 (en) * | 2007-11-29 | 2009-06-04 | Enanta Pharmaceuticals, Inc. | Bicyclic, c5-substituted proline derivatives as inhibitors of the hepatitis c virus ns3 protease |
US8263549B2 (en) * | 2007-11-29 | 2012-09-11 | Enanta Pharmaceuticals, Inc. | C5-substituted, proline-derived, macrocyclic hepatitis C serine protease inhibitors |
JP5529036B2 (en) * | 2007-12-05 | 2014-06-25 | エナンタ ファーマシューティカルズ インコーポレイテッド | Fluorinated tripeptide HCV serine protease inhibitor |
US8361958B2 (en) * | 2007-12-05 | 2013-01-29 | Enanta Pharmaceuticals, Inc. | Oximyl HCV serine protease inhibitors |
US8193346B2 (en) | 2007-12-06 | 2012-06-05 | Enanta Pharmaceuticals, Inc. | Process for making macrocyclic oximyl hepatitis C protease inhibitors |
WO2009079353A1 (en) | 2007-12-14 | 2009-06-25 | Enanta Pharmaceuticals, Inc. | Triazole-containing macrocyclic hcv serine protease inhibitors |
CN101903351B (en) | 2007-12-19 | 2014-09-10 | 贝林格尔.英格海姆国际有限公司 | Viral polymerase inhibitors |
US8202996B2 (en) | 2007-12-21 | 2012-06-19 | Bristol-Myers Squibb Company | Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide |
WO2009094443A1 (en) * | 2008-01-24 | 2009-07-30 | Enanta Pharmaceuticals, Inc. | Difluorinated tripeptides as hcv serine protease inhibitors |
JP2011510926A (en) * | 2008-01-24 | 2011-04-07 | エナンタ ファーマシューティカルズ インコーポレイテッド | Heteroaryl-containing tripeptide HCV serine protease inhibitor |
ES2437147T3 (en) | 2008-02-04 | 2014-01-09 | Idenix Pharmaceuticals, Inc. | Macrocyclic serine protease inhibitors |
WO2009100225A1 (en) | 2008-02-07 | 2009-08-13 | Virobay, Inc. | Inhibitors of cathepsin b |
JP5608563B2 (en) | 2008-02-25 | 2014-10-15 | メルク・シャープ・アンド・ドーム・コーポレーション | Therapeutic compounds |
CA2719008A1 (en) * | 2008-03-20 | 2009-09-24 | Enanta Pharmaceuticals, Inc. | Fluorinated macrocyclic compounds as hepatitis c virus inhibitors |
TW200946541A (en) * | 2008-03-27 | 2009-11-16 | Idenix Pharmaceuticals Inc | Solid forms of an anti-HIV phosphoindole compound |
BRPI0911260A2 (en) | 2008-04-15 | 2015-09-29 | Intermune Inc | compound, pharmaceutical composition, method of inhibiting ns3 / ns4 protease activity in vitro, and uses of compounds |
US8163921B2 (en) * | 2008-04-16 | 2012-04-24 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
AU2009241445A1 (en) * | 2008-04-28 | 2009-11-05 | Merck Sharp & Dohme Corp. | HCV NS3 protease inhibitors |
US8211891B2 (en) * | 2008-04-30 | 2012-07-03 | Enanta Pharmaceuticals, Inc. | Difluoromethyl-containing macrocyclic compounds as hepatitis C virus inhibitors |
US20090285774A1 (en) * | 2008-05-15 | 2009-11-19 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
CN101580535B (en) * | 2008-05-16 | 2012-10-03 | 太景生物科技股份有限公司 | Hcv protease inhibitors |
WO2009148923A1 (en) | 2008-05-29 | 2009-12-10 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
US7964560B2 (en) | 2008-05-29 | 2011-06-21 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8173621B2 (en) | 2008-06-11 | 2012-05-08 | Gilead Pharmasset Llc | Nucleoside cyclicphosphates |
AU2009277172B2 (en) | 2008-07-02 | 2014-05-29 | Idenix Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of viral infections |
RS53420B (en) * | 2008-07-22 | 2014-12-31 | Msd Italia S.R.L. | Combinations of a macrocyclic quinoxaline compound which is an hcv ns3 protease inhibitor with other hcv agents |
CN102099335A (en) | 2008-07-23 | 2011-06-15 | 弗·哈夫曼-拉罗切有限公司 | Heterocyclic antiviral compounds |
US8207341B2 (en) | 2008-09-04 | 2012-06-26 | Bristol-Myers Squibb Company | Process or synthesizing substituted isoquinolines |
UY32099A (en) | 2008-09-11 | 2010-04-30 | Enanta Pharm Inc | HEPATITIS C SERINA PROTEASAS MACROCYCLIC INHIBITORS |
ME01831B (en) * | 2008-09-16 | 2014-12-20 | Boehringer Ingelheim Int | Crystalline forms of a 2-thiazolyl-4-quinolinyl-oxy derivative, a potent hcv inhibitor |
KR20110054003A (en) * | 2008-09-17 | 2011-05-24 | 베링거 인겔하임 인터내셔날 게엠베하 | Combination of hcv ns3 protease inhibitor with interferon and ribavirin |
JP2012503620A (en) | 2008-09-26 | 2012-02-09 | エフ.ホフマン−ラ ロシュ アーゲー | Pyrin or pyrazine derivatives for treating HCV |
US8044087B2 (en) | 2008-09-29 | 2011-10-25 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8563505B2 (en) | 2008-09-29 | 2013-10-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
EP2341924A4 (en) | 2008-10-02 | 2013-01-23 | David Gladstone Inst | Methods of treating hepatitis c virus infection |
KR20110075019A (en) * | 2008-10-15 | 2011-07-05 | 인터뮨, 인크. | Therapeutic antiviral peptides |
CN102186823A (en) | 2008-10-30 | 2011-09-14 | 弗·哈夫曼-拉罗切有限公司 | Heterocyclic antiviral arylpyridone derivatives |
ES2445516T3 (en) * | 2008-11-21 | 2014-03-03 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition of a potent HCV inhibitor for oral administration |
BRPI0922366B8 (en) | 2008-12-03 | 2021-05-25 | Presidio Pharmaceuticals Inc | compound, pharmaceutical composition and use of a compound |
US8865756B2 (en) | 2008-12-03 | 2014-10-21 | Presidio Pharmaceuticals, Inc. | Inhibitors of HCV NS5A |
US20100272674A1 (en) * | 2008-12-04 | 2010-10-28 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
US8283310B2 (en) | 2008-12-15 | 2012-10-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
CN102300871A (en) | 2008-12-19 | 2011-12-28 | 吉里德科学公司 | Hcv ns3 protease inhibitors |
JP2012513397A (en) | 2008-12-22 | 2012-06-14 | ギリアード サイエンシーズ, インコーポレイテッド | Antiviral compounds |
KR20110094352A (en) | 2008-12-22 | 2011-08-23 | 에프. 호프만-라 로슈 아게 | Heterocyclic antiviral compounds |
SG172361A1 (en) | 2008-12-23 | 2011-07-28 | Pharmasset Inc | Nucleoside analogs |
AU2009329872B2 (en) | 2008-12-23 | 2016-07-07 | Gilead Pharmasset Llc | Synthesis of purine nucleosides |
AR074897A1 (en) | 2008-12-23 | 2011-02-23 | Pharmasset Inc | NUCLEOSID PHOSPHORAMIDATES |
EP2385838A1 (en) | 2009-01-07 | 2011-11-16 | Scynexis, Inc. | Cyclosporine derivative for use in the treatment of hcv and hiv infection |
WO2010082050A1 (en) | 2009-01-16 | 2010-07-22 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Macrocyclic and 7-aminoalkyl-substituted benzoxazocines for treatment of hepatitis c infections |
GB0900914D0 (en) | 2009-01-20 | 2009-03-04 | Angeletti P Ist Richerche Bio | Antiviral agents |
US8102720B2 (en) * | 2009-02-02 | 2012-01-24 | Qualcomm Incorporated | System and method of pulse generation |
AR075584A1 (en) | 2009-02-27 | 2011-04-20 | Intermune Inc | THERAPEUTIC COMPOSITIONS THAT INCLUDE beta-D-2'-DESOXI-2'-FLUORO-2'-C-METHYLYCTIDINE AND A CARDIEX ISOINDOL ACID DERIVATIVE AND ITS USES. COMPOUND. |
US8193372B2 (en) | 2009-03-04 | 2012-06-05 | Idenix Pharmaceuticals, Inc. | Phosphothiophene and phosphothiazole HCV polymerase inhibitors |
KR20110122874A (en) | 2009-03-06 | 2011-11-11 | 에프. 호프만-라 로슈 아게 | Heterocyclic antiviral compounds |
US8975247B2 (en) | 2009-03-18 | 2015-03-10 | The Board Of Trustees Of The Leland Stanford Junion University | Methods and compositions of treating a flaviviridae family viral infection |
US9150554B2 (en) | 2009-03-27 | 2015-10-06 | Presidio Pharmaceuticals, Inc. | Fused ring inhibitors of hepatitis C |
US8927576B2 (en) | 2009-04-06 | 2015-01-06 | PTC Therpeutics, Inc. | HCV inhibitor and therapeutic agent combinations |
TW201040181A (en) | 2009-04-08 | 2010-11-16 | Idenix Pharmaceuticals Inc | Macrocyclic serine protease inhibitors |
US20110182850A1 (en) | 2009-04-10 | 2011-07-28 | Trixi Brandl | Organic compounds and their uses |
US8512690B2 (en) | 2009-04-10 | 2013-08-20 | Novartis Ag | Derivatised proline containing peptide compounds as protease inhibitors |
SG175774A1 (en) | 2009-04-25 | 2011-12-29 | Hoffmann La Roche | Heterocyclic antiviral compounds |
US8936781B2 (en) | 2009-05-13 | 2015-01-20 | Enanta Pharmaceuticals, Inc. | Macrocyclic compounds as hepatitis C virus inhibitors |
US8618076B2 (en) | 2009-05-20 | 2013-12-31 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
TWI583692B (en) | 2009-05-20 | 2017-05-21 | 基利法瑪席特有限責任公司 | Nucleoside phosphoramidates |
AR077004A1 (en) * | 2009-06-09 | 2011-07-27 | Hoffmann La Roche | ANTIVIRAL HETEROCICLIC COMPOUNDS |
TW201103545A (en) | 2009-06-24 | 2011-02-01 | Hoffmann La Roche | Heterocyclic antiviral compound |
US8232246B2 (en) * | 2009-06-30 | 2012-07-31 | Abbott Laboratories | Anti-viral compounds |
WO2011003063A2 (en) * | 2009-07-02 | 2011-01-06 | Dr. Reddy's Laboratories Ltd. | Enzymes and methods for resolving amino vinyl cyclopropane carboxylic acid derivatives |
MX2011013824A (en) | 2009-07-07 | 2012-01-30 | Boehringer Ingelheim Int | Pharmaceutical composition for a hepatitis c viral protease inhibitor. |
WO2011014487A1 (en) | 2009-07-30 | 2011-02-03 | Merck Sharp & Dohme Corp. | Hepatitis c virus ns3 protease inhibitors |
WO2011017389A1 (en) | 2009-08-05 | 2011-02-10 | Idenix Pharmaceuticals, Inc. | Macrocyclic serine protease inhibitors useful against viral infections, particularly hcv |
WO2011019066A1 (en) * | 2009-08-10 | 2011-02-17 | 住友化学株式会社 | Method for producing optically active 1-amino-2-vinylcyclopropanecarboxylic acid ester |
US8324417B2 (en) | 2009-08-19 | 2012-12-04 | Virobay, Inc. | Process for the preparation of (S)-2-amino-5-cyclopropyl-4,4-difluoropentanoic acid and alkyl esters and acid salts thereof |
LT2477980T (en) * | 2009-09-15 | 2016-09-26 | Taigen Biotechnology Co., Ltd. | Hcv protease inhibitors |
CA2775697A1 (en) * | 2009-09-28 | 2011-03-31 | Intermune, Inc. | Cyclic peptide inhibitors of hepatitis c virus replication |
WO2011049908A2 (en) * | 2009-10-19 | 2011-04-28 | Enanta Pharmaceuticals, Inc. | Bismacrokyclic compounds as hepatitis c virus inhibitors |
KR20120106942A (en) | 2009-10-30 | 2012-09-27 | 베링거 인겔하임 인터내셔날 게엠베하 | Dosage regimens for hcv combination therapy comprising bi201335, interferon alpha and ribavirin |
WO2011063076A1 (en) | 2009-11-19 | 2011-05-26 | Itherx Pharmaceuticals, Inc. | Methods of treating hepatitis c virus with oxoacetamide compounds |
CA2781614A1 (en) | 2009-11-25 | 2011-06-09 | Vertex Pharmaceuticals Incorporated | 5-alkynyl-thiophene-2-carboxylic acid derivatives and their use for the treatment or prevention of flavivirus infections |
SG181797A1 (en) | 2009-12-18 | 2012-07-30 | Idenix Pharmaceuticals Inc | 5,5-fused arylene or heteroarylene hepatitis c virus inhibitors |
AU2010336355A1 (en) | 2009-12-24 | 2012-07-05 | Vertex Pharmaceuticals Incorporated | Analogues for the treatment or prevention of flavivirus infections |
US20110178107A1 (en) * | 2010-01-20 | 2011-07-21 | Taigen Biotechnology Co., Ltd. | Hcv protease inhibitors |
JP5833022B2 (en) | 2010-01-27 | 2015-12-16 | エービー・ファーマ・リミテッド | Polyheterocyclic compounds as hepatitis C virus inhibitors |
US8530497B2 (en) | 2010-03-11 | 2013-09-10 | Boehringer Ingelheim International Gmbh | Crystalline salts of a potent HCV inhibitor |
TW201141857A (en) | 2010-03-24 | 2011-12-01 | Vertex Pharma | Analogues for the treatment or prevention of flavivirus infections |
WO2011119870A1 (en) | 2010-03-24 | 2011-09-29 | Vertex Pharmaceuticals Incorporated | Analogues for the treatment or prevention of flavivirus infections |
WO2011119853A1 (en) | 2010-03-24 | 2011-09-29 | Vertex Pharmaceuticals Incorporated | Analogues for the treatment or prevention of flavivirus infections |
TW201139438A (en) | 2010-03-24 | 2011-11-16 | Vertex Pharma | Analogues for the treatment or prevention of flavivirus infections |
EP2752422B1 (en) | 2010-03-31 | 2017-08-16 | Gilead Pharmasset LLC | Stereoselective synthesis of phosphorus containing actives |
US8563530B2 (en) | 2010-03-31 | 2013-10-22 | Gilead Pharmassel LLC | Purine nucleoside phosphoramidate |
MX2012011222A (en) | 2010-04-01 | 2013-01-18 | Centre Nat Rech Scient | Compounds and pharmaceutical compositions for the treatment of viral infections. |
EP2575866A4 (en) | 2010-05-24 | 2013-10-16 | Presidio Pharmaceuticals Inc | Inhibitors of hcv ns5a |
WO2011156545A1 (en) | 2010-06-09 | 2011-12-15 | Vertex Pharmaceuticals Incorporated | Viral dynamic model for hcv combination therapy |
US20130157258A1 (en) | 2010-06-15 | 2013-06-20 | Vertex Pharmaceuticals Incorporated | Hcv ns5b protease mutants |
EP2585448A1 (en) | 2010-06-28 | 2013-05-01 | Vertex Pharmaceuticals Incorporated | Compounds and methods for the treatment or prevention of flavivirus infections |
UY33473A (en) | 2010-06-28 | 2012-01-31 | Vertex Pharma | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS |
WO2012006070A1 (en) | 2010-06-28 | 2012-01-12 | Vertex Pharmaceuticals Incorporated | Compounds and methods for the treatment or prevention of flavivirus infections |
CA2808291A1 (en) | 2010-08-17 | 2012-02-23 | Vertex Pharmaceuticals Incorporated | Compounds and methods for the treatment or prevention of flaviviridae viral infections |
HUE028384T2 (en) | 2010-09-21 | 2016-12-28 | Enanta Pharm Inc | Macrocyclic proline derived hcv serine protease inhibitors |
BR112013007423A2 (en) | 2010-09-30 | 2016-07-12 | Boehringer Ingelheim Int | combination therapy with regard to the treatment of hcv infection |
AU2011311880B2 (en) | 2010-10-08 | 2014-07-24 | Novartis Ag | Vitamin E formulations of sulfamide NS3 inhibitors |
ES2716158T3 (en) | 2010-11-30 | 2019-06-10 | Gilead Pharmasset Llc | 2'-spiro-nucleotides for the treatment of hepatitis C |
WO2012083170A1 (en) * | 2010-12-16 | 2012-06-21 | Abbott Laboratories | Anti-viral compounds |
WO2012092409A2 (en) | 2010-12-30 | 2012-07-05 | Enanta Phararmaceuticals, Inc | Macrocyclic hepatitis c serine protease inhibitors |
EP2658858A4 (en) | 2010-12-30 | 2014-06-25 | Enanta Pharm Inc | Phenanthridine macrocyclic hepatitis c serine protease inhibitors |
WO2012109398A1 (en) | 2011-02-10 | 2012-08-16 | Idenix Pharmaceuticals, Inc. | Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating hcv infections |
WO2012107589A1 (en) | 2011-02-11 | 2012-08-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment and prevention of hcv infections |
WO2012123298A1 (en) | 2011-03-11 | 2012-09-20 | F. Hoffmann-La Roche Ag | Antiviral compounds |
WO2012154321A1 (en) | 2011-03-31 | 2012-11-15 | Idenix Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of viral infections |
US20120252721A1 (en) | 2011-03-31 | 2012-10-04 | Idenix Pharmaceuticals, Inc. | Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor |
US8957203B2 (en) | 2011-05-05 | 2015-02-17 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
US8691757B2 (en) | 2011-06-15 | 2014-04-08 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
CA2857705A1 (en) | 2011-06-16 | 2012-12-20 | AB Pharma Ltd. | Macrocyclic heterocyclic compounds for inhibiting hepatitis c virus and preparation and use thereof |
EP2725012A1 (en) | 2011-06-21 | 2014-04-30 | Mitsubishi Gas Chemical Company, Inc. | 1-amino-2-vinyl cyclopropane carboxylic acid amide, salt of same, and method for producing same |
WO2012175581A1 (en) | 2011-06-24 | 2012-12-27 | F. Hoffmann-La Roche Ag | Antiviral compounds |
CN102807607B (en) * | 2011-07-22 | 2013-10-23 | 爱博新药研发(上海)有限公司 | Fused ring heterocycle compound for restraining hepatitis c virus, midbody and application of fused ring heterocycle compound |
WO2013016499A1 (en) | 2011-07-26 | 2013-01-31 | Vertex Pharmaceuticals Incorporated | Methods for preparation of thiophene compounds |
AR087344A1 (en) | 2011-07-26 | 2014-03-19 | Vertex Pharma | ACID POLYMORPHIC FORMS 5- (3,3-DIMETIL-BUT-1-INIL) -3 - [(TRANS-4-HIDROXI-CICLOHEXIL) - (TRANS-4-METHYL-CYCLHEXANCARBONYL) -AMINO] -TIOFEN-2- CARBOXILICO AND ITS USE IN THE TREATMENT OF HEPATITIS C |
DE202012012998U1 (en) | 2011-08-31 | 2014-06-13 | Daniel Elias | Bioactive, regenerative mixture for the preparation of a supplementary food |
TW201329096A (en) | 2011-09-12 | 2013-07-16 | Idenix Pharmaceuticals Inc | Substituted carbonyloxymethylphosphoramidate compounds and pharmaceutical compositions for the treatment of viral infections |
JP2014526474A (en) | 2011-09-12 | 2014-10-06 | アイディニックス ファーマシューティカルズ インコーポレイテッド | Compounds and pharmaceutical compositions for the treatment of viral infections |
CN103917541B (en) | 2011-10-10 | 2016-08-17 | 弗·哈夫曼-拉罗切有限公司 | Antiviral compound |
EP2768838A1 (en) | 2011-10-14 | 2014-08-27 | IDENIX Pharmaceuticals, Inc. | Substituted 3',5'-cyclic phosphates of purine nucleotide compounds and pharmaceutical compositions for the treatment of viral infections |
GB2515942A (en) | 2011-10-21 | 2015-01-07 | Abbvie Inc | Combination treatment (e.g. with ABT-072 or ABT-333) of DAAs for use in treating HCV |
US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
US8492386B2 (en) | 2011-10-21 | 2013-07-23 | Abbvie Inc. | Methods for treating HCV |
US8853176B2 (en) | 2011-10-21 | 2014-10-07 | Abbvie Inc. | Methods for treating HCV |
EP2780026B1 (en) | 2011-11-15 | 2019-10-23 | Merck Sharp & Dohme Corp. | Hcv ns3 protease inhibitors |
US8889159B2 (en) | 2011-11-29 | 2014-11-18 | Gilead Pharmasset Llc | Compositions and methods for treating hepatitis C virus |
US9089574B2 (en) | 2011-11-30 | 2015-07-28 | Emory University | Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections |
BR112014013649A2 (en) | 2011-12-06 | 2020-10-27 | The Board Of Trustees Of The Leland Stanford Junior University | methods and agents for the treatment of viral diseases and uses of said agents |
US9133170B2 (en) | 2011-12-16 | 2015-09-15 | Hoffmann-La Roche Inc. | Inhibitors of HCV NS5A |
CA2856179C (en) | 2011-12-20 | 2017-02-28 | F. Hoffmann-La Roche Ag | 2',4'-difluoro-2'-methyl substituted nucleoside derivatives as inhibitors of hcv rna replication |
SI2794628T1 (en) | 2011-12-20 | 2017-07-31 | Riboscience Llc | 4'-azido-3'-fluoro substituted nucleoside derivatives as inhibitors of hcv rna replication |
WO2013106344A1 (en) | 2012-01-12 | 2013-07-18 | Ligand Pharmaceuticals, Inc. | 2 '-c-methyl nucleosides containing a cyclic phosphate diester of 1, 3-propanediol (2-oxo-[1, 3, 2]-dioxaphosphorinane) at position 5' |
CA2861041A1 (en) | 2012-01-12 | 2013-07-18 | Boehringer Ingelheim International Gmbh | Stabilized pharmaceutical formulations of a potent hcv inhibitor |
US20130217644A1 (en) | 2012-02-13 | 2013-08-22 | Idenix Pharmaceuticals, Inc. | Pharmaceutical Compositions of 2'-C-Methyl-Guanosine, 5'-[2[(3-Hydroxy-2,2-Dimethyl-1-Oxopropyl)Thio]Ethyl N-(Phenylmethyl)Phosphoramidate] |
BR112014015582A8 (en) * | 2012-02-24 | 2017-07-04 | Hoffmann La Roche | antiviral compounds |
WO2013137869A1 (en) | 2012-03-14 | 2013-09-19 | Boehringer Ingelheim International Gmbh | Combination therapy for treating hcv infection in an hcv-hiv coinfected patient population |
WO2013142157A1 (en) | 2012-03-22 | 2013-09-26 | Alios Biopharma, Inc. | Pharmaceutical combinations comprising a thionucleotide analog |
WO2013147749A1 (en) | 2012-03-27 | 2013-10-03 | Boehringer Ingelheim International Gmbh | Oral combination therapy for treating hcv infection in specific patient subgenotype populations |
WO2013147750A1 (en) | 2012-03-27 | 2013-10-03 | Boehringer Ingelheim International Gmbh | Oral combination therapy for treating hcv infection in specific patient sub-population |
JP2015512900A (en) | 2012-03-28 | 2015-04-30 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Combination therapy to treat HCV infection in a special patient genotype subpopulation |
NZ702744A (en) | 2012-05-22 | 2016-12-23 | Idenix Pharmaceuticals Llc | D-amino acid compounds for liver disease |
EP2852604B1 (en) | 2012-05-22 | 2017-04-12 | Idenix Pharmaceuticals LLC | 3',5'-cyclic phosphoramidate prodrugs for hcv infection |
WO2013177195A1 (en) | 2012-05-22 | 2013-11-28 | Idenix Pharmaceuticals, Inc. | 3',5'-cyclic phosphate prodrugs for hcv infection |
US20140010783A1 (en) | 2012-07-06 | 2014-01-09 | Hoffmann-La Roche Inc. | Antiviral compounds |
EA030189B8 (en) | 2012-10-08 | 2018-10-31 | Иденикс Фармасьютикалз Ллс | 2'-chloro nucleoside analogs for hcv infection |
US20140112886A1 (en) | 2012-10-19 | 2014-04-24 | Idenix Pharmaceuticals, Inc. | Dinucleotide compounds for hcv infection |
PT2909205T (en) | 2012-10-19 | 2017-02-06 | Bristol Myers Squibb Co | 9-methyl substituted hexadecahydrocyclopropa(e)pyrrolo(1,2-a)(1,4)diazacyclopentadecinyl carbamate derivatives as non-structural 3 (ns3) protease inhibitors for the treatment of hepatitis c virus infections |
US10723754B2 (en) | 2012-10-22 | 2020-07-28 | Idenix Pharmaceuticals Llc | 2′,4′-bridged nucleosides for HCV infection |
US9643999B2 (en) | 2012-11-02 | 2017-05-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US9334279B2 (en) | 2012-11-02 | 2016-05-10 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US9598433B2 (en) | 2012-11-02 | 2017-03-21 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US9409943B2 (en) | 2012-11-05 | 2016-08-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
CN103804208B (en) * | 2012-11-14 | 2016-06-08 | 重庆博腾制药科技股份有限公司 | A kind of preparation method of hepatitis C pharmaceutical intermediate |
EP2938624A1 (en) | 2012-11-14 | 2015-11-04 | IDENIX Pharmaceuticals, Inc. | D-alanine ester of sp-nucleoside analog |
WO2014078427A1 (en) | 2012-11-14 | 2014-05-22 | Idenix Pharmaceuticals, Inc. | D-alanine ester of rp-nucleoside analog |
WO2014099941A1 (en) | 2012-12-19 | 2014-06-26 | Idenix Pharmaceuticals, Inc. | 4'-fluoro nucleosides for the treatment of hcv |
RU2015132550A (en) | 2013-01-23 | 2017-03-02 | Ф. Хоффманн-Ля Рош Аг | TRIAZOLE ANTIVIRAL DERIVATIVES |
WO2014121418A1 (en) | 2013-02-07 | 2014-08-14 | Merck Sharp & Dohme Corp. | Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c |
WO2014121417A1 (en) | 2013-02-07 | 2014-08-14 | Merck Sharp & Dohme Corp. | Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c |
WO2014134251A1 (en) | 2013-02-28 | 2014-09-04 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions |
US9309275B2 (en) | 2013-03-04 | 2016-04-12 | Idenix Pharmaceuticals Llc | 3′-deoxy nucleosides for the treatment of HCV |
US9339541B2 (en) | 2013-03-04 | 2016-05-17 | Merck Sharp & Dohme Corp. | Thiophosphate nucleosides for the treatment of HCV |
CA2900319A1 (en) | 2013-03-05 | 2014-09-12 | F. Hoffmann-La Roche Ag | Antiviral compounds |
JP6342922B2 (en) | 2013-03-07 | 2018-06-13 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | Hepatitis C virus inhibitor |
WO2014138374A1 (en) | 2013-03-08 | 2014-09-12 | Boehringer Ingelheim International Gmbh | Oral combination therapy for treating hcv infection in specific patient sub-population |
CA2905433A1 (en) | 2013-03-14 | 2014-09-25 | Achillion Pharmaceuticals, Inc. | Novel processes for producing sovaprevir |
US9187515B2 (en) | 2013-04-01 | 2015-11-17 | Idenix Pharmaceuticals Llc | 2′,4′-fluoro nucleosides for the treatment of HCV |
US20180200280A1 (en) | 2013-05-16 | 2018-07-19 | Riboscience Llc | 4'-Fluoro-2'-Methyl Substituted Nucleoside Derivatives as Inhibitors of HCV RNA Replication |
US9249176B2 (en) | 2013-05-16 | 2016-02-02 | Riboscience Llc | 4′-azido, 3′-deoxy-3′-fluoro substituted nucleoside derivatives as inhibitors of HCV RNA replication |
EA035301B1 (en) | 2013-05-16 | 2020-05-26 | Рибосайенс Ллк | 4'-fluoro-2'-methyl substituted nucleoside derivatives |
US10005779B2 (en) | 2013-06-05 | 2018-06-26 | Idenix Pharmaceuticals Llc | 1′,4′-thio nucleosides for the treatment of HCV |
WO2015017713A1 (en) | 2013-08-01 | 2015-02-05 | Idenix Pharmaceuticals, Inc. | D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease |
ES2900570T3 (en) | 2013-08-27 | 2022-03-17 | Gilead Pharmasset Llc | Combination formulation of two antiviral compounds |
US20160229866A1 (en) | 2013-09-20 | 2016-08-11 | Idenix Pharmaceuticals Inc. | Hepatitis c virus inhibitors |
WO2015061683A1 (en) | 2013-10-25 | 2015-04-30 | Idenix Pharmaceuticals, Inc. | D-amino acid phosphoramidate and d-alanine thiophosphoramidate pronucleotides of nucleoside compounds useful for the treatment of hcv |
WO2015066370A1 (en) | 2013-11-01 | 2015-05-07 | Idenix Pharmaceuticals, Inc. | D-alanine phosphoramidate pronucleotides of 2'-methyl 2'-fluoro guanosine nucleoside compounds for the treatment of hcv |
EP3074399A1 (en) | 2013-11-27 | 2016-10-05 | Idenix Pharmaceuticals LLC | 2'-dichloro and 2'-fluoro-2'-chloro nucleoside analogues for hcv infection |
US9717797B2 (en) | 2013-12-05 | 2017-08-01 | International Business Machines Corporation | Polycarbonates bearing aromatic N-heterocycles for drug delivery |
WO2015095419A1 (en) | 2013-12-18 | 2015-06-25 | Idenix Pharmaceuticals, Inc. | 4'-or nucleosides for the treatment of hcv |
WO2015103490A1 (en) | 2014-01-03 | 2015-07-09 | Abbvie, Inc. | Solid antiviral dosage forms |
EP2899207A1 (en) | 2014-01-28 | 2015-07-29 | Amikana.Biologics | New method for testing HCV protease inhibition |
EP3113763A1 (en) | 2014-03-05 | 2017-01-11 | Idenix Pharmaceuticals LLC | Solid prodrug forms of 2'-chloro-2'-methyl uridine for hcv |
WO2015134561A1 (en) | 2014-03-05 | 2015-09-11 | Idenix Pharmaceuticals, Inc. | Pharmaceutical compositions comprising a 5,5-fused heteroarylene flaviviridae inhibitor and their use for treating or preventing flaviviridae infection |
EP3114122A1 (en) | 2014-03-05 | 2017-01-11 | Idenix Pharmaceuticals LLC | Solid forms of a flaviviridae virus inhibitor compound and salts thereof |
WO2015161137A1 (en) | 2014-04-16 | 2015-10-22 | Idenix Pharmaceuticals, Inc. | 3'-substituted methyl or alkynyl nucleosides for the treatment of hcv |
WO2017189978A1 (en) | 2016-04-28 | 2017-11-02 | Emory University | Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto |
EP3684374A4 (en) | 2017-09-21 | 2021-06-16 | Riboscience LLC | 4'-fluoro-2'-methyl substituted nucleoside derivatives as inhibitors of hcv rna replication |
KR20210098504A (en) | 2018-12-04 | 2021-08-10 | 브리스톨-마이어스 스큅 컴퍼니 | Analytical Methods Using In-Sample Calibration Curves by Monitoring Multiple Isotope Responses |
Citations (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH05155827A (en) | 1991-12-09 | 1993-06-22 | Banyu Pharmaceut Co Ltd | Production of cis-2-aminocyclopropanecarboxylic acid derivative |
US5633388A (en) | 1996-03-29 | 1997-05-27 | Viropharma Incorporated | Compounds, compositions and methods for treatment of hepatitis C |
DE19600034A1 (en) | 1996-01-02 | 1997-07-03 | Huels Chemische Werke Ag | New 1,1,2-tri:substituted cyclopropane compounds |
WO1998017679A1 (en) | 1996-10-18 | 1998-04-30 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease |
WO1998053814A1 (en) | 1997-05-29 | 1998-12-03 | Merck & Co., Inc. | Heterocyclic amide compounds as cell adhesion inhibitors |
WO1999007733A2 (en) | 1997-08-11 | 1999-02-18 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis c inhibitor peptides |
US6323180B1 (en) * | 1998-08-10 | 2001-11-27 | Boehringer Ingelheim (Canada) Ltd | Hepatitis C inhibitor tri-peptides |
US6337394B2 (en) | 1997-12-05 | 2002-01-08 | Astrazeneca Ab | Compounds |
US6455571B1 (en) | 1998-04-23 | 2002-09-24 | Abbott Laboratories | Inhibitors of neuraminidases |
US6608027B1 (en) | 1999-04-06 | 2003-08-19 | Boehringer Ingelheim (Canada) Ltd | Macrocyclic peptides active against the hepatitis C virus |
US6642204B2 (en) * | 2002-02-01 | 2003-11-04 | Boehringer Ingelheim International Gmbh | Hepatitis C inhibitor tri-peptides |
US6767991B1 (en) * | 1997-08-11 | 2004-07-27 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis C inhibitor peptides |
US6908901B2 (en) * | 2003-03-05 | 2005-06-21 | Boehringer Ingelheim International, Gmbh | Hepatitis C inhibitor peptide analogs |
US6919423B2 (en) * | 2003-03-05 | 2005-07-19 | Boehringer Ingelheim International, Gmbh | Hepatitis C inhibitor compound |
US7091184B2 (en) * | 2002-02-01 | 2006-08-15 | Boehringer Ingelheim International Gmbh | Hepatitis C inhibitor tri-peptides |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0475255A3 (en) * | 1990-09-12 | 1993-04-14 | F. Hoffmann-La Roche Ag | Process for the preparation of optically pure (s)-alpha-((tert-butylsulfonyl)methyl)hydro cinnamic acid |
CN1141591A (en) * | 1994-02-23 | 1997-01-29 | 布·安格莱荻公司分子生物学研究所 | Method for reproducing in vitro the proteolytic activity of the NS3 protease of hepatitis C virus (HCV) |
IT1272179B (en) | 1994-02-23 | 1997-06-16 | Angeletti P Ist Richerche Bio | METHODOLOGY TO REPRODUCE IN VITRO THE PROTEOLITHIC ACTIVITY OF THE NS3 PROTEASE OF THE VIRUS HCV. |
GB9517022D0 (en) | 1995-08-19 | 1995-10-25 | Glaxo Group Ltd | Medicaments |
IT1277914B1 (en) * | 1995-08-22 | 1997-11-12 | Angeletti P Ist Richerche Bio | PROCEDURE TO PRODUCE - IN PURE FORM AND IN HIGH QUANTITIES - POLYPEPTIDES WITH THE PROTEOLYTIC ACTIVITY OF THE NS3 PROTEASE OF HCV, AND |
CA2165996C (en) * | 1995-12-22 | 2002-01-29 | Murray Douglas Bailey | Stereoselective preparation of 2-substituted succinic derivatives |
DE19835120C1 (en) * | 1998-08-04 | 1999-10-21 | Westfalia Separator Ag | Regulating fluid contents in centrifugal separator outlet |
US6277830B1 (en) * | 1998-10-16 | 2001-08-21 | Schering Corporation | 5′-amino acid esters of ribavirin and the use of same to treat hepatitis C with interferon |
-
1999
- 1999-08-05 US US09/368,866 patent/US6323180B1/en not_active Expired - Lifetime
- 1999-08-09 CA CA2445938A patent/CA2445938C/en not_active Expired - Lifetime
- 1999-08-09 HU HU1300080A patent/HU230701B1/en unknown
- 1999-08-09 DE DE69940817T patent/DE69940817D1/en not_active Expired - Lifetime
- 1999-08-09 CN CN2007101407405A patent/CN101143892B/en not_active Expired - Lifetime
- 1999-08-09 WO PCT/CA1999/000736 patent/WO2000009543A2/en active Application Filing
- 1999-08-09 CN CNB998105503A patent/CN100339389C/en not_active Expired - Lifetime
- 1999-08-09 AU AU52731/99A patent/AU769738B2/en not_active Expired
- 1999-08-09 EA EA200100228A patent/EA003906B1/en not_active IP Right Cessation
- 1999-08-09 PE PE1999000800A patent/PE20000949A1/en not_active IP Right Cessation
- 1999-08-09 EE EEP200100081A patent/EE05517B1/en unknown
- 1999-08-09 ME MEP-2008-585A patent/ME00381B/en unknown
- 1999-08-09 EP EP08169026A patent/EP2028186B1/en not_active Expired - Lifetime
- 1999-08-09 IN IN127MUN2001 patent/IN211493B/en unknown
- 1999-08-09 ES ES99938084T patent/ES2326707T3/en not_active Expired - Lifetime
- 1999-08-09 PH PH11999002002A patent/PH11999002002B1/en unknown
- 1999-08-09 KR KR1020017001786A patent/KR100631439B1/en not_active IP Right Cessation
- 1999-08-09 SI SI9931033T patent/SI1105413T1/en unknown
- 1999-08-09 NZ NZ510396A patent/NZ510396A/en not_active IP Right Cessation
- 1999-08-09 RS RSP-2009/0459A patent/RS20090459A/en unknown
- 1999-08-09 ID IDW20010316A patent/ID27839A/en unknown
- 1999-08-09 IL IL14101299A patent/IL141012A0/en unknown
- 1999-08-09 SK SK50026-2009A patent/SK288068B6/en not_active IP Right Cessation
- 1999-08-09 CA CA2338946A patent/CA2338946C/en not_active Expired - Lifetime
- 1999-08-09 SK SK206-2001A patent/SK286994B6/en not_active IP Right Cessation
- 1999-08-09 MY MYPI99003397A patent/MY127538A/en unknown
- 1999-08-09 ES ES08169026T patent/ES2405930T3/en not_active Expired - Lifetime
- 1999-08-09 HU HU0105144A patent/HU229262B1/en unknown
- 1999-08-09 PT PT99938084T patent/PT1105413E/en unknown
- 1999-08-09 KR KR1020067010736A patent/KR100672229B1/en not_active IP Right Cessation
- 1999-08-09 BR BRPI9917805-2B1A patent/BR9917805B1/en active IP Right Grant
- 1999-08-09 DK DK99938084T patent/DK1105413T3/en active
- 1999-08-09 BR BRPI9913646A patent/BRPI9913646B8/en not_active IP Right Cessation
- 1999-08-09 DK DK08169026.5T patent/DK2028186T3/en active
- 1999-08-09 TR TR2001/00432T patent/TR200100432T2/en unknown
- 1999-08-09 CZ CZ20090004A patent/CZ302766B6/en not_active IP Right Cessation
- 1999-08-09 TR TR2002/00129T patent/TR200200129T2/en unknown
- 1999-08-09 JP JP2000564993A patent/JP4485685B2/en not_active Expired - Lifetime
- 1999-08-09 PL PL346626A patent/PL204850B1/en unknown
- 1999-08-09 RS YU20090459A patent/RS53562B1/en unknown
- 1999-08-09 TW TW088113586A patent/TWI250165B/en not_active IP Right Cessation
- 1999-08-09 EP EP99938084A patent/EP1105413B1/en not_active Expired - Lifetime
- 1999-08-09 AT AT99938084T patent/ATE430158T1/en active
- 1999-08-09 CZ CZ20010516A patent/CZ301268B6/en not_active IP Right Cessation
- 1999-08-09 PT PT81690265T patent/PT2028186E/en unknown
- 1999-08-09 SI SI9931071T patent/SI2028186T1/en unknown
- 1999-08-09 RS YUP-94/01A patent/RS50798B/en unknown
- 1999-08-10 CO CO99050714A patent/CO5261542A1/en active IP Right Grant
- 1999-08-10 AR ARP990103977A patent/AR020880A1/en active IP Right Grant
- 1999-09-08 UA UA2001031603A patent/UA75026C2/en unknown
- 1999-09-28 SA SA99200617A patent/SA99200617B1/en unknown
-
2000
- 2000-09-12 US US09/660,030 patent/US6268207B1/en not_active Expired - Lifetime
- 2000-09-29 US US09/675,398 patent/US6329379B1/en not_active Ceased
- 2000-11-01 US US09/703,751 patent/US6329417B1/en not_active Ceased
-
2001
- 2001-01-22 IL IL141012A patent/IL141012A/en not_active IP Right Cessation
- 2001-02-05 ZA ZA200100971A patent/ZA200100971B/en unknown
- 2001-02-07 MX MXPA06004222 patent/MX257413B/en unknown
- 2001-02-07 MX MXPA01001423 patent/MX261584B/en active IP Right Grant
- 2001-02-07 IN IN127MU2001 patent/IN2001MU00127A/en unknown
- 2001-02-08 HR HR20010102A patent/HRP20010102B1/en not_active IP Right Cessation
- 2001-02-08 BG BG105232A patent/BG65738B1/en unknown
- 2001-02-09 NO NO20010683A patent/NO328952B1/en not_active IP Right Cessation
- 2001-04-06 US US09/827,976 patent/US6420380B2/en not_active Expired - Lifetime
- 2001-05-04 US US09/849,057 patent/US6410531B1/en not_active Expired - Lifetime
-
2002
- 2002-02-25 HK HK02101407.3A patent/HK1040085B/en not_active IP Right Cessation
- 2002-03-05 US US10/091,293 patent/US6534523B1/en not_active Ceased
-
2005
- 2005-09-30 US US11/241,899 patent/USRE40525E1/en not_active Expired - Lifetime
-
2007
- 2007-05-11 IN IN706MU2007 patent/IN2007MU00706A/en unknown
-
2008
- 2008-03-05 US US12/042,627 patent/USRE41894E1/en not_active Expired - Lifetime
- 2008-05-12 US US12/118,926 patent/USRE41356E1/en not_active Expired - Lifetime
- 2008-05-13 US US12/119,609 patent/USRE42164E1/en not_active Expired - Lifetime
- 2008-08-12 HK HK08108883.5A patent/HK1113164A1/en not_active IP Right Cessation
- 2008-12-05 AR ARP080105301A patent/AR069583A2/en active IP Right Grant
-
2009
- 2009-01-15 IL IL196545A patent/IL196545A/en not_active IP Right Cessation
- 2009-07-23 CY CY20091100795T patent/CY1109291T1/en unknown
- 2009-11-18 JP JP2009262835A patent/JP5021711B2/en not_active Expired - Lifetime
- 2009-11-27 AR ARP090104583A patent/AR073428A2/en not_active Application Discontinuation
-
2010
- 2010-01-05 NO NO20100004A patent/NO336663B1/en not_active IP Right Cessation
-
2013
- 2013-04-18 CY CY20131100317T patent/CY1113935T1/en unknown
Patent Citations (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH05155827A (en) | 1991-12-09 | 1993-06-22 | Banyu Pharmaceut Co Ltd | Production of cis-2-aminocyclopropanecarboxylic acid derivative |
DE19600034A1 (en) | 1996-01-02 | 1997-07-03 | Huels Chemische Werke Ag | New 1,1,2-tri:substituted cyclopropane compounds |
US5633388A (en) | 1996-03-29 | 1997-05-27 | Viropharma Incorporated | Compounds, compositions and methods for treatment of hepatitis C |
WO1998017679A1 (en) | 1996-10-18 | 1998-04-30 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease |
WO1998053814A1 (en) | 1997-05-29 | 1998-12-03 | Merck & Co., Inc. | Heterocyclic amide compounds as cell adhesion inhibitors |
US6767991B1 (en) * | 1997-08-11 | 2004-07-27 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis C inhibitor peptides |
WO1999007733A2 (en) | 1997-08-11 | 1999-02-18 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis c inhibitor peptides |
US6337394B2 (en) | 1997-12-05 | 2002-01-08 | Astrazeneca Ab | Compounds |
US6455571B1 (en) | 1998-04-23 | 2002-09-24 | Abbott Laboratories | Inhibitors of neuraminidases |
US6329379B1 (en) * | 1998-08-10 | 2001-12-11 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis C inhibitor tri-peptides |
US6323180B1 (en) * | 1998-08-10 | 2001-11-27 | Boehringer Ingelheim (Canada) Ltd | Hepatitis C inhibitor tri-peptides |
US6410531B1 (en) * | 1998-08-10 | 2002-06-25 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis C inhibitor tri-peptides |
US6420380B2 (en) * | 1998-08-10 | 2002-07-16 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis C inhibitor tri-peptides |
US6329417B1 (en) * | 1998-08-10 | 2001-12-11 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis C inhibitor tri-pepitides |
USRE40525E1 (en) * | 1998-08-10 | 2008-09-30 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis C inhibitor tri-peptides |
US6608027B1 (en) | 1999-04-06 | 2003-08-19 | Boehringer Ingelheim (Canada) Ltd | Macrocyclic peptides active against the hepatitis C virus |
US6642204B2 (en) * | 2002-02-01 | 2003-11-04 | Boehringer Ingelheim International Gmbh | Hepatitis C inhibitor tri-peptides |
US7091184B2 (en) * | 2002-02-01 | 2006-08-15 | Boehringer Ingelheim International Gmbh | Hepatitis C inhibitor tri-peptides |
US6908901B2 (en) * | 2003-03-05 | 2005-06-21 | Boehringer Ingelheim International, Gmbh | Hepatitis C inhibitor peptide analogs |
US6919423B2 (en) * | 2003-03-05 | 2005-07-19 | Boehringer Ingelheim International, Gmbh | Hepatitis C inhibitor compound |
Non-Patent Citations (9)
Title |
---|
Chen, et al.; "Chirally selective hydrolysis of D, L amino acid esters by alkaline protase", J. Chem, Soc. Chem Commun., vol. 20, 1986, pp. 1514-1516. |
Chen, et al.; "Kinetic resolution of esters of amino acids in t-butanol containing 5% water catalyzed by a stable industrial alkaline protease"; Chirality, vol. 6, 1994, pp. 572-576. |
Fliche, et al.; "Enantioselective synthesis of (1R,2S) and (1S,2S) dehydrocoronamic acids", Synthetic Communications, vol. 24, No. 20, 1994, p. 2873-2876. |
Gaucher, et al.; Palladium (0) Catalyzed Tandem Alkylation and SN' Cyclization of 1,4-Dichlorobut -2-ene by the N-(Diphenylmethylene) acetonitrile. A Steroselective Synthesis of 1-Aminocyclo-propanecarboxylic Acids:, Tetrahedron Letters, vol. 36, No. 17, pp. 2979-2982, 1995. |
Gershonov, et al.; "1-Aminocyclobutanecarboxylic acid derivatives as novel structural elements in bioactive peptides: application to tuftsin analogs", Journal of Medical Chemistry, vol. 39, No. 24, 1996, p. 4833-4843. |
Llinas-Brunet M., et al.; "Peptide-based inhibitors of the hepatitis C virus serine protease", Bioorganic & Medicinal Chemistry Letters, vol. 8, No. 13, p. 1713-1718; 1998. |
Ogawa, Tomohisa, et al.; "2,3-Methanophenylalanine and Alpha., Beta.-Dehydrophenylalanine Derivatives as Chymotrypsin Inhibitor", Pept. Chem. (1990), vol. 27, p. 379-382. |
U.S. Appl. No. 09/368,670; Aug. 5, 1999; Llinas-Brunet, M. et al. * |
U.S. Appl. No. 09/760,946; Jan. 16, 2001; Tsantrizos, Y. S. et al. * |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
USRE42164E1 (en) | Hepatitis C inhibitor tri-peptides | |
EP1105422B1 (en) | Hepatitis c inhibitor peptides | |
CA2370396A1 (en) | Hepatitis c inhibitor tri-peptides | |
MXPA01001422A (en) | Hepatitis c inhibitor peptides |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FEPP | Fee payment procedure |
Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
FPAY | Fee payment |
Year of fee payment: 12 |